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Alzheimer’s disease is the most common neurodegenerative disease in the world. Alzheimer’s 
disease is clinically characterised by decreased cognitive performance and pathologically 
characterised by formation of fibrillar amyloid plaques, so called Aβ-plaques and neurofibrillary 
tangles, which are aggregated tau proteins. It was first described by the German physician Alois 
Alzheimer in 1906. Even after 100 years, no therapies are available which can cure the disease or 
stop its progression. Current drugs only alleviate the symptoms and even this is strongly limited. 
Reason for the lack of effective drugs is that, to date, many questions remain unanswered. The 
exact biochemical processes which lead to the Aβ-plaques and to the cell death are not known. 
Since elevated levels of redox-active transition metals, primarily copper and iron, were found in 
the Aβ-plaques, evidence is provided that these processes are metal-mediated. Several 
biological markers indicate an increased oxidative stress in Alzheimer’s disease afflicted brain 
tissues, which could be induced by the enrichment of metals. In contrast to iron, which is 
associated with ferritin, copper is directly incorporated in the Aβ-plaques. Thus, an involvement 
of copper is more likely than of iron. A redox cycle was thus proposed which focuses on copper 
as the cause of increased oxidative stress. However, without an analytical tool which can 
intercept the cycle through coordination of intermediary formed Cu+, this and other hypotheses 
involving copper are yet to be unambiguously proven. The aim of this study is the synthesis and 
characterisation of such a tool. For the desired application a system is necessary which is not 
only selective for Cu+ but also targets the Aβ-plaques. This was achieved by the synthesis of a 
multifunctional compound consisting of two subunits, a Cu+-selective chelating moiety and one 
with a high affinity for Aβ-plaques. For the synthesis of the latter, dyes which can intercalate in 
the β-sheet structure of the Aβ-plaques were used as a basis. By combining modern drug design 
with inorganic aspects, a set of tripodal {NS2} and tetradentate {N2S2} ligands were synthesised 
and evaluated with respect to their metal binding properties. The systems with the best results 
with respect to affinity, selectivity, and stability, were then introduced into the multifunctional 
tool. Three multifunctional systems could be synthesised and first studies indicate that the 
compounds can be used for in vivo studies. 
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1.1 Alzheimer´s Disease - Some General Information 
One of the most common neurodegenerative diseases in the world is Alzheimer's disease (AD).[1] 
One of six people aged 70-74 is afflicted by AD and this number increases with age, resulting in 2 
% of the world population.[2] In Germany, as in many other industrialised nations, this number 
will greatly increase in future due to demographic changes and increasing life expectancy, so it is 
essential to elucidate the biochemical mechanisms of AD in order to develop therapeutic 
options. 
In 1906, AD was first described by the German physician Alois Alzheimer, whom it was named 
after.[3–5] AD is a neurodegenerative disease of the brain, during which progressive loss of 
neurons in different cognitive domains occurs, in particular the entorhinal cortex, hippocampus, 
basal forebrain and the amygdale. The clinical course can be divided into seven stages, from no 
impairment (Stage 1) to severe AD (Stage 7), which describe the continuously on-going mental 
decline.[6] The diagnosis of AD is problematic since the clinical symptoms match with many other 
neurological defects, such as vascular dementia, which is caused by circulatory disturbances in 
the brain. It is true that imaging diagnoses provide reasonable assurance but a final confirmation 
of the diagnosis is only possible post mortem. Characteristic for AD is the accumulation of 
protein aggregates, which can be detected via pathological examination. These include β-
amyloid plaques (Aβ plaques) and intracellular neurofibrillary tangles (NFTs).[4,7] Another 
pathological finding in Alzheimer's disease is the increased concentration of various transition 
metals, namely iron, copper and zinc.  
 
1.2 The Origin of Aβ Peptide: Amyloid Hypothesis 
AD is clinically characterised by decreased cognitive performance and pathologically 
characterised by formation of fibrillar Aβ and formation of NFTs, which consist of aggregated tau 
protein plaques.[8–11] The amyloid protein (Aβ), typically a 40/42 amino acid protein,[9][10] is 
produced through metabolism of the amyloid precursor protein (APP), which is a 695-770 
residue ubiquitous transmembrane protein.[14,15] Physiological function of the APP has still to be 
elucidated but functions such as neurite outgrowth, synaptogenesis, cell adhesion, neuronal 
survival, apoptosis and axonal transport have been proposed.[16] In vivo two proteolytic 
metabolic pathways are known, the amyloidogenic and the non-amyloidogenic pathway 
(Scheme 1).[17,18] The non-amyloidogenic pathway leads first to the α-amyloid by cleavage of the 
687-residue through α-secretase and then after further cleavage by γ-secretase[19,20] to the P3 
peptide.[21] In contrast to this, in the amyloidogenic pathway, cleavage of the 671-residue of APP 
by ß-secretase[22–25] occurs first to yield the β-amyloid precursor protein. A second cleavage of 
the 711 or 713-residue with γ-secretase releases Aβ1-40 or Aβ1-42, respectively.
[26] Both pathways 
are present under physiological conditions and are strongly dependent of the cell 
environment.[27] The amino acid sequences of the natural Aβ proteins as well as the most 
important truncated analogues Aβ16 and Aβ28 are shown in Figure 1.
[10] Aβ1-40 is the dominant Aβ 
species in neuronal cultures with an expression of 90 to 95 %, but in AD the more fibrillogenic 
Aβ1-42 is the predominant species. 
[28–32] The Aβ proteins differ in many aspects, although 
structural differences are only minor. 
 




Scheme 1 Cleavage of the amyloid precursor protein (APP) resulting in Aβ1-40 and Aβ1-42 
The truncated analogue Aβ1-16 shows no tendency to aggregate and is therefore used in studies 
which require an unchanged protein structure, for example ROS (reactive oxygen species) or 
metal binding studies. For studies on the aggregated protein or direct studies on aggregation, 
Aβ1-28 is often used, because the aggregation under moderate concentration and conditions is 
quite slow in comparison with Aβ1-40/42. The Aβ´s consist of a large hydrophilic N-terminal domain 
(1-28) and a hydrophobic C-terminus domain (29-40/42). In the monomeric form Aβ is soluble 
and can also be found in the healthy brain, indicating that it is nontoxic.[33–35] Even the opposite 
seems to be the case. Studies with metal induced oxidative stress have shown a protective 
function of Aβ, leading to the hypothesis that Aβ normally functions as an antioxidant and 
regulator of free metal concentration in the brain.[36] When Aβ is bound to an appropriate 
amount of Cu2+ and Zn2+ it can catalyse the dismutation of superoxide to hydrogen peroxide. 
Thus, Aβ can operate as an antioxidant.  
 
Figure 1 Amino acid sequence of natural and truncated Aβ proteins 
Formation of Aβ-plagues is one of the hallmarks of AD and it seems that the aggregation process 
from Aβ to fibrils is the key event. According to the amyloid hypothesis, the self-assembly 
process of Aβ involves increased release of amyloid protein, which accumulates and then 
aggregates forming first small oligomers, and then protofibrils.[17,37] These small hydrophobic 
aggregates appear to be the most toxic species in the AD process, as they can insert into 
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neuronal lipid bilayers and increase levels of oxidised products through increased lipid 
peroxidation.[38–40] Further aggregation finally leads to the Aβ-plaque found in the AD brain. 
Under physiological conditions the amyloid protein is present in an α-helical structure, but in the 
aggregated fibrils only ß-sheet structures are found (Figure 2).[41] 
 
Figure 2 3D core structure of two stacked Aβ1-42 protofilaments along the different axes (A and B). The figure 
illustrates the nature of the inter-β-strand interactions present in fibrils. K28 and D23 can interact via an 
intermolecular salt bridge, which is indicated by the dotted line in B. The picture was taken from the literature.[41] 
This finding raises the question whether the change in the protein structure initiates the 
aggregation or if the transformation towards β-sheets occur in situ, when the fibrils are 
formed.[42,43] In the last few years evidence was found for a metal induced aggregation resulting 
in the metal enriched fibrils found in AD.[7] One hypothesis suggests that a conformational 
change is induced by metal coordination in the Aβ proteins, which then aggregate by pure 
peptide-peptide contacts (Scheme 2).[44] 
 
Scheme 2 Putative mechanism of the metal induced aggregation of Aβ to protofibrils.  
It is worth mentioning that protein misfolding leading to amyloid-like fibrils is not only found in 
AD, but also in the normal homeostasis of some proteins.[45] Recently such plaques were also 
found in healthy brain tissues, where the person shows no clinical symptoms of AD.[46] One 
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hypothesis, which has been formed, is a protective mechanism against toxic misfolded 
intermediates through sequestration. Part of this theory is an equilibrium between the soluble 
monomer and the formed fibrils (Scheme 3).[47–50] Taking this into consideration, metal 
accumulation could be a trigger for promoting the pathway towards the toxic oligomers. 
 
Scheme 3 Aggregation pathways to Aβ plaques 
 
1.3 Detection of Aβ Plaques 
From the pathological point of view Alzheimer’s disease is relatively complex. The various 
hallmarks and their development over time allow a selective observation of the current state of 
AD and its progress. For in vivo visualisation of these pathological hallmarks non-invasive 
methods like magnetic resonance imaging (MRI) are necessary. MRI is a technique which can 
also visualise NFTs in AD.[51–55] The advantage in comparison with topographic techniques, such 
as positron emission tomography (PET)[56–59], which are also used in AD, is that with MRI no 
exposure to radiation occurs. Since Aβ plaques are predominantly β-pleated sheets, dyes can 
selectively intercalate the secondary structure. Thus, in order to image Aβ plaques, a series of 
dyes were synthesised with binding affinities in the low nanomolar region, the ability to cross 
the blood brain barrier (BBB), fast retention, and fast clearance from healthy brain tissues 
(Figure 3). Congo red was the first reported molecule known to function as a dye in AD, as it 
undergoes an absorption band shift upon interaction with Aβ.[60,61] Later it could be shown that 
Thioflavin T (ThT) and Thioflavin S (ThS) have not only similar affinities to Aβ, but also many 
advantages, for example, higher selectivity towards Aβ plaques and a unique change in the 
absorption and in the fluorescence spectra.[62,63] The reason or mechanism which causes the 
spectral alteration and induces the noteable 115 nm hypochromic spectral red shift of ThT is 
presently unknown. Thus, even today ThT is widely utilised in many studies to detect the 
formation of Aβ plaques in vivo and in vitro. The second generation of dyes for AD granted 
access to new imaging techniques, namely positron emission tomography (PET)[56–59], single 
photon emission computed tomography (SPECT)[64–66] and multiphoton imaging.[67,68]  




Figure 3 The first and second generation dyes used to visualise Aβ plaques in vivo. The second generation is also 
utilised for topographic methods through radiolabeling. 
 
From the second generation compounds 11C-BIP (Pittsburgh Compound B) and 18F-FDDNP are of 
specific interest.Both compounds have passed several clinical trials. They show differences in the 
regional retention and also in their intercalation properties. The lower retention for 18F-FDDNP 
could be explained by its lower binding affinity, but 18F-FDDNP has the advantage of also imaging 
NFTs.[69] However, insufficient sensitivity and a lack of its specificity, as determined by 
immunohistochemistry, are still challenges which have to be overcome. For a clear diagnosis 
different methods are often combined to complete the picture.[51]  
 
1.4 Transition Metals in AD 
For a variety of specific processes of life, nature uses the special properties of transition metals. 
Proteins which include one or more metals as a cofactor are called metalloproteins. If these 
proteins also have catalytic activity they are called metalloenzymes. As well as for the rest of the 
human body, transition metals are also essential for natural metabolism in the brain. Iron, zinc 
and copper are especially necessary for neuronal activities. These three transition metals are 
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involved in neurotransmission, synaptogenesis, neurogenesis, neurite outgrowth, neuro-
transmitter biosynthesis, oxidative phosphorylation, and oxygen transport.[70]  
In the AD brain microparticle-induced X-ray emission (PIXE) and other techniques have shown up 
to 3-5 fold excesses of different trace metals in comparison with age matched control.[71–73] In 
the senile plaques high metal deposits could also be detected in the mM or μM range 
(zinc/iron ≈ 1 mM, copper ≈ 400 μM) (Table 1).[74] Under physiological conditions iron, copper and 
zinc can induce fast Aβ aggregation. The redox active iron and copper are especially of great 
interest and are in the main focus of research. There is evidence that cell damage and also 
neuronal loss could have their origin in oxidative stress, which makes these two metals good 
candidates to play an important role in the progression of AD.[74–77] Thus, dysregulation of brain 
metals has been implicated in the pathogeneses of AD.[34][78,79] In the following, the metals 
accumulated in AD will be discussed in more detail with respect to their binding affinities and 
influence on the aggregation. 
Table 1 Copper, iron and zinc concentration in senile plaque, in AD and in controls subjects modified after Lovell 
et al.
[80] 
 Copper [μg/g] Iron [μg/g] Zinc [μg/g] 
Senile Plaque 25.0 ± 7.8  52.4 ± 13.7  69.0 ± 18.4 
AD neuropil 19.3 ± 6.3 38.8 ± 9.4  51.4 ± 11.0 
Control neuropil  4.4 ± 1.5 18.9 ± 5.3 22.6 ± 2.8 
 
1.4.1 Copper in AD 
With around 70 mg/person (70 Kg) copper is the third most common essential transition metal 
in the human body.[81] Physiologically, it is mainly found in protein-bound form, where it can be 
present in both the oxidised (Cu2+) and the reduced (Cu+) form. The most important copper 
metalloproteins in the human body are Cu,Zn superoxide dismutase (Cu,Zn-SOD, antioxidant 
defence), cytochrome c oxidase (CCO, electron transport and oxidative phosphorylation), 
tyrosinase (pigmentation), ceruplasmin (copper transporter), albumin (copper transporter) and 
dopamine β-hydrolase (neurotransmission). Copper containing proteins can be divided into 
three classes according to their coordination geometry and ligand sphere. Type 1 copper 
proteins, also known as blue copper proteins, are characterised by a strongly distorted 
tetrahedral structure and an absorption of the oxidised species at 600 nm. The coordination 
sphere consists of two histidine residues, a hydrogen bond-forming cysteine residue and another 
amino acid (e.g. methionine). Type 2 copper proteins, which are not blue in colour, have a nearly 
planar geometry. In this case there are three histidine residues and one water molecule 
coordinated to the metal. The last class, the type 3 copper proteins, comprises two copper ions, 
in contrast to the type 1 and type 2 centres. The spatial arrangement of the ligands, six histidine 
residues and one or two bridging molecules results in a pyramidal geometry for each metal ion. 
Of all the copper in the human body 7.3 % is located in the brain, where it is released as a 
neurotransmitter in the glutamatergic synapses of the cortex and hippocampus.[82,83] Due to the 
high redox activity of copper and the relatively low antioxidant levels in the brain, tight 
regulation of copper transporters is necessary.[84] Age dependent dyshomeostasis can lead to 
copper enrichment in extracellular amyloid plaques.[85–88] Controversially, copper levels in 
cerebrospinal fluid and plasma of AD published so far differ in a broad range.[89–97] Furthermore, 
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the brain tissues of AD patients show a decrease of copper levels in comparison to aged match 
control.[72,97] Recently, together with an elevated Aβ level, an increased “labile copper pool” was 
reported in the AD affected human brain.[98] As a consequence, all previous assumptions of an 
enrichment of copper seem to be wrong. Treatment methods using metal chelating need to be 
reconsidered. The copper imbalance and missregulation needs to be re-equilibrated from the 
labile pool to the copper proteins.[99] Under physiological conditions (pH ≈ 6.6) Cu2+ can promote 
Aβ aggregation, but unlike Zn2+ and Fe3+, without fibril formation.
[100–102] Instead, highly toxic 
small oligomers are formed.[103] Furthermore, cultured neurons treated with Cu2+ result in 
hydrogen peroxide production by the [AβCu]2+ complex.[104,105] The copper promoted 
aggregation, the generation of oxidative stress through the [AβCu]2+ complex, the high copper 
levels found in senile plaques and the imbalance in the copper pool all point in one direction; 
copper is part of the AD progression, if not the key to the disease and its cure. To understand the 
many possible interactions in AD, structural features of the copper-APP and copper-Aβ complex 
firstly have to be evaluated. 
 
Copper-Protein Complexes in AD 
Under conditions of copper deficiency the amyloidogenic degradation pathway of APP is 
promoted, whereas elevation of intracellular copper levels enhances the non-amyloidogenic 
pathway and diminishes Aβ release.[106–112] The change in metabolism is likely due to structural 
changes in the APP.[113] Therefore, the copper binding sites of APP are of great interest. APP has 
two Cu2+ binding domains, one in the N-terminus and another in the later Aβ protein sequence. 
The first binding domain involves one methionine, one tyrosine and two histidine residues 
(His147, His151, Tyr168 and Met170) and binds Cu2+ relatively strong, with a dissociation constant Kd
 
of approximately 10 nM.[113,114] The Aβ protein also shows two binding sites for Cu2+, which can 
sequentially bind Cu2+.[102,115,116] However, the relatively low binding constant of the second 
binding pocket (see Table 2) and the substoichiometric amount of copper found in Aβ indicates 
that the second binding domain is unoccupied. The apparent Kd values for [AβCu]
2+ vary with 0.1 
to 47 μM in a large range, which is a result of the different conditions and also the sensitivity of 
the used methods.[117] A pH dependence of coordination could be determined. Under 
physiological conditions (pH ≈ 6.7) species I is predominant. However, at higher pH values 
(pH ≈ 8.9) a second species is formed.[36][56] Interconversion of the two species can be observed 
at pH 8 ± 1 (Figure 4).[42,88,116,118,127–129] It is noteworthy, that under mildly acidic conditions 
(pH ≈ 6.6), where species I is predominant, Cu2+ can promote Aβ aggregation.[100] Under 
physiological conditions species I appears to be the predominant species, where the metal is 
coordinated in {N3O1} environment similar to type II Cu proteins.
[56][58][130–133]. The His residues 
which are most likely involved in Cu2+ coordination are His6, His13 and His14, but it is still unknown 
if these coordinate in vivo. Concerning the O-donor atom, the carboxylate groups of Asp1 and 
Tyr10 are of great interest, since surveys indicate an interaction with Cu2+.[42][131,134][135] UV/Vis 
experiments confirmed the unlikelihood of the Tyr10 binding to Cu2+.[58][116,118] Instead the 
coordination via Asp1 is much more likely, since EPR data with a mutant, Asn1 instead of Asp1, 
show drastic changes in the spectra.[128]  
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Table 2 Reported dissociation constants (Kd values) for the [AβCu]2+ complex. a) numbers in brackets are according 
to the low affinity second binding domain. 
Utilised 
Aβ 





1-16/28  0.21/0.024 (7.4) Potentiometry[118] 
1-40/42 1.6-2.0  10 mM TRIS (7.4) Tyr fl.[119] 
1-16/28  100 Gly (His, 7.8) Tyr fl.[88] 
1-
16/28/40 
11-47  100 mM TRIS (7.4) Tyr fl.[120] 
1-40 8  50 mM PO4
- (7.2) Tyr fl.[121]  
1-40 2.5  10 mM HEPES (7.2) Tyr fl.[122] 
 0.4  10 mM PO4
- (7.2) Tyr fl.[122] 
1-40 1.2/3.8/3.0  20/50/100 mM TRIS (7.4) Tyr fl.[123] 
 0.6/0.9/2.5  20/50/100 mM HEPES 
(7.4) 
Tyr fl.[123] 
1-16/28 0.1  50 mM HEPES (7.4) ITC[116] 
1-40 16  5 mM PO4
- at 4 °C (7.3) NMR[124] 
1-16/40  0.4 Gly (His, 7.4) ITC[125] 
1-40  13 (0.05)a) different chelator (7.4) Chelator/Aβ 
separation[126] 
1-42  5(610-9) a) different chelator (7.4) Chelator/Aβ 
separation[126] 
1-40/42 4/0.3  20 mM CH3COO
- (7.4) Abs. at 214 nm[100] 
 
A 3D structural model of species I at low pH is given in Figure 5. At pH values above 8, and with 
large reorganisation of the Cu2+ binding site, species II is formed. This structural change is most 
likely induced by deprotonation of an amide backbone or a lateral side chain. Thus, His13 and/or 
His14 are no longer within a distance suitable for coordination.[42] For the second binding pocket 
with lower affinity to Cu2+, a {N3O1} as well as a {N2O2} coordination could be possible.
[55][56] All 
coordination modes described so far concern only the soluble monomeric Aβ, but of much 
greater interest are the binding modes of Cu2+ in the small toxic aggregates and in the fibrils. 
Relatively few studies were done so far on Cu2+ loaded aggregates, which indicated also a {N3O1} 
coordination sphere in the oligomers.[115,120]  
 
 
Figure 4 Species I and II of [CuAβ]2+ complex. Interconversion occurs around pH 8. 




Figure 5 3D structural models of the possible coordination modes in species I at low pH. Left: The coordination by 
the N-terminus, His6, His13 or His14, Asp1-COO- and, right: the coordination by three His and Asp1-COO-. The picture 
was taken from the literature.[117] 
The brain has a rather reductive environment. The Intracellular potential is -300 mV vs. NHE and 
in the extracellular environment an ascorbate concentration of approximately several hundred 
micromolar is present.[136,137] Therefore, an involvement of Cu+ in the progression of AD is 
possible. Binding studies on the protein are quite complicated, since the metal can easily be re-
oxidised and many analysing methods (e.g. EPR and UV) do not detect Cu+. However, through X-
ray absorption studies the 3D structure of the [AβCu]+ complex could be elucidated, revealing a 
linear coordination geometry.[138–140] Two nitrogen atoms from His13 and His14 coordinate Cu+ in a 
linear fashion.[141–143] Furthermore, dissociation constants of the [AβCu]+ complex could be 
determined, showing an affinity of Aβ in the micromolar region (Table 3). Recently, it could be 
demonstrated that, in contrast to Cu2+, the Cu+-fibril complex undergoes significant structural 
changes from the monomeric form.[144] Thus, XANES data have shown that even a tetrahedral 
coordination could be possible. However, further research is necessary for verification. 










1-16/40 7.5/19 different chelator (7.4) chelator/Aβ separation[145] 
1-40 6107  different chelator (7.4) chelator/Aβ separation[146] 
    
After defining the distinct coordination pockets for Cu2+ and Cu+, kinetics for the 
electrochemistry of copper loaded Aβ were investigated (Figure 6).[147] Three different 
mechanisms were suggested. The first is an electron transfer mechanism, where the 
coordination sphere changes from the distorted square planar {N3O1} coordination to the linear 
N-Cu-N structure. This mechanism requires a large rearrangement which, due to the high 
reorganisation energy, is relatively unlikely. The second mechanism is the so called square 
scheme mechanism. Pathway A and pathway B describe mechanisms already known for other 
copper complexes.[148–151] Pathway A progresses from Cu+ to Cu2+ through a metastable complex 
which is similar to the final complex.[147] The same is proposed in pathway B, where a similar Cu2+ 
complex coordinated by only the two His residues is formed. Even with this structural 
“intermediate” the reorganisation energy is still too high, therefore the third proposed 
mechanism seems to be most likely. The third mechanism proceeds through reorganised 
complexes, where small fractions of the [AβCu]+ and [AβCu]2+ complexes adopt similar 
structures, and which therefore affords relatively low reorganisation energy of the electron-
transfer. In this mechanism the pre-organised metastable [AβCu]+ and [AβCu]2+ complexes are in 
rapid equilibrium with the stable forms. 




Figure 6 Different pathways possible for the redox [AβCu]2+/ [AβCu]+ system. The picture was taken from the 
literature.[147] 
 
1.4.2 Zinc in AD 
After iron, Zinc is the second-most abundant element in the human organism and is involved in 
many processes. With 0.12 to 0.15 mM zinc is one of the most abundant metals in the central 
nervous system.[152] In the hippocampus zinc functions as an endogenous neuromodulator in 
synaptic neurotransmission and is released together with glutamine.[153,154] In AD altered brains 
elevated zinc levels could be detected not only in the frontal cortex but also in the senile 
plaques.[74] 
 




In contrast to Cu2+, there is only one binding site for Zn2+ in Aβ. The binding pocket lies in the 
N-terminus of the protein and allows formation of a 1 : 1 [AβZn]2+ complex (Figure 7).[155,156] It is 
commonly assumed that three histidine residues (His6, His13 and His14) coordinate the metal, but 
the identity of further ligands is still unknown. Other amino acid residues such as Tyr1 or Asp10, as 
well as exogenous ligands are viable donors in order to complete a four to six ligand 
coordination sphere.[44,122,131,133,155,157]  
 
Figure 7 Structure of the [AβZn]2+complex determined by NMR studies. Further exogenous ligands cannot be 
excluded. The picture was taken from the literature.[156] 
The Kd for Zn(Aβ) is in the range of 1-20 μM, although higher values have also been reported 
(Table 4).[117] Upon coordination of Zn2+, fast aggregation of Aβ takes place and nontoxic fibrils 
are formed, similar to the natural ones.[44] Thus, at current, the zinc-induced fibril formation is 
being considered as a curative competition for the toxic pathway in AD.[49,103] In the Aβ 
aggregates all three histidine residues seem to provide the primary binding domain.[42] 
Intermolecular His-Zn-His bridges are supposed to be present in the aggregates, which could also 
explain the fast formation of the fibrils induced by Zn2+ coordination.[43,85] Besides the Aβ 
aggregation, altered Zn2+ levels also have a direct influence on APP metabolism. High zinc levels 
promote the amyloidogenic pathway, since zinc ions are directly involved in the modulation of 
α- and γ-secretase.[158–160] In contrast to iron and copper, zinc is redox silent with distinct 
chemical properties. Metal induced oxidative stress is therefore not possible. Thus, the role of 
the interaction between Zn2+ and Aβ is still unclear. A protective function of elevated Zn2+ levels 
is still a possibility but current knowledge is too limited to evaluate such a hypothesis. 
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1-40/42 30/57  10 mM TRIS (7.4)  Tyr fl.[119] 
1-16/28/40 22/10/7  HEPES ans TRIS (7.4) ITC[161] 
Soluble 1- 
16/28/40/42 






HEPES competition with 
Zincon[161] 
1-40 1.1  10 mM PO4
- (7.2) Tyr fl. of Zn/Cu 
competition NMR[122]  
1-40 60/184  10/100 mM PO4
- (7.2) Tyr fl.[123]  
 65  20 mM HEPES (7.4) Tyr fl.[123] 
1-40/42  2 Zincon (7.4) competition with 
Zincon after 30 min[123] 
  >11 Zincon (7.4) before incubation[123] 
1-40 3.2  10 mM HEPES or TRIS 
(7.4) 
displacement assay 
with cold and 
radioactive Zn2+[162] 
 5  20 mM TRIS (7.4) displacement assay 
with cold and 
radioactive Zn2+[163] 




1.4.3 Iron in AD 
As the most abundant transition metal in the human body iron is found in a wide variety of 
proteins and enzymes.[81] Besides in proteins, iron is also found in the cellular tissue in the so-
called "labile iron pool" (LIP).[165]. For normal functioning of the brain, and neural development a 
specific amount of iron (around 60 mg[166]) is needed.[167] Like copper, iron is also a redox active 
transition metal with Fe2+ and Fe3+ as the main oxidation states. Low iron levels can therefore 
cause deficiency symptoms, whereas increased iron levels can cause cellular damage through 
metal induced oxidative stress. Thus, strict regulation of iron levels is necessary. Post mortem 
brain tissue samples reveal increased Fe3+ levels in AD afflicted brains but, in contrast to Zn2+ and 
Cu2+, Fe3+ cannot be co-purified with Aβ although in vitro studies indicate Fe3+-Aβ 
interactions.[97,168–172] Instead Fe3+ is associated with ferritin, an iron storage protein, within the 
fibrils themselves.[173] This finding is accompanied by a change in the natural iron homeostasis. 
Increased level of ferritin and transferritin are present not only in the senile plaques, but also in 
other non-neuronal cells, indicating a dysfunction of the iron metabolism in AD.[174–176]  
 
The Fe(Aβ)complex 
The role of iron in AD is controversially discussed in literature. The strongest evidence for 
participation of iron in the amyloidosis of AD involves metal induced oxidative stress.[75,104,177,178] 
In vivo and in vitro studies have shown iron induced lipid peroxidation, which could be 
diminished by the addition of iron chelators or amplified by increasing intracellular iron levels. 
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As a consequence of elevated iron levels, even cell death could be observed. Metal reduction by 
Aβ and shuttling of the iron to the membrane is one proposed mechanism for the observed cell 
death.[179] Another indication for iron involvement in AD progression is Fe3+ induced aggregation, 
which takes place under mildly acidic conditions.[120][179,180] Very recently the coordination 
environment of the Fe2+(Aβ) complex was partially revealed in vitro, indicating dynamic 
exchanges between various coordination modes.[166,181] Most likely three histidine residues (His6, 
His13 and His14) as well as the NH2 group of the N-terminus are involved in coordination. Further 
ligands could be the COO- groups of Asp1 and Glu3 (Scheme 4). 
 
Scheme 4 Comparison of the possible coordination environments for the [AβCu]2+ complex (left) and [AβFe]2+ complex 
(right) 
It is likely that dyshomeostasis of iron metabolism takes place in AD, but iron does not seem to 
play a key role in amyloidosis. Firstly, it cannot be co-purified with the Aβ plaques and, secondly, 
no direct correlation between iron accumulation and increased senile plaques could be 
detected.[170] 
 
1.5 Oxidative Stress in Alzheimer´s Disease 
Reactive oxygen species (ROS) are highly reactive forms of oxygen (hydrogen peroxide H2O2, 
superoxide anion radical O2˙
-, hydroxyl radical OH˙) which are harmful to an organism and are 
involved in various diseases like cancer[182], Parkinson's disease, Alzheimer's disease, heart 
failure[183], myocardial infarction[184], Bipolar disorder[185], fragile X syndrome[186], Sickle Cell 
Disease[187], and chronic fatigue syndrome[188]. In particular, they play an important 
pathophysiological role in aging, since progressing age leads to an increased dysregulation of 
protective or repair mechanisms of the body. This imbalance between the generation of ROS 
and the repair mechanisms is called oxidative stress and occurs when either the production of 
oxidising species increases or the effectiveness of the antioxidants decreases. The free radicals 
produced in oxidative stress can damage all parts of the cell through reaction with lipids, 
proteins or DNA. In the early phases this leads first to disturbance of normal cell function and 
later even to cell death. The natural origin of ROS often lies in the respiration chain, or to be 
more precise, in the oxidative phosphorylation in mitochondria.[189] Other sources are enzymes 
(Cytochrome P450 or NADPH oxidases) which produce ROS as a key intermediate to 
oxidise/metabolise substrates.[81] Thus, the production of ROS is essential for cell function, as 
signal transporter, not mentioned prior, or oxidative reagent, but has to be tightly regulated. The 
same also applies for redox active transition metals like iron or copper. These metal ions can 
produce ROS and therefore as “free” metals, not bound by enzymes or proteins, are highly toxic.  
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1.5.1 Indication for Oxidative Stress in AD  
As there is a high accumulation of different transition metals in AD brain tissues (chapter 1.4) 
and the brain is the most aerobic organ in the body, it is likely that cell damage in AD could be 
the result of oxidative stress. Evidence for extensive oxidative stress in AD afflicted neocortex 
could be revealed by various biomarkers (lipid peroxidation[190–192], oxidised proteins[193–197], 
oxidised DNA and RNA[80,198–200]).[201,202] Further confirmation of altered oxygen metabolism is 
found in high concentrations of reactive electrophilic aldehydes (e.g. malondialdehyde), 
carbonyls and free 4-Hydroxy-2-nonenal (HNE)[203–206]. The high toxicity of these compounds is 
not due to an extremely high reactivity but rather because of their metastability. Their long half-
lifes allow them to diffuse through the cell and damage it extensively, especially through 
reaction with biochemical nucleophiles, such as DNA, lipids and proteins. Further evidence is 
also the absence of poly unsaturated fatty acids, which are easy to oxidise. This is consistent 
with the increased levels of lipid peroxidation. Further indicators are increased activity of heme 
oxygenase and glucose-6-phosphate dehydrogenase, as well as a change of the normal 
antioxidant levels in the AD brain. One example for the latter is superoxide dismutase (SOD) 
expression. SOD´s are enzymes that catalyse the dismutation of superoxide into oxygen and 
hydrogen peroxide and therefore are important antioxidants. In comparison to healthy brain 
tissues higher expression levels of SOD were found in AD brains which, is known to be a 
biochemical response to increased oxidative stress. An analogous confirmation of this is found in 
red blood cells and lymphopblasts. Here the levels of antioxidants are also elevated leading to 
the same conclusion.[207]  
 
1.5.2 Mechanisms of Metal Induces Oxidative Stress in AD  
As mentioned previously, iron and copper are the main redox active transition metals which can 
cause oxidative stress in biological systems. Metal induced cytotoxicity with respect to AD was 
thus studied in many cases, but did not provide any valuable information about the role of the 
metal and the conditions responsible for oxidative damage. While Aβ tissues incubated with Zn2+ 
show rapid aggregation to fibrills, no direct cell damage occurs, and it is proposed that Zn2+ 
cooperation with Aβ may protect neuronal cells against ROS. In contrast, after incubation with 
Aβ, Cu2+ and Fe3+ show increased cell toxicity through the generation of ROS, especially 
H2O2.
[104,177] Experiments with the H2O2 scavenging enzyme catalase have shown inhibition of Aβ 
toxicity, leading to the conclusion that the neurotoxicity in AD is mediated by ROS generation. In 
the case of Fe3+ the toxicity could also be decreased by adding desferrioxamine, a strong Fe3+ 
chelator.[178] Toxicity could then be restored by further addition of Fe3+. Cu2+ has shown 
analogous behaviour to Fe3+. On the basis of Haber-Weiß and Fenton chemistry, a catalytic 
mechanism of metal induced oxidative stress in AD was postulated (eq. 1.1-1.5). 
                        (1) 
        
         
        (2) 
  
     
                      (3) 
          
                               (4) 
  
            
           (5) 
Chapter 1 Alzheimer’s Disease 
16 
 
In AD, the metals in equation 1 and 2 are proposed to be Cu2+ and Fe3+.[208] Aβ has a strong 
reduction potential and can rapidly reduce Cu2+ and Fe3+.[208] In the second step, the reduced 
metal ion can be re-oxidised via oxygen to generate superoxide, which can then form hydrogen 
peroxide followed by the Fenton (equation 4) and Haber-Weiß reaction (equation 5). The end 
products are hydroxide and the highly reactive cytotoxic hydroxide radical.  
The significance of iron in AD progression is still controversially discussed in the literature and 
indication is given that it plays only a minor role. Hence, the focus in the following section lies on 
Cu2+. A proposed Cu2+ redox cycle of the cascade leading to ROS, cellular dysfunction and finally 
to cell death is shown in Scheme 5.[173] The cycle starts with the reduction of Cu2+ to Cu+ through 
the uptake of one electron from Aβ. The Aβ radical can then further react with lipids and 
proteins to generate HNE or reactive carbonyls. On the other side the cycle is closed by the re-
oxidation of Cu+ to Cu2+ in which oxygen reacts to superoxide.  
 
Scheme 5 Possible Cu+/Cu2+ controlled redox cycle in AD, generating Carbonyls (HNE) and superoxide[173] 
One open question in this reaction cycle is the localisation of the radical on the Aβ protein. The 
Aβ protein sequence shows only two possible positions which could directly stabilise a radical, 
the Met35 or the Tyr10 residues DFT calculations indicate a reduction of Cu2+ via proton-coupled 
electron transfer (PCET) from ascorbate on the Tyr10 residue.[135] Inhibition of the redox process 
by substitution of the Tyr10 by alanine strongly supports this hypothesis. In contrast, there is also 
evidence given which indicates that the radical is more likely stabilised by the Met35 residue. 
Under relatively mild conditions, through a specific support of the Lys31, Met35 can be reversibly 
oxidised to a diastereotopic pure methionine sulfoxide.[209–213] Of greater significance than the 
mere oxidation is the generation, stability and reactivity of the radical localised on the sulphur. 
Mechanistic studies revealed a fast radical oxidation to a sulfuramyl radical cation (R-S˙+-CH3).
[209] 
In a subsequent step the radical is shifted to a carbon centred radical which immediately reacts 
with paramagnetic oxygen to a peroxylradical. The propagating radical process starts after 
reaction with other electrophilic biomolecules. Products of this process can be the above 
mentioned HNE and other lipid peroxidation products. In this mechanism the intermediate, R-
S+H(CH3), is generated, which has a pKa value of -5
[214] and therefore is directly deprotonated, 
reforming Met35. Thus, the Aβ protein can function as a catalyst.  
Through substitution of the Met35 to norleucine (S to CH2) all oxidative and neurotoxic properties 
of Aβ1-42 to cultured neurons were suppressed.
[215] Even when methionine sulfoxide was used 
instead of the normal Met35 no protein oxidation could be observed.[216] These two results gave 
evidence that the Met35 can undergo a radical oxidation to the sulfuramyl radical cation without 
further reaction to the methionine sulfoxide, which would be inactive in ROS production. 
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Furthermore it could be proven that the Met35 is crucial for Aβ induced oxidative stress in AD. 
Still, independent from the modification of the Met residue, norleucine or methionine sulfoxide, 
small aggregated fibrils were formed.[216] 
 
1.6 Treatment of AD 
Since the discovery of AD 100 years ago, a steady increase in afflicted persons has been 
recorded, not only through better diagnostic techniques but also due to the increase in life span. 
The consequence is exploding costs in the pharmaceutical sector and health care. The growing 
interest in developing new drugs and therapeutically strategies is therefore only natural. The 
first developed drugs for the treatment of AD were based on enhancing the acetylcholine level in 
the synaptic cleft by inhibiting the acetylcholinesterase (AChE).[217] These drugs were developed 
after the discovery of elevated release of acetylcholine in the mid 1970s. After further 
investigation it could be shown that this kind of treatment with, for example, 
tetrahydroaminoacridine, donepezil, huperzine A or galantamine simply reduces the symptoms 
but does not cure the disease.
[26]
 The progressive development of isolation, analytic and 
structural determination techniques allowed the development of new therapeutical strategies. 
One approach is the suppression of Aβ aggregation.[48] Three different strategies which already 
reached phase II clinical trials should be mentioned in this context. The first is vaccination using 
Aβ-derived immunogens (Elan’s Aβ vaccine).[218,219] The second strategy targets monomeric Aβ 
directly.[220] Small compounds can bind to the protein and create complexes which cannot 
aggregate. The third and last approach involves the cleavage of APP.[221] By inhibition of γ-
secretase the amount of total Aβ can be reduced and with this the amount of aggregates. 
With increasing evidence for metal accumulation combined with metal induced oxidative stress 
in AD, chelating therapies are favoured. The first ligand systems used for application in AD were 
“classical” ligands with strong binding affinities for most transition metals (Figure 8). Clioquinol 
(5-chloro-7-iodoquinolin-8-ol, CQ) is one of the ligands which has to be highlighted for several 
reasons. CQ is a lipophilic brain-permeating ligand with mid-nanomolar affinity, not only to zinc 
but also to copper. With the small doses used in AD treatment, the formed metal complex does 
not precipitate.[222–224] Therefore CQ and its derivatives were widely studied and even reached 
clinical trials. Although CQ and several other systems have the required coordination abilities 
and show good in vitro results, their application in AD research is limited. Most of the systems 
(DFO, TETA, etc.) cannot cross the blood brain barrier (BBB) and show no selectivity towards a 
specific metal. Nonetheless these ligands opened the door to chelating therapies in AD. A 
second generation of CQ, PBT2 (8-hydroxyquinoline), was developed. Due to impressive positive 
results, such as lowering the Aβ levels, reduced formation of phosphorylated tau, and better 
cognitive performance, a phase IIa clinical trial was started.[225–227] PBT2 is not only a chelating 
agent, in addition it fulfils the duty of a chaperon, functions as transport and regulation protein, 
and can redistribute Cu2+.  
 




Figure 8 First generation of chelators used to remove metal ions from AD tissues. 
As mentioned previously, a copper imbalance in AD leads to accumulation of Cu2+ in affected 
brain regions.[228] Therefore, a chaperon-like activity could be the key to restore the copper 
distribution.[99] At the moment PBT2 is still under research and has already shown promising 
results in clinical trials.[226] A relatively new approach is the combination of two or more 
functional building blocks to create multifunctional systems with high potential for applications 
in AD (Figure 9). Often one of these components is a metal-binding compound. The classical 
chelators or their derivatives were often used as a basis. These compounds were then linked to 
an amyloid binding-motif, antioxidant, or inhibitor of Aβ aggregation. Simple glycol-conjugated 
or peptide coupled systems are also known. Since this approach is quite new, and combination 
possibilities are more or less endless, the efficacy of drugs generated by this approach has to be 
proven. In conclusion many questions relating to AD are still unanswered. While some drugs and 
therapies with promising performance in clinical trials have been developed, so far these cannot 
cure the disease, nor stop its progression. They can only temporarily reduce the symptoms. 
Therefore a better understanding of AD progression is essential for the synthesis of new, more 
effective drugs. 
 




Figure 9 Multifunctional tools with applications in AD (NP = nanoparticle). 
 
1.7 Modern Drug Design 
Drug design is an important part of medical science. One approach is target-orientated drug 
design with consideration of the biological and chemical behaviour of the targeted molecule. 
Normally these molecules play an important role in physiological metabolism. An important and 
challenging task is that drugs have to bind to the target but should not affect other molecules 
similar to the target. Thus, prior to the synthesis, a model has to be created considering all 
chemical, biochemical and medical aspects. From an economic point of view drugs should fulfil 
several requirements like low manufacturing cost and appropriate stability for storage and 
transport. However the main issues arise from biological factors: absorption, distribution, 
metabolism, selectivity, excretion and toxicity (ADMET).[229,230] In the following, the ADMET 
concept will be shortly explained. 
Absorption: Orally administrated medication is preferred over inhalation and injection. For an 
oral medication to take effect the drug must be well absorbed from the digestive tract. In 
general, drugs must be able to pass through cell membranes and to be transportable in the 
blood. For neuro-pharmaceutics, there is an additional requirement: The pharmaceutics have to 
cross the blood brain barrier (BBB). Since this is not always possible, precursors are frequently 
used which are able to cross the BBB and release the active molecule afterwards. 
Distribution: The distribution and transport of the drug is the second important biological 
aspect. It has to be ensured that the distribution of the drug is selective for the diseased organs 
or regions. Otherwise an insufficient distribution would result in an ineffective treatment. 
Medications with severe side effects can even lead to serious damage in the case of wrong 
distribution in the body. 
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Metabolism: In some cases the metabolism of the pharmaceutical is desired, e. g. prodrugs. 
Generally it should not be too easily metabolised by the body because its effectiveness would be 
too low. 
Excretion: Many drugs are only temporarily necessary and an accumulation would also lead to 
several problems. Most drugs are excreted after an extended time, whereas others are 
metabolised. 
Toxicity: The non-toxicity of a drug is one of the most difficult challenges to be achieved. Drugs 
are designed to change or interrupt biological processes. Unfortunately the interaction of the 
drug with the body often results in side effects like headaches, allergic reactions or dizziness. 
Nowadays already during the design of new drugs, partial focus lies on reducing possible side 
effects but a complete prevention is not always possible e.g. in the case of anti-cancer drugs.  
To sum up all the biological aspects and develop a chemical concept out of it is a difficult task. 
Fortunately a connection between the uptake, the distribution and the chemical properties of a 
drug was found empirically.[231] “Lipinski’s Rule of Five” outlines the essential characteristics an 
orally administered drug should possess: 
 Not more than 5 hydrogen bond donors (NH2, NH, OH) 
 Not more than 10 hydrogen acceptors (N, O) 
 A molar mass of less than 500 daltons 
 A partition coefficient log P (octanol-water) not greater than 5   
The name “Rule of Five” originates from the fact that each rule includes a number which can be 
divided by five. It should also always be considered that it is only an empirical finding which 
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Around 2 % of the population in the industrial countries is currently affected by Alzheimer 
disease (AD). This disease is of increasing importance especially under consideration of the 
demographic development from both financial and ethnic point of view. Since its discovery 100 
years ago, no efficient therapies for AD have been found.[217] One reason for this is the limited 
knowledge about the exact formation of Aβ plaques and their specific neuro-toxic effects. Metal 
induced oxidative stress, which damages the cell and finally leads to neuronal loss in specific 
regions in the brain, is proposed to be the main event in AD progression. For the elucidation of 
the specific redox processes in the cell unfortunately only a small number of studies have been 
accomplished. Besides, most of the studies were performed in vitro and extrapolation of the 
data to the cells is not always possible. Therefore, the production of ROS in the AD afflicted brain 
remains a process that requires further investigation. Previous inhibition of ROS generation 
using metal chelators targeting Cu2+ and Fe3+ yields promising results. However in order to prove 
the proposed redox cycles (Scheme 5), the intermediates have to be captured. Therefore Cu+ or 
Fe2+ selective ligands are needed and their coordination properties toward the metals have to be 
evaluated. As discussed in the previous chapter, the involvement of Cu+ in the AD progression 
seems to be more likely than iron participation. The aim of this study is therefore not to develop 
new drugs for AD, but to provide a multifunctional tool for further investigation on the relatively 
unknown Cu+-Aβ interaction. Nevertheless, ligand design was done on basis of modern drug 
design to keep the path open for advanced biological studies in mammals. In order to achieve 
the goals a five-stage plan for the gradual course of the study was developed (Scheme 6). 
 
Scheme 6 Five-stage plan for the development of multifunctional tools for applications in AD. 




2.2 The Chelator – Inorganic Aspects Combined with Modern Drug Design 
Selectivity is an essential requirement for all drugs and biomarkers. Especially metal targeting 
drugs have to be selective, not only for the targeted metal, but also for the specific protein, since 
otherwise serious consequences are looming. Metals are not only used in the active centre of 
various proteins, but are also involved in many biological activities like signal transduction, 
electron transfer, structure factors and others. Dysregulation of the natural metal homeostasis, 
which is a tightly regulated process, can therefore lead to several disease patterns and also to 
cell death. Thus, for pharmaceutics and compounds with biological applications is selective 
coordination essential. The overriding aim of this study is to achieve a more profound 
understanding of the Cu+ chemistry in AD. A multifunctional tool, which not only selectively 
binds Cu+ with a defined stability constant, but comprises selectivity for Aβ plaques, should 
therefore be developed.  
Coordination of a metal depends on the donor strength of the ligand, including the size of the 
binding pocket, the charge, electronegativity, bond lengths and angles in the ligand but also on 
the concentrations, of the reaction partners as well as of co-ligands. Especially the latter is an 
important factor for in vivo studies, complicating simple metal-ligands reactions. A better 
description of ligation reactions would therefore be the equilibrium between the aqueous 
M(H2O)X
n+ complexes and the chelated LM complexes. Thus, basic concepts like the principle of 
Pearson are of limited application.[232] More precise is the Irving-Williams series, which directly 
considers the aqueous milieu and compares equilibrium constants for most donor groups. The 
Irving-Williams series shows that the most stable Cu2+ complexes are formed with a mixed {NS-} 
donor set.[233] Although, Cu2+ has different chemical behaviours than Cu+, this empirical finding 
was used as starting point for the synthesis of Cu+ selective ligands and was refined with the 
HSAB (hard and soft acids and basis) concept from Pearson.[232] After Pearson, Cu+ has a softer 
character, since it is big, has a low charge and can easily be polarised. Cu+ should therefore 
prefer soft donor atoms like sulphur. Thus, a {NS2} and {N2S2} donor set was chosen in the ligands 
(Figure 10). Conversely, Lewis acids like Mg2+ or Ca2+ will not be coordinated and according to the 
Irving-Williams series also the chelation of Mn2+, Fe2+, Co2+ and Ni2+ is disfavoured in the 
presence of copper. The second aspect considered in the ligand design is the complex geometry. 
Cu+ comprises due to its closed d10 electron shell no ligand field stabilisation energy (LFSE). The 
complex geometry is therefore defined by the steric demand of the ligands, which results for 
four donor atoms in a preferred tetrahedral geometry. In contrast to that, Cu2+ forms square 
planar complexes with four and square pyramidal or trigonal pyramidal complexes with five 
ligands. A tetrahedral complex formation can be achieved by a strong pre-organisation of the 
ligand. Complex formation with Cu2+ should therefore be disfavoured and selectivity towards Cu+ 
should be given.  
The increased copper levels involved in AD could have their origin in a dyshomeostasis forming a 
labile copper pool.[98] Taken this into account rather weak ligand systems are required, which do 
not remove the excessive copper, but can relocate it and thus restore normal copper levels. To 
be more precise, the chelator should have a higher affinity than the Aβ protein but low enough, 
that the Cu+ can be released again to metal transport proteins. Under consideration of this, the 
first generation of ligands developed in this project features only a tridentate {NS2} donor set. 
The corresponding Cu+ complexes should therefore be thermodynamically metastable and be 
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able to release the metal again. In a second generation more stable tetradentate ligands with a 
{N2S2} donor set, to ensure tight Cu
+ coordination, were synthesised. As nitrogen donors pyridine 
and imidazole groups were chosen. Both are good σ-donors and can tightly coordinate to 
copper. The sulphur donor groups are realised by thioether functionalities instead of thiolate 
groups. This offers various advantages to the ligand system: i) less hydrogen bond donors 
enhance the chance to cross the BBB and to permeate cell membranes due to the hydrophobic 
character, ii) thiolate groups have a high tendency to form thiolate bridges between two metal 
ions[234–236], iii) possible cell toxicity due to the formation of disulphide bridges and thus 
generation of ROS is reduced,[237–241] iv) lower binding affinities, since no charge is compensated. 
The latter increases the chance for a copper release and also weakens coordination of other 
transition metals besides Cu+. Thus, the ligands should not be able to compete with the 
M(H2O)X
n+ complexes, except in the case of Cu+. The ligands will be evaluated with regard to 
their coordination properties and the most suitable candidates will then be coupled to a 
compound, which is sensitive for Aβ-plaques. To give access to coupling reactions an alcohol 
function was introduced in the ligands. The alcohol should also allow the attachment of other 
functional groups or molecules to confer chemical and biochemical properties (e.g. water 
solubility by coupling with an alkyl sulfonate) to the chelators. Overall, the ligands were designed 
as plain as possible to follow “Lipinski’s Rule of Five” and ensure their absorption and 
permeation of cell membranes.  
One aspect in modern drug design is the distribution of the compound. In the previous chapter 
dyes like ThT and PIB were presented with the remarkable ability to selectively interact with Aβ 
plaques and with low clearance times from healthy tissues. By coupling of such a benzothiazole 
derivative with the evaluated ligands via a spacer a multifunctional compound can be created, 
which should be suitable for the desired application. This compound exhibits on one side a 
selective metal binding unit and on the other side a marker for Aβ plaques (Figure 10). Although, 
different pathways for the synthesis of benzothiazole derivatives are known, they lack flexibility 
in the variation of functional groups.[242,243] Herein, a synthetic route was created with Suzuki 
Coupling as the key step, which offers the possibility to combine various building blocks leading 
to new benzothiazoles.  
 
Figure 10 Design of multifunctional systems for application in AD research. 
Tripodal pre-organised ligand systems, like tris(pyrazol)borate (tpb) or tris(pyrazol-1-yl)methane 
(tpm), have been used for many years in model complexes in bioinorganic chemistry. Their 
specific binding properties were also utilised with respect to CO releasing molecules (CORMs), 
with remarkable results.[244–246] The compounds synthesised in this study provide with their soft 
{NS2} binding moiety a unique type of tripodal pre-organised chelator with unknown reactivity. 
Thus, besides the applications in AD, the tripodal ligands were also used for the synthesis of a 
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In order to investigate the role of Cu+ in AD, selective ligands have to be provided. Under 
consideration of the labile copper pool, the formed complexes should not be too stable allowing 
a redistribution of the copper and recovery of normal copper levels. Five tripodal ligands with a 
{NS2} binding motive were synthesised, to fulfil this task. The ligand design was done according 
to the concept outlined in chapter 2.2. The synthesised ligands were evaluated with respect to 
their complexation properties towards Cu2+ and Cu+ and to determine which systems are most 
suited for the desired application in AD research.  
 
3.2 Ligand Synthesis 
The ligand systems follow two different approaches which should lead to metastable Cu+ 
complexes. The first approach comprises of two relatively flexible ethyl thioether sidearms. 
These should allow a rearrangement of the ligands upon coordination. The two ligands, L1H and 
L2H, belong to the first approach and are only slightly pre-organised (Scheme 7). In the second 
approach a cyclic thioether side chain was introduced in the ligands. The resulting ligands are 
more pre-organised and should enforce mononuclear Cu+ complex formation with a tetrahedral 
geometry. Furthermore, cyclic thioethers have shown higher affinities towards Cu+ than acyclic 
analogues.[247,248] Thus, the rigid ligands should comprise higher affinities. L3H, L4H and L5H belong 
to these chelators.  
The ligands L1H-L5H used in the present study were synthesised in a two-step synthesis (Scheme 
7). Starting reagent for all five ligands was the commercially available 1,3-dichloroacetone, in 
which thioether groups were introduced via Williamson ether synthesis in the first step. The 
precursor I for the synthesis of L1H and L2H was synthesised by the reaction of 1,3-
dichloroacetone with ethane thiole under basic conditions. In the second step, I was diluted in 
THF and the solution cooled to -78 °C. The reaction mixture was then treated with either lithium 
pyridin-2-yl or lithium methyl pyridine-2-yl, which was prepared prior, resulting in the formation 
of L1H and L2H, respectively. The mechanism of the reaction is a nucleophilic attack of the lithium-
organyl on the electrophilic ketone function. The ketone functionality becomes in situ reduced, 
providing the alcohol functionality, which is desired for subsequent coupling reactions. For the 
second approach 1,2-ethanedithiole was coupled to 1,3-dichloroacetone, providing the cyclic 
ketone II. Analogous to the synthesis of L1H and L2H, lithium-organyl solutions were prepared and 
added to II at -78 °C. After aqueous workup the ligands could be obtained in moderate to good 
yields of 52 to 82 %. It should be mentioned that L1H is literature known.[249] However, 
optimisation of the reaction conditions led to higher yields in both steps. 





Scheme 7 Synthetic route for the tridentate ligands L1H-L5H. 
In addition to the mixed {NS2} ligands, the literature known system L
6H was synthesised to 
compare the affinity of the thioether donor atoms of L1H - L5H to stronger σ-donors, such as 
pyridine. The ligand L6H is also a tripodal pre-organised system and should therefore form 
analogous complexes to the {NS2} ligands. L
6H was synthesised according to literature starting 
from the commercially available 2-(aminometyl)pyridine and 2-(chloromethyl)pyridine and could 
be provided in good yields of 87 % (Scheme 8).[250,251] Although, various complexes with L6H are 
literature-known, its coordination properties towards Cu+ have not been investigated so far. 
However, complexes with Cu2+ and Zn2+ have already been widely studied and show that the 
ligand is not selective. 
 
Scheme 8 Synthesis of L6H.  
Complexation and affinity studies require analytic purity of the used compounds. Thus, all 
compounds were purified by column chromatography on silica and purity was determined by 
NMR, MS and EA (for details see experimental section). 




3.3 Synthesis of Cu+ Complexes 
Cu+ complexes were synthesised by treating either [Cu(MeCN)4]PF6 or [Cu(MeCN)4]OTf in MeCN 
with equimolar amounts of the ligands (Scheme 9) under inert atmosphere. Table 5 summarises 
the obtained complexes with their yield. The complexes 1-6 were then precipitated by addition 
of diethyl ether to the reaction solution or layering a saturated complex solution in MeCN with 
diethyl ether. All compounds were analysed by 1H- and 13C-NMR spectroscopy and ESI-MS 
spectrometry. The utilised ligands are tridentate and leave a vacant coordination site on the 
metal. In the presence of MeCN, this site will be saturated by one MeCN molecule, which is a 
good donor for Cu+.[252]  
 
Scheme 9 General procedure for the synthesis of Cu+ complexes.  
In ESI-MS spectra the peaks of the highest mass/charge ratio could be assigned to either the 
[LCu]+ or [LCu(MeCN)]+ species, whereas peaks of the highest intensity belonged to a [LH]+ 
species, indicating a rather weak coordination. Applying 1H- and 13C-NMR spectroscopy the 
complex spectra could be detected, except for L4H were a paramagnetic spectrum was recorded. 
Both experiments indicate, that in solution complexes of the structure [LxCu(MeCN)]+ could be 
present. Thus all five ligands should be suitable for the desired applications in AD. 
Table 5 Yields of synthesised Cu+ complexes. 
 Complex Yield [%] 
1 [L1HCu(MeCN)]OTf 85 
2 [L2HCu(MeCN)]OTf 78 
3 [L3HCu(MeCN)]PF6 76 
4 [L42 Cu
2+Cu+2(MeCN)3](PF6)2 30 
5 [L5HCu(MeCN)]PF6 65 
6 [L6HCu(MeCN)]PF6 93 
 
In order to select the most promising ligand and to explore the unexpected complexation 
behaviours of L4H, complex formation was studied in solid state. With exception of 4, crystals 
useable for X-ray crystallography could be obtained by slow diffusion of diethyl ether in 
saturated complex solutions in MeCN. The most flexible ligand L2H forms a complex which 
crystallises in a chain structure (Figure 11). The tetrahedral complex is constituted by the 
pyridine, a thioether group of the same ligand and a thioether sidearm of a second ligand. The 
vacant coordination site is saturated with one MeCN molecule. The alcohol group forms a 
hydrogen bonding to one fluorine atom of the triflate counterion (2.0790 Å). It is possible that 
also L1H forms a chain structure in solid state due to the similar ligand structure. However, since 
no crystalline material suitable for X-ray crystallography could be obtained no evidence is given 
for this hypothesis. In contrast to the molecular structure of 2, 3 crystallises in the desired 
mononuclear complex structure. The metal ion is coordinated by the {NS2} moiety and one 




MeCN molecule. The hydrogen of the alcohol forms a hydrogen bond (2.0094 Å) to one of the 
fluorine atoms of the hexafluorophosphate counterion. For 5 was a similar structure expected as 
for 3. However, a chain structure was instead obtained, although L5H is structurally more related 
to L3H than to L2H. This leads to the suggestion that the solid state structure strongly depends on 
crystallisation conditions. In the structure of 5, the thioether sidearm bridges two Cu+ ions. With 
a distance of 2.2332 Å a hydrogen bond is formed between the free alcohol and one fluorine 
atom of the hexafluorophosphate. 
 
 
Figure 11 Molecular structure of 2 (top left), 3 (top right) and 5 (bottom). 2 and 5 crystallise in a chain structure, 
whereas 3 crystallises in a mononuclear structure. Hydrogen atoms and the triflate counterion of 2 were omitted for 
a better overview. 
Crystals could also be obtained from an attempt to crystallise [L4HCu(MeCN)]PF6, but instead of a 
mononuclear or a chain structure a trinuclear [(L4H)2Cu(II)Cu(I)2](PF6)2 complex crystallised under 
inert conditions. Hence it was possible to explain the paramagnetic behaviour of 4 in the NMR 
experiments. In situ the Cu+ is partially oxidised, and since the oxidation takes place only in the 
presence of L4H, it is likely that L4H is a non-innocent ligand. One possible mechanism includes the 
reduction of the proton of the alcohol and formation of H2. Disproportionation of Cu
+ could be 








that the oxidation of the Cu+ is caused by the ligand and not by trace amounts of oxygen, the 
reaction was repeated several times and also in a clove box. Furthermore, reaction was carried 
out utilising [Cu(MeCN)4]OTf instead of [Cu(MeCN)4]PF6. Crystalline material could be obtained 
directly from the saturated solution, but could not be successfully refined. Thus only a picture 
could be obtained after solving the data, but this picture strongly resembles 4.  
 
Figure 12 Molecular structure of 4 (left) and picture of [L4Cu2+Cu+2(MeCN)2]OTf2 (right). Hydrogen atoms and 
counterions were omitted for a better overview. 
Complex 6 crystallises in the space group P-1 and reveals a mononuclear complex structure 
(Figure 13). The Cu+ is distorted tetrahedrally coordinated by the three pyridine sidearms and 
one MeCN molecule. Although the amino functionality could also coordinate to Cu+, the 
formation of three six-membered rings is preferred by the strong σ-donor and π-acceptor 
character of the pyridines. The amino functionality forms a hydrogen bond to one fluorine atom 
of the counterion hexafluorophosphate.  
 
Figure 13 Molecular structure of 6. Hydrogen atoms were omitted for a better overview. 
In all five crystal structures Cu+ is coordinated in a distorted tetrahedral fashion by a {NS2}, a 
{NOS2} or a {N3} donor set and by one MeCN molecule. Prominent structural parameters of the 
Cu+ complexes are summarised in Table 6 and Table 7. With 2.2843 Å to 2.3919 Å the Cu─S 
distances are in or just slightly above the literature known range for thioether-Cu+ bond lengths 
(2.26 Å to 2.36 Å).[253,254] The same applies also for the pyridine groups with distances of 
2.0063 Å to 2.0806 Å and the MeCN molecule with 1.8793 Å to 1.9891 Å.[255,256] Comparison of 
the bond angles shows, that in 2, with 5 to 6 °, the smallest deviation from the ideal tetrahedral 
coordination is present. This was anticipated since L2H has the highest flexibility. The Cu+ centres 
6 
4 




in the other complexes are with up to 20 ° deviation much greater distorted. The largest angles 
are in all complexes found toward the MeCN molecule. Since there is no steric hindrance from 
the ligand also bigger molecules, like buffer, counterions ore small proteins should be able to 
coordinate and even formation of ternary complexes is possible. This reactivity has to be 
considered, for all further experiments and data interpretation.  
Table 6 Selected bond lengths of 2-6. 





































 - - 2.0313(15) 
 
Table 7 Selected bond angles of 2-6. 
 S1─Cu─S2 [°] N─Cu─N/O[°] S1─Cu─N1/O [°] 
2 110.50(2) 111.16(7) 105.80(5) 














 - 122.64(8) - 
 
From the structural characterisation in solution and also in solid state, L3H seems to have the 
highest potential for further applications. L3H was the only tridentate {NS2} ligand which showed 
mononuclear complex formation not only in solution but also in solid state. Second in order 
would then be ligand L5H, because of its structural similarity with L3H. L1H and L2H have shown in 
the characterisation in solid state, that their flexibility could be disadvantageous. 
 
3.4 Synthesis of Cu2+ Complexes 
In the previous chapter, it could be demonstrated that the synthesised ligands can coordinate 
Cu+ in organic solvents. However, the desired ligands should be selective for Cu+. Thus, their 
complexation properties towards Cu2+ have to be evaluated. Since complexation properties of 




L6H with Cu2+ have already been reported in the literature, no Cu2+ complexes were synthesised 
utilising L6H. The complexation properties of L6H strongly depend on the used reaction condition. 
Mononuclear complexes of the structure [L6HCuX2]
+ can be formed in the presence of 
coordinating counterions like acetate. Otherwise octahedral complex species with two ligands 
are formed. The metal centre in these complexes is coordinated by two pyridine and the amine 
function of each ligand.[250] L1H and L5H were also not considered for Cu2+ complexation 
experiments due to the structural similarity to L2H and L3H. Thus, only L2H, L3H and L4H were used 
for the synthesis of Cu2+ complexes.  
Cu2+ complexes were synthesised by either stirring acetonitrile solutions of the corresponding 
Cu+ complexes in air over night or in a direct pathway using CuCl2. After stirring the Cu
+ 
complexes for 1 to 2 h oxidation takes place and the reaction solution started to turn green. 
Precipitation by addition of diethyl ether did not provide the pure complexes. The crude 
products were therefore recrystallised from MeCN/Et2O. With this procedure [L
2
2Cu2Cl2] (7), 
[L42Cu2(MeCN)2]OTf2 (8) and [L
3
4Cu4]OTf4 (9) could be synthesised. It is worth mentioning that in 
all three complexes the alcohol is deprotonated in situ by the acidifying effect of the metal. 
Thus, in the absence of any base an acidic complex solution is formed, from which crystals of the 
complexes, but no crystals of the protonated ligands could be obtained. Molecular structures 
obtained via X-ray crystallography are pictured in Figure 14. Reaction of L2H with CuCl2, results in 
the neutral [L22Cu2Cl2] complex (7), which crystallises in the space group P21/c. The two metal 
ions are bridged by the deprotonated alcohol function of the ligand, a behaviour that could also 
be observed in the molecular structure of the trinuclear complex 4. Besides the alcohol, each 
metal is further coordinated by one pyridine, one chlorine ion and one a thioether sidearm. With 
the sulphur atoms in the axial positions, the metal ions are coordinated in a distorted square 
pyramidal coordination geometry. To define the distortion in more detail the parameter τ can be 
determined.[257] The τ value for an ideal trigonal bipyramid (β = 180 ° and α = 120 °) is τ = 1 and 
τ = 0 for an ideal square pyramid (β = α = 180 °). For the complex 7 a τ value of 0.16 could be 
determined. 
By stirring L4H with equimolar amounts of [Cu(MeCN)4]OTf in MeCN over night in an open vessel, 
the complex [L42Cu2(MeCN)2]OTf2 (8) could be synthesised. Crystallisation succeeded by 
overlayering the reaction solution with diethyl ether and storage at 4 °C. The obtained complex 
geometry of 8 is similar to 7. Two Cu2+ ions are constituted by the nitrogen of a pyridine, one 
sulphur atom of a thioether group and the two bridging alkoxide groups in the square plane. In 
the axial position one MeCN molecule is coordinated, completing the square pyramidal 
geometry (τ = 0.08). The second thioether group is in a distance of 2.9922(5) Å where 
interactions cannot be excluded and therefore the complex geometry could also be regarded as 
a very strongly distorted octahedron (NMeCN─Cu─S2 angle = 148.81 °).  
 






Figure 14 Molecular structures of 7 (left top), 8 (right top) and 9 (left bottom). Picture of the possible molecular 
structure of [L13Cu3PF6](PF6)2 is on the right bottom. Hydrogen atoms and counterions were omitted for a better 
overview. 
Following the same procedure crystalline material could also be obtained for 9. A dinuclear 
divalent molecule structure was expected, similar to 7 and 8. However, instead the tetranuclear 
complex 9 was formed. The reason for the different solid state structures is the short distance 
between the alcohol and the pyridine sidearm. Thus, upon coordination a five-membered 
chelation ring is formed. In 7 and 8, picoline sidearms are present, which can enclose the metal 
more easily. Thus, the formation of dinuclear complexes is due to the rigid ligand structure not 
possible and instead a tetranuclear complex is generated. In the molecular structure of 9, each 
metal centre is coordinated in a distorted square pyramid (τ = 0.19). The plane of the pyramid is 
constituted by one sulphur atom of a thioether, one nitrogen atom of a pyridine and two 
bridging alkoxide groups. In the axial position the metal is saturated by another sulphur atom. To 
gain further evidence, that the ligands with smaller biting angles are not capable to form 
dinuclear complexes, attempts were carried out to crystallise a Cu2+ complex with L1H. 
Unfortunately, refinement was not possible. Thus, only a picture of a possible molecular 








Structural features of the three complexes 7 - 9 are summarised in Table 8 and Table 9. With 
2.3256 Å to 2.8075 Å for the S-Cu2+ bond lengths and with 1.9588 Å to 2.0031 Å for the 
NPy/Im─Cu
2+ bond lengths, the synthesised complexes have shown similar structural features to 
analogous systems reported in the literature.[258–261]  
Table 8 Selected bond lengths of 7-9. 










































Table 9 Selected bond angles of 7-9. 
 O─Cu─O [°] N1─Cu─O [°] S1─Cu─O [°] Cu─O─Cu [°] 
7 105.28(7) 93.51(8) 72.42(6) 74.72(7) 


















Structural characterisation of the complexes 7 and 8 showed that both Cu2+ ions and both 
bridging alkoxides are constituted in one plane. These systems should therefore be 
predestinated for magnetic superexchange. Thus, SQUID measurements performed (Figure 15) 
for 7 - 9. Due to an antiferromagnetic superexchange interaction, all three complexes have the 
diamagnetic ST = 0 ground state. Coupling constants for the magnetic exchange were 
determined by using a fitting procedure to the appropriate Heisenberg-Dirac-van-Vleck (HDvV) 
spin Hamiltonian for isotropic exchange coupling and Zeeman splitting (for 7 and 8 was equation 
6 used and for 9 equation 7 was used). Temperature-independent paramagnetism (TIP) and a 
paramagnetic impurity (PI) with spin S = 1/2 and Curie behaviour were included according to 








































Figure 15 MT versus temperature for 7, 8 and 9 at 0.5 T. 
The J values for di-µ-alkoxo Cu2O2 complexes depend linearly on the Cu–O– –
2 J = 82.1 -7857. Thus, the expected J values for 7 and 8 are -291 cm–1 ) and -222 cm–
1  = 101.1 °). With J = -108, just a half so large coupling constant could be observed in the 
2O2 
plan and C–O axis (35.7 °), which also strongly influences the coupling strength.[263] The 
experimental J value determined for 7 is with J = -421 however larger than expected and cannot 
be explained alone by the small ). Also other structural parameters such as the 
dihedral angle formed by the two coordination planes can influence the coupling constant.[264] 
However, the influence is too minor and the other structural parameters are similar to 8 and 
cannot explain the large J value for 7. 
Table 10 Magnetic parameters of 7, 8 and 9.  
 Cu-O-Cu [°] J [cm-1] g TIP [cm3/mol] PI [%] 
7 102.8 –421 2.18 3.5·10–4 7.5 
8 101.1 -108 1.88 0.0 0.0 
9 121.1 
121.9 
-111 2.05 0.9·10–4 0.5 
 
For complex 9 a very strong antiferromagnetic interaction of ca. 1000 cm–1 was expected due to 
the correlation between J  °). However, only a relative weak magnetic 
coupling could be observed (J = -111). This difference can be mainly e -
alkoxide bridge and other structural reasons. As mentioned before, the dihedral angle formed by 
the two coordination planes has significant influence on the strength of the magnetic coupling. 
In case of 9 the torsion amounts 75.3 ° and causes a poor overlap of the magnetic orbitals. 
Complexes were further characterised by UV/Vis spectroscopy. In MeCN four absorption bands 
could be recorded (Figure 16). Assignment of the transitions were done according to the 
literature.[248,265]The most intensive band at around 265 nm could be assigned to the π → π* 
transition of the pyridine sidearms.  





























Figure 16 UV/Vis-spectra of the Cu2+ complexes 7 (green), 8 (red) and 9 (blue) in MeCN (0.16 mM). The small graph 
shows the d-d metal transition at higher concentrations (5 M). 
The absorption bands at 335 nm and 420 nm (440 nm) are most likely ligand to metal charge 
transfers (LMCT’s), but differentiation between oxygen and sulphur induced transfer is not easy 
to assign. Since sulphur atoms have lone pairs relatively high in energy the more intense 
absorption band is likely induced by the sulphur. Thus, the less intense band at lower 
wavelength was assigned to LMCT from the bridging oxygen. In the red region of the 
electromagnetic spectrum a relatively weak absorption could be monitored and assigned to a d-
d metal transition. The possibility of an enhancement of the transition, due to a π(S)-d(Cu) 
charge transfer, cannot completely be eliminated. Prominent spectroscopic parameters of the 
complexes are summarised in Table 11. 
Table 11 UV/Vis-parameter of the Cu2+ complexes 7, 8 and 9 in MeCN. 









π → π* (pyridine) 
σ(S) → dx2-y2 LMCT 
σ(O) → dx2-y2 LMCT 









π → π* (pyridine) 
σ(S) → dx2-y2 LMCT 
σ(O) → dx2-y2 LMCT 









π → π* (pyridine) 
σ(S) → dx2-y2 LMCT 
σ(O) → dx2-y2 LMCT 
d-d metal transition 
 
3.5 Conclusion 
Six tripodal pre-organised, tridentate ligands have been synthesised and were investigated with 
respect to their complexation behaviour towards Cu+ and Cu2+. The synthesised ligands were 
therefore treated with Cu+ salts providing the corresponding complexes, which were studied in 
solution as well as in solid state. The MS and NMR experiments indicate mononuclear complex 
formation with all ligands except for ligand L4H, where a paramagnetic NMR spectrum was 





partially oxidised and forms the trinuclear [L42Cu
2+Cu+2(MeCN)2]OTf2 complex. Furthermore, the 
molecular structures revealed, that the flexibility of L1H and L2H can lead to chain structures. 
Surprisingly, also complex 5 crystallised in a chain structure. The ligand L3H was the only ligand, 
which forms mononuclear Cu+ complex in solution as well as in solid state. Thus, L3H and the 
structurally similar L5H were chosen for further investigation. Besides the Cu+ complexes, Cu2+ 
complexes were synthesised with the new ligands to get a first impression of their reactivity 
towards Cu2+. The characterisation shows that in organic solvents the tripodal ligands lack the 
desired selectivity for Cu+. However, the affinity to Cu2+ is most likely based on the coordination 
by an in situ generated alkoxide. The aim of this study is the synthesis and characterisation of a 
multifunctional tool, were the ligands will be integrated via coupling at their alcohol function. 
Thus, deprotonation and coordination of the alcohol should no more possible. To prove this 
hypothesis, model systems have to be synthesised, were the alcohol function is protected and 









Synthesis and Characterisation of Tetradentate Ligands 











Tridentate ligands with promising properties for applications in AD were described in the 
previous chapter. Under non-aqueous conditions model complexes with Cu+ as well as Cu2+ could 
be synthesised and completely characterised. The structural parameters in solid state indicate 
that the rigid ligand L3H is the most promising candidate, since it forms a mononuclear Cu+ 
complex. However, the synthesis of Cu2+ complexes illustrates that the tripodal system are not 
selective to Cu+. To obtain a higher affinity and more stable complexes, the ligand design was 
changed to tetradentate ligands. Introduction of a fourth sidearm carrying another donor atom 
should furthermore remarkably increase the inertness towards oxidation, due to the closed 
coordination sphere, while the desired high affinity towards Cu+ is maintained. Thus, an 
additional functional group, containing a strong σ-donor was attached to L3H. This was done in 
two ways, either by substitution of the tertiary alcohol by an amine or via expansion of the 
ligand through another pyridine sidearm (Figure 17). 
 
Figure 17 Schematic representation of the desired tetradentate ligands L7H and L8H. 
 
4.2 Attempts to Synthesise Tetradentate Ligands  
4.2.1 Synthesis of L7H 
Retrosynthetic analysis of L7H suggests reductive amination as the simplest synthetic route 
towards the desired molecule (Scheme 10). 
 
Scheme 10 Retrosynthetic analysis of L7H. 
Although a number of different reaction conditions were applied to couple ketone II and the 
commercially available 2-aminomethyl pyridine, like high temperatures or catalytic amounts of 
HCl or TiCl4
[266], no imine formation could be observed neither by 1H-NMR spectroscopy nor MS. 
Instead the reagent could be recovered in most of the reactions or, in case of TiCl4, only a side 
reaction, probably the complexation of the Ti4+ ion by 2-aminomethyl pyridine analogous to the 
literature, could be observed.[267] Reason for the unsuccessfully amination is most likely the low 
reactivity of the reactants. Reductive amination of a ketone is more hindered then in case of an 
aldehyde. Furthermore, the nucleophilic character of the amine is weakened by the electron 
withdrawing pyridine.  





Scheme 11 Synthetic approach to L7H. 
To maintain the reductive amination as coupling reaction, the functionalities on the molecules 
were exchanged. Instead of 2-aminomethyl pyridine the commercially available 2-
pyridinecarboxaldehyde could be used, which changes the electrophile from a ketone to a more 
reactive aldehyde. Thus, the coupling reaction should be more favoured. For the synthesis of the 
amine group, two different approaches were carried out (Scheme 12). In a first attempt, a direct 
pathway was chosen, letting II react with NH4Cl in the presence of [Ti(O
iPr)4].
[268] Even at higher 
temperature no reaction with the ketone II could be observed and thus it could be completely 
recovered. Another procedure to convert a ketone into an amine proceeds over an oxime 
intermediate. The oxime III could be synthesised in good yields (87 %) by the reaction of II with 
hydroxylamine[269], but the following reduction of III with LiAlH4 or NaBH4 in THF were performed 
without success.[270] According to the literature NiCl2 can promote the reduction.
[271] However, 
the desired amine could not be obtained. After addition of a concentrated sodium EDTA 
solution, to remove the Ni2+ ion, the reactant could be extracted with DCM. Therefore the 
reductive amination was discarded and in a new approach, a nucleophilic substitution was 
carried out instead. 
 
Scheme 12 Synthetic approach of the conversion of the ketone of II to a primary amine, a precursor for reductive 
amination.  
The required electrophile V was synthesised according to literature in two steps (Scheme 13).[272] 
The first step was the reduction of ketone II with NaBH4 in THF, followed by chlorination of the 
generated alcohol with thionyl chloride. Noteworthy is that the underlying mechanism results in 
an intramolecular arrangement, reducing the thioether ring size from a seven-membered to a 
six-membered ring. The last step of the ligand synthesis was the nucleophilic attack by 2-
aminomethyl pyridine forming the hydrochloride. The product was in situ deprotonated by a 
second equivalent of the pyridine. The ligand L7H could be obtained in good yields (80 %) as a 
brown liquid.  





Scheme 13 Synthesis of the tetradentate ligand L7H. 
4.2.2 Synthesis of L8H 
Since L3H was the most promising tripodal ligand for Cu+ coordination, the tetradentate ligand L8H 
was developed with the intention to preserve the present coordination motive as much as 
possible. The easiest way to achieve this was simple expansion of the ligand by a further pyridine 
comprising sidearm. This can either be done by coupling the pyridine directly to a derivative of 
L3H or by introducing the additional group in the first step of the ligand synthesis. For the former, 
the general synthetic route of the tridentate ligand was preserved. In the first step, 2,6-dibromo 
pyridine was coupled to ketone II using nBuLi at -78 °C to provide VI in low yields (23 %) (Scheme 
14). Before the second pyridine could be attached, the alcohol had to be protected, which was 
done by methylation. The alcohol was therefore deprotonated with sodium hydride and 
afterwards methyl iodide was added. The last reaction, the attachment of 2-methyl pyridine, 
was attempted by treating VII with nBuLi at -78 °C and also at higher temperature (up to room 
temperature). However, the final product could not be obtained. The reason for this is either the 
insufficient reactivity of VII, which prevents the transmetalation with nBuLi or chelation of the 
formed lithium-organyl intermediate by another ligand molecule, which would shield the 
reactive centre. 





Scheme 14 Synthetic approaches to a tetradentate ligand. 
The second strategy for the synthesis of L8H starts with the synthesis of the {N2} sidearm (Scheme 
15). Therefore, a solution of 2-methyl pyridine in THF is prepared at -78 °C. Successive addition 
of nBuLi and 2,6-dibromo pyridine provides VIII. The formed methylene bridge is relatively acidic, 
due to the two electron withdrawing pyridine substituents and would therefore hinder the 
transmetalation in the next step. In addition to this, it is known that such electron deficient 
bridging groups can be activated and oxidised by transition metals like copper.[273–277] In order to 
prevent such reactions and also enable the last synthetic step, the hydrogen atoms of the 
methylene bridge were substituted by two methyl groups. Therefore methyl iodide was reacted 
with VIII in the presence of KtOBu. Afterwards the {N2} sidearm was attached to II under 
standard nBuLi conditions at -78 °C. L8H could only be obtained in moderate yields (67 %) in small 
scales. Attempts to increase the yield by changing the transmetalation reagent to tBuLi, LDA, 
magnesium-organyls and zinc-organyls did not work.  
 
Scheme 15 Synthetic approaches in the synthesis of L8H. 




In addition to the synthesis of L8H, further attempts were carried out using a bipyridine sidearm 
(Scheme 16). Bipyridine is a strongly coordinating bidentate chelating agent, which should 
provide an even higher affinity than the {N2} sidearm used in L
8H. The first step of the ligand 
synthesis is the attachment of a methyl group to the commercially available 2,2-bipyridine via 
MeLi.[278] The product X could be obtained in good yields (54 %, Lit.: 59 %[278]) after reoxidation of 
the aromatic system with MnO2. Although X is quite similar to 2-methyl pyridine, a direct 
coupling with BuLi analogue to the synthesis of L2H and L4H did not afford the desired ligand. Even 
usage of other transmetalation reagents (tBuLi, LDA) could not provide the desired ligand. Thus, 
the reaction was optimised by favouring the transmetalation reaction. This was done by 
modification of X to 6-chloromethyl-2,2-bipyridine XI and 6-bromomethyl-2,2-bipyridine 
XII.[279,280] Unfortunately, the desired ligand could not be obtained. Nevertheless, with L7H and L8H 
two tetradentate ligands were synthesised which should be able to coordinate Cu+. Especially 
the latter one, L8H, is a promising candidate due to the strong tetrahedrally pre-organised 
geometry.  
 
Scheme 16 Synthetic approaches to a 2,2-bipyridine-based tetradentate ligand. 
 
4.3 Complex Formation with Tetradentate Ligands 
The tetradentate ligands L7H and L8H were investigated with respect to their complexation 
properties for Cu+, Cu2+ and Zn2+. [L7HCu(MeCN)]OTf 10 could be synthesised by addition of L7H 
under inert atmosphere to a solution of [Cu(MeCN)]OTf in MeCN. A white complex powder could 
be obtained by evaporation of the solvent under reduced pressure. To verify the ligand to metal 
ratio MS and NMR studies were performed. In the ESI-MS only the expected mononuclear 
species with a 1 : 1 ligand to metal ratio was recorded, thus, mononuclear complex formation 
seems to be favoured in solution. 1H-NMR spectroscopy supports this finding. The complex was 
dissolved in MeOD-d4 and equimolar amounts of CHCl3 were added as reference. Comparison of 
the intensities showed only mononuclear complex formation. By this procedure only one ligand 
molecule could be determined in the complex. Unfortunately, no crystalline material suitable for 
X-ray crystallography could be provided, therefore the solid state structure of 10 is unknown. 




The redox-stability of 10 was tested by stirring it for 24 h under ambient atmosphere. Within 15 
minutes the Cu+ starts to become oxidised, which can be followed by a colour change of the 
complex solution from yellow to blue. By ether diffusion in a saturated complex solution in 
MeCN purple crystals of the complex [L7H2Cu]OTf2  2MeCN (11) could be obtained (Figure 18). 
Complex 11 crystallises in a monoclinic crystal system in the space group P21/c. The structure 
reveals an octahedral coordination of the metal centre by two ligands. Of the four possible 
donors only the pyridine, the amine and one sulphur atom of the thioether sidearm are 
coordinating per ligand. The strong nitrogen donors are roughly located in a plane and the 
sulphur atoms coordinate in the axial positions, resulting in a stretched octahedron. With 80.82 ° 
the N1-Cu1-N2 bite angle deviates most clearly from the ideal angle of 90 °. Thus, the complex is 
strongly distorted from an ideal octahedral geometry. Prominent structural features of the 
complex are summarised in Table 12 and Table 13. From the present 2 : 1 coordination motif 
containing a coordinatively saturated Cu2+ and from the fast oxidation of the Cu+ complex 10 it 
can be assumed, that the ligand L7H is not selective for Cu+.  
 
Figure 18 Molecular structure of 11. Hydrogen atoms and counterions were omitted for a better structural 
overview. 
Nevertheless, also the Zn2+ complexation was studied in solution. The complex solution was 
prepared by dropwise addition of Zn(ClO4)2  6 H2O, dissolved in MeOH, to a 0.3 M solution of L
7H 
in MeOH. By the successive addition of Zn2+ the formation of a precipitate could be observed, 
which reaches its maximum at a ligand to metal ratio of approximately 2 : 1 and gets partially 
dissolved by further addition of Zn2+. The mixture was stirred over night to complete the 
reaction. The formed precipitate was separated by filtration and analysed by ESI-MS in MeCN. 
The spectrum contains a peak at 302.9 (m/z), which can be assigned to [L7Zn]+ and also a peak at 
272.1 (m/z), which can be assigned to [(L7H)2Zn]
+. Thus, it can be assumed that in the presence of 
excess L7H most likely a [L7H2Zn]
2+ complex analogue to the [L7H2Cu]
2+ complex 11 is formed. 
Further addition of Zn2+ could then lead to the mononuclear [L7HZn]2+ species. Thus, L7H can form 
Zn2+ complexes not only in a 1 : 1 but also in a 2 : 1 ratio. For the desired application selectivity of 
the ligands is essential. Due to the characterisation of the Cu+, Cu2+ and Zn2+ complexes no 
satisfying selectivity could be found. The molecular structure of 11 even indicates the opposite. 
L7H seems to be relatively flexible in its structure and formation of undesired [L7H2M]
2+ complexes 
11 




takes place. Thus, the chance is high that in aqueous solution L7H shows no selectivity towards 
Cu+ and also coordinates Cu2+ and Zn2+. Thus, the ligand is not useful for the desired application.  
L8H, in contrast to L7H, is more tetrahedrally pre-organised and should therefore not be able to 
form octahedral bis(ligand) complexes with Cu2+ or Zn2+. To prove this hypothesis, complexes 
were synthesised with the relevant transition metals. First of all the monovalent complex 
[L8HCu]PF6 (12) was synthesised analogous to the previously described Cu
+ complexes. 12 could 
be crystallised by slow ether diffusion into a saturated complex solution in MeCN at 4 °C. The 
coordination sphere of the Cu+ is completely saturated by the four donor atoms of the ligand in a 
strongly distorted tetrahedral geometry. Since N1 is almost orthogonal to the other donor atoms 
the complex geometry could also be described as a distorted trigonal pyramid. Bond lengths of 
2.2506 Å and 2.3822 Å for the Cu-S bonds are present in the complex and are in the same range 
as for the tripodal ligands presented in chapter 3. Also the Cu─N bond lengths with 1.9780 Å and 
2.0549 Å are in the same range as in the tripodal complexes (Table 12). The 
hexafluorophosphate counterion forms a hydrogen bond with the alcohol function of the ligand 
and can therefore be found close to the core structure. With 149.26 ° the N2─Cu─S2 bite angle 
clearly deviates from the ideal tetrahedron angle of 109.47 ° (Table 13). The distortion has its 
origin in the short bridging unit between the two pyridines in the sidearm. Thus, the sidearms 
are not able to fully reach around the Cu+.  
 
Figure 19 Molecular structure of 12. Hydrogen atoms and counterions were omitted for a better structural 
overview. 
Complex 12 was oxidised on air by stirring the complex solution in MeCN in an open vessel over 
night. By introduction of the forth binding site the ligand should remarkably increase the stability 
of the Cu+ complexes but the experiment indicates that oxidation to Cu2+ is still possible under 
aerobic conditions. Within 2 h the solution starts to become green, indicating oxidation of the 
metal. Unfortunately, no crystalline material suitable for X-ray crystallography could be 
obtained. Instead only crystals with an amorphous structure or non-diffracting substances could 
be prepared. In the ESI-MS of the oxidised complex powder the most intensive peak at 408.9 
[m/z] could be assigned to the [L8Cu]+ species. This leads to the assumption that the 
deprotonated alcohol is involved in the coordination similar to the Cu2+ complexes with the 
tripodal ligands (7, 8 and 9). Furthermore a peak at 470.9 [m/z] was assigned to the [L8Cu2]
+ 
species, which indicates the formation of a multinuclear complex.  
12 




Table 12 Selected bond lengths of 11 and 12. 
Complex Cu─S [Å] Cu─NPy [Å] Cu─NH [Å] 








Table 13 Selected bond angles of 11 and 12. 
Complex S─Cu─S [°] N1─Cu─N2[°] S1─Cu─N1 [°] S2─Cu─N1 [°] 
11 180.00(0) 80.82(14) 94.90(10) - 
12 87.67(3) 97.56(9) 98.33(7) 101.66(7) 
 
The previously described experiments were all performed in organic solvent, thus it has to be 
proven that the expected selectivity of L8H is also effective in aqueous solution. To define the Cu+ 
and Cu2+ complexation abilities in aqueous solution a 1H-NMR experiment was performed. The 
experimental conditions were 300 µM Cu2+ and 300 µM L8H in 0.2 M deuterated phosphate buffer 
(pH 7.4). For the ligand a stock solution (10 mM) in DMSO-d6 was prepared and as copper source 
a stock solution of CuSO4 (10 mM) was used. The low concentrations were necessary due to the 
poor solubility of L8H. First the spectrum of the free ligand was recorded and then Cu2+ added to 
the sample. The addition of Cu2+ does not induce a shift of the signals, but the spectra changes 
after the addition of dithionite as reductant (Figure 20). The in situ generated Cu+ is coordinated 
by the ligand, which can be easily followed by a low field shift of the pyridine signals and also by 
a signal shift of the aliphatic protons. Thus, in aqueous solutions L8H can coordinate Cu+ but does 
not chelate Cu2+. The coordination of the bivalent and highly solvated Cu2+ seems to be 
disfavoured due to the structural pre-organisation of the ligand and the relatively soft donor set.  
 
Figure 20 Aromatic region of the 1H-NMR spectra of L8H (300 μM) and [L8HCu]+ (300 μM) in 0.2 M deuterated 


































































As mentioned in the introduction, zinc is another important transition metal, which is postulated 
to play an important role in AD. Since Zn2+ is isoelectronic with Cu+ it shows similar reactivity in 
its complexation behaviour. Both metals can form stable complexes with tetradentate ligands 
and also prefer similar donor atoms. From complex 11, it can be anticipated that the ligand L8H 
should also be suitable for Zn2+ complexation. The smaller ionic radius of Zn2+ (74 pm) in 
comparison to Cu+ (77 pm) should even slightly favour tetrahedral metal complex formation.[281] 
Zn2+ complexes were synthesised by adding a solution of Zn(ClO4)2  6 H2O in MeOH to a solution 
of L8H in MeOH. To complete the reaction the mixture was stirred for 12 h. After removal of the 
solvent under reduced pressure and washing the crude product with diethyl ether, a white 
complex powder could be provided. To confirm the structure of the synthesised complex, 
crystals were produced by dissolving the complex powder in a mixture of MeCN/MeOH and 
subsequent slow evaporation of the solvent. The molecular structure of [L82Zn3(μ-
OH)MeOH(MeCN)0.5(H2O)0.5]ClO4  1.5 MeOH (13) is shown in Figure 21. Interestingly, no 
monomeric, but a trinuclear complex structure is formed, where each metal ion has a distinct 
individual environment. Zn1 is coordinated by the pyridine sidearms of one ligand, one μ-OH 
group and the deprotonated alcohol of the ligand, which bridges two Zn2+ ions. The trigonal 
pyramidal coordination sphere is saturated by a disordered water and acetonitrile molecule, 
with the same occupation. In contrast to Zn1, Zn2 is found in a rather soft donor set. The 
octahedral coordination is constituted by the two deprotonated alcohol groups and all four 
sulphur atoms of the thioether sidearms. Zn3 is coordinated by the pyridine sidearms of the 
second ligand, the μ-OH bridge, one MeOH molecule and also by one bridging alcoholate group.  
 
Figure 21 Molecular structure of 13 with a coordinating MeCN molecule. Hydrogen atoms and the counterion were 
omitted for a better structural overview. 
Zn1 and Zn3, the two Zn2+ ions which are coordinated by hard donor molecules, are found in a 
trigonal pyramidal geometry, whereas Zn2 is found in an octahedral environment with six 
donors. Structural parameters of 13 are summarised in Table 14. The complex 13 was further 
characterised by ESI-MS. The peak with the highest m/z ratio could be assigned to a [L8HNa]+ 
species. No indication for a zinc complex was observed. Thus, the formed complex is probably 
not stable enough for the ESI-MS measurements. However, the solid state structure of 13 shows 







prefer the coordination of the in situ formed alcoholates. The reasons for this binding motif are 
most likely the compensation of the charge and that the {N2S2} moiety is too soft for Zn
2+. In the 
targeted final multifunctional tool, the chelator is coupled to a spacer, which is attached to a 
benzothiazole derivative. The alcohol function of the ligand in this final molecule is than no 
longer available for coordination, therefore Zn2+ coordination should be disfavoured. 
Furthermore, Zn2+ is stabilised in aqueous solution by formation of the [Zn(H2O)6]
2+ complex. 
Therefore, a coordination of the Zn2+ under cellular conditions should not be possible. 
Nevertheless, model complexes have to be synthesised, where the alcohol is protected, to 
define the metal binding affinities in the targeted multifunctional compound. 
Table 14 Selected bond lengths in the molecular structures of 13. 


















4.4 Conclusion  
Two tetradentate ligands L7H and L8H could be synthesised and evaluated with respect to their 
complexation properties. The flexible less pre-organised ligand L7H can not only coordinate to Cu+ 
but can also form stable complexes with Zn2+ and Cu2+. In these octahedral complexes a [L7H2M]
2+ 
species is formed, which could be completely characterised in case of Cu2+. For the desired 
application, selectivity towards Cu+ is essential. The fast oxidation and complex formation of 
[L7H2Cu]
2+ indicates that Cu2+ can as well be coordinated by L7H. In contrast to this, the strongly 
tetrahedrally pre-organised ligand L8H does not coordinate Cu2+, but Cu+ in an aqueous buffer 
solution. The Cu+ complex could also be prepared in organic solvents and structural analysis of 
the complex showed that the coordination sphere is completely saturated by the ligand. 
Although a Zn2+ complex could be synthesised with L8H, coordination in aqueous solution can be 
excluded for several reasons. Thus, with L8H a Cu+ selective ligand was synthesised, which reveal 
























The aim of this study is the synthesis and characterisation of multifunctional tools with a Cu+ 
selective chelator and an Aβ-plaque sensitive subunit. In the two previous chapters ligand 
systems were presented which are promising candidates to fulfil this aim. The structural 
analyses of the tripodal ligands have shown good results for L3H. Here, formation of mononuclear 
Cu+ complexes in solution as well as in the solid state could be observed. Thus, the ligand was 
chosen for further investigations. Since L5H is structurally similar to L3H, it was also selected and 
will be further analysed. From the two tetradentate ligand systems, only L8H has shown the 
desired selectivity for Cu+ and was therefore used in the synthesis of model complexes. In the 
targeted final molecules the alcohol group of the ligands is attached to a spacer, linking the 
chelator with the Aβ-plaque attracting benzothiazole moiety. To gain first insights into the 
behaviour of these compounds, model ligands will be synthesised, were the alcohol group is 
protected. The synthesised model ligands were evaluated in terms of their ability to selective 
coordinate Cu+ in organic solvents as well as in aqueous solution.  
 
5.2 Synthesis of Model Ligands  
To evaluate the complexation properties of the multifunctional tools, model ligands have to be 
synthesised, which structurally mimic the chelator subunit. The chelator will be attached to a 
spacer, which could be an aliphatic alkyl chain, a polyether chain or another bridging molecule. 
However, the alcohol will be directly coupled to a secondary carbon atom. Thus, a methyl group 
was attached to provide simple model ligands. The attachment was done via Williamson ether 
synthesis by stirring L3H, L5H and L8H with methyl iodide in THF at 60 °C in the presence of sodium 
hydride (Scheme 17).  
  
Scheme 17 Synthesis of model ligands (L3Me, L5Me and L8Me), which mimic the coordination motif of the final product. 
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The underlying reaction is a nucleophilic attack (SN2) by the deprotonated alcoholate of the 
ligand at the methyl iodide. After quenching with water and extraction with Et2O the crude 
products could be obtained. Further purification by column chromatography on silica leads to 
the final products in high yields (95 % - 100 %). A solid state crystal structure of L3Me could be 
provided by slow ether diffusion in a concentrated solution of L3Me in DCM at 4 °C. L3Me 
crystallises as a neutral molecule in the space group P 21/c with two molecules per unit cell 
(Figure 22). By introduction of the methyl group, the donor ability of the oxygen atom is reduced 
significantly. Thus, after modification, the Cu+ complexes should be more inert against oxidation.  
 
Figure 22 Molecular structure of L3Me. For a better overview hydrogen atoms were omitted. 
 
5.3 Influence of a CO as Strong Donor 
The tripodal ligands are special, with respect to their tripodal character and the resulting vacant 
binding site on the complex. In the presented complexes these binding sites were always 
occupied by weakly coordinating solvent molecules, which can easily be substituted by other 
donor molecules. In neuronal cells a great number of different donors are present, which can 
replace the solvent and bind to the metal centre more tightly. Possible candidates would be 
sulphydryl, hydroxyl, carboxyl, imidazole and amino residues of proteins, amino acids (e.g. 
glutamate, which is released in high concentrations[82,83]), oxygen and nitrogen donors of 
heterocyclic bases or small molecules. To get a first impression of the influence of a stronger 
donor saturating the coordination sphere, metal carbonyl complexes of the type [LXMeCu(CO)]+ 
were synthesised. Furthermore, the stretching vibration can be used as an indirect measure for 
the binding properties of the ligands. Synthesis and characterisation of the metal carbonyl 
complexes will be discussed in detail in the appendix A.  
Table 15 summarise the observed stretching vibration ṽ and determined force constants k for 
L3MeCu(CO)]+ and [L5MeCu(CO)]+. Comparison of the vibrational modes shows only a difference of 
ṽ = 4 cm-1 between. Thus it can be assumed that the electronic structures in the complexes and 
thus the binding properties of both ligands are almost the same.  
Table 15 Stretching vibration (ṽ ) and force constant (k) of [L3MeCu(CO)]+ and [L5MeCu(CO)]+. 
 ṽCO [cm
-1] k[N m-1] 
[L3MeCu(CO)]+ 2118 1813 
[L5MeCu(CO)]+ 2114 1806 
 
L3Me 




5.4 Synthesis of Model Complexes with Tripodal Ligands Systems  
To gain insight into the reactivity and selectivity of the chelators, model complexes were 
synthesises with the in AD relevant transition metals, namely Cu+, Cu2+ and Zn2+. Model 
complexes with Cu+ were synthesised by adding equimolar amounts of ligand to a solution of 
either [Cu(MeCN)4]PF6 or [Cu(MeCN)4]OTf in MeCN. The reaction solutions were stirred over 
night to complete the complex formation. Precipitation by addition of Et2O afforded the 
complexes [L3MeCuMeCN]OTf (14) and [L5MeCuMeCN]PF6 (15) as colourless powders in very good 
yields (63 % / 76 %). The compounds were characterised by ESI-MS and NMR spectroscopy. The 
ESI-MS analysis of the products indicates only mononuclear complex formation. Further proof 
for the formation of mononuclear complexes is given by the 1H- and 13C-NMR spectra. The 
spectra obtained from the Cu+ complexes with the unprotected ligand systems 3 and 4 were 
compared with 14 and 15 to prove that the methylation of the chelators has no significant 
influence on the Cu+ coordination. The 1H-NMR spectra show a remarkable similarity. Thus, it 
can be assumed that the modification has no influence on the Cu+ coordination in solution. 
Crystalline material suitable for X-ray crystallography could be obtained from saturated solutions 
of 14 and 15 in MeCN by slow ether diffusion at 4 °C or at room temperature. In the molecular 
structure of 14, the Cu+ is coordinated in a distorted tetrahedral fashion by the {NS2} moiety of 
the ligand and one MeCN molecule (Figure 23). Due to the protective group, hydrogen bond 
formation is no longer possible and the triflate counterion is separated from the cation 
structure. Although the introduction of the methyl group should not influence the coordination 
of the Cu+, minor deviations can be observed in solid state by overlaying 14 and 3. The nitrogen 
donor of the pyridine (N1), one sulphur atom of the thioether sidearm (S1) and the metal centre 
were taken as fixed points for creating a structural overlay. The bridging methylene and the 
ethylene groups in the cyclic thioether sidearm differ in the molecular structures. In 14 the 
MeCN molecule is bend stronger and thus the geometry is also distorted more clearly from the 
ideal tetrahedron, than in the case of 3. The small differences in the structures are most likely 
induced by the arrangement of the molecules in the solid state. Bond lengths and bond angles 
presented in 14 are similar to those of 3. The structural features of 14 are summarised in Table 
16 and Table 17. 
 
Figure 23 Molecular structure of 14 (left) and structural overlay (right) of 3 (orange) with 14 (green). Hydrogen 
atoms and counterions were omitted for a better structural overview. 
In contrast to compound 5, where a chain structure was obtained utilising L5H, the complex 15 
crystallises as a mononuclear complex similar to 3 and 14 (Figure 24). The metal is coordinated 
14 
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by the {NS2} moiety of the tridentate ligand and the tetrahedral coordination sphere is again 
saturated by one MeCN molecule. The missing alcohol leads to a clear separation of the 
counterion. Since there is no difference in the binding mode between L5Me and L5H, the 
assumption presented in chapter 3 that the molecular structure in solid state strongly depends 
on the crystallisation conditions and also on the molecule arrangement in the crystal seems to 
be right. Nevertheless the mononuclear structure obtained for 5 demonstrates also that L5Me and 
L5H may be suitable ligands for further investigation. In order to compare the structural features 
of the two obtained model complexes 14 and 15, an overlay was prepared. The best overlay 
could be provided by using both sulphur atoms and the metal centre as fixed points. The overlay 
clearly illustrates, that only in the region of the thioether sidearm 14 resembles 15. The 
orientations of the MeCN molecules and also of the methyl groups are clearly different. 
Furthermore, the N─Cu─N bite angle in 15 is with 136.781 ° larger than in 14 by more than 20 ° 
(Table 17). Although small differences are present, all bond lengths are quite similar and 
comparable to other Cu+ complexes discussed in the previous chapters. Table 16 summarises 
prominent bond lengths of 14 and 15. Thus, it can be assumed that L3Me and L5Me have a similar 
reactivity and affinity towards Cu+. An analogous result could be obtained by studying the Cu+ 
carbonyl complexes (see appendix A). Thus, both ligands have presumably the same reactivity. 
 
Figure 24 Molecular structure of 15 (left) and structural overlay (right) of 14 (green) and 15 (blue). Hydrogen 
atoms and counterions were omitted for a better structural overview. 
Mainly all studies carried out so far were prepared in an anaerobic and non-aqueous 
environment due to the better solubility of the compounds and the facilitated preparation of the 
compounds. Information provided by X-ray crystallography and obtained from the MS and the 
NMR experiments have shown promising results for an application of the ligands. However, it is 
still unclear if these results can be easily transferred to aqueous solutions or even to cellular 
conditions. As a first step in this direction 14 was dissolved in MeOH under inert conditions and 
crystallised by ether diffusion at 4 °C by overlayering the saturated solution with diethyl ether. 
Thus, the solvent was changed from polar aprotic to polar protic, which is more similar to the 
aqueous medium. MeOH was used instead of water, because complex 14 is not soluble in water. 
The main idea behind this experiment was to study the complexation behaviour of L3Me in a polar 
protic medium. Especially, the fate of the free fourth coordination side was of great interest: Can 
the binding side also be saturated by weaker co-ligands like MeOH or water? Crystals could be 
obtained and the molecular structure of [L3MeCu(MeOH)]OTf (16) could be refined. Surprisingly, 
16 did not crystallise in a mononuclear structure like 3 or 13. Instead, 16 crystallises in a chain 
15 




structure. Similar to earlier obtained chain structures, the thioether sidearm bridges two Cu+. 
Again the metal is coordinated by the nitrogen atom and one sulphur atom of the same ligand 
and one sulphur atom of a second ligand. The free coordination side of the complex is saturated 
by one MeOH molecule that completes the distorted tetrahedral geometry. The angle, which 
deviates most from an ideal tetrahedron, is the S─Cu─S angle with 127.90 °. This expansion is 
caused by the steric demand of the neighbouring ligand. Although this might be possible, no 
hydrogen bond is present in the molecular structure. The counterion can be found separated 
from the chain structure.  
 
Figure 25 Molecular structure of 16. Hydrogen atoms and counterions were omitted for a better structural 
overview. 
Table 16 Selected bond lengths of the molecular structures of 14, 15 and 16. 




















Table 17 Selected bond angles of the molecular structures of 14, 15 and 16. 
 S─Cu─S [°] N─Cu─N/O [°] S1─Cu─N1 [°] 
14 87.103(18) 111.949(17) 99.081(15) 
15 81.549(7) 136.781 (14) 92.931(9) 
16 127.90(2) 97.47(7) 98.97(5) 
 
NMR and ESI-MS studies performed with 16 indicate that upon dissolving the complex, the chain 
structure is cleaved and a mononuclear species is present in solution. Thus, with 16 the first 
example is given for complex formation in protic solutions. However complex formation with 
L3Me and L5Me in aqueous solution has still to be evaluated and will be discussed in chapter 5.7. 
Analogous to the complexes with the unprotected ligands, solutions of 14 and 15 were dissolved 
in MeCN and exposed to air in order to study the redox stability. After a few hours the reaction 
solutions turned green. After stirring for 24 h, to ensure that the oxidation was completely 
finished, different attempts were carried out to crystallise Cu2+ complexes. All crystals and 
complex powders obtained could be assigned to a [Cu(MeCN)n]
2+ species; no complex formation 
with the ligands could be observed. Thus, the hypothesis that the methylation stabilises Cu+ and 
16 
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hindered oxidation was not confirmed. The conclusion form the empirical observation could be 
verified by cyclic voltammetry. Voltammograms were recorded of 3 and 14 and the potential for 
the oxidation was determined against ferrocen. For a better comparison were these values 
converted against the standard hydrogen electrode. For both complexes was a non-reversible 
oxidation recorded with a potential of 1.47 V vs. HNE for 3 and 1.40 V vs. HNE for 14. The 
protection of the alcohol has therefore no influence on the stability of the Cu+ complexes, which 
leads to the assumption that oxidation of the metal and formation of bi-and tetra-nuclear Cu2+ 
complexes is a stepwise process (Scheme 18). However, more important than the formation of 
the Cu2+ complexes is the fact that the modified ligands are no longer able to coordinate Cu2+ 
even in organic solvents. Thus, selectivity is given for Cu+ in the presence of Cu2+.  
 
Scheme 18 Stepwise oxidation and formation of the dinuclear Cu2+ complexes  
The unprotected tripodal ligands were not examined with respect to their ability to coordinate 
Zn2+, since a huge number of Zn2+ complexes are known in the literature, where an alcohol 
function becomes deprotonated in situ due to the acidifying effect of the zinc.[282–284] Di- and 
multi-nuclear complex formation similar to the Cu2+ complexes is therefore most likely. The 
methylated ligands are not able to form these kinds of complexes. Thus, with L3Me and L5Me a first 
impression on the zinc-coordination behaviour of the {NS2} donor set can be gained by the 
synthesis of the corresponding Zn2+ complexes. [(L3Me)2Zn](OTf)2 (17) and [(L
5Me)2Zn](OTf)2 (18) 
were prepared by addition of ZnOTf2 to the ligand solutions in methanol. The reactions were 
stirred over night at room temperature and the products were precipitated by the addition of 
diethyl ether. Complexes 17 and 18 could be obtained as grey solids. ESI-MS analysis of 17 and 
18 indicated formation of mononuclear complexes coordinated by one ligand and one sulfonate 
counterion. Surprisingly, the 1H-NMR spectra recorded in MeCN-d4 show the formation of a 
[LX2Zn] species, indicating that L
3Me and L5Me cannot only coordinate Cu+ but also Zn2+. 
  
5.5 Synthesis of Model Complexes with a Tetradentate Ligand  
A Cu+ model complex with a tetradentate ligand was synthesised by stirring [Cu(MeCN)4]OTf 
with L8Me in MeCN over night at room temperature. The product [L8MeCu]OTf (19) was 
precipitated by the addition of diethyl ether and then characterised by NMR spectroscopy and 
ESI-MS spectrometry. Both analytic techniques indicate formation of a mononuclear complex 
similar to 13. Unfortunately no solid state structure could be obtained during this study. 
Although complex formation of L8H with Cu2+ could not be observed, neither in organic nor in 
aqueous solution, it has to be proven that L8Me can also not coordinate Cu2+. For the synthesis of 
a Cu2+ complex were equimolar amounts of L8Me and Cu(ClO4)2  6 H2O stirred together for 12 h in 
MeCN. To increase the chance of metal coordination was the reaction heated at 60 °C. The 
solvent of the green coloured solution was removed under reduced pressure. The residue was 
taken up in diethyl ether and the resulting suspension was filtrated. The filtrate as well as the 
residue was characterised by ESI-MS analysis. The spectra of the filtrate show only the free 
ligand, whereas the spectra of the residue show no traces of neither the ligand or of the 
targeted Cu2+ complex. Thus, Cu2+ complex formation is probably prevented due to the strong 




pre-organisation of the ligand. In addition to the Cu+ complex 19, also attempts to synthesise a 
Zn2+ complex using L8Me as ligand were performed. Therefore, Zn(ClO4)2  6 H2O was dissolved in 
different solvents (ethanol, methanol and water) and added to a ligand solution of L8Me dissolved 
in methanol. 
The solutions were stirred over night at room temperature. After removal of the solvent under 
reduced pressure a slightly yellow solid could be obtained, which was analysed by ESI-MS. The 
measured spectra showed only the protonated ligand and its fragments. In the negative region 
only the perchlorate anion was detected. Thus, the MS analysis indicates no complex formation. 
To verify the result, 1H-NMR spectrum was recorded. The spectrum showed no shift of the 
pyridine signals compared to the free ligand and also the aliphatic proton signals did not change. 
With this experiment evidence is given that the tetradentate model ligand cannot coordinate 
Zn2+ in protic solvents. Since Zn2+ coordination is even more unlikely in aqueous solution due to 
the relative high stability of the [Zn(H2O)6]
2+ complex, L8Me should be selective for Cu+. 
 
5.6 Attempts to Prepare Water-Soluble Ligand Systems 
Ligand design was done with according to “Lipinski’s Rule of Five”[231], which resulted in nonpolar 
compounds. On one hand, this increases the chance of the compounds to cross the BBB and to 
permeate the cells. However, on the other hand the nonpolar character reduces its solubility in 
water. Thus, analytic measurements in aqueous solutions become more difficult and are 
performed in the presence of DMSO. In the case of L8Me the ligand becomes so insoluble in water, 
after protection of the hydroxide function, that even 10 % DMSO is not enough to keep it in 
solution at ≈200 mM. For further investigation of the ligand systems, especially when cells or 
proteins are involved, the solvent plays an important role. Dynamics, reactivity and protein 
folding strongly depend on the solvent. A value equal or smaller than 5 % of DMSO should not 
influence the measurement, but larger amounts could affect the reactivity of the Aβ protein and 
also of the compounds. Water-soluble ligands would be therefore most suited for metal 
exchange experiments, cell viability tests and ROS-inhibition studies. In particular for the 
determination of the metal exchange NMR experiments with L8Me would be an increased 
solubility desirable. The solubility of compounds is influenced by their functional groups. Polar 
groups like –OH, –SH or –NH2 increase the polarity and thus the solubility in water. In the ligand 
systems only one alcohol function is present, which is insufficient to dissolve the ligands in 
water. Thus, the ligand systems have to be attached to molecules with more polar groups or 
ionic groups like sulfonate (–SO3
-). Herein different approaches for the synthesis of water-soluble 
model ligand systems will be presented. Reactions were carried out using L3H.  
In the first approach towards water-soluble ligand systems the host-guest principle of 
β-cyclodextrine was used. β-Cyclodextrine is a water-soluble cyclic oligosaccharide.[285] The 
hydrophilic exterior is responsible for the solubility and bioavailability and through the 
hydrophobic cavity on the inside formation of inclusion complexes with hydrophobic guest 
molecules, like 4-dimethylaminoazobenzene-4-sulfonyl, is possible.[286] Therefore β-
cyclodextrine becomes a drug carrier molecule.[287] In this study an attempt was carried out to 
attach 4-dimethylaminoazobenzene-4-sulfonyl chloride to L3H (Scheme 19). The sodium salt of 
the ligand was prepared in THF via sodium hydride and afterwards a small excess of the chloride 
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was added. After stirring the reaction solution for 24 h under reflux at 70 °C no product 
formation could be observed. Increasing the temperature to 100 °C and extension of the 
reaction time to 3 d had no influence on the reaction. The low reactivity, most likely results from 
the steric demand of the ligand. In the second approach, L3H should be directly coupled to β-D-
glucose. β -Glucose is one of the few polar molecules which can cross the BBB. Therefore it can 
also be used as a drug carrier and even applications for the treatment of AD are known.[288] For 
the coupling reaction of L3H, the activated and protected β-D-glucose pentaacetate was used. 
Reaction was performed at different temperatures in THF and also in DMF, but no glucose-
conjugated product was observed. This observation supports the hypothesis that the steric 
demand of the ligand prevents the attachment of other bulky molecules. However, attachment 
of small molecules should be possible. Thus, attempts were carried out to couple L3H with 
sodium 2-chloroethylsulfonate and sodium 2-bromoethylsulfonate. After stirring for 3 d under 
reflux no product could be obtained. Instead, the ligand could be completely recovered. Due to 
the low reactivity of the ligands further attempts to synthesise water-soluble ligands were 
forfeited and analytic measurements, described in the following chapter, were carried out in the 
presence of DMSO.  
 
Scheme 19 Synthetic attempts to water-soluble ligands. 
 
5.7 Selectivity and Metal Exchange Studies 
5.7.1 Metal Selectivity  
In the synthetic approaches presented so far only the chelating capabilities towards Cu+, Cu2+ 
and Zn2+ have been tested, since these transition metals are postulated to play an important role 
in AD. However, in general a coordination of all metals present in cells has to be considered. As 
mentioned in chapter 2 the coordination of most transition metals can theoretically be excluded 
due to the specific equilibrium, and concentration control in cells. 




Nevertheless, one attempt to prove the expected reactivity was carried out. Therefore were the 
ligands L3H and L5H coupled to N-ethyl-1,8-naphthalimide (NCLs, appendix B), because analogous 
systems are known as fluorescence sensors for transition metals.[256,289] Figure 26 illustrates one 
of the literature known systems and the systems synthesised in this study. To follow the metal 
coordination UV/Vis spectra and fluorescence spectra were recorded in water and in 0.1 M 
HEPES buffer (7.4). Coordination of the following metals were tested: Cu+, Cu2+, Zn2+, Fe2+, Ag+, 
Co2+, Ni2+, Hg2+,Na+, K+, Cr3+, Zr4+ and Mn2+. Unfortunately, no changes of the absorbance or 
fluorescence bands could be observed. Comparison with the literature known system shows, 
that in case of the synthesised compounds, the linker chain is elongated by one ether function. 
The distances to the next coordinating atoms are even larger, since coupling was done over the 
ligand backbone. Therefore, the conjugated π-system of the detector is separated from the 
chelating unit and does not respond upon metal coordination. However, as mentioned before, 
the coordination of a transition metal in aqueous solution and especially in cells is restricted by 
many factors and from the structural features of the ligands should the ligands be selective for 
Cu+. Thus, in the following only the selectivity of Cu+ in the presence of Cu2+ and Zn2+ will be 
examined. 
 
Figure 26 The literature known cyclam-based Zn2+ sensor (top)[290] and NCL3 and NCL5 synthesised in this study 
(bottom).  
 
5.7.2 Cu+ vs. Cu2+ 
None of the experiments presented so far for the tripodal ligands were conducted in aqueous 
solution and extrapolation of the obtained results to other solvents is not always possible. To 
prove that the ligands can also coordinate copper in aqueous solution, in the presence of buffer, 
1H-NMR experiments were performed (Figure 27). L8Me could not be used in this experiment due 
to its low solubility in aqueous buffer solution. However, the preparation of the model 
complexes as well as the 1H-NMR experiment performed with the unprotected ligand proved 
that the Cu+ selectivity for the tetradentate ligand system. First of all Cu+ coordination was 
followed. The experimental conditions for this study were 1 mM Cu+, 1 mM L3Me/L5Me in 0.2 M 
deuterated phosphate buffer (pH 6.9). A stock solution of CuSO4  5 H2O in D2O was used, which 
was reduced with dithionite in situ. For the ligands a stock solution in DMSO-d6 (10 mM) was 
prepared due to the insolubility of the compounds in water. The insolubility results from the 
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plain, nonpolar ligand design, which favours the crossing of the BBB and permeation of the cells, 
but also makes them insoluble in water. Figure 27 shows the 1H-NMR spectra recorded in the 
course of the experiment. Upon addition of Cu+ all proton signals of the ligands are shifting. The 
aromatic signals of the pyridine and imidazole sidearm shift towards lower field, whereas the 
aliphatic signals are shifted to higher field. In common is the observed broadening of all 
resonances. This could be an indication for a dynamic process of the donating atoms. Thus, Cu+ 
coordination takes place, but may be rather weak. To ensure this hypothesis either temperature- 
dependend NMR studies could be performed or stability constants have to be determined. The 
latter was done and the results will be presented in the next chapter. As mentioned before Cu+ 
selectivity has to be ensured and Cu2+ coordination has to be excluded. With the same set-up, no 
signal shift could be observed by addition of one equivalent of Cu2+ to the ligand. Thus, the 
assumption from the synthetic approach of the Cu2+ complexes with L3Me and L5Me could be 
proven by NMR studies: The tripodal ligands are able to coordinate Cu+, but not Cu2+. These 
results show that the target orientated ligand design results in the desired selectivity. 
 
Figure 27 1H-NMR spectra of L3Me, L5Me and their corresponding Cu+ complexes. Experiment was conducted with 
1 mM Cu+, 1 mM L3Me/L5Me in 0.2 M deuterated phosphate buffer (pH 6.9). 
5.7.3 Cu+ vs. Zn2+ 
In AD afflicted brain and also in the Aβ plaques, not only copper but also elevated zinc levels 
have been detected. Thus, the synthesised ligands have to selectively coordinate Cu+ in the 
presence of Cu2+ and also Zn2+. As mentioned in chapter 2, a distinction between Cu+ and the 
isoelectronic Zn2+ through targeted ligand design is not as simple as with Cu2+. Both metal ions 
prefer tetrahedral coordination geometry and form the most stable complexes with a mixed 
{NxS
-
y} donor set. However, they differ by their charge and therefore also by their acid character 
after the Pearson concept.[232] Cu+ is softer than Zn2+ and prefers softer donors, whereas Zn2+ is 
harder and forms stable complexes with harder ligands. In the ligand systems soft thioether 
donors are present, which should be better suited for Cu+ than for Zn2+ coordination. To prove 
this 1H-NMR titration experiments of L3Me and L5Me were performed focusing on the metal 



















determined in organic solutions. Figure 28 shows the 1H-NMR spectra of successive addition of 
Zn2+ to a solution of 0.40 mM 9 (left) and 10 (right) in MeCN-d3. A stepwise replacement of Cu
+ by 
Zn2+ is visible for both complexes. Surprisingly, even a tenfold excess of Zn2+ to 9 does not lead to 
the spectra of the [(L3Me)2Zn]
2+ complex. The H6 pyridine proton shifts further to higher field, but 
does not reach the same shift as in the pure Zn2+ complex. After addition of 0.5 eq. of Zn2+, 
[L5MeCu(MeCN)]+ is completely transformed into the [(L5Me)2Zn]
2+ complex. Additional Zn2+ does 
not cause any further changes in the spectra. Although complete conversion of the Cu+ 
complexes can be observed small deviations from the pure zinc-complexes are still present. The 
differences in the shifts are most likely induced by the presence of water from the utilised 
Zn(ClO4)2  6 H2O salt. However, the metal exchange experiment shows that L
3Me and L5Me are 
selective for Zn2+ in MeCN, forming [L2Zn]
2+ complexes. Driving force of this reaction is not only 
the formation of the [L2Zn]
2+ complexes, but also the stabilisation of the replaced Cu+ ion by 
formation of [Cu(MeCN)4]
+. 
    
Figure 28 1H-NMR spectra of the low field region in the metal exchange experiment. Successive addition of Zn2+ 
[L3MeCu(MeCN)]OTf (9, left) and [L5MeCu(MeCN)]PF6 (10,right). 
The experiment was also carried out under more cellular like conditions in 0.1 M deuterated tris 
(2-amino-2-hydroxymethyl-propane-1,3-diol) buffer (pH 7.4). Tris buffer was used instead of the 
phosphate buffer, since phosphate can coordinate to Zn2+. From the NMR studies in MeCN-d3 it 
is known that Zn2+ complexes are formed with a ligand to metal ratio of 2 : 1. Thus, a stock 
solution of ZnSO4  7 H2O in D2O was added stepwise and 
1H-NMR spectra were recorded with 0, 
0.5 and 1.0 eq. of Zn2+ (Figure 29). Instead of the spectra of 17, respectively 18, only the signals 
of the free ligands could be observed. Thus, L3Me and L5Me cannot coordinate to Zn2+ in aqueous 
solution. This finding is completely different from the result obtained in MeCN, where Zn2+ could 
displace Cu+. Reason for the different results is the different coordination properties of the used 
solvents. MeCN is a good ligand for Cu+, which stabilises it by forming a [Cu(MeCN)4]
+ complex, 
which can even protect Cu+ against oxidation.[252] Zn2+ ions instead prefer harder ligands, such as 
water, resulting in the formation of a [Zn(H2O)6]
2+ complex. The [Zn(H2O)6]
2+ complex is even 
better stabilised than [L3Me2Zn]
2+ and [L5Me2Zn]
2+ respectively, although the latter are entropically 
favoured. Other metal ions like iron were not tested since they should be strongly disfavoured 
according to the concept of Pearson and the Irving-Williams series.[232,233] Thus, the metal 
exchange experiments prove that the synthesised ligands are in vitro selective for Cu+ and can 
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Figure 29 Aliphatic region of the 1H-NMR spectra of the successive addition of Zn2+ to 300 μM L3Me (left) and L5Me 
(right) in 0.1 M deuterated tris buffer (pH 7.4). 
 
5.8 Conclusion 
The ligands were modified in order to mimic the structural features of the targeted 
multifunctional tool by attaching a methyl protective group to the backbone alcohol group. With 
these altered ligands, model complexes could be synthesised and characterised in solution and 
in solid state. The characterisation in solid state revealed formation of mononuclear complexes 
for both tripodal ligands. Furthermore, first attempts were carried out to determine the 
complexation properties in aqueous solution in the presence of buffer. Metal exchange 
experiments, show a selective coordination of Cu+ in aqueous solution. Consequently both 
ligands L3H and L5H seem to be suitable candidates to be coupled to the benzothiazole. For the 
tetradentate ligand L8H, metal selectivity could already be proven with the unprotected ligand. 
Nevertheless, also the methylated system was synthesised and evaluated with respect to its 
coordination properties, which are in agreement with the previous described results. Thus, 
besides the two tripodal ligand systems also L8H is a suitable candidate for the chelator subunit in 
the targeted multifunctional tool. However, L8H and especially L8Me are slightly soluble in water, 
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The selectivity of the developed ligand systems could be proven in buffer solution. However, to 
be suitable for application in AD research, ligands have to comply with the following conditions:  
i) The chelators should be able to not only coordinate Cu+, but extract the Cu+ from the Aβ 
protein. To do this, the ligand systems need higher Cu+ affinities than Aβ. 
ii) Metal induced oxidative stress is proposed to be the main event in AD progression, which 
damages the cell and finally leads to neuronal loss especially in the entorhinal cortex, 
hippocampus and basal forebrain.[5] Intercepting the reaction through chelating of Cu+ in vivo 
would give evidence, whether the proposed Cu2+/+ redox cycle is operative or not. Thus, the 
ligand should be able to inhibit metal induced ROS generation.  
iii) The synthesised compounds must be nontoxic and be able to protect cells against metal 
induced oxidative stress. 
In this chapter the synthesised chelators will be investigated with respect to these conditions.  
 
6.2 Determination of Stability Constants 
Recently association constants for different Cu+(Aβ) complexes were published.[145] The stability 
constants were determined by following the characteristic UV/Vis band of the chromophoric 
[Cu(Fz)2]
3- complex (Fz = ferrozine, 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine-4,4’’-disulfonic acid) 
at 470 nm (ε = 4320 M-1 cm-1) upon successive addition of different types of Aβ proteins. For a 
successful inhibition of the proposed redox cycle (presented in chapter 1) the ligands have to 
possess a greater affinity and thus a greater stability constant than Aβ. Therefore the 
determination of the stability constants for the ligands is necessary. Association constants for 
L3Me, L5Me and also their unprotected precursor were determined similar to the literature known 
procedure (see experimental section for further information). Figure 30 shows exemplary the 
UV/Vis spectrum of the titration experiments with L8. The shoulder at 562 nm (ε = 2600 M-1 cm-1) 
is assignment to the [Fe(Fz)2]
4- complex, which is formed by trace amounts of iron in the used 
chemicals. In contrast to the literature was a CuSO4 stock solution in situ reduced as Cu
+-source, 
instead of [Cu(MeCN)4]BF4. Upon coordination, the tridentate ligands leave a vacant binding site 
on the metal, which could in case of [Cu(MeCN)4]BF4 be saturated by one MeCN molecule and 
thus influence the determined stability constants. To reduce the Cu2+, a freshly prepared 
dithionite solution (100 mM) was used. The conducted experiment is very sensitive, since all 
solutions have to be degassed and used under inert atmosphere. Additional dithionite was 
added after each titration experiment to determine the amount of Cu2+ which was formed 
during the experiment. For the calculation of the stability constants only measurements were 
taken into account with less than 5 % increase in the absorption band of the [Cu(Fz)2]
3- complex. 
The partially oxidation of Cu+ was considered in the listed errors. 
















Figure 30 UV/Vis spectrum of the titration of the [Cu(Fz)2]3- (50 μM) with L8H (20 μM/per step) in HEPES (0.1 M, 
pH 7.4). The band at 470 nm corresponds to the absorbance of the [Cu(Fz)2]3- complex and the band at 562 nm 
corresponds to the [Fe(Fz)3]4- complex.  
Table 18 summarises the calculated values. Comparison of the results leads to different 
conclusions. There are only minor differences between the ligands with and without a methyl 
group. No significant difference could be observed for L3H and L5H, thus substitution of pyridine 
by imidazole has no big influence on the affinity towards Cu+. Indication of this was already given 
by the structural comparison of the model complexes and also by the synthesised [LXMeCu(CO)]+ 
complexes (see appendix A). However, with this metal exchange experiment further proof is 
given. The obtained values for the tridentate ligands L3H and L5H are with 5.40 to 6.37 one 
magnitude lower than the reported one for the Cu+(Aβ) complex. As consequence the tripodal 
ligands L3H and L5H should not be able to extract Cu+ from Aβ under equimolar conditions. In 
contrast L6H should with a log β value of 7.51 be able to displace the protein. Furthermore, this 
result shows that substitution of the sulphur donor by stronger σ-donors results in a stronger 
Cu+ affiniy. Therefore, L6H would be a better candidate for further applications than L3H or L5H. 
Unfortunately, L6H shows also a high affinity towards Cu2+ and thus lack the essential selectivity. 
The ability of L6H to coordinate to Cu2+ and form stable complexes could also be indirectly 
represented in this experiment. By using L6H the highest amounts of Cu2+ could be determined at 
the end of the experiment. However, all measurements showed less than 5 % increase of the 
[Cu(Fz)2]
3- absorption.  
Table 18 Determined brutto stability constants (log β values) of the [LXCu]+ species in presence of 0.1 M HEPES 
buffer (pH 7.4) by competition with Fz. 
 log β  log β 
L3H 6.37 ± 0.3 L3Me 5.40 ± 0.6 
L5H 6.22 ± 0.3 L5Me 5.56 ± 0.4 
L6H 7.51 ± 0.5 - - 
L8H 7.31 ± 0.2 L8Me 7.05 ± 0.2 
Aβ1-16 ≈ 6.9 Aβ1-42 ≈ 7.3 
 
L8H forms with a log β value of 7.31 also more stable Cu+ complexes than the tripodal ligands L3H 
and L5H. In theory, L8H and also L8Me should be able to remove Cu+ not only from the truncated 
Aβ1-16 but also from the natural Aβ1-42 if an excess of ligand is used. The strong increase in the 
binding constant is due to the second pyridine, which not only saturates the coordination sphere 




of Cu+ but also stabilises the complex through its strong σ-donor and π-acceptor character. 
Surprisingly, the determined value is still lower than the stability constant determined for L6H, 
although L8H is entropic favoured; three vs. four donor atoms. Thus, the experiment not only 
elucidated, which ligands should be able to remove Cu+ from the Aβ protein complex, but also 
illustrates the influence of the different donating groups in the ligands, and this provides an 
outlook for further ligand design. Thus, investigation of a {N4}-ligand generation would be 
interesting.  
 
6.3 Metal Exchange Studies on Aβ1-16 
6.3.1 Metal Exchange with Tridentate Ligands 
In order to confirm the result from the Fz competition experiment a metal exchange 1H-NMR 
experiment was performed for L3Me and L5Me. Set up for the experiment were 1 mM ligand, 1 mM 
Aβ1-16 and 1 mM Cu
+ in 0.2 M phosphate buffer (pH 6.9). For verification of the result both the 
LXCu+ and the Cu+(Aβ) complex were supplied and the corresponding compound added yielding 
in the same spectra. Since there are some overlapping signals of the ligand with the protein in 
the high field only the aromatic regions are shown in Figure 31. All pyridine signals of L3Me shift to 
low field upon coordination, whereas the aliphatic signals of the thioether sidearm shift to high 
field. The broadening of the ligand signals indicates a fast exchange of the donor atoms. The 
proton signals of the [L3MeCu]+ complex shift back towards the free ligand spectrum upon 
addition of the Aβ1-16. However, they do not reach the same values as the free ligand. 
Furthermore, the broadening is kept. The Aβ protein behaves analogously. Coordination of the 
complex yields in a shift of the involved amino residues, such as His13 and His14. In the mixed 
spectra these groups still deviate from their original metal-free values. This leads to the 
conclusion that a ternary ligand-Cu+-Aβ complex is formed under the given conditions. Under 
consideration of the determined stability constants it is very likely that the metal is mostly 
localised on the protein and the different donor atoms of the ligands are in a fast exchange. 




Figure 31 1H-NMR spectra of the metal exchange experiment between L3Me and Aβ1-16. Spectra were recorded with 
1 mM L
3Me
, 1 mM Aβ1-16 and 1 mM Cu
+ 
in 0.2 M phosphate buffer (pH 6.9). 
The experiment was also performed with L5Me as competitor to Aβ1-16 (Figure 32). The prediction 
from the determined stability constant would be again that the ligand is not able to remove Cu+ 
from the protein. L5Me has only two aromatic signals from the imidazole sidearm. Thus, 
coordination can be followed by detection of their shift. Especially, the nitrogen-neighboured 
proton signal shifts to higher ppm values upon metal coordination (marked with *). After 
addition of Aβ1-16, ternary complex formation can be observed similar to L
3Me. Thus, under 
physiological conditions, both tridentate ligands cannot extract Cu+ from the Aβ1-16 protein. 
Instead ternary complexes were most likeyl formed. For the desired application of this study a 
Cu+ selective ligand is necessary, which can extract Cu+ from the Cu+(Aβ1-42) complex. In this 
experiment it could be proven that neither of the two tripodal ligands is capable of this. 
Nevertheless, the utilised ligands can interact with the Cu+(Aβ) complex and it would be 
interesting to study their influence, e. g. on the protein aggregation. It could be possible that the 
steric demand of the ligand prevents the formation of oligomers or even favour fibril formation. 
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Figure 32 1H-NMR spectra of the metal exchange experiment between L5Me and Aβ1-16. Spectra were recorded with 
1 mM L
5Me
, 1 mM Aβ1-16 and 1 mM Cu
+ 
in 0.2 M phosphate buffer (pH 6.9). 
  
6.3.2 Metal Exchange with Tetradentate Ligands 
The metal exchange experiment which was performed with the tridentade ligands was also 
carried out with the tetradentate ligand. L8H was used instead of L8Me due to the low solubility of 
the methylated ligand. However, the determined stability constant already proved that there is 
no difference between the protected and unprotected system. Although L8H is better soluble the 
used ligand concentration had to be decreased. Thus, the specified set up for the 1H-NMR 
experiment were 300 μM ligand, 300 μM Aβ1-16 and 300 μM Cu
+ in phosphate buffer (pH 7.4). 
Unfortunately trace amounts of Cu2+ lead to a broadening of the histidine signals of the Aβ1-16 
and the ligand signals are diminished due to the bad solubility of the ligand and its complex. 
Thus, as indicator for the replacement of the protein were the aliphatic signals of the Val12 
residue used. By coordination of Cu+ the Val12 signals shift due to structural reorganisation of the 
protein (Figure 33). Addition of equimolar amounts ligand causes a shift, back to the free 
protein. In combination with the determined stability constants indicates this result, that the 
ligand can extracted the Cu+ from the protein. Thus, it seems that in contrast to the tripodal 
ligands, L8H is able to partially compete with Aβ1-16, but not able to completly displace the 
protein. However, the detection of the Val12 shift is only an indirect measurement, since it is not 
directly involved in metal binding. To verify the results additional measurements are necessary 
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Figure 33 1H-NMR spectra of the aliphatic region of the metal exchange experiment between L8H and Aβ1-16. The two 
duplets corresponds to the amino acid residue Val12. The dotted lines better demonstrate the shifts. Spectra were 
recorded with 300 μM L
8H
, 300 μM Aβ1-16 and 300 μM Cu
+ 
in 0.2 M phosphate buffer (pH 7.4). 
 
6.4. Ascorbate Reduction as Extent of the Ligand Interception in ROS 
Origin 
To study the capacity of the ligands to intercept in a Cu2+/+ redox cycle, analogous to the one 
which is proposed for ROS generation in AD[173], time dependent ascorbate consumption was 
monitored by UV spectroscopy. The standard set up for the experiment was 100 μM sodium 
ascorbate, 5 μM Cu2+ and 7 μM of ligand or Aβ1-16 in 50 mM phosphate buffer. The order of 
addition was buffer, ascorbate, ligand/protein, copper. The ascorbate stock solution was freshly 
prepared and no longer used than 5 h. The excess of ligand was used in order to make sure that 
no free Cu+ is present. Ascorbate consumption was followed over a time period of 5 minutes and 
evaluation was graphically done by plotting the absorption (265 nm, ԑ = 14500 M-1 cm-1) against 
time. The metal becomes re-oxidised by O2 from the air. The experiment was performed with 
both the methylated and the not methylated ligands to verify the results obtained in the Fz 
experiment (chapter 6.2). Each measurement was repeated at least three times to minimise 
errors and quantify the results. The detected ascorbate consumption should be slow in case of a 
strong Cu+ chelator and fast in case of weakly coordinating ligand systems. Thus, the following 
order could be assumed according to the determined stability constants: L6H (slow) < L8H < Aβ1-16  
<< L3H ≈ L5H (fast).  
Figure 37 shows the time depended ascorbate consumption for the methylated and not 
methylated ligand systems. Between the methylated and the not methylated systems no 
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L3Me. However, the experiment is very sensitive, so that the deviation lies within the error 
margin. Overall, the experiment again proves that the alcohol is not involved in metal 
coordination and methylation has no influence on the Cu+ affinity. The slowest ascorbate 
consumption could be observed for L8H, followed by Aβ1-16. L
6H, which even has a higher Cu+ 
affinity than L8H, is only the third most active compound. L3H and L5H have according to the 




































Figure 34 Time depended ascorbate consumption at 265 nm. Conditions were 100 μM sodium ascorbate, 5 μM Cu2+ 
and 7 μM LX or Aβ1-16 in 50 mM phosphate buffer (pH 7.4). Left the not modified ligands and right the methylated 
ligands. 
The different inhibition capacities of L6H/Me  compared to the stability constants can be explained 
by different redox pairs formed during the experiment and should also be considered by the 
interpretation for the other ligand systems(Scheme 20). Aβ1-16 has a relatively strong affinity to 
Cu2+ and binds it in the nM range.[113,114] Thus, after addition of Cu2+, the Cu2+(Aβ1-16) complex is 
formed, which gets reduced by the ascorbate leading to Cu+(Aβ1-16). Thus, in case of Aβ1-16 the 
observed redox pair is [Aβ1-16Cu]
2+/[Aβ1-16Cu]
+. The oxidation as well as the reduction requires 
reorganisation of the protein. The single redox states are therefore stabilised and the re-
oxidation hindered. As a consequence the protein shows a remarkably strong inhibition in the 
ascorbate oxidation. The ligands L3Me, L5Me and L8Me are in contrast only selective for Cu+. The 
observed redox partners are therefore the [LXCu]+ complex and the ligand free [Cu(H2O)5]
2+ 
complex and thus the ascorbate experiment resembles the determined stability constants. As 
mentioned before L6H can not only coordinate to Cu+, but also form a stable complex with Cu2+. 
The formed redox pair is likely 2 [L6HCu]+/[(L6H)2Cu]
2+ + [Cu(H2O)5]
2+. The low activity of L6H is most 
likely induced due to the stabilisation of the oxidised [(L6H)2Cu]
2+ species. As a consequence the 
Ligand L6H shows a higher activity than L3Me and L5Me but still much less active than the Aβ1-16, 





































Scheme 20 Reaction pathways in the ascorbate consumption experiment. LX can be L3H, L5H, L8H or their 
corresponding methylated derivatives.  
The experiment was repeated at different conditions to further investigate the inhibition 
capacity of the most active chelator, L8H. Figure 35 shows the ascorbate consumption at 2.5 μM 
and 7 μM in the presence of Aβ1-16 and without. By lowering the concentration of ligand to 
equimolar concentration of the copper a remarkably increase of the ascorbate consumption 
could be observed. One reason for this increase could be the presence of free Cu+. Even small 
inaccuracies in the pipettes or minimal impurities in the used compounds could lead to an excess 
of copper and thus a significant increase in the ascorbate consumption. Further decrease of the 
ligand concentration, to 2.5 μM, results in a loss of the protective function. Besides low ligand 
concentration higher concentration were tested. However, increase to 10 μM or higher (15 μM, 























































Figure 35 Time depended ascorbate consumption at 2.5 μM, 5 μM and 7 μM of L8H in the presence of Aβ1-16 and 
without. Spectra were recorded in 50 mM phosphate buffer (pH 7.4). 
The experiment was also carried out in the presence of Aβ to study the influence of the protein 
on the sensitive redox system. The addition of Aβ1-16 leads to a further decrease of the ascorbate 
oxidation. One possible explanation for this increased inhibition would be that a ternary complex 
is formed where the Cu+ is tightly bound by the protein and the chelator. However, formation of 
such a complex is unlikely because it was not observed in the NMR metal exchange experiment. 
In Scheme 21 is a proposed redox cycle presented, which comprises all important intermediates 
and could explain the observed reactivity’s. The redox cycle starts with the free Cu2+, which 
becomes coordinated by the Aβ1-16. In the next step takes the reduction place and generates the 
[Aβ1-16Cu]
+ complex. The higher affinity of L8H should than lead to a replacement of the protein 




and coordination of the ligand, like observed in the NMR experiment. This [L8Cu]+ complex 
becomes then oxidised by air and releases the Cu2+, which can again be coordinated by the 
Aβ1-16. Since no studies were done concerning the kinetics, it can only be conjectured what the 
rate determining step is. The reduction and oxidation of the metal is more or less known from 
the previous experiments and in both cases faster ascorbate consumption was observed. The 
metal exchange rate instead, is not specified. However, it could be seen in the ferrozine 
experiment (see chapter 6.2) that such a metal exchange can be relatively slow. Thus, the 
increased inhibition activity is not induced by a stronger coordination, but most likely due to an 
intermediate were the Aβ1-16 gets replaced by the ligand.  
 
Scheme 21 Proposed redox cycle for the ligand inhibited ascorbate consumption in the presence of Aβ1-16. 
The 1H-NMR experiment showed that L3Me and L5Me can, together with Aβ1-16, probably form 
ternary Cu+ complexes. Thus, the ascorbate consumption experiment in the presence of Aβ1-16 
was also repeated for L3Me and L5Me to study the influence of these complexes. A higher inhibition 
capacity was expected, since an additional ligand is involved in the coordination of the Cu+. 
However, the comparison with the Aβ1-16 alone showed no significant deceleration of the 
ascorbate consumption. This leads to the assumptions that either no ternary complex is formed 
or that the coordination of the ligand is too weak and does not influence the re-oxidation of the 
Cu+. The latter hypothesis is disfavoured by the fact that the tripodal ligands have already shown 
an activity. Thus, coordination should induce a change in the inhibition. 
 
6.5 Cell Viability Tests 
Cell viability tests or viability assays are studies which determine the ability of cells to maintain 
or recover their viability.[291] The cultured cells can be used to determine the cytotoxicity of 
chemical compounds and for drug screening. The synthesised ligands and also the final 
multifunctional tools should be at least suitable for in vivo studies or in best case used as drugs. 
Thus, the toxicity of the compounds had to be determined. The utilised test was a colorimetric 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) test for cell viability based 
on the activity of the mitochondrion of living cells. Cell viability was determined by a 
mitochondria enzyme dependent reaction of MTT as described elsewhere.[292] MTT (a yellow 
tetrazole) is reduced by the mitochondrial reductase to a purple farmazan (Scheme 22). The 
mitochondria play an important role in the respiration cycle of living cells and thus their activity 
can be used as a measure of enzymatic activity and cell viability, respectively. The colour change, 
induced by the metabolised MTT, can be measured by UV/Vis-spectroscopy. The purple 
farmazan has an absorption maximum at 570 nm, which can be shifted by solvatochromism 
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(500-600 nm). MTT was added to the neuronal cells (human tumor cells SH-SY5Y) at final 
concentration of 5 mg/ml at 37 °C for 4 h, 24 h after testing the compound. Undifferentiated 
human neuroblastoma SH-SY5Y cells were grown under standard culture conditions in an 
incubator containing a humidified atmosphere with 5 % CO2 at 37 °C. The medium used was 
DMEM (Dubelcoo’s Modified Eagle’s Medium) supplemented with 15 % foetal bovine serum 
(FBS). The reaction was terminated by removal of the supernatant and addition of 1.5 ml DMSO 
to dissolve the formazan product and afterwards, the absorbance was measured. The 
experiment was performed three times with three batches per measurement. The error margin 
for cell studies like the presented MTT assay can be up to 20 % and in this study only a low 
number of batches were conducted. Thus, the cell studies should be reconsidered as a first 
indication of the reactivity of the compounds with respect to cellular conditions. The Cell studies 
were performed by Isabelle Sasaki in the laboratories of the Institut de Pharmacologie et de 
Biologie Structurale (IPBS) in Toulouse, France.  
 
Scheme 22 Reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by mitochondria. 
The toxicity of the ligands L3Me, L5Me and L8H (L8H was used due to the better solubility than L8Me) 
were determined by the MTT viability assay (Figure 36). L3Me and L5Me show no toxic behaviour. 
Mainly all cells survived in the case of L3Me and L5Me. Unfortunately, the ligand L8H, which has the 
highest affinity towards Cu+ and also shows the highest activity in the inhibition of ascorbate 
consumption, seems to by cytotoxic. The reason for the toxic behaviour of L8H is not known and 
can only be speculated. The comparison with L3Me and L5Me leads to the hypothesis that the 
specific toxic behaviour could be induced by the alcohol function of L8H. After coupling with the 
benzothiazole, the alcohol function would be protected and probably the generated 
multifunctional compound would show no cytotoxicity. Since no measurements were available 
to follow the pathway of the ligand, the cytotoxic mode of action remains unknown. One 
hypothesis is that since the ligand L8H is relative nonpolar and highly lipophilic, it should be able 
to penetrate the cells and react with proteins or enzymes in the cell. Such reactivity could 
disturb the natural respiration of the cell and could than lead to cell death. Another possibility 
for the low survival rate is an interaction of L8H with the FBS and a disturbance of the sensitive 
cell environment.  
























Figure 36 Viability assays with L3Me, L5Me and L8. Percentage of living cells after the treatment with 10 uM of the 
compounds. 
By modification of the experiment it could be used to measure the protective function against 
metal induced ROS. The ROS can be artificially generated by adding Cu2+ and ascorbate to the 
cell medium (Figure 37). In this experiment only the ligands were examined, which have shown 
no toxic behaviour. Thus, the experiment was only performed with L3Me and L5Me. The first, black 
bar is the average survival rate of cells treated with ascorbate and copper, and serves as 
reference. The results show for both chelators a slight protective function. This result directly 
corresponds with the determined stability constants and also with the performed ascorbate 
consumption experiment. Thus, L3Me and L5Me seem to be able, even though only weakly, to 
stabilise Cu+ in aqueous solution. Thus, with this study a first impression is given for the metal-

























Figure 37 Modified viability assays to with L3Me and L5Me. Percentage of living cells after the treatment with 5 uM 








For L3H, L5H, L8H and their methyl protected derivatives were brutto stability constants 
determined. The values indicated that all ligands should be able to compete with Aβ1-16. 
However, in the performed 1H-NMR metal exchange experiment only L8H was able to extract the 
copper from the Cu+(Aβ1-16) complex. The tripodal ligand system can interact with the metallo 
protein complex, but their affinity is too low to displace the Aβ1-16. The ligands and their 
derivatives were further investigated with respect to their redox-inhibition capacity in an metal 
mediated ascorbate consumption experiment. Out of the series only L8H is able to slow down the 
ascorbate consumption more than the Aβ1-16. For L
3H and L5H only a minor deceleration of the 
ascorbate consumption could be observed. Since the final aim is an in vivo application, the ligand 
systems were tested of their cytotoxicity. The performed cell viability test revealed that L3Me and 
L5Me are not toxic, whereas L8H shows a toxic behaviour. The specific toxic mechanisms are not 
known, but it is possible that the free alcohol function is responsible for this reactivity and 
therefore it could be possible that the final molecule shows a different behaviour. However, the 
obtained results in the ascorbate consumption experiment and the determined stability 
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Since the discovery of Aβ plaques as one of the main features of AD, several dyes have been 
developed for Aβ plaques to ensure an early AD-therapy. Small fluorescent molecules like Congo 
red, Thioflavin or Stilbene and their derivatives become of great interest in this context, since 
they can intercalate in the β-sheet structure of the Aβ plaques and allow the use of tomographic 
techniques (PET or SPECT).[56,64,293] One of the best known representatives of these Aß dyes is 
Thioflavin T, which stands out due to its spectral alteration upon binding to Aβ fibrils. Free ThT 
absorbs at 342 nm and has a characteristic fluorescence excitation at 430 nm. Binding to the 
fibrils induces a red shift of the absorbance to 442 nm and also a shift of the fluorescence 
excitation to 482 nm.[62,294] One further developed ThT derivative is the Pittsburgh Compound B 
(PIB), where the benzothiazole moiety is slightly modified (Figure 38). However, this small 
variation remarkably increases the binding affinity to Aβ plaques and provides other advantages, 
such as a short clearance time from healthy brain tissues.[57,58] Responsible for the different 
affinity and improved intercalation is most likely the combination of aromatic π-π-interactions 
and hydrogen bridges between PIB and the fibrils.  
 
Figure 38 Hydrophobic and hydrophilic sides of PIB 
AD is a very complex disease with various hallmarks like miss-regulation and dyshomeostasis of 
transition metals, formation of Aβ plaques, hyperphosphorylation of the tau protein. Classical 
therapeutic strategies which target only one of the hallmarks have shown low efficiency.[217] 
Certain symptoms can be treated with these drugs, but not the cause of AD. Thus, the trend 
goes to drugs, which do not target the symptoms but the cause itself.[222,227] In order to provide 
these therapeutic strategies, a more profound understanding of the disease is necessary. To 
enlighten the specific mechanisms involved in the AD, molecules become favoured that 
comprising more than one active functional group.[295] Thus, the compounds can modulate 
multiple targets that characterise the neurodegenerative disease. In the last decade 
multifunctional systems of different types were synthesised and evaluated for their efficiency in 
the treatment of AD (Figure 39). For the first type a proven active molecule gets an additional 
functionalisation to increase its activity or introduce a new beneficial property (e.g. solubility 
increase or crossing the BBB). The second type consists of single molecules which combine 
multiple functions, to allow interaction with more than one target. The third and last type are 
compounds with two molecules or functional groups with intrinsic activity, which are bridged by 
a linker, resulting in hybrid molecules. Depending on the nature of the spacer both active sites 
can interact or react completely independently. 





Figure 39 General representation of different multifunction types developed in the last decade. a) functionalisation, 
b) incorporation and c) coupling over an spacer. 
The second type of multifunctional systems has high potential for applications due to its ability 
to “kill two birds with one stone”.[295] Therefore, they were announced as most promising 
compounds in comparison with the other types.[295] Their advantage to interact with multiple 
targets, is a major disadvantage in medical applications, since the observed activity cannot be 
assigned to a certain functional group or target. 
Aim of this study is the synthesis of a multifunctional tool which can enlighten the interaction of 
Cu+ with Aβ. For this task, a multifunctional type three system was developed, containing a Cu+ 
chelator and an Aβ plaque sensitive unit. The synthesis and characterisation of suitable chelators 
for Cu+ recognition was reported in the previous chapters. Due to the promising results for L3H, 
L5H and L8H, these systems will be used in the multifunctional tools. In this chapter, the synthesis 
of the Aβ recognition subunit ─ a benzothiazole analogue of PIB ─ and coupling attempts with 
the ligands will be presented. Coupling of these two molecules via a linker, should form a hybrid 
with the following attributes: i) selective coordination of Cu+, ii) selectivity towards Aβ plaques 
and iii) luminescence properties.  
 
7.2 Synthetic Approach to Benzothiazole Derivatives 
Although many different approaches for the synthesis of benzothiazole derivatives are known in 
the literature, most of the synthetic routes lack flexibility.[242,243] In this study, a synthetic route 
was developed with Suzuki Coupling as the key step, which offers the possibility to combine 
different building blocks, leading to various benzothiazoles (Scheme 23).[296,297] Nevertheless, in 
this study only one benzothiazole derivative (BTA) was synthesised. The synthetic route starts 
with the synthesis of the precursors for Suzuki Coupling reactions: a halogenated benzothiazole 
and a boron derivative which can either be a boronic acid or boronic ester.  
 
Scheme 23 Retrosynthetic analysis of the targeted benzothiazole derivative. 
The halide can be synthesised by a two-step synthesis from 4-methoxyanilin. In the first step 2-
amino-6-methoxybenzothiazole XIII is generated by reaction of 4-methoxyanilin with potassium 
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thiocyanate and elemental bromine in acetic acid (Scheme 24).[298] During the reaction the 
temperature has to be kept lower than 20 °C to ensure a high yield. The amine can be activated 
with a nitrite and then substituted to a halide. In the first approach the literature known 
substitution to 2-bromo-6-methoxybenzothiazole (XIV) was carried out.[299] The amine was 
therefore activated with tert-butyl nitrite. Further reaction of the activated intermediate with 
CuBr2 provided XIV in good yields (74 % Lit.: 79 %
[299]). Unfortunately, the synthesis could only be 
used in small scales, since upscaling would require a few litres of solvent and HCl. The aim was to 
find a simple pathway, which also works on bigger scale. Thus, the last step was changed and 
instead of a bromide an iodide was attached to the benzothiazole. Activation of XIII was 
achieved with sodium nitrite and potassium iodide was used as halide transfer agent. In the 
presence of catalytic amounts of para-toluenesulfonic acid, 2-iodo-6-methoxybenzothiazole XV 
could be synthesised in moderate yields (58 %). 
 
Scheme 24 Synthetic pathway of the halides XIV and XV as precursor for Suzuki coupling. 
The boronic acid or ester was synthesised starting from the commercially available 4-
bromoanilin. According to the scaffold in Figure 38, a methyl group has to be introduced on the 
amine to create a hydrophobic and a hydrophilic side. This is needed for a good intercalation of 
the multifunctional tool in the Aβ fibrils. Two approaches were carried out providing the mono 
methylated compound XVIII (Scheme 25). In the first approach 4-bromoaniline was methylated 
with methyl iodide in the presence of Et3N. After attachment of the first methyl group the pKa 
value of the remaining secondary amines increased only slightly and therefore the amine 
became methylated twice. Thus, the main product of this reaction was 4-bromo-N,N-
dimethylaniline and the desired mono methylated product XVI could only be obtained in low 
yields (40 %). The second approach proceeds over the boc-protected intermediate XVII, which 
could be synthesised by reaction of 4-bromoaniline with di-tert-butyl dicarbonate. In the next 
step, the methyl group could be attached by treating XVII with methyl iodide after 
deprotonation with sodium hydride. The desired boron functionality was afterwards introduced 
via transmetalation with nBuLi and addition of the trimethoxyborane. The mild acidic workup 
with NH4Cl partially cleaves the ester providing not only XIX but also XX as a side product. 
However, XIX as well as XX can be used in the cross coupling reactions. Thus, the products were 
not separated. 





Scheme 25 Synthesis of the boron-precursors XIX and XX for Suzuki coupling. 
Suzuki Cross Coupling reactions were carried out with both the bromide XIV and the iodide XV. 
As coupling partner, the mixture of XIX and XX was used (Scheme 26). Reaction conditions for 
the cross coupling were stoichiometric amounts of the provided precursors and catalytic 
amounts of CuSO4 and Pd(PPh3)4. The reaction was stirred under reflux for 24 h - 48 h at 120 °C. 
Yields up to 98 % could be achieved utilising both halides, but the iodide requires a longer 
reaction time. The reaction time could be shortened to 0.5 h to 1 h by microwave irradiation 
(250 W). The last step of the benzothiazole synthesis was the cleavage of the protection groups, 
namely the boc protection group on the amine and the methoxy group on the alcohol. Both 
groups can be cleaved in one step via BBr3 in DCM, providing XXII in very good yields (98 %). As 
mentioned before, the utilised synthetic strategy theoretically provides a fast excess to a broad 
variety of different benzothiazoles and with Suzuki Coupling as key step, many functional groups 
are tolerated.[296,297] With 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol XXII (BTA) the second 
molecule for the synthesis of multifunctional tools is provided. Thus, in the following, different 
approaches to introduce a spacer and couple the Cu+ chelator subunit with BTA will be discussed 
in more detail.  
 




Scheme 26 Synthesis of Benzothiazole XXII. 
 
7.3 Synthetic Approach to Multifunctional Systems via Nucleophilic 
Substitution 
The use of PIB in multifunctional systems has already been investigated.[295] Often the 
derivatives have been modified on the amine function. As has been explained before, this 
function is announced to be essential for an effective binding to the fibrils. In contrast to that 
modifications on the benzylic alcohol are rare. One reason for this could be, that little is known 
about its influence on the intercalation. In the few literature known systems, where the alcohol 
was substituted, only small groups like iodide, a methyl group or a methoxy group were 
implemented.[58,243] Since these derivatives show overall a high activity, the benzylic alcohol was 
in this work chosen as coupling position for the spacer.  
 
7.3.1 Attempts for an Ethylene Linker  
In the first approach towards a multifunctional system an ethylene bridge was chosen as spacer 
between the two functional groups. The small bridging unit should allow an intramolecular 
interaction of the chelator with the fluorescence sensor. Upon metal coordination, a shift or a 
change in the intensity of the fluorescence signal should therefore be observed, providing a tool 
to detect not only the intercalation into the fibrils but also metal coordination. Introduction of 
the ethylene bridge on the benzothiazole was done by reacting the alcohol with ethylene 
epoxide in the presence of stoichiometric amounts of potassium hydroxide (Scheme 20). In 
addition to this, attempts to introduce the spacer on the ligand were carried out. Only the 
reaction with the benzothiazole yielded the desired product XXIII. A reason for this might be the 
steric demand of the bulky residues on the tertiary alcohol, which shield it and prevent a 
nucleophilic attack. The benzothiazole provides, in contrast to that, a high reactivity due to the 
phenolic proton and missing steric demand of the sp2-hybridised C-atom. Thus, the product was 
obtained in good yields (81 %).  





Scheme 27 Synthetic attempts to introduce an ethylene spacer on the ligand L3H and on the benzothiazole XXII. 
Different synthetic approaches to couple XXIII with the ligands were carried out. The first 
attempt was an activation of the ligands. L3H was therefore heated under reflux with an excess of 
hydrobromic and hydrochloric acid in the presence of H2SO4 (Scheme 28). The reaction was 
performed at different conditions but no products could be obtained. With 1H-NMR 
spectroscopy, protonation of the pyridine could be observed. 
 
Scheme 28 Synthetic attempts to activate L3H by halogenations. 
Since activation of the ligands did not succeed, attempts to activate the BTA were carried out 
(Scheme 29). Activation of the benzothiazole in situ with stoichiometric amounts and an excess 
of HCl or PPh3 did not lead to the desired coupled product. In a different attempt, Mitsunobu 
reaction conditions were used. Equimolar amounts of L3H, benzothiazole, PPh3 and DIAD 
(diisopropyl azodicarboxylate) in the absence and presence of benzoic acid were stirred at 
different temperatures. Although formation of triphenylphosphine oxide could be observed via 
TLC, no product could be isolated nor detected by 1H-NMR. 




Scheme 29 Synthetic attempts to activate and couple XXIII with the Ligand L3H. On the right side are attempts of the 
in situ activation of the alcohol. On the left side are different activation trials shown. 
The synthetic pathway was changed to a stepwise process in order to gain more control over the 
reaction. The attachment of the ligand should proceed via a nucleophilic attack. Thus, good 
leaving groups on the spacer should promote the coupling reaction. The alcohol of XXIII was 
therefore substituted by a chloride, a bromide and a tosylate group. At high temperatures 
normally used in the substitution of alcohols to halides, no product formation could be 
observed. An intramolecular attack of the ether group and formation of an oxonium 
intermediate would explain the observed result.[300] The subsequent reaction with water could 
then result in the recovery of the reactant. XXII was treated with 1,2-dibromoethane and 
successively heated from room temperate to 60 °C to verify the hypothesis (Scheme 30). The 
reaction was monitored via TLC. After increasing the temperature over 40 °C, formation of a 
XXIII could be observed. As a consequence of this experiment, activation of XXIII has to be done 
at room temperature. Thus, activation of XXIII with para-toluenesulfonyl chloride could be 
quantitatively achieved at room temperature providing XXIV. 
 
Scheme 30 Mechanism of the intramolecular nucleophilic attack of the ether and formation of the oxonium 
intermediate.  
For the nucleophilic attack of the ligand, the sodium salt of L3H was prepared by addition of 
sodium hydride to a ligand solution in THF. XXIV was added afterwards and the reaction was 




stirred at room temperature to avoid side reactions. Monitoring with TLC showed no conversion 
after 24 h. Thus, temperature was slowly increased over an interval of 4-5 hours to enhance the 
reactivity. Over 40 °C, formation of the oxonium intermediate could again be observed. The 
reaction was further heated up to 60 °C to investigate if the ligand could react with the oxonium 
species (Scheme 31). However, only XXIII and minor amounts of an elimination side product 
could be obtained after aqueous workup. Due to the various side reactions and the low 
reactivity of the ligand, the introduction of an ethylene spacer was forfeited. 
 
Scheme 31 Synthetic attempt to couple XXIV with L3H.  
 
7.3.2 Attempts for a Propylene Linker  
The fast intramolecular formation of the hydroxonium species prevented the successful coupling 
of the ligand to the spacer. Thus, the spacer was extended by a further -CH2- group. For the 
attachment of the propylene spacer XXII was treated with 1,3-dibromopropane under basic 
conditions (Scheme 32). The nucleophilic attack of the benzylic alcohol provided XXV in good 
yields (88 %).  
 
Scheme 32 Synthesis of XXV. 
For the coupling reaction of XXV the sodium salt of L3H was used again and the reaction 
temperature successively increased. The reaction was again monitored by TLC and 1H-NMR. No 
reaction could be observed at room temperature and upon raising the temperature over 40 °C, 
the benzothiazole was fast converted to the elimination product XXVI (Scheme 33). 1H-NMR 
indicated a complete transformation of the reactant to XXVI within 30 min. To promote the 
nucleophilic attack over the elimination, potassium iodide was added to the reaction (Finkelstein 
reaction[301]), but no change in the reaction outcome could be observed. Thus, it can be assumed 
that the nucleophilic character of the ligands is not sufficient, likely due to the steric demand. 
 




Scheme 33 Synthetic attempt to couple XXV with L3H. 
 
7.4 Synthetic Approach to Multifunctional Systems via Click Chemistry 
Since attempts via nucleophilic substitutions have failed due to the low reactivity of the ligands 
and other side reactions, an alternative synthetic pathway had to be provided. The protection of 
the alcohol function of the ligands with methyl iodide has shown that small molecules can be 
attached to the ligand. Therefore, it should also be possible to attach a propargyl group. With 
this a terminal acetylene group can be introduced, giving acces to click chemistry. Indeed, 
reaction with propargyl bromide, under basic reaction conditions, led to the desired compounds 
(Scheme 34). 
 
Scheme 34 Synthesis of acetylene derivatives of L3H, L5H and L8H. 
For the click chemistry, the benzothiazole had to be further functionalised to an azide. Since 
activation of the ethylene bridged derivative often resulted in side reactions, only the bromo- 
propylene derivative XXV was further used. The necessary azide group was introduced by 
treatment of XXV with sodium azide in THF (Scheme 35).  





Scheme 35 Conversion of the bromide XXV to the azide XXVII. 
Click reactions were carried out under inert atmosphere with equimolar amounts of Cu2+ and 
tenfold excess of sodium ascorbate (Scheme 36). The unusual high amount of catalyst was used, 
since the ligand can reduce the concentration of free Cu+ by coordination. After heating the 
solution for 24 h under reflux, the reaction was allowed to cool to room temperature. A 
concentrated solution of sodium EDTA was added, to remove the copper. The resulting solution 
was poured into brine (200 ml) and cooled to 4 °C. The precipitate was separated by filtration 
and suspended in methanol. The resulting suspension was filtrated and the solvent of the filtrate 
removed under reduced pressure. The crude products were purified by column chromatography 
on silica. With this synthetic route, the coupling of all three ligands to the benzothiazole was 
possible in low to moderate yields (16 % - 54 %). For the desired application and the 
measurements a high purity has to be ensured. Thus, purification was done by column 
chromatography on silica and the products were recrystallisation in DCM/Et2O prior to use.  
 
Scheme 36 Synthesis of L3BTA, L5BTA and L8BTA via click chemistry. 
 
7.5 Characterisation of the Multifunctional Tools 
The synthesised multifunctional tools were characterised by various analytic techniques. The 
specific spectroscopic behaviour of the LXBTA compounds, their solubility in water, as well as 
their purity, will be discussed in more detail. 




7.5.1 Characterisation by NMR Spectroscopy 
Purity of the compounds had to be ensured for highly sensitive experiments such as binding 
studies to Aβ fibrils or viability assays. Exemplary only the characterisation of L3BTA will be 
discussed. Figure 40 shows the 1H-NMR spectrum of L3BTA recorded in DMSO-d6. All signals 
could be assigned, by the help of HH-COSY experiments and comparison with the precursors. 
The detected water signal at 3.34 ppm is an impurity of the deuterated DMSO-d6 and vanishes 
when measured in CDCl3. The –NH proton signal (6.42 ppm) can also not be observed in CDCl3 
likely due to broadening and/or H-D exchange. Although, clean spectra were also obtained for 
L5BTA and L8BTA, all compounds were recrystallised from DCM/Et2O before use, to ensure their 
purity.  
Figure 40 1H-NMR spectrum of L3BTA after column chromatography on silica recorded in DMSO-d6. Signals were 
assigned by comparison with the reactants and increment tables.  
 
7.5.2 Solubility of LXBTA 
The low solubility of the chelators impeded already the metal exchange experiments. After 
coupling the ligands to the rather nonpolar benzothiazole, the water-solubility should be further 
decreased. To prevent a falsification of the experiments due to precipitation of the compounds, 
the water-solubility was tested via UV/Vis-spectroscopy. Stock solutions of the compounds were 
prepared in DMSO and samples were prepared in 0.1 M HEPES buffer at different 
concentrations. The UV/Vis spectrum was measured directly after addition of the compounds, 
and after 5 minutes in a centrifuge. Even at low concentrations (10 μM) all three compounds 
precipitated from the buffer solution. By a stepwise increase of the amount of DMSO the 
H2O Solvent 




compounds could be kept in solution and a solubility order was determined: L8BTA << L5BTA < 
L3BTA. This order directly correlates with the solubility of the corresponding ligands. The least 
soluble ligand is L8H respectively L8Me. The second in order is L5H which could also be easily 
precipitated out of DMSO by addition of water. In contrast to this, L3H is quit soluble in a water-
DMSO mixture, most likely due to the pyridine group, which can form strong hydrogen bonds in 
water. As a consequence of the poor water-solubility, measurements in neutral buffer solutions 
were not possible. Two different approaches were used to avoid the precipitation of the LXBTA 
compounds. One way is the increase of the DMSO concentration up to 5-15 % (v/v). However, in 
case of studying the intercalating abilities of the compounds into fibrils, the amount of DMSO 
should be limited. A high concentration of DMSO, around 80 % (v/v), might cleave the bonds 
between the single Aβ molecules and dissolve the fibrils.[302] But also smaller amounts can 
influence the intermolecular fibril bonding and favour formation of small oligomers.[303] The 
other way to keep the LXBTA in solution would be lowering the pH value. In an acidic solution a 
water-soluble charged HLXBTA+ species is formed. The pH value has to be chosen carefully, since 
only the chelator unit should be protonated and not the intercalating benzothiazole moiety, 
which also bears two basic nitrogen atoms. Table 19 summarises the different relevant pKa 
values. The upper limit for the pH value is given by the pyridine group (pKa = 5.25) and the lower 
limit is given by the BTA moiety (pKa = 3.0). To ensure the protonation of the chelator, but not of 
the benzothiazole the pH value has to be in this range. Thus, a pH value of 4.5 was chosen and 
adjusted with HCl. Unfortunately, this method cannot be used in case of studying the 
coordination abilities, due to the protonation of the chelator subunit.  








Imidazole 7.05, (14.5)[307] 
 
It is worth mentioning that both approaches comprise the disadvantage that they do not 
resemble biological conditions, which has to be reconsidered for the data interpretation. 
 
7.5.3 Characterisation by UV/Vis- and Fluorescence Spectroscopy 
To completely characterise the multifunctional tools UV/Vis spectra were recorded in DMSO and 
in water at pH 4.5 (Figure 41). The spectra recorded in DMSO show only one absorption band 
around 358 – 364 nm. The absorption band can be assigned to the π-π* transition of the BTA. 
The pyridine band of L3BTA and L8BTA, which is normally observed at around 260 nm, is not 
visible due to the absorption of the solvent (λDMSO = 265 nm). Since water does not absorb in the 
UV/Vis range, the pyridine absorption could be obtained by performing the experiment in water 
at pH 4.5. Since water is more polar than DMSO, due to the higher dielectric constant, a positive 
solvatochromism (red shift in more polar solvents) is present. The observed shift is not equal for 
all three compounds. Table 20 summarises the observed LXBTA absorption bands in the different 
solvents. 
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Figure 41 UV/Vis absorption spectra of 20 μM L3BTA, L5BTA and L8BTA in DMSO (left) and in water at pH 4.5 
(right).  
Table 20 UV/Vis- and fluorescence parameter of L3BTA, L5BTA and L8BTA. 
 DMSO pH 4.5 
 absorption 
[nm]  





ԑ [M-1cm-1] emission  
(excitation)  
[nm] 
L3BTA 364 10872 415 (364) 361 6850 428 (361) 
L5BTA 360 8072 413 (360) 325 4144 418 (325) 
L8BTA 358 8194 414 (358) 341 4744 414 (341) 
 
The fluorescence spectra were recorded after irradiation at the determined absorption 
wavelengths. The measurements were performed in DMSO and at pH 4.5 (Figure 42). The 
compounds were irradiated at their absorption wavelengths. L3BTA has the strongest 
fluorescence in DMSO, followed by L5BTA. The lowest intensity was thus observed for L8BTA. The 
order changes at pH 4.5, where L5BTA has the highest intensity in its fluorescence band. 
Comparison of the two measurements shows that in general the intensity decreases at pH 4.5, 
which could be either the result of the protonation or a solvatochromism effect. 























Figure 42 Fluorescence spectra of 10 μM L3BTA, L5BTA and L8BTA in DMSO (left) and in water at pH 4.5 (right).  
























































Compounds were further examined with respect to their metal detecting ability. Therefore, 
different metals (Cu+, Cu2+, Zn2+, Fe2+, Ag+, Co2+, Ni2+, Hg2+,Na+, K+, Cr3+, Zr4+ and Mn2+) were added 
to the LXBTA compounds and the UV/Vis- and fluorescence spectra were recorded. The spectra 
were recorded with 10 μM LXBTA, 10 μM and 20 μM metal in 50 mM HEPES buffer (pH 7.4). No 
visible changes could be observed, even in case of Cu+, where an interaction is known from the 
NMR and ferrozine experiment. Thus, it can be assumed that the spacer unit is too long to allow 
an interaction of the chelator with the fluorescent BTA system. 
 
7.6 Conclusion 
A convenient pathway for the synthesis of BTA derivatives via cross coupling reaction as key step 
was developed and established for the synthesis of the BTA compound XXIII. In a first step 
towards the desired multifunctional tools, a set of different ethylene and propylene spacers 
were attached to XXIII. Unfortunately, nucleophilic attachment of the ligand was not possible 
due to various side reactions. Therefore, a coupling reaction was chosen, where the low 
nucleophilic character of the ligand becomes irrelevant. Finally, the three multifunctional tools 
L3BTA, L5BTA and L8BTA could be synthesised via click chemistry and were characterised with 
various methods. Especially the solubility of these compounds was studied by UV/Vis-
spectroscopy. All three compounds are unfortunately insoluble in water, even in the presence of 
3 % DMSO. Therefore, modified experimental conditions have to be used to further investigate 
the activity of the LXBTA compounds. One modification consists of an increase of the DMSO 
concentration, whereas another targets the pH value. At low pH values (< 5) the chelator unit 




























The 10 step synthesis of the three multifunctional tools L3BTA, L5BTA and L8BTA for applications 
in AD research and their characterisation was presented in the previous chapter. Although, these 
compounds were called as multifunctional so far no prove was given that they really can fulfil 
the assigned tasks, namely selective chelation of Cu+ and thus inhibition of metal induced 
oxidative stress and intercalation in Aβ fibrils. Thus, in this chapter, the reactivity of the 
multifunctional tools will be discussed. 
 
8.2 Binding Studies 
The beta sheet structure of Aβ fibrils and also in the Aβ plaques creates a cavity, where 
conjugated, aromatic compounds like Congo red or Thioflavin T (ThT) can interact.[60,61] Due to 
the chromophoric abilities of these compounds, they have become of great interest as dyes in 
AD.[294,308] Until today, ThT is the most common dye for Aβ plaques, since its absorption band 
dramatically red shifts upon intercalation. The shift of the UV band is accompanied by a change 
in its fluorescence excitation. The exact mechanisms, that lead to the 115 nm hypochromic 
spectral shift are still unknown, but it is most likely induced by the lipophilic environment in the 
plaques.[62,63]  
The multifunctional compounds L3BTA, L5BTA and L8BTA were investigated with respect to their 
intercalating ability in Aβ plaques. The main question is, if the compounds can still interact with 
the fibril structure or not? Although the spacer is relatively long a hindrance due to the bulky 
ligands cannot be excluded. As mentioned above, the change in the environment of ThT and its 
derivatives can be easily followed by UV/Vis- and fluorescence spectroscopy. Thus to study the 
intercalation properties of the synthesised compounds was a combined UV/Vis-fluorescence 
experiment performed. 
The synthesised compounds are insoluble in neutral buffer solutions (pH 7). Thus, experimental 
conditions for the binding studies have to be modified to keep the compounds in solution. As 
discussed in chapter 7.5.2, either the amount of DMSO can be increased or the pH value can be 
lowered to achieve the desired solubility. Since DMSO is able to cleave the bonds between the 
single Aβ molecules in the fibrils, measurements were performed at pH 4.5. UV/Vis-samples 
were prepared at 10 μM LXBTA and 20 μM fibrils. The pH value was adjusted with HCl before the 
addition of the fibrils. UV/Vis spectra were recorded before and after the addition of the fibrils. 
Upon addition of the fibrils no spectral changes could be observed, indicating that the 
compounds are not intercalating in the fibrils. However, the recorded fluorescence spectra 
proved the opposite. After addition of the fibrils an increase in the fluorescence intensity could 
be observed. This elevation of the fluorescence is most likely induced by an intercalation of the 
compounds in the rather lipophilic β sheet structure of the fibrils.[62,63] Nevertheless, the 
interaction seems to be relatively week, since it does not affect the absorbance spectra, such as 
in case of PIB or ThT.[69,294] Thus, a simple interaction with the fibril surface could be as well 
possible. However, the experiment showed that the benzothiazole subunit keeps an affinity for 
the fibrils even when coupled to a bulky ligand system.  















































Figure 43 Fluorescence spectra of 3.33 μM L3BTA (top left), L5BTA (top right) and L8BTA (bottom) before and after 
the addition of 6.66 μM fibrils at pH 4.5. 
 
8.3 Determination of the Cytotoxicity via Cell Viability Tests  
In the viability assay with the ligands, the chelators L3Me and L5Me already have shown no 
cytotoxic behaviour, whereas L8H was toxic to the cells (see chapter 6.6). Since the exact toxic 
mechanism of L8H is unknown, it could also be induced by the alcohol function of L8H. The alcohol 
function is in L8BTA not available for side reaction and thus, the viability assay with L8BTA could 
probably enlighten the toxic reactivity of the ligand. Unfortunately, L8BTA could not be used in 
this study due to its low solubility. However, the experiment was performed with L3BTA and 
L5BTA to study the influence of the coupling to the BTA. The precise experimental set up is 
described in detail in chapter 11.5.4. Two samples were measured for each compound. With this 
the test has to been seen as a first indication of the reactivity. To determine the toxicity of the 
final multifunctional compounds, cells were incubated with the LXBTA compounds. Comparison 
with the reference shows an increased survival rate of the LXBTA-treated cells (Table 21). In case 
of L3BTA 118 % of the cells have survived and in case of L5BTA the value is 105 %. Since L3Me and 
L5Me did not increase the survival rate of the cells is this effect most likely induced by the 
benzothiazole moiety. The nonpolar character of the LXBTA compounds favours cell penetration 
and therefore the uptake of the multifunctional tools in the cells. Thus, it is most likely that the 
protection function evolves in the cells. As mentioned before, methods to determine the 
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metabolism of the compounds in the cell were not available. Thus, the exact protective function 
of the LXBTA compounds remains unknown. More important than the slightly increased survival 
rate is, that after coupling with the benzothiazole, the compounds are still not toxic and thus 
useable for in vivo studies. 
Table 21 Cell viability test performed with 10 μM L3BTA and L5BTA. 100 % corresponds to the average survival rate 
of reference cells.  
 L3BTA L5BTA 
Living cells [%] 105 118 
 
After conformation of the non-toxic character of the LXBTA compounds, also a modified viability 
assay was performed to determine their inhibition capacity in metal induced ROS. The model 
ligands L3Me and L5Me have shown a slight protection function against ROS. However, the 
reactivity has to be tested again after coupling to the BTA subunit. Oxidative stress was 
artificially induced by incubation of ascorbate and copper in the cell medium. Figure 44 shows 
the results of the modified viability assay for the LXBTA compounds. The observed protective 
function for L3BTA and L5BTA corresponds with the result obtained for the model ligands. The 
small differences between the LXBTA compounds and their corresponding model ligands as well 
as between L3H and L5H are within the error margin and therefore negligible. Thus, the 
experiment indicates that the ligand subunit keeps, although coupled, its chelating properties 






















Figure 44 Modified viability assay with metal induced ROS. Percentage of living cells after the treatment with 5 uM 
Cu+, 100 uM ascorbate and 10 uM of the compounds. 
 
8.4 Ascorbate Consumption 
Different attempts were carried out to perform the ascorbate consumption experiment, which 
was already presented in chapter 6.4 for the model ligands. In the main focus of this experiment 
was L8BTA, since L8H was the only system which has shown higher inhibition activity than Aβ1-16. 
The experiment had to be modified due to the poor solubility of L8BTA. Experimental conditions 
like in the binding studies cannot be used, since the ligand becomes protonated and cannot 
coordinate Cu+. Thus, instead of the pH value the amount of DMSO was increased. To keep 




L8BTA in solution a DMSO content of 5 – 10 % was necessary. Unfortunately, no experimental 
conditions could be found, where the ascorbate consumption could be determined. It is known, 
that even low DMSO concentrations can interact with the ascorbate radical and generate the 
ascorbyl free radical (AFR)*DMSO complex.[309,310] Thus, DMSO cannot be used in measurements 
in which radicals are formed, due to its scavenging effect.[311,312] Attempts were carried out with 
other organic solvents such as methanol. However, also methanol and the other solvents are 
radical scavenger and disturb in the measurements.[313] During this study, no solvent was found 
which does not interact with the ascorbyl radical.  
 
8.5 Conclusion 
The synthesised multifunctional tools were examined with respect to their intercalation capacity 
in Aβ fibrils, their inhibition of ascorbate consumption and their cytotoxicity. In the binding 
study, an intercalation of the LXBTA compounds could be observed. Thus, the affinity of the BTA 
could be successfully implemented in the multifunctional tool. Although many attempts and 
various conditions were tried no conditions could be found to perform the ascorbate experiment 
with the final multifunctional tools. Nevertheless, coupling of the chelator should not influence 
its coordination capabilities. Thus, it can be assumed that the inhibition ability of the final 
systems resembles the model complexes. This hypothesis is supported by the results of the 
modified viability assay, where the same reactivity could be observed for L3BTA, L5BTA and their 
corresponding model ligands. Furthermore, could the viability assay show that neither L3BTA nor 
L5BTA is cytotoxic and thus both compounds are suitable for in vivo studies. Unfortunately, the 
solubility of the most promising multifunctional tool, L8BTA, has to be improved before useable 
in such studies, for example: through the attachment of a sulfonate alkyl at the triazole 


















9.1 Summary  
AD is the most common neuro-degenerative disease in the world.[1] AD is clinically characterised 
by a decreased cognitive performance resulting from neuronal losses in different cognitive 
domains, and can pathologically be characterised by formation of β-amyloid plaques (Aβ 
plaques) and intracellular neurofibrillary tangles (NFTs).[3,4,7] Although AD is the most frequent 
form of dementia, no therapeutic strategy which can cure the disease or restore the cellular 
losses is yet available.[217] The main reason for this lack is that AD is a very complex disease with 
various hallmarks and the current understanding of its origin and progression is only limited. 
Evidence exists that these processes may be copper-mediated.[99] Specifically, neuronal losses 
may originate from metal induced oxidative stress.[216] Thus, different reaction pathways and 
redox cycles have been proposed which may play a significant role in AD.[173] However, 
involvement of Cu+ in AD has yet to be proven as most analytic methods and techniques cannot 
detect it. Thus, the aim of this study was the development, synthesis and characterisation of a 
multifunctional tool, which can be used in vivo and in vitro to gain a more profound 
understanding of the Cu+ chemistry in AD. This multifunctional compound should consist of two 
subunits: a Cu+-selective chelating moiety and an Aβ-plaques sensitive benzothiazole derivative. 
In order to achieve this goal, a five-stage plan was developed and will be evaluated in this 
chapter. 
1. Synthesis and characterisation of Cu+ selective ligands considering inorganic and biological 
aspects. 
The ligand design was undertaken with consideration of the Irving-Williams series[233] and the 
concept of Pearson[232], resulting in a mixed {NXSY} donor set for selective Cu
+ coordination. The 
second aspect considered in the ligand design was the complex geometry. LFSE does not 
contribute to Cu+ coordination. Thus, complex geometry is defined by the steric demand of the 
ligands, which for four donor atoms results in a preferred tetrahedral geometry. Ligands were 
therefore designed to be pre-organised towards tetrahedral cooridnation. Taking these aspects 
into account eight ligands were synthesised in moderate to good yields were in two different 
approaches. The first approach consisted of five tripodal ligands with an {NS2} moiety (L
1H-L5H) 
and one ligand with an {N3} moiety (L
6H). In the second approach two tetradentate ligands were 
synthesised with an {N2S2} moiety (L
7H and L8H). Ligand design was kept as simple as possible in 
order to follow “Lipinski’s Rule of Five” and ensure their absorption and permeation of cell 
membranes.  
2. Exploring the complexation abilities of the designed ligands with respect to selectivity, stability 
and metal exchange properties.  
The synthesised ligands were investigated with respect to their complexation behaviour towards 
Cu+ and Cu2+ on order to determine their selectivity. Most of the obtained metal complexes could 
be characterised in solution as well as in the solid state, indicating that, only the rigid chelators, 
L3H and L5H from the tripodal systems, and L8H from the tetradentate ligands, are suitable for the 
desired application. In 1H-NMR experiments it could be demonstrated that these three ligands 
can selectively coordinate Cu+ in buffer solution. The stability constants of the three compounds 
were determined by UV/Vis ligand replacement experiments in order to study their affinity 




towards Cu+. Furthermore, the ability of chelators to extract Cu+ from the Cu(Aβ)+ complex was 
evaluated. Thus, a 1H-NMR metal exchange experiment was conducted, indicating that only L8H 
can compete with the protein, whereas the tripodal systems form ternary complexes. 
Nevertheless, the three ligand systems can interact with the Cu(Aβ)+ complex and should 
therefore be able to alter the progression of AD.  
3. Studies of the inhibition of ROS generation. 
Since metal induced ROS is proposed to be involved in AD progression, ligands were investigated 
with respect to their protective function against ROS. This was done via time dependent 
ascorbate consumption and cell viability tests. Although all ligand systems showed a protective 
functionality in the ascorbate consumption experiment, only the tetradentate ligand L8 was 
more active than Aβ. Unfortunately, this result could not be extended to the cell viability tests as 
L8H showed toxic behaviour. In contrast to this, L3Me and L5Me were not toxic and even showed a 
slight protective functionality against metal induced ROS. 
 4. Synthesis of benzothiazole derivatives of Aβ-plaque markers and coupling with the evaluated 
ligands. 
Although many different approaches for the synthesis of benzothiazole derivatives are known in 
the literature, most of the synthetic routes lack flexibility.[242,243] In this study a convenient 
pathway was established, which offers the possibility to combine different building blocks via 
Suzuki Coupling as the key step, leading to various benzothiazoles.[296,297] In a first approach 
towards the target multifunctional tools, a set of different ethylene and propylene spacers were 
attached to the synthesised BTA. Unfortunately, nucleophilic attachment of the ligand was not 
possible due to various side reactions. Finally, the three multifunctional tools L3BTA, L5BTA and 
L8BTA could be synthesised via click chemistry and were characterised with various methods, 
including UV/Vis-spectroscopy and NMR spectroscopy. In cell viability tests, L3BTA and L5BTA 
showed the same reactivity as the corresponding ligands, whereas L8BTA could not be used most 
likely due to its poor solubility. 
5. Binding studies of the final compounds with Aβ-plaques.  
The synthesised multifunctional tools were examined with respect to their intercalation capacity 
in Aβ fibrils, to prove if the affinity of the BTA could be successfully implemented. No 
intercalation could be detected at neutral pH due to the low solubility of the compounds. 
However, at a pH of 4.5 the intercalation could be followed by fluorescence spectroscopy. As no 
changes were visible in the UV/Vis spectra, it can be assumed that the interaction between 
fibrils and LXBTA is rather weak. 
 
9.2 Conclusion and Outlook  
The aim of this study was the synthesis and characterisation of a multifunctional tool suitable for 
selective coordination of Cu+, which could be achieved in a five-stage plan. Besides the synthesis 
of Cu+ selective chelators, a new synthetic pathway to benzothiazoles was established. Coupling 
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of the evaluated ligands with such a benzothiazole afford three multifunctional tools, L3BTA, 
L5BTA and L8BTA, which are not only metal selective but also contain an Aβ plaque sensitive unit.  
In according with “Lipinski’s Rule of Five”, the final molecules are relatively nonpolar and should 
be able to cross the BBB and cell walls. However, this also resulted in poor aqueous solubility of 
the compounds, which complicates the analytics. Specifically, the most promising system L8BTA 
is poorly soluble in water and therefore could not be used in the cell viability tests. Thus, 
increasing the solubility would be the next step in the project progress. This could be achieved 
by the introduction of a water soluble group, e.g. a sulfonate group, on the ligand, the 
benzothiazole, or on the triazole.[314] This would allow for cell viability tests and also binding 
studies in neutral buffer solution. Furthermore, water soluble compounds would allow studies 
on their alteration of the Aβ aggregation. Nevertheless, two multifunctional tools, L3BTA and 
L5BTA, could be synthesised, which show protective functionality against metal induced ROS and 
which are not toxic. Thus, these two compounds are suitable for preliminary in vivo testing.  





















Carbon monoxide (CO) is a stable, highly toxic gas, which is endogenously produced in plants, 
bacteria and animals by heme oxygenase enzymes.[315] CO serves as a natural detoxicate and can 
protect cells against oxidative stress.[316–318] In vivo CO can bind tightly to heme-containing 
targets (e.g. soluble guanylate cyclase, cytochrome c oxidase, NADPH oxidase, and BK potassium 
channels). It has been demonstrated that besides nitric oxide[319] and hydrogen sulphide,[320] CO 
is involved in the intracellular signal transduction.[321] Furthermore, CO participation in important 
biological activities such as resolution of inflammatory states, vasorelaxation, anti-apoptotic, and 
cyto-protective actions could be shown.[322,323] In low doses even a protective function against 
ROS could be proven.[322] Thus, the growing interest for pharmaceutical applications of CO in the 
last decades is no surprise, but implementation is not a simple task, since overdoses are highly 
toxic. The discovery of CO-releasing molecules (CORMs), compounds that serve as carriers and 
can release CO in a controlled fashion finally opened a pathway to new therapies.[324,325] In 
general two different types of CORMs can be distinguished. The first type of CORMs consists of 
boranocarbonates with sodium boranocarbonate (CORM-A1) as representative. These 
boranocarbonates can spontaneously release CO under physiological conditions, which make 
them superior for medical applications. [326–328] The second type comprises of metal carbonyl 
complexes with different transition metals, mainly ruthenium, rhodium, iron or 
manganese.[322,329] The most famous representatives of this group are the lipid-soluble 
tricarbonyldichlororuthenium(II) dimer (CORM-2) and the water-soluble 
tricarbonylchloro(glycinato)ruthenium(II) (CORM-3) (Figure 45).[324,325]  
 
Figure 45 Literature known CO-releasing molecules (CORMs). 
The aim of the current research mainly lies in the development of CORMs, which can under 
physiological conditions achieve a beneficial delivery of CO. To provide this, the compounds have 
to release CO in specific amounts over an extended time period or by an external trigger. 
Photoactive CORMs fulfil these requirements and are announced as potential therapeutics.[330–
333] Especially the manganese-containing systems have already shown remarkable cytotoxicity 
against cancer cells. Investigation of the take-out of HT-29 and MCF-7 human cancer cells with 
[CpMn(CO)3] (cymantrene) and its conjugate with cell-penetrating peptides (CPP) have shown a 
good activity. However, the long half-life of several hours and slow photolytic release alleviate 
the results (Figure 46).[334,335] The next generation, the [Mn(CO)3(tpm)]
+ 
(tpm = tris(pyrazolyl)methane) complex and its derivatives have a shorter half-life and feature by 
a higher activity, e.g. cytotoxicity on human colon cancer cells.[244–246] Nevertheless, for 
pharmaceutical applications the irradiation has to be done at high wavelengths were the skin 
becomes permeable and so far no CORM is available, which combines all requirements.  





Figure 46 Manganese based light induced CORMs (tpm = tris(pyrazolyl)methylene, tpp = tris(pyridine-2yl)-
phosphane). 
Thus, most of the new developed CORMs consist of aromatic donor groups, such as pyridine or 
pyrazol. Fine-tuning of the physical and chemical properties of the CORMs is normally done by 
different substituent on the aromatic system. Variation of the donor set is only rarely done, 
since prognosis of the resulting CORMs behaviour is not easy, because it depends on various 
factors. Although there is a broad variation of reported CORMs in literature, up to date no mixed 
donor system with a {NS2} binding motif is known. The tripodal ligands L
3Me and L5Me consist of 
two relatively weak thioether donors and one strong pyridine donor. The prepared Cu+ complex, 
presented in appendix A, shows that relatively few electron density is provided by the ligand. In 
case of manganese-based CORMs should this result in a weak Mn-CO bonding, which could 
induce a short half-life and a fast CO release. Thus the chelators stand out from previously 
reported systems. Furthermore, it could be demonstrated, that the synthesised ligands can be 
easily modified to precursors for click chemistry, allowing the coupling of the ligands to CPP or 
other molecules. L3Me and L5Me are therefore perfect candidates for the synthesis of CORMs. In 
the following chapter, the synthesis and characterisation of four new CORMs and first studies of 
their capabilities as CO suppliers will be presented. The main focus of this work lies in answering 
the question: Does the {NS2} moiety lead to a new type of CORMs? Besides L
3Me and L5Me also L6H 
was used to have a direct comparison. With its three pyridines, L6H is similar to the previously 
reported tpp (tris(pyridine-2yl)-phosphane) chelator.[336] However, in contrast to the literature 
known system, L6H has the advantage, that it can be easily modified on the amine and thus 
coupling e.g. to CPPs is possible. 
 
10.2 Synthetic Approach to New CO–Releasing Complexes 
The first step of the synthesis of the {NS2}-CORMs is the preparation of the manganese precursor 
(Figure 47). The commercially available dimanganese decacarbonyl was therefore halogenated 
with elemental bromine. After sublimation, the precursor [Mn(CO)5Br] could be obtained as fine 
yellow crystals in very good yields (65 %) according to literature (58-67 %).[337]  
 
Figure 47 Synthesis of manganese based CO-releasing molecules. 
The manganese complex was activated in situ by treating [Mn(CO)5Br] with silver triflate in 
acetone.[334,335] After 1.5 h heating under reflux was the salt metathesis completed and the 
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precipitated silver bromide was separated by filtration. To the filtrate equimolar amounts of 
ligand were added and the reaction heated for further 90 min. The reaction solution was 
reduced to a few ml and afterwards the final complexes were crystallised from 
dichloromethane/diethyl ether. The products could be obtained as yellow crystals. All reactions 
were carried out under light exclusion to avoid decomposition. By crystallisation only moderate 
yields could be achieved (Table 22). Higher yields could be provided without crystallisation, by 
precipitating the complexes with diethyl ether directly out of the reaction solution.  
Table 22 Synthesised CORMs and their yields. The numbers in brackets corresponds to yields obtained by 
crystallisation.  
 Complex Yield [%] 
20 [L3MeMn(CO)3]OTf 92 (65) 
21 [L5MeMn(CO)3]OTf 97 (71) 
22 [L6HMn(CO)3]OTf 95 (28) 
 
10.3 CORM Characterisation in Solid State 
Molecular structures of all three complexes could be elucidated by X-ray crystallography, 
revealing an interesting behaviour in solid state (Figure 48). Expected was manganese 
coordination by the {NS2} moiety of L
3Me and L5Me, which was indeed observed for 21. However 
the structural refinement of 20 reveals coordination by the two sulphur atoms of the thioether 
sidearm and, instead of the pyridine, the methoxy group is coordinated. One explanation for this 
unexpected binding motive could be that the ether coordination allows a tighter bonding of the 
CO molecule in trans position. Ether groups are weakly coordinating donor groups without π 
acceptor properties. Thus, the trans CO has no competitor for the d-orbitals and can form a 
strong π-backbond. Indeed, comparison of the bond lengths shows that the CO opposing the 
ether group is most strongly bond to the manganese (1.8010 Å vs. 1.8215 Å and 1.8234 Å). The 
CO molecules trans to the thioether groups are longer most likely due to their, though weak, π-
acceptor character.[338] The CO molecules in 21 are with Mn─CO bond lengths between 1.8057 Å 
and 1.8146 Å in general slightly tighter bound then in 20. Prominent bond length are 
summarised in Table 23. Both molecular structures reveal an almost ideal octahedral complex 
geometry for the Mn+ ion. The square planes are in each case constituted by the two sulphur 
atoms and two CO molecules. Important bond angles are summarised in Table 24.  
 
Figure 48 Molecular structure of 20 (left) and 21 (right). Hydrogen atoms and the counterion were omitted for a 
better structural overview. 
20 21 




For the molecular structure of 22 was a coordination of the three pyridine groups expected. 
However, similar to 20, one pyridine is not coordinated and the octahedral complex geometry is 
saturated by the amine. Another similarity is the short M─CO bond length of the trans CO 
molecule, which is with 1.7859 Å more tightly bound than the other two CO molecules (1.8054 Å 
and 1.8210 Å).  
 
Figure 49 Molecular structure of 22 (left) and 23 (right). Hydrogen atoms and the counterion were omitted for a 
better structural overview. 
To disfavour the coordination of the amine and forcing the coordination of the third pyridine, L6H 
was acetylated. L6H was treated with acetic anhydride to synthesise L6Acet.[339] According to the 
literature L6Acet could be synthesised in good yields (71 %, Lit.: 71 %[339]) and with the standard 
procedure for the synthesis of CORMs also [L6AcetMn(CO)3]OTf (23) could be provided. 
Surprisingly, even in the molecular structure of 23 is the amine still coordinated instead of the 
pyridine, although the acetyl group withdraws electron density from the amine and thus 
weakens its donor capacity. The shortest Mn─CO bond is again found for the CO in trans position 
of the amine (1.8044 Å). The octahedral complexes 22 and 23 are in the square plane each 
constituted by two pyridine groups, and two CO molecules, and in the axial positions by the 
amine group and one CO molecule. 
Table 23 Selected bond lengths in the molecular structures of 20-24. Numbers marked with a) refer to the amine. 










































Table 24 Selected bond angles of the molecular structures of 20-24. 
 S1─Mn─S2 [°] S1─Mn─N/O[°] S2─Mn─N/O [°] 
20 82.93(3) 83.89(6) 81.09(6) 
21 81.07(4) 90.58(9) 88.65(9) 
 N1─Mn─N4 [°] N4─Mn─N2 [°] N1─Mn─N2 [°] 
22 77.03(13) 78.17(14) 84.47(9) 
23 75.72(9) 78.52(9) 84.65(14) 
 
10.4 DFT Calculations of CORMs 
To get an impression whether the coordination of the weak donor groups is thermodynamically 
induced by stabilisation of the CO or induced by other effects, theoretical calculations were 
performed by Prof. Ulrich Schatzschneider (Institut für Anorganische Chemie der Julius-
Maximilians-Universität Würzburg, Germany). Basis of the calculations were the atom 
coordinates from the structure refinement. The relative energies for the crystallised binding 
mode and for the corresponding alternative binding mode were calculated. In Figure 50 and 
Figure 51 the optimised structures and their energies are illustrated. The energies calculated for 
the binding modes, which crystallised were set to zero for a better comparison. The structure of 
20 revealed a coordination of the {OS2} moiety. However, the theoretical calculation shows that 
the coordination of {NS2} moiety should be energetically favoured (+82.0 kJmol
-1). An analogous 
result was obtained for 21 with an energy difference of 55.4 kJmol-1. Although, the energy 
difference between the two possible modes in 22 is only minor (9.5 kJmol-1), the coordination of 
the amine is energetically favoured. With the electron withdrawing acetyl group of L6Acet is 
coordination of the amine unlikely, which could also be shown in the calculation. The 
coordination of the three pyridine groups is strongly favoured (-58.1 kJmol-1). Thus, the 
hypothesis from the structural characterisation, that the coordination of the weak donor groups 
stabilises the complexes due to the formation of strong π-backbonding to the trans CO molecule 
seems only to apply to 22. Consequently, the coordination of the rather weak ether in case of 20 
or amine group, in case of 22 and the resulting loss in energy must be compensated by packing 
effects in the crystal structures. Since in 20 and also in 23, the crystallised binding modes are 
strongly disfavoured, the crystal structures were further examined, to get more information 
about how the loss in energy could be balanced.  






Figure 50 Optimised structures and relative energies of 20, 20b, 21 and 21b (RI-BP86). Structures marked with b 
correspond to the alternative binding mode. 
 
 
Figure 51 Optimised structures and relative energies of 22, 22b, 23 and 23b (RI-BP86). Structures marked with b 
correspond to the alternative binding mode. 
The view of the molecular arrangement revealed a π-π stacking of the unbound pyridine rings in 
case of 20, 22 and 23 (Figure 52). Even energetically disfavoured binding modes, like the 
observed ones, can be stabilised by π-π stacking, since electron deficient aromatic rings, such as 
pyridine, can form strong π-π interactions due to the polarisation induced by the 
heteroatom.[340] For pyridine rings are two different π-π stacking modes possible: i) face to face, 
with perfect alignment of the aromatic rings, or ii) offset, with a parallel displacement.[341] In the 
latter case, one carbon atom of each ring is often found orthogonal to the centre of the other 
ring. The distance between two parallel molecular planes reaches between 3.3 Å for strong 
20 (0.0 kJmol-1) 20b (+82.0 kJmol-1) 
21 (0.0 kJmol-1) 21b (-55.4 kJmol-1) 
22 (0.0 kJmol-1) 22b (+9.5 kJmol-1) 
23 (0.0 kJmol-1) 23b (-58.1 kJmol-1) 
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interactions to 3.8 Å for rather weak interactions.[341] In the molecular structure of 20 is each 
pyridine neighboured by two other pyridine. The closer one is in a centroid-centroid distance of 
around 4.7 Å and shows only a minor overlap were only two carbons are parallel aligned (3.6 Å). 
The long distance and large displacement of the aromatic rings indicate a rather weak π-π 
interaction. The second pyridine is offset aligned in a centroid-centroid distance of 5.2 Å. 
Although a fitting overlay is present, in which one carbon atom of each ring is aligned orthogonal 
to the centre of the other aromatic ring, is the interaction diminished due to the long distance. 
 
Figure 52 Molecular structures of 20 (a), 22 (b, c) and 23 (d, e). Counterions and hydrogen atoms are omitted for a 
better overview. 
The structure of 22 and 23 showed completely separated pyridine pairs. Two pyridine rings are 
in 22 aligned in a centroid-centroid distance of approximately 3.8 Å. The displaced arrangement 
is typical for pyridine-pyridine stacking with one carbon atom orthogonal to the ring centre. The 
same arrangement could also be found in the structure of 23 with a centroid-centroid distance 
of 3.8 Å. Besides the characterisation in solid state, the complexes were also characterised in 
solution by ESI-MS and NMR techniques. In solution π-π interaction are hindered due to the 
formed solvent shell. Thus, the thermodynamically most stable binding mode should be formed. 
The 1H-NMR spectrum of 21 shows a broadening of all resonances which could be either induced 
by a fast exchange or by paramagnetic impurities. However, the imidazole signals are shifted, 
indicating their coordination. For complex 22 was calculated, that the coordination of the amine 
is slightly favoured over the coordination of the pyridine. Accordingly, the 1H-NMR spectrum 








spectrum of 23 shows separated resonances for each pyridine. Furthermore, the signals are 
broadened, indicating a fast exchange or paramagnetic impurities.  
 
10.5 Spectroscopic Behaviours of the Synthesised CORMs 
In order to study the potential of 20 - 23 as photo active CORMs their spectroscopic behaviour 
were examined. First of all, UV/Vis spectra were recorded to determine the excitation 
wavelengths and the extinction coefficients. Figure 53 shows the spectra of 0.5 μM complex in 
0.1 M phosphate buffer (pH 7.4). Direct comparison of the four complexes shows that 21 has the 
highest excitation wavelength (379 nm) and thus contains the lowest LFSE (141 kJmol-1); than 
follows 20 with a LFSE of 151 kJmol-1. The complexes 22 and 23 have the highest LFSE 
(155 kJmol-1 and 159 kJmol-1) and the lowest excitation wavelengths. The order can be reasoned 
by the different donor groups in the ligands. As mentioned before, pyridine is a strong σ-donor 




















Figure 53 UV/Vis spectra of 20, 21, 22 and 23 at 0.5 μM n 0.1 M phosphate buffer (pH 7.4). 
The weak {NS2} donor set in 21 and 20 barely provides electron density to the metal and thus the 
ligands induce only a low LFSE. The small deviation between 22 and 23 is most likely induced by 
the acetyl group, which causes a slightly higher LFSE. However, all complexes have their 
excitation in the short wavelength range, which is a typical region for many manganese 
containing CORMs.[342,343] The determined extinction coefficients for 20 and 21 are low and only 
one-third of the extinction coefficients for 22 and 23. The larger values most likely results from 
the different electronic structures in the complexes. Table 25 summarises the determined 
excitation wavelengths, extinction coefficients and LFSEs of the synthesised CORMs. The LFSE is 
inversely proportional to the excitation wavelength and was calculated by equation 7 (NL = 
Loschmidt constant, h = Planck constant, c = velocity of light).[281]  
           
 
 
     (7) 
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20 380 730 140  
21 355 759 150 
22 345 2304 155 
23 335 2193 159 
 
The compounds were further characterised by IR spectroscopy (Figure 54). In solution 
(dichloromethane) one strong IR band (A1 mode) at around 2050 cm
-1
 and two additional bands 
(A2 mode, B2 mode) between 1933 cm
-1 and 1980 cm-1 could be observed. 




































Figure 54 IR spectra of 20 (red), 21 (blue), 22 (violet) and 23 (pink) in dichloromethane. 
This is an expected pattern for fac-Mn(CO)3 complexes with Cs symmetry. The measurements in 
solution are essential, since in solid state a different binding mode is present. Table 26 
summaries the CO vibration bands of the synthesised CORMs. Stretching vibrations decrease in 
the series according to 20 > 21 ≈ 23 > 22 and results from the electronic structure in the 
complex. Thus, the IR spectroscopic analysis is similar to the measured UV/Vis spectra. 
Furthermore, the recorded CO stretching vibrations are in accordance with comparable 
literature known CORMs.[330,336]  








































Table 26 CO stretching vibrations ṽ co of 20-24 and literature known complexes (tpm = tris(pyrazolyl)methylene, 
tpp = tris(pyridine-2yl)-phosphane). For the spectra in solution compounds were dissolved in dichloromethane. 
 ṽCO [cm
-1] 
 in solution  in solid state 
20 2052, 1974, 1953 2047, 1967, 1944 
21 2047, 1967, 1945 2043, 1980, 1954 
22 2042, 1958, 1933  2046, 1960, 1940 
23 2047, 1964, 1944 2046, 1960, 1940 
[Mn(CO)3tpm]OTf
[330] 2050, 1950 - 
[Mn(CO)3tpp]OTf
[336]
 2042, 1951 - 
 
10.6 Photoinduced Time Dependent CO Release 
As mentioned above, the stability of CORMs in the dark and selective CO release upon 
irradiation are essential features for therapeutic applications.[245,330] In order to study the 
stability in solution, UV/Vis spectra were recorded after 12 h and 24 h incubation time of the 
compound under light exclusion. All four complexes are stable in solution and do not release CO 
in the dark. Photolytic activity of the compounds was followed by UV/Vis. Figure 55 shows the 
time-dependent changes of the UV/Vis spectra of 21 as an example. The specific complex 
absorption at 380 nm vanishes upon irradiation at 365 nm and a new band appears at around 
500 nm. Since no isosbestic points could be observed, it can be assumed that a stepwise CO 
release takes place.  




































Figure 55 Photolysis experiment of 21 in 0.1 M phosphate buffer (pH 7.4). The sample was irradiated at 365 nm.  
In order to study the photoactivity, a myoglobin was assay performed.[329,344,345] Horse skeletal 
muscle myoglobin was dissolved in degassed 0.1 M phosphate buffer (pH 7.4). The myoglobin 
was reduced in situ by a freshly prepared dithionite solution and afterwards the CORM complex 
in DMSO was added. The experiment was at least repeated three times with different incubation 
durations in the dark (between 1 h and 21 h). However, before determining the CO release, a 
dark measurement was carried out to verify again the stability of the CORMs in solution. The 
samples were therefore kept in the dark for 16 h or 21 h at 8 °C and every 5 min the absorption 
at 510 nm, 540 nm, 557 nm and 577 nm were measured. Again, no CO release was detected. In 
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the second step, the samples were irradiated for 5 min at 365 nm. After 1 h, the irradiation-time 
was expanded to 10 min. Figure 56 exemplary shows the CO release of 21. 














Figure 56 CO release of 10 μM 21 after 2 h in the dark. The fit corresponds to the equation: y = Aexp(x/t1/2)+y0. 
21 and also the other synthesised CORMs can release up to approximately two CO molecules 
upon irradiation (Table 27). Comparison with other CORMs shows that only systems with bulky 
ligands release one equivalent CO.[336] Small ligands like L3Me, L5Me, L6H and L6Acet should be able to 
release up to two mole CO per mole CORM. Thus, the myoglobin assay supports the hypothesis 
from the photolysis experiment, that a stepwise CO release is taking place. Another important 
value, besides the number of released CO molecules (nCO), is the half-life (t1/2), which were also 
determined.  







20 16 41.16  2.23 
20 1 87.03  2.11 
20 2 74.31  1.52 
21 16 14.68  2.18 
21 1 49.2  1.77 
21 1 24.13  1.48 
21 2 42.68  2.34 
22 16 9.55  1.95 
22 2 15.64  1.27 
22 1 18.2  1.49 
23 2 21.95  2.45 
23 2 13.56  2.05 
23 21 5.558  2.79 
[Mn(CO)3tpm]OTf
[330] - 20  1.96 
[Mn(CO)3tpp]OTf
[336]
 - 17  2.28 
[Mn(CO)3tip
iPr2]OTf[336] - 13  1.04 
 




 The longest half-life and thus the most stable complex was found for 20 (41 - 87 min). 21 follows 
with a half-live of 15 - 49 min. 22 and 23 show a similar reactivity and have a similar half-life (6 -
 22 min) and are the only systems which can compete with literature known complexes. Both 
complexes show a higher activity than [Mn(CO)3tpm]
+, but not surpass the currently known 
CORMs. Nevertheless, this synthesised CORMs show good results for a first generation and 
provide a good starting point for further developments. The Myoglobin assay illustrates that the 
measurement of the number of released CO is no simple task and depends on various factors. 
The comparison of the results shows that the longer the incubation times, the shorter are the 
observed half-lifes. The shortened half-lifes are probably due to an interaction between the 
myoglobin and the CORMs. However, studies on the kinetics were not done. Thus, the 
mechanism of the exact CO release is not known and can only be speculated about. Scheme 37 
illustrates possible reaction pathways in the CO release experiment. The first step is the 
irradiation of the CORMs, which results in an excited complex. This complex can either release 
one CO molecule or react back to the not ground state via relaxation. After release of one CO 
molecule, a vacant position is left on the metal, which should be saturated by a solvent 
molecule. For this new complex are three reaction pathways possible. The complex could either 
also be irradiated by light or it could dimerise or decompose. All three pathways could lead to 
the release of another CO molecule. The performed experiments only indicate a stepwise CO 
release, but do not provide any information on the origin of the second CO molecule. Thus, 
without further studies on the intermediates which are formed during the experiments, it is 
impossible to define the right reaction pathway. It is noteworthy to mention that also more than 
just one reaction pathway could take place. Thus, the systems would become even more 
complicated.  
 
Scheme 37 Possible reaction pathways for the CORMs upon irradiation.  
 
10.7 Conclusion 
Besides the two trispyridyl-CORMs 22 and 23, with 20 and 21 a new class of manganese-based 
CORMs were developed. The two complexes contain a unique {NS2} binding moiety, which had 
not been tested before in this context. All four CORMs were characterised by several 
spectroscopic techniques and in solid state. The structural analysis revealed an interesting 
switch in the binding mode due to the formation of π-π stacking of the pyridines in solid state. 




pyridine donors by rather weak methoxy or amine groups. The synthesised complexes were used 
for first studies of their CO-release capability. It could be demonstrated that all four complexes 
can release up to two equivalents of CO upon irradiation by light. Only the irradiation 
wavelength under 400 nm and the long half-lifes of 20 and 21 compromise the overall good 
results. Nevertheless, the two complexes 20 and 21 are the first examples of thioether-
containing CORMs and should be useful as starting point for a next generation. Especially the 
substitution of the sulphur atoms by a heavy atom such as selenium would be very interesting.  
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11.1 General Remarks 
Reactions Under Inert Atmosphere 
Reactions, which were carried out under inter atmosphere were performed in an anaerobic and 
anhydrous atmosphere of dry nitrogen flashed over copper catalyst, by employing standard 
Schlenk techniques. Solvents were dried as follows: Et2O over sodium benzophenone ketyl; THF 
over potassium benzophenone ketyl; MeCN, DMSO over CaH2; CH2Cl2 and CHCl3 over P4O10 and 
MeOH over Mg. The deuterated solvents were dried and distilled analogous. Glassware was 
cleaned by passing through an ethanolic KOH bath followed by HCl bath (in each 24 h) and dried 
over night at 100 °C.  
Preparation of Metal Precursors 
[Cu(MeCN)4]OTf and [Cu(MeCN)4]PF6 were synthesised according to the literature.
[346] The metal 
salts were crystallised from MeCN/Et2O and stored under N2-atmosphere to prevent oxidation. 
[Mn(CO)5Br] for the synthesis of the CORMs was synthesised according to the literature.
[337] The 
complex was stored under exclusion of light.  
Utilised Analytical Methods and Devices for the Synthetic Part 
1H-NMR and 13C-NMR spectra of the synthesised compounds were recorded on Bruker Avance 
200 MHz, 300 MHz and 500 MHz spectrometers. No internal standard was used in the 
measurements, thus calibration is based on the residual signal of the solvent (CDCl3 = 7.24 ppm 
and 77.1 ppm, MeCN-d3 = 1.94 ppm and 118.3 ppm, MeOH-d4 = 3.31 ppm and 49.1 ppm, DMSO-
d6 = 2.46 ppm and 29.9 ppm). The abbreviations s (singlet), d (doublet), t (triplet) indicate the 
spin multiplicity and J corresponds to the coupling constants. The assignment of the signals takes 
place according to the IUPAC numbering of the molecules. Sample preparation for IR spectra of 
the solids were done by grounding the sample with KBr in a mortar and then pressing under 
vacuum at 100 Kg/cm2 into a tablet. Liquid samples were homogeneously applied between two 
KBr windows and directly measured. The used IR spectrometer was a Digilab Excalibur. The 
abbreviations are s (strong), m (medium), w (weak), b (broad signal). EI mass spectra were 
measured on a Finnigan MAT 8200 and ESI mass spectra were recorded on a Thermo Finnigan 
Trace LCQ spectrometer. UV/Vis spectra were recorded in quartz cuvettes with an Analytik Jena 
Specord S100 spectrometer and the fluorescence spectra were recorded with a Jasco FP-6200 
spectrofluorometer. Temperature-dependent magnetic susceptibilities of crystalline material 
were recorded on a Quantum Design MPMS-5S SQUID magnetometer at 0.5 T. Recorded data 
were corrected for the underlying diamagnetism by using tabulated Pascal constants 
(incremental method) and for temperature independent paramagnetism (TIP). Elemental 
analysis was performed by the Analytical Laboratory at the Institute of Inorganic Chemistry at 
the Georg-August University on a Vario EL II from Elementar. Melting points were determined on 
a SRS OptiMelt. The microwave used for the Suzuki coupling reaction was a CEM Discovery, 
which was used with 250 W. 
Utilised Analytical Methods and Devices for the Metal Selectivity and Affinity Studies 
The 1H-NMR metal exchange experiments were carried out on Bruker Avance 500 MHz 
spectrometer equipped with a 5 mm triple resonance inverse Z-gradient probe (TBI 1H, 31P, BB). 
Spectra were collected at 298 K in deuterated buffer solution. The water signal was suppressed 




in the measurements. UV/Vis spectra were recorded in quartz cuvettes with an Analytik Jena 
Specord S100 or a Hewlett Packard Agilent 8453 spectrometer at 25 °C. The fluorescence spectra 
were recorded with a Jasco FP-6200 spectrofluorometer. All UV/Vis and NMR experiments were 
performed in argon-degassed solutions and under argon atmosphere. 
Utilised AnalyticalMmethods and Devices for the CO Release Studies 
For the CO release studies UV/Vis spectra were recorded with the kinetic function of an Agilent 
8453 spectroscopy system. The measurements were performed in argon-degassed solutions and 
under argon atmosphere. 
Theoretical Calculations of the CORMs 
Density functional theory (DFT) calculations were carried out on the Linux cluster of the Leibniz-
Rechenzentrum (LRZ) in Munich with ORCA version 2.8[347] using the BP86 functional with the 
resolution-of-the-identity (RI) approximation, a def2-TZVP/def2-TZVP/J basis set,[348,349] the 
tightscf and grid4 options, and the COSMO solvation model with DMSO as the solvent for 
geometry optimisations. The DFT calculations were performed by Prof. Dr. Ulrich 
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Synthesis of 1,3-bis(ethylsulfanyl)acetone (I) 
Ethanethiol (10.3 g, 12.4 ml, 167 mmol, 2.0 eq.) was added to a solution of potassium hydroxide 
(8.64 g, 167 mol, 2.0 eq.) in water and stirred for 30 min at room temperature. The solution was 
then cooled to 0°C and a solution of 1,3-dichloro acetone (10.5 g, 82.9 mmol, 1.0 eq.) in diethyl 
ether (100 ml) was slowly added. The reaction was stirred over night and allowed to warm to 
room temperature. The phases were separated and the aqueous phase was washed with diethyl 
ether (100 ml). The combined organic solutions were dried over Na2SO4 and the solvent 
removed under reduced pressure. The crude product was purified by column chromatography 
on silica to give the product as yellow oil. 
Yield:   11.8 g (66.1 mmol, 80 %) 
Rf:    0.48 (hexane : ethyl acetate / 6 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  3.41 (s, 4 H, CH2), 2.50 (q,
 3J(H,H) = 7.4 Hz, 4 H, CH2CH3), 1.22 (t, 
3J(H,H) = 7.4 Hz, 6 H, CH2CH3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:   200.2 (C=O), 38.0 (CH2), 26.1 (CH2CH3), 14.0 (CH2CH3) 
Mass spectrometry ESI+ (70 eV, MeOH) 
m/z (%): 178 (100) [M]+, 152 (65.6) [M - C2H2]
+, 117 (48.8) [M - C2H5S]
+ 
IR KBr 
ṽ [cm-1]: 2969 (m), 2928 (m), 2872 (w), 1703 (s), 1451 (m), 1408 (w), 1354 (m), 
1257 (m), 1187 (w), 1146 (w), 1078 (w), 1051 (w), 972 (w), 783 (w), 756 
(w), 570 (w), 492 (w) 
Elemental analysis C7H14OS2 (178.32 gmol
-1) 
Calculated (%):   C: 47.15, H: 7.91, S: 35.96 
Found (%):  C: 46.97, H: 7.28, S: 34.25 
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Synthesis of 1,4-dithiepan-6-one (II) 
In a 500 ml flask, 1,2-ethandithiol (22.20 g, 19.75 ml, 236 mmol, 1.0 eq.) was added to a solution 
of potassium hydroxide (26.45 g, 314 mmol, 2.0 eq.) in water. After 30 min stirring at room 
temperature the solution was cooled to 0 °C and a solution of 1,3-dichloro acetone (30.00 g, 
236 mmol, 1.0 eq.) in diethyl ether (250 ml) was slowly added. The reaction mixture was stirred 
over night and allowed to warm to room temperature. The phases were separated and the 
aqueous phase was washed with diethyl ether (100 ml). The combined organic solutions were 
dried over Na2SO4 and the solvent removed under reduced pressure. The product could be 
obtained as yellow oil. 
Yield:    28.43 g (191.7 mmol 84 %) 
Rf:    0.23 (hexane : ethyl acetate / 6 : 1) 
1H-NMR   (300 MHz, CDCl3) 
 δ [ppm]:   3.65 (s, 4 H, CH2), 3.09 (s, 4 H, SCH2CH2S)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  204.8 (C=O), 40.6 (CH2), 38.2 (SCH2CH2S) 
Mass spectrometry ESI+ (70 eV, MeOH) 
m/z (%): 148 (100) [M]+, 106 (17) [C3H6S]
+ 
IR KBr 
ṽ [cm-1]: 2905 (m), 1750 (w), 1699 (s), 1406 (s), 1279 (w), 1236 (m), 1161 (m), 
1088 (w), 912 (m), 830 (w), 763 (w), 679 (w), 525 (w), 454 (w), 427 (m) 
Elemental analysis C5H8OS2 (148.25 gmol
-1) 
Calculated (%):   C: 40.51, H: 5.44, S: 43.26 
Found (%):  C: 40.32, H: 5.60, S: 43.35  
 
 




Synthesis of 1,4-dithiepan-6-one oxime (III) 
Hydroxylamine hydrochloride (0.47 g, 6.75 mmol) and II (1.00 g, 6.75 mmol) were dissolved in 
ethanol (50 ml) and sodium acetate (0.55 g, 6.75 mmol) was added. The reaction was stirred for 
24 h at room temperature. Afterwards, the solvent was evaporated under reduced pressure and 
the solid residue was purified by column chromatography on silica to provide the product as 
white solid. 
Yield:   0.96 g (5.87 mmol, 87 %) 
Rf:    0.43 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  3.84 (s, 2 H, CHH), 3.74 (s, 2 H, CHH), 3.10-3.01 (m, 4 H, SCH2CH2S)
 
13C-NMR   (75 MHz, CDCl3):  
δ [ppm]:  160.48 (C=O), 39.27 (CHH), 37.12 (CHH’), 35.34 (SCH2CH2S), 29.72 
(SCH2CH2S) 
Mass spectrometry EI+ 
m/z (%):  163 (100) [M]+, 146 (23) [M - OH]+ 
IR KBr 
ṽ [cm-1]: 3268 (w), 2904 (w), 1485 (w), 1447 (m), 1403 (s), 1381 (s), 1284 (m), 
1250 (m), 1231 (m), 1186 (m), 1142 (m), 1102 982 (s), 926 (s), 892 (m), 
857 (m), 817 (m), 746 (m), 677 (m), 613 (m), 494 (m), 422 (s) 
Elemental analysis C5H9NOS2 (163.26 gmol
-1) 
Calculated (%):   C: 36.78, H: 5.56, N: 8.58, S: 39.28 
Found (%):  C: 36.79, H: 5.37, N: 8.29, S: 38.92 
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Synthesis of 1,4-dithiepan-6-ol (IV) 
A solution of II (1.00 g, 6.75 mmol) and sodium borohydride (0.26 g, 6.75 mmol) in abs. THF 
(50 ml) was stirred for 16 h at room temperature. The reaction was quenched by the addition of 
water (20 ml). The solution was adjusted to pH 7, using HCl and afterwards extracted with DCM. 
The combined organic phases were dried over Na2SO4. After evaporation of the solvent under 
reduced pressure, the product was re-crystallised from ethanol/hexane and could be obtained 
as white solid. 
Yield:   1.01 g (6.75 mmol, 100 %) 
Rf:    0.33 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  4.99 (d, 3J(H,H) = 6 Hz, 1 H, CHOH), 4.08-3.99 (m, 1 H, CHOH), 3.03 (dd, 
2J(H,H) = 6 Hz, 
3J(H,H) = 9 Hz, 2 H, CHH), (dd, 
2J(H,H) = 6 Hz, 
3J(H,H) = 9 Hz, 2 H, 
CHH), 2.87 (q, 3J(H,H) = 3 Hz, 4 H, SCH2CH2S)
 
13C-NMR   (75 MHz, CDCl3)  
δ [ppm]:   71.16 (CHOH), 37.49 (CHH), 38.96 (SCH2CH2S) 
Mass spectrometry EI+ 
m/z (%):  150 (100) [M] +, 132 (40) [M - H2O]
+, 104 (22) [C3H4S2]
+  
IR KBr 
ṽ [cm-1]: 3271 (w), 2897 (w), 1455 (s), 1411 (s), 1397 (s), 1344 (s), 1326 (m), 1293 
(s), 1269 (s), 1230 (m), 1204 (m), 1183 (m), 1163 (m), 1132 (m), 1095 
(m), 1032 (s), 998 (m), 949 (m), 918 (m), 848 (s), 802 (s), 755 (w), 698 
(w), 667 (s), 598 (w), 552 (w) 
Elemental analysis C5H10OS2 (150.26 gmol
-1) 
Calculated (%):   C: 39.97, H: 6.71, S: 42.68 
Found (%):  C: 39.84, H: 6.39, S: 42.19 




Synthesis of 2-(chloromethyl)-1,4-dithiane (V) 
Compound V was synthesised according to the literature.[272]  
Yield:   71 % (Lit.: 75 %) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  4.09 (dd, 3J(H,H) = 12 Hz, 
3J(H,H) = 9 Hz, 1 H, CH
2), 3.84 (dd, 3J(H,H) = 12 Hz, 
3J(H,H) = 6 Hz, 1 H, CHH
3), 2.94 (m, 7 H, CH2
5,6,7, CHH3) 
13C-NMR   (75 MHz, CDCl3)  





Mass spectrometry EI+ 
m/z (%): 168 (100) [M]+, 133 (68) [M - Cl]+, 119 (35) [M - CH2Cl]
+  
IR KBr 
ṽ [cm-1]: 2947 (m), 2906 (s), 2803 (w), 1431 (m), 1411 (s), 1323 (w), 1281 (m), 
1220 (m), 1163 (w), 1127 (w), 1070 (w), 999 (w), 926 (w), 908 (m), 886 
(m), 860 (m), 829 (w), 745 (m), 703 (s), 673 (s), 631 (m) 
Elemental analysis C5H9ClS2 (168.71 gmol
-1) 
Calculated (%):   C: 35.60, H: 5.38, S: 38.01 
Found (%):  C: 35.60, H: 5.38, S: 37.38 
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Synthesis of 6-(6-bromopyridin-2-yl)-1,4-dithiepan-6-ol (VI) 
Under a N2-atmosphere 2.5 M 
nBuLi (20.4 ml, 0.51 mmol, 1.5 eq.) was slowly added to a -78 °C 
cooled solution of 2,6-dibromopyridine (11.98 g, 0.51 mmol, 1.5 eq.) in abs. THF (300 ml). The 
solution was stirred for 1 h at this temperature. Afterwards the solution was added to a cooled 
solution of II (5.00 g, 0.34 mmol, 1.0 eq.) in THF (50 ml). After 4 h at -78 °C the reaction was 
quenched by the addition of brine (30 ml). The THF was removed under reduced pressure and 
the solution was extracted with chloroform after adjusting to a pH value of 7. The combined 
organic phases were dried over Na2SO4 and the solvent was removed under reduced pressure. 
After column chromatography on silica the product could be obtained as brown oil, which 
solidified at 4 °C.  
Yield:   2.39 g (78 mmol, 23 %) 
Rf:    0.34 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.57 (dd, 3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz, 1 H, CH
Py, 4), 7.45 (d, 3J(H,H) = 6 Hz, 1 H, 
CHPy, 5), 7.41 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 3), 5.54 (sbr, 1 H, COH) 3.59 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.18 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.02 (s, 4 H, 
SCH2CH2S)
 
13C-NMR   (75 MHz, CDCl3)  
δ [ppm]:   163.27 (CPy, 6), 141.11 (CPy, 2), 138.98 (CHPy, 4), 127.23 (CHPy, 3), 120.25 
(CHPy, 5), 68.34 (COH), 41.34 (CHH), 38.98 (SCH2CH2S) 
Mass spectrometry ESI+ (70 eV, MeOH) 
m/z (%): 345.9 (7) [M + K]+, 329.9 (100) [M + Na]+, 308.0 (14) [M + H]+, 290.0 (39) 
[M - OH]+ 
General Information C10H12BrNOS2 (306.24 gmol
-1) 
Calculated (%):   C: 39.22, H: 3.95, N: 4.57, S: 20.94   




Synthesis of 2-bromo-6-(6-methoxy-1,4-dithiepan-6-yl)pyridine (VII) 
Under a N2-atmosphere VI (350 mg, 1.14 mmol, 1.0 eq.) was dissolved in abs. THF (30 ml) and 
NaH (60 %, 54 mg, 1.37 mmol, 1.2 eq.) was added. The reaction was heated under reflux for 
30 min and afterwards methyl iodide (195 mg, 1.37 mmol, 1.2 eq.) was added. The reaction was 
heated for further 14 h under reflux and then quenched with water (5 ml). The THF was 
removed under reduced pressure and the residue was extracted with chloroform. The combined 
organic phases were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was purified by column chromatography on silica and the product was 
obtained as yellow solid. 
Yield:   227 mg (0.71 mmol, 62 %) 
Rf:    0.39 (hexane : ethyl acetate / 5 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.59 (dd, 3J(H,H) = 6 Hz, 
3J(H,H) = 6 Hz, 1 H, CH
Py, 4), 7.43 (d, 3J(H,H) = 6 Hz, 1 H, 
CHPy, 5), 7.42 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 3), 3.61 (d, 2J(H,H) = 15 Hz, 2 H, 
CHH), 3.21 (d, 2J(H,H) = 15 Hz, 2 H, CHH), 3.08 (s, 3 H, COCH3), 3.03 (s, 4 H, 
SCH2CH2S) 
13C-NMR   (75 MHz, CDCl3)  
δ [ppm]:  163.13 (CPy, 6), 141.06 (CPy, 2), 138.99 (CHPy, 4), 127.18 (CHPy, 3), 120.23 
(CHPy, 5), 68.30 (COCH3), 51.47 (COCH3), 41.28 (CHH), 38.94 (SCH2CH2S) 
Mass spectrometry ESI+ (70 eV, MeOH) 
m/z (%): 342.0 (100) [M + Na]+, 321.0 (12) [M + H]+, 288.0 (14) [M - OMe]+ 
General Information C11H14BrNOS2 (320.27 gmol
-1) 
Calculated (%):   C: 41.25, H: 4.41, N: 4.37, S: 20.02  
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Synthesis of 2-bromo-6-(pyridin-2-ylmethyl)pyridine (VIII) 
Under a N2-atmosphere 2.5 M 
nBuLi (20.0 ml, 50.0 mmol, 2.0 eq.) was slowly added to a -20 °C 
cooled solution of 2-methylpyridine (5.0 ml, 50.0 mmol, 2.0 eq.) in THF (50 ml). After stirring for 
120 min at -20 °C, a solution of 2,6-dibromopyridine (5.92 g, 25.0 mmol, 1.0 eq.) in THF (50 ml) 
was added and the reaction was allowed to warm up to room temperature. The reaction was 
then stirred under reflux for further 90 min at 50 °C. The reaction was quenched by the addition 
of iced water (10 ml) and THF was removed under reduced pressure. The aqueous phase was 
extracted with DCM and the combined organic phases were dried over Na2SO4. After removal of 
the solvent under reduced pressure the product was purified by column chromatography on 
silica. The product could be obtained as brown oil.  
Yield:   8.58 g (34.4 mmol, 69 %) 
Rf:    0.05 (hexane : ethyl acetate / 5 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.56 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz,
 5J(H,H) = 1 Hz,  1 H, CH
Py, 10), 7.64 (ddd, 
3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz, 1 H, CH
Py, 12), 7.47 (dd, 3J(H,H) = 9 Hz,
 
3J(H,H) = 9 Hz, 1 H, CH
Py, 4), 7.35 (dd, 3J(H,H) = 9 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 5), 
7.30 (d, 3J(H,H) = 6 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 3), 7.22 (dd, 3J(H,H) = 6 Hz,
 
4J(H,H) = 1 Hz, 1 H, CH
Py, 13), 7.16 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 1 Hz,
 
5J(H,H) = 1 Hz, 1 H, CH
Py, 11), 4.33 (s, 2 H, CH2)
 
13C-NMR   (75 MHz, CDCl3)  
δ [ppm]:  160.93 (CPy, 6), 158.56 (CPy, 8), 149.49 (CHPy, 10), 141.51 (CPy, 2), 138.83 
(CHPy, 4), 136.72 (CHPy, 3), 125.86 (CHPy, 12), 123.75 (CHPy, 11), 122.40 
(CHPy, 5), 121.73 (CHPy, 13), 46.75 (CH2) 
Mass spectrometry EI+ 
m/z (%): 250 (32) [M+H]+, 249 (100) [M]+, 168 (22) [M - HBr]+ 
IR KBr 
ṽ [cm-1]: 3396 (m), 3061 (s), 3008 (m), 2930 (m), 2303 (w), 1974 (w) 1589 (s), 1554 
(s), 1474 (s), 1433 (s), 1404 (s), 1297 (w), 1152 (m), 1117 (s), 986 (s), 924 
(w), 864 (m), 781 (s), 749 (s), 673 (s) 
Elemental analysis C11H9BrN2 (249.11 gmol
-1) 
Calculated (%):   C: 53.04, H: 3.64, N: 11.25 
Found (%):  C: 52.70, H: 3.68, N: 11.68 




Synthesis of 2-bromo-6-(pyridin-2-ylmethyl)pyridine (IX) 
Potassium tert-butanolate (3.52 g, 31.0 mmol, 1.5 eq.), methyl iodide (0.52 g, 31.0 mmol, 1.5 
eq.) and VIII (5.21 g, 20.9 mmol, 1.0 eq.) were dissolved in abs. THF (100 ml) and stirred at room 
temperature. After 8 h, additional potassium tert-butanolate (3.52 g, 31.0 mmol, 1.5 eq.) and 
methyl iodide (0.52 g, 31.0 mmol, 1.5 eq.) were added and the reaction was stirred for 
additional 16 h. The reaction was quenched by the addition of brine, THF was removed under 
reduced pressure and the aqueous residue was extracted with chloroform. The combined 
organic phases were combined and dried over Na2SO4. After removal of the solvent under 
reduced pressure, the product was purified by column chromatography on silica. The product 
could be obtained as yellow oil. 
Yield:   3.95 g (14.3 mmol, 68 %) 
Rf:    0.48 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.57 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz,
 5J(H,H) = 1 Hz,  1 H, CH
Py, 10), 7.62 (ddd, 
3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz, 1 H, CH
Py, 12), 7.41 (dd, 3J(H,H) = 9 Hz,
 
3J(H,H) = 9 Hz, 1 H, CH
Py, 4), 7.30-7.24 (m, CHPy, 3, 5), 7.14 (dd, 3J(H,H) = 6 Hz,
 
4J(H,H) = 1 Hz, 1 H, CH
Py, 13), 7.07 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 1 Hz,
 
5J(H,H) = 1 Hz, 1 H, CH
Py, 11), 1.80 (s, 6 H, CH3) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  169.34 (CPy, 6), 166.82 (CPy, 8), 148.70 (CHPy, 10), 141.02 (CPy, 2), 138.37 
(CHPy, 4), 136.28 (CHPy, 12), 125.29 (CHPy, 3), 121.31 (CHPy, 11), 121.16 
(CHPy, 5), 120.41 (CHPy, 13), 48.19 (CC4), 28.30 (CH3) 
Mass spectrometry EI+ 
m/z (%): 278 (27) [M(Br81)]+, 276 (28) [M(Br79)]+, 263 (97) [M(Br81) -Me]+, 261 
(100) [M(Br79) -Me]+, 120 (30) [C8H10N]
+ 
IR KBr 
ṽ [cm-1]: 3051 (m), 2972 (s), 2931 (s), 2872 (m), 1586 (m), 1553 (m), 1472 (m), 
1423 (m), 1396 (m), 1295 (w), 1174 (m), 1118 (m), 1049 (w), 984 (m), 
931 (w), 825 (s), 786 (s), 744 (s), 664 (s), 601 (m), 561 (w) 
Elemental analysis C13H13BrN2 (277.16 gmol
-1) 
Calculated (%):   C: 56.34 H: 4.73 N: 10.11 
Found (%):  C: 56.34 H: 3.96 N: 10.19 
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Synthesis of 6-methyl-2,2'-bipyridine (X) 
Compound X was synthesised according to the literature.[278] 
Yield:    54 % (Lit.: 59 %) 
Rf:    0.39 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (500 MHz, CDCl3) 
δ [ppm]:  8.64 (d, 3J(H,H) = 5 Hz,
 4J(H,H) = 2 Hz,, 1 H, CH
Py, 12), 8.37 (d, 3J(H,H) = 8 Hz, 1 H, 
CHPy, 3), 8.14 (d, 3J(H,H) = 8 Hz, 1 H, CH
Py, 9), 7.77 (ddd, 3J(H,H) = 8 Hz,
 
3J(H,H) = 8 Hz,
 4J(H,H) = 2 Hz,
  1 H, CHPy, 11), 7.66 (dd, 3J(H,H) = 8 Hz, 
3J(H,H) = 8 Hz, 
1 H, CHPy, 4), 7.26-7.23 (mCHPy, 10), 7.13 (d, 3J(H,H) = 8 Hz, 1 H, CH
Py, 5), 2.60 
(s, 3 H, CH3) 
13C-NMR   (125 MHz, CDCl3)  
δ [ppm]:  157.88 (CPy, 2), 156.43 (CPy, 7), 155.50 (CPy, 6), 149.08 (CHPy, 9), 137.01 (CHPy, 
4), 136.79 (CHPy, 11), 123.44 (CHPy, 3), 123.20 (CHPy, 5), 121.12 (CHPy, 10), 
118.05 (CHPy, 12), 24.60 (CH3) 
Mass spectrometry EI+ 
m/z (%):  170 (100) [M]+, 155 (17) [M - CH3]
+ 
IR KBr 
ṽ [cm-1]: 3061 (m), 3012 (w), 2923 (w), 1677 (w), 1580 (s), 1516 (w), 1460 (s), 
1428 (s), 1374 (w), 1256 (m), 1152 (w), 1083 (m), 1043 (m), 994 (m), 897 
(w), 818 (w), 771 (s), 745 (m), 640 (m), 621 (m), 603 (w), 553 (w) 
Elemental analysis C11H10N2 (170.21 gmol
-1) 
Calculated (%):   C: 77.62, H: 5.92, N: 16.46 
Found (%):  C: 76.14, H: 5.97, N: 16.66 




Synthesis of 6-chloromethyl-2,2'-bipyridine (XI) 
Compound XI was synthesised according to the literature.[279]  
Yield:   39 % (Lit.: 60 %) 
1H-NMR   (200 MHz, CDCl3) 
δ [ppm]:  8.63 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 12), 8.39 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 3), 8.15 
(d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 9), 7.82 (d, 3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz,
 1 H, CHPy, 
11), 7.67 (dd, 3J(H,H) = 6 Hz, 
3J(H,H) = 6 Hz, 1 H, CH
Py, 4), 7.28 (dd, 3J(H,H) = 6 Hz, 
 
3J(H,H) = 6 Hz, CH
Py, 10), 7.15 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 5), 4.72 (s, 3 H, CH3) 
Mass spectrometry EI+ 
m/z (%):  206 (33) [M(35Cl)]+, 204 (100) [M(37Cl)]+, 170 (75) [M - Cl]+ 
General Information C11H9ClN2 (204.66 gmol
-1) 
Calculated (%):   C: 64.56, H: 4.43, N: 13.69 
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Synthesis of 6-bromomethyl-2,2'-bipyridine (XII) 
Compound XII was synthesised according to the literature.[280]  
Yield:   45 % (Lit.: 60 %) 
1H-NMR   (200 MHz, CDCl3) 
δ [ppm]:  8.62 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 12), 8.45 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 3), 8.25 
(d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 9), 7.82-7.68 (m, 2 H, CHPy, 11, 4), 7.43 (d, 
3J(H,H) = 6 Hz, CH
Py, 10), 7.33-7.28 (m, 1 H, CHPy, 5), 4.61 (s, 3 H, CH3) 
Mass spectrometry EI+ 
m/z (%):  247 (100) [M(81Br)]+, 245 (97) [M(79Br)]+, 170 (83) [M - Br]+, 155 (14) [M -
 CH3]
+ 
General Information C11H9BrN2 (249.11 gmol
-1) 
Calculated (%):   C: 53.04, H: 3.64, N: 11.25 
  
 




Synthesis of 1,3-bis(ethylthio)-2-(pyridin-2-yl)propan-2-ol (L1H) 
Under an atmosphere of dry N2 a 2.5 M solution of 
nBuLi in hexanes (8.6 ml, 21.6 mmol, 1.5 eq.) 
was slowly added to a solution of 2-bromopyridine (3.41 g, 21.6 mmol, 1.5 eq.) in THF (50 ml) at 
-78 °C. After 30 min stirring, the reaction mixture was allowed to warm to room temperature. 
After 10 min at room temperature the solution was again cooled to -78 °C and slowly added to a 
solution of 1 (2.13 g, 14.4 mmol, 1.0 eq.) in THF (50 ml). After 3 h at -78 °C the reaction was 
quenched by the addition of water (10 ml). The solvent THF was removed under reduced 
pressure. Chloroform (30 ml) was added and with diluted HCl a pH value of 7 was adjusted. The 
resulting emulsion was extracted with chloroform. The combined organic phases were dried 
over Na2SO4 and the solvent was removed under reduced pressure. After column 
chromatography on silica the product could be obtained as dark brown oil. 
Yield:   2.89 g (11.2 mmol, 52 %) 
Rf:    0.27 (hexane : ethyl acetate / 4 : 1) 
1H-NMR   (500 MHz, CDCl3) 
δ [ppm]:  8.53 (ddd, 3J(H,H) = 4.9 Hz,
 4J(H,H) = 1.8 Hz,
 5J(H,H) = 1.0 Hz, 1 H, CH
Py, 6), 7.73 
(ddd, 3J(H,H) = 8.0 Hz,
 4J(H,H) = 7.4 Hz, 
3J(H,H) = 1.8 Hz, 1 H, CH
Py, 4), 7.58 (ddd, 
3J(H,H) = 8.0 Hz,
 4J(H,H) = 1.2 Hz,
 5J(H,H) = 1.1 Hz, 1 H, CH
Py, 3), 7.20 (ddd, 
3J(H,H) = 7.4 Hz,
 4J(H,H) = 4.9 Hz,
 5J(H,H) = 1.2 Hz, 1 H, CH
Py, 5), 4.60 (sbr, 1 H, 
OH), 3.24 (d, 2J(H,H) = 13.5 Hz, 2 H, CHH), 3.07 (d, 
2J(H,H) = 13.5 Hz, 2 H, 
CHH), 2.37 (q, 3J(H,H) = 7.4 Hz, 4 H, CH2CH3), 1.13 (t, 
3J(H,H) = 7.4 Hz, 6 H, 
CH2CH3)
 
13C-NMR   (125 MHz, CDCl3) 
δ [ppm]:  162.4 (CPy, 2), 147.9 (CHPy, 6), 136.8 (CHPy, 4), 122.4 (CHPy, 3), 120.6 (CHPy, 5), 
77.1 (COH), 42.8 (CH2), 27.5 (CH2CH3), 14.8 (CH2CH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 280.2 (100) [M + Na]+, 264.3 (10) [M]+, 258.1 (17) [M + H]+, 240.2 (10) 
[M - OH]+ 
IR KBr 
ṽ [cm-1]: 3429 (m), 3054 (w), 2964 (s), 2924 (s), 2870 (m), 2359 (w), 1703 (w), 
1590 (s), 1571 (m), 1451 (m), 1434 (s), 1402 (m), 1376 (m), 1343 (m), 
1294 (m), 1263 (m), 1244 (m), 1193 (w), 1153 (m), 1113 (m), 1077 (m), 
1051 (m), 996 (m), 972 (m), 845 (w), 784 (m), 752 (s), 717 (w), 618 (m), 
565 (w), 469 (w) 
Elemental analysis C12H19NOS2 (257.42 gmol
-1) 
Calculated (%):   C: 55.99, H: 7.44, N: 5.44, S: 24.91 
Found (%):   C: 54.74, H: 7.26, N: 6.26, S: 23.90 
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Synthesis of 1,3-bis(ethylthio)-2-(pyridin-2-ylmethyl)propan-2-ol (L2H) 
Under an atmosphere of dry N2 a 2.5 M solution of 
nBuLi in hexanes (9.6 ml, 24.0 mmol, 1.5 eq.) 
was slowly added to a solution of 2-metylpyridine (2.23 g, 24.0 mmol, 1.5 eq.) in THF (50 ml) at -
78 °C. After 30 min stirring the reaction mixture was allowed to warm to room temperature. 
After 10 min at room temperature the solution was again cooled to -78 °C and slowly added to a 
solution of 1 (2.37 g, 16.0 mmol, 1.0 eq.) in THF (50 ml). After 3 h at -78 °C the reaction was 
quenched by the addition of water (10 ml). The THF was removed under reduced pressure. DCM 
(30 ml) was added and with diluted HCl a pH value of 7 was adjusted. The solution was extracted 
with DCM until the organic phase becomes colourless. The combined organic phases were dried 
over Na2SO4 and the solvent was removed under reduced pressure. After column 
chromatography on silica the product could be obtained as dark brown oil.  
Yield:   4.3 g (15.8 mmol, 66 %) 
Rf:    0.33 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (500 MHz, CDCl3): 
δ [ppm]:  8.48 (d, 3J(H,H) = 5.0 Hz, 1 H, CH
Py, 6), 7.63 (ddd, 3J(H,H) = 7.0, 
3J(H,H) = 7.0 Hz, 
4J(H,H) = 2.0 Hz, 1 H, CH
Py, 4), 7.22 (d, 3J(H,H) = 7.0 Hz, 1 H, CH
Py, 3), 7.16 (ddd, 
3J(H,H) = 7.0 Hz, 
3J(H,H) = 5.0 Hz,
 4J(H,H) = 2.0 Hz, 1 H, CH
Py, 5), 6.25 (sbr, 1 H, 
OH), 3.10 (s, 2 H, CPyCH2), 2.81 (d, 
2J(H,H) = 13.1 Hz , 2 H, CHH), 2.67 (d, 
2J(H,H) = 13.1 Hz, 2 H, CHH), 2.57 (q, 
3J(H,H) = 7.5 Hz, 4 H, CH2CH3), 1.19 (t, 
J(H,H) = 7.5 Hz, 6 H, CH2CH3)
 
13C-NMR   (125 MHz, CDCl3) 
δ [ppm]:  159.0 (CPy, 2), 148.3 (CHPy, 6), 137.0 (CHPy, 4), 124.9 (CHPy, 3), 121.7 (CHPy, 5), 
76.2 (COH), 43.2 (2 C, CH2), 40.7 (C
PyCH2), 27.7 (CH2CH3), 14.9 (CH2CH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 294.2 (100) [M + Na]+, 272.2 (64) [M + H]+, 254.2 (58) [M - OH]+, 210 (9) 
[M - SC2H5]
+, 192.2 (73) [M - C5H5N]
+ 
IR KBr 
ṽ [cm-1]: 3308 (m), 3058 (w), 3013 (w), 2963 (s), 2925 (s), 2869 (m), 1737 (w), 
1595 (s), 1569 (m), 1474 (s), 1439 (s), 1375 (m), 1331 (w), 1261 (m), 1195 
(m), 1150 (m), 1100 (w), 1050 (w), 1001 (w), 971 (w), 906 (w), 865 (w), 
811 (w), 756 (m), 725 (w), 629 (w), 549 (w), 496 (w), 474 (w) 
Elemental analysis C13H21NOS2 (271.44 gmol
-1) 
Calculated (%):   C: 57.52, H: 7.80, N: 5.16, S: 23.63 
Found (%):  C: 57.12, H: 8.23, N: 4.94, S: 22.73   




Synthesis of 6-(pyridin-2-yl)-1,4-dithiepan-6-ol (L3H) 
Under an atmosphere of dry N2 a 2.5 M solution of 
nBuLi in hexanes (8.6 ml, 21.6 mmol, 1.5 eq.) 
was slowly added to a solution of 2-bromopyridine (3.41 g, 21.6 mmol, 1.5 eq.) in THF (50 ml) at 
-78 °C. After 30 min stirring the reaction mixture was allowed to warm to room temperature. 
After 10 min at room temperature the solution was again cooled to -78 °C and slowly added to a 
solution of 2 (2.13 g, 14.4 mmol, 1.0 eq.) in THF (50 ml). After 3 h at -78 °C the reaction was 
quenched by the addition of water (10 ml). The solvent THF was removed under reduced 
pressure. Chloroform (30 ml) was added and with diluted HCl a pH value of 7 was adjusted. The 
resulting emulsion was extracted with chloroform. The combined organic phases were dried 
over Na2SO4 and the solvent was removed under reduced pressure. After column 
chromatography on silica the product could be obtained as orange solid.  
Yield:   1.83 g (8.06 mmol, 56 %) 
Rf:    0.23 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.51 (ddd, 3J(H,H) = 4.9 Hz, 
4J(H,H) = 1.7 Hz, 
5J(H,H) = 1.0 Hz, 1 H, CH
Py, 6), 7.82-
7.70 (m, 2 H, CHPy, 4, CHPy, 3), 7.25 (ddd, 3J(H,H) = 7.1 Hz, 
4J(H,H) = 4.9 Hz, 
5J(H,H) = 1.5 Hz, 1 H, CH
Py, 5), 5.51 (sbr, 1 H, OH), 3.33 (d, 
2J(H,H) = 14.6 Hz, 
2 H, CHH), 3.11 (d, 2J(H,H) = 14.6 Hz, 2 H, CHH), 3.08 (s, 4 H, SCH2CH2S)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]: 162.8 (CPy, 2), 147.5 (CHPy, 6), 137.4 (CHPy, 4), 122.9 (CHPy, 3), 119.8 (CHPy, 5), 
78.1 (COH), 45.4 (CH2), 38.7 (SCH2CH2S) 
Mass spectrometry  EI+  
m/z (%): 227.1 (13) [M]+, 209.1 (17) [M - OH]+, 121.1 (100) [C7H7NO]
+, 79.1 (41) 
[pyridine]+ 
IR KBr 
ṽ [cm-1]: 3367 (m), 2924 (w), 2903 (w), 1680 (w), 1589 (s), 1569 (m), 1474 (s), 
1431 (s), 1400 (s), 1375 (s), 1307 (w), 1283 (w), 1262 (m), 1217 (m), 1167 
(m), 1119 (m), 1100 (w), 1048 (s), 995 (m), 971 (w), 924 (m), 898 (w), 857 
(m), 800 (w), 764 (s), 714 (w), 679 (m), 640 (m), 617 (m), 567 (w), 532 (s), 
481 (m), 442 (w), 410 (m) 
Elemental analysis C10H13NOS2 (227.35 gmol
-1) 
Calculated (%):   C: 52.83, H: 5.76, N: 6.16, S: 28.21 
Found (%):  C: 52.29, H: 5.95, N: 5.73, S: 28.74  
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Synthesis of 6-(pyridin-2-yl)-1,4-dithiepan-6-ol (L4H) 
Under an atmosphere of dry N2 a 2.5 M solution of 
nBuLi in hexanes (9.6 ml, 24.0 mmol, 1.5 eq.) 
was slowly added to a solution of 2-metylpyridine (2.23 g, 24.0 mmol, 1.5 eq.) in THF (50 ml) at -
78 °C. After 30 min stirring, the reaction mixture was allowed to warm to room temperature. 
After 10 min at room temperature the solution was again cooled to -78 °C and slowly added to a 
solution of 2 (2.85 g, 16.0 mmol, 1.0 eq.) in THF (50 ml). After 3 h at -78 °C the reaction was 
stirred for 24 h at room temperature. The reaction was then quenched by the addition of brine 
(50 ml) and with diluted HCl a pH value of 7 was adjusted. The solution was extracted with 
chloroform until the organic phase becomes colourless. The combined organic phases were 
dried over Na2SO4 and the solvent was removed under reduced pressure. After column 
chromatography on silica the product could be obtained as orange solid. 
Yield:   2.16 g (9.00 mmol, 56 %) 
MP:   54.3 °C 
Rf:    0.23 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (500 MHz, CDCl3) 
δ [ppm]:  8.44 (d, 1 H, 3J(H,H) = 4.8 Hz, CH
Py, 6), 7.61 (ddd, 1 H, 3J(H,H) = 7.7 Hz,
 
4J(H,H) = 7.7 Hz,
 5J(H,H) = 1.8 Hz, CH
Py, 4), 7.24-7.13 (m, 2 H, CHPy, 3, CHPy, 5), 
6.25 (sbr, 1 H, OH), 3.02 (s, 2 H, C
PyCH2), 2.97-2.83 (m, 8 H, CH2, SCH2CH2S)
 
13C-NMR   (125 MHz, CDCl3) 
δ [ppm]: 158.5 (CPy, 2), 148.5 (CHPy, 6), 137.1 (CHPy, 4), 124.6 (CHPy, 3), 121.8 (CHPy, 5), 
78.9 (COH), 44.4 (CPyCH2), 43.5 (CH2), 38.3 (SCH2CH2S) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 505.1 (17) [M2 + Na]
+, 280.2 (10) [M + K]+, 264.2 (100) [M + Na]+, 242.2 
(51) [M + H]+, 224.1 (50) [M - OH]+ 
IR   KBr 
ṽ [cm-1]: 3328 (m), 2920 (w), 2901 (w), 1697 (w), 1591 (s), 1564 (m), 1472 (s), 
1441 (s), 1420 (s), 1406 (s), 1323 (w), 1273 (m), 1179 (w), 1148 (m), 1098 
(m), 1038 (s), 997 (w), 972 (w), 941 (w), 906 (m), 895 (m), 854 (m), 814 
(m), 795 (m), 768 (s), 719 (w), 679 (w), 621 (m), 546 (w), 534 (w), 480 
(m), 452 (w), 413 (w) 
Elemental analysis C11H15NOS2 (241.37 gmol
-1) 
Calculated (%):   C: 54.74, H: 6.26, N: 5.80, S: 26.57 
Found (%):  C: 54.34, H: 6.19, N: 5.58, S: 27.06 
 




Synthesis of 6-(1-methyl-1H-imidazol-2-yl)-1,4-dithiepan-6-ol (L5H) 
Under an atmosphere of dry N2 a 1.6 M solution of 
nBuLi in hexanes (12.6 ml, 20.2 mmol, 1.5 eq.) 
was slowly added to a solution of 2-methylimidazole (1.66 g, 20.2 mmol, 1.5 eq.) in THF (50 ml) 
at -78 °C. After 30 min stirring the reaction mixture was allowed to warm to room temperature. 
After 10 min at room temperature the solution was again cooled to -78 °C and slowly added to a 
solution of 1 (2.00 g, 13.5 mmol, 1.0 eq.) in THF (50 ml). After 3 h at -78 °C the reaction was 
quenched by the addition of water (10 ml). The solvent THF was removed under reduced 
pressure. Chloroform (30 ml) was added and with diluted HCl a pH value of 7 was adjusted. The 
solution was extracted with chloroform and the combined organic phases were dried over 
Na2SO4 and the solvent was removed under reduced pressure. After column chromatography on 
silica the product could be obtained as yellow solid.  
Yield:   2.55 g (11.1 mmol, 82 %) 
Rf:    0.17 (methanol : chloroform / 1 : 6) 
MP:   181 °C 
1H-NMR   (500 MHz, CDCl3) 
δ [ppm]:  6.93 (s, 1 H, CHIm, 5), 6.82 (s, 1 H, CHIm, 4), 3.87 (s, 3H, NCH3), 3.57 (d, 
2J(H,H) = 15.0 Hz, 2 H, CHH), 3.14 (d, 
2J(H,H) = 15.0 Hz, 2 H, CHH), 3.03 (s, 4 H, 
SCH2CH2S)
 
13C-NMR   (125 MHz, CDCl3): 
δ [ppm]:  148.2 (CIm, 2), 126.6 (CHIm, 4), 123.1 (CHIm, 5), 75.8 (COH), 44.3 (CH2), 
36.8 (SCH2CH2S), 35.1 (NCH3) 
Mass spectrometry  EI+  
m/z (%): 230 (9) [M]+, 213 (4) [M - OH]+, 183 (42) [M -SCH3]
+, 156 (84) [C6H8N2OS]
+, 
124 (60) [C6H8N2O]
+, 114 (100) [C5H10N2O]
+, 82 (28) [C4H6N2]
+ 
IR KBr 
ṽ [cm-1]: 3104 (m), 2923 (m), 2902 (m), 1599 (w), 1526 (w), 1473 (s), 1406 (s), 
1370 (m), 1337 (w), 1300 (w), 1275 (s), 1251 (m), 1221 (w), 1192 (m), 
1181 (w), 1145 (w), 1106 (m), 1036 (s), 999 (m), 979 (m), 938 (w), 918 
(s), 854 (w), 806 (m), 787 (w), 763 (s), 732 (s), 689 (m), 658 (m), 555 (w), 
492 (w), 470 (w), 431 (w) 
Elemental analysis C9H14N2OS2 (230.35 gmol
-1) 
Calculated (%):   C: 46.93, H: 6.13, N: 12.16, S: 27.84 
Found (%):  C: 47.60, H: 6.00, N: 11.54, S: 27.18 
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Synthesis of tris(2-pyridylmethyl)amine (L6H) 
The ligand L6H was synthesised according to the literature.[251] 
Yield:   87 % (Lit.: 99 %)  
Rf:     0.42 (chloroform : methanol / 9 : 1) 
MP:   60.8 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.59 (d, 3J(H,H) = 3 Hz, 3 H, CH
Py, 3,3’,3’’), 7.63 (t, 3J(H,H) = 6 Hz, 3 H, CH
Py, 4,4’,4’’), 
7.38 (d, 3J(H,H) = 6 Hz, 3 H, CH
Py, 6,6’,6’’), 7.17 (t, 3J(H,H) = 6 Hz, 3 H, CH
Py, 5,5’,5’’), 
3.19 (s, 2 H, CNH2) 
13C-NMR  (75 MHz, CDCl3) 
δ [ppm]:  165.02 (CPy, 2,2’,2’’), 148.76 (CHPy, 3,3’,3’’), 136.21 (CHPy, 4, 4’,4’’), 123.07 (CHPy, 
6,6’,6’’), 121.83 (CHPy, 5,5’,5’’), 70.20 (CNH2) 
Mass spectrometry  EI+  
m/z (%):  262 (46) [M]+, 184 (100) [M - pyridine]+, 80 (26) [pyridine + H]+ 
IR KBr 
ṽ [cm-1]: 3363 (w), 3295 (w), 3051 (w), 3004 (w), 1983 (w), 1949 (w), 1874 (w), 
1678 (w), 1585 (s), 1467 (s), 1427 (s), 1324 (w), 1291 (m), 1237 (w), 1147 
(m), 1117 (m), 1097 (m), 1049 (m), 994 (s), 903 (m), 874 (s), 785 (s), 772 
(s), 747 (s), 659 (s), 617 (s), 584 (m), 504 (m), 457 (w), 405 (s) 
Elemental analysis C16H14N4 (262.31 gmol
-1) 
Calculated (%):   C: 73.26, H: 5.38, N: 21.36 
Found (%):  C: 72.35, H: 5.36, N: 21.00 




Synthesis of N-((1,4-dithian-2-yl)methyl)-N-(methylpyridin-2-yl)amine (L7H) 
(2-Aminomethyl)pyridine (1.27 g 11.97 mmol, 1.5 eq.) and V (1.32 g, 7.86 mmol, 1 eq.) were 
dissolved in propane-2-ol (50 ml). The reaction was stirred under reflux at 120 °C for 6 d. The 
solvent was removed under reduced pressure and the product was purified by gradient column 
chromatography on silica. The product was obtained as brown oil.  
Yield:   1.51 g (6.29 mmol, 80 %) 
Rf:     0.44 (chloroform : methanol / 9 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.52 (dd, 3J(H,H) = 9 Hz, 
4J(H,H) = 3 Hz, 1 H, CH
Py, 6), 7.67-7.60 (m, 1 H, CHPy, 4), 
7.32 (d, 3J(H,H) = 9 Hz, 1 H, CH
Py, 3) 7.15 (ddd, 3J(H,H) = 12 Hz, 
4J(H,H) = 6 Hz, 1 
H, CHPy, 5), 4.01-3.91 (m, 2 H, CH2), 3.50-2.63 (m, 11 H, CH2, CH2
Cylc, CHCylc) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  158.66 (CPy, 2), 149.29 (CHPy, 6), 136.55 (CHPy, 4), 122.19 (CHPy, 3, 5), 54.46 
(CH2
9), 52.47 (CH2
7), 40.61 (CH10), 37.48 (CH2
14), 28.39 (CH2
 11), 28.92 
(CH2
13) 
Mass spectrometry  ESI+ (70 eV, MeOH)  
m/z (%):  263 (64) [M + Na]+, 241 (100) [M + H]+  
IR   KBr 
ṽ [cm-1]: 3306 (s), 3051 (m), 3007 (m), 2902 (s), 2825 (s), 1725 (w), 1672 (w), 1591 
(s), 1569 (s), 1474 (m), 1434 (m), 1411 (m),1355 (w), 1283 (m), 1146 (m), 
1124 (m), 1048 (m), 995 (m), 887 (w), 849 (w), 758 (m) 
Elemental analysis C11H16N2S2 (240.39 gmol
-1) 
Calculated (%):   C: 54.96, H: 6.71, N; 11.65, S: 26.68 
Found (%):  C: 53.55, H: 6.73, N: 11.38, S: 24.94 
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Synthesis of 6-(6-(2-(pyridin-2-yl)propan-2-yl)pyridin-2-yl)-1,4-dithiepan-6-ol (L8H) 
Under a N2-atmosphere 1.6 M 
nBuLi (1.81 ml, 2.89 mmol, 1.2 eq.) was slowly added to a -78 °C 
cooled solution of IX (0.80 g, 2.89 mmol, 1.2 eq.) in THF (120 ml) and stirred for 45 min. Then the 
mixture was allowed to warm to room temperature, stirred for 10 min at this temperature 
before it was recooled to -78 °C and II (0.36 g, 2.41 mmol, 1.0 eq.) was slowly added. After 4 h at 
-78 °C the reaction was allowed to warm to room temperature and quenched by the addition of 
brine (30 ml). THF was removed under reduced pressure and the pH was adjusted to 7. The 
solution was extracted with chloroform, the combined organic phases were dried over Na2SO4 
and the solvent was removed under reduced pressure. After column chromatography on silica 
the product could be obtained as yellow oil. 
Yield:   0.56 g (1.62 mmol, 67 %) 
Rf:    0.38 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.56 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 1 Hz,
 5J(H,H) = 1 Hz, 1 H, CH
Py, 10), 7.67-7.57 
(m, 3 H, CHPy, 4, 5, 12), 7.21 (dd, 3J(H,H) = 9 Hz, 
 4J(H,H) = 1 Hz, 1 H, CH
Py, 3), 7.13 
(m, 2 H, CHPy, 11, 13), 5.79 (s, 1 H, OH), 3.26 (d, 2 H, 3J(H,H) = 15 Hz, CHH), 
3.26 (d, 2 H, 3J(H,H) = 15 Hz, CHH),  3.04 (s, 4 H, SCH2CH2S) 1.81 (s, 6 H, CH3) 
13C-NMR  (75 MHz, CDCl3) 
δ [ppm]:  166.00 (CPy, 2), 164.63 (CPy, 6), 160.05 (CPy, 8), 147.68 (CHPy, 10), 136.74 
(CHPy, 4), 135.18 (CHPy, 12), 120.16 (CHPy, 13), 120.15 (CHPy, 11), 119.45 
(CHPy, 5), 118.98 (CHPy, 3), 77.45 (COH), 47.10 (CC4), 44.37 (CHH), 38.10 
(SCH2CH2S), 27.43 (CH3) 
Mass spectrometry  ESI+ (70 eV, MeOH)  
m/z (%):  369.1 (100) [M + Na]+, 347.1 (52) [M + H]+, 329.1 (33) [M - OH]+ 
IR   KBr 
ṽ [cm-1]: 3328 (w), 2968 (w), 2922 (w), 1574 (s), 1472 (m), 1452 (m), 1429 (m), 
1408 (m), 1265 (w), 1181 (w), 1174 (s), 1115 (m), 1049 (m), 993 (m), 790 
(m), 749 (s), 609 (w), 560 (w), 500 (w) 
Elemental analysis C18H22N2OS2 (346.51 gmol
-1) 
Calculated (%):   C: 62.39, H: 6.40, N: 8.08, S: 18.51  
Found (%):  C: 61.90, H: 6.38, N: 7.86, S: 17.56 




Synthesis of 2-(6-methoxy-1,4-dithiepan-6-yl)pyridine (L3Me) 
L3H (300 mg, 1.33 mmol, 1.0 eq.) and NaH (60 %, 63 mg, 1.59 mmol, 1.2 eq.) were dissolved in 
abs. THF (25 ml) and heated under reflux at 60 °C for 30 min. Methyl iodide (226 mg, 1.59 mmol, 
1.2 eq.) was added to the formed suspension and heating was continued for an additional 1 h. 
Then the reaction was allowed to cool to room temperature and quenched by the addition of 
brine (20 ml). The solution was extracted with chloroform, the combined organic phases were 
dried over Na2SO4 and the solvent was removed under reduced pressure. After column 
chromatography on silica the product could be obtained as brown solid. 
Yield:   313 mg (1.30 mmol, 98 %) 
Rf:    0.38 (hexane : ethyl acetate / 2 : 1) 
MP:   120.2 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.62 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 1 Hz,
 5J(H,H) = 1 Hz, 1 H, CH
Py, 6), 7.73 (ddd, 
3J(H,H) = 9 Hz, 
3J(H,H) = 9 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 4), 7.49 (ddd, 3J(H,H) = 9 Hz, 
3J(H,H) = 3 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 3), 7.23 (ddd, 3J(H,H) = 9 Hz, 
 3J(H,H) = 
3 Hz, 4J(H,H) = 1 Hz, 1 H, CH
Py, 5), 3.71 (d, 2J(H,H) = 15 Hz, 2 H, CHH), 3.35 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.09 (s, 4 H, SCH2CH2S), 3.04 (s, 3 H, OCH3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  161.43 (COCH3), 148.70 (C
Py, 2), 136.71 (CHPy, 6), 122.75 (CHPy, 4), 121.35 
(CHPy, 3), 86.58 (CHPy, 5), 51.37 (OCH3), 41.37 (CHH), 38.99 (SCH2CH2S) 
Mass spectrometry  ESI+, (70 eV, MeOH)  
m/z (%): 264.1 (33) [M + Na]+, 242.1 (43) [M + H]+, 210.1 (100) [M - OMe]+, 150.1 
(33) [C8H8NS]
+ 
IR   KBr 
ṽ [cm-1]: 3047 (w), 2981 (m), 2948 (m), 2932 (m), 2901 (m), 2827 (m), 1972 (w), 
1872 (w), 1849 (w), 1730 (w), 1669 (w), 1584 (s), 1566 (m), 1470 (s), 
1431 (s), 1407 (s), 1296 (m), 1270 (m), 1236 (m), 1190 (m), 1178 (m), 
1153 (m), 1122 (m), 1096 (m), 1073 (s), 1009 (m), 995 (s), 982 (s), 930 
(m), 850 (m), 802 (s), 775 (s), 763 (s), 740 (m), 712 (m), 682 (m), 638 (m), 
614 (m), 492 (m), 465 (w), 436 (m), 403 (w) 
Elemental analysis C11H15NOS2 (241.37 g/mol) 
Calculated (%):   C: 54.74, H: 6.26, N: 5.80, S: 26.57 
Found (%):  C: 54.51, H: 6.18, N: 5.73, S: 26.38 
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Synthesis of 2-(6-methoxy-1,4-dithiepan-6-yl)-1-methyl-1H-imidazole (L5Me) 
L5H (300 mg, 1.30 mmol, 1.0 eq.) and NaH (60 %, 62 mg, 1.59 mmol, 1.2 eq.) were dissolved in 
abs. THF (25 ml) and stirred under reflux at 60 °C for 30 min. Methyl iodide (221 mg, 1.59 mmol, 
1.2 eq.) was added to the formed suspension and heating was continued for an additional 1 h. 
The reaction was allowed to cool to room temperature and quenched by the addition of brine. 
The solution was extracted with chloroform, the combined organic phases dried over Na2SO4 and 
the solvent was removed under reduced pressure. After column chromatography on silica the 
product could be obtained as orange solid. 
Yield:   318 mg (1.30 mmol, 100 %) 
Rf:    0.50 (chloroform : methanol / 2 : 1) 
MP:   106.0 °C 
1H-NMR   (300 MHz, CDCl3)  
δ [ppm]:  6.69 (d, 3J(H,H) = 3 Hz, 1 H, CH
Im, 5), 6.88 (d, 3J(H,H) = 3 Hz, 1 H, CH
Im, 4), 3.79 
(s, 3 H, NCH3), 3.75 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.43 (d, 
2J(H,H) = 15 Hz, 2 
H, CHH), 3.08 (s, 4 H, SCH2CH2S), 3.02 (s, 3 H, OCH3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  146.42 (1 C, CIm, 2), 127.09 (1 C, CHIm, 4), 123.55 (1 C, CHIm, 5), 84.03 (1 C, 
COCH3), 51.39 (OCH3), 40.08 (CHH), 38.68 (SCH2CH2S), 33.99 (1 C, NCH3) 
Mass spectrometry  EI  
m/z (%):  244 (8) [M]+, 213 (100) [M - OMe]+ 
IR   KBr 
ṽ [cm-1]: 3127 (w), 3100 (m), 2976 (m), 2948 (w), 2934 (m), 2903 (m), 2826 (m), 
1682 (w), 1599 (w), 1520 (w), 1472 (s), 1461 (s), 1443 (m), 1414 (s), 1396 
(s), 1341 (w), 1302 (m), 1273 (s), 1254 (w), 1214 (m), 1185 (m), 1161 (m), 
1140 (m), 1110 (m), 1073 (s), 1004 (w), 987 (w), 969 (s), 913 (m), 842 
(m), 788 (m), 762 (s), 732 (w), 677 (m), 654 (m), 529 (m), 467 (w), 440 
(w) 
Elemental analysis C10H16N2OS2 (244.38g/mol) 
Calculated (%):   C: 49.15, H: 6.60, N: 11.46, S: 26.24 
Found (%):  C: 48.96, H: 6.54, N: 11.42, S: 26.36 




Synthesis of 2-(6-methoxy-1,4-dithiepan-6-yl)-6-(2-(pyridin-2-yl)propan-2-yl)pyridine (L8Me) 
L8H (50 mg, 0.14 mmol, 1.0 eq.) and NaH (60 %, 6 mg, 0.16 mmol, 1.1 eq.) were dissolved in abs. 
THF (5 ml) and stirred under reflux for 30 min. Methyl iodide (23 mg, 0.16 mmol, 1.1 eq.) was 
added to the formed suspension and heating was continued for an additional 1 h. Then the 
reaction was allowed to cool to room temperature and quenched by the addition of brine. The 
solution was extracted with chloroform, the combined organic phases dried over Na2SO4 and the 
solvent was removed under reduced pressure. After column chromatography on silica the 
product could be obtained as brown oil. 
Yield:   48 mg (0.13 mmol, 95 %) 
Rf:    0.51 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.47 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz,
 5J(H,H) = 1 Hz,  1 H, CH
Py, 10), 7.54-7.44 
(m, 2 H, CHPy, 4, 12), 7.21 (dd, 3J(H,H) = 6 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 3), 7.18 
(ddd, 3J(H,H) = 6 Hz,
 4J(H,H) = 1 Hz,  CH
Py, 5), 7.03 (dd, 3J(H,H) = 6 Hz,
 
4J(H,H) = 1 Hz, 1 H, CH
Py, 13), 6.98 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 1 Hz,
 
5J(H,H) = 1 Hz, 1 H, CH
Py, 11), 3.62 (d, 2J(H,H) = 15 Hz, 2 H, CHH), 3.20 (d, 
2J(H,H) 
= 15 Hz, 2 H, CHH), 2.95-7.89 (m, 7 H,SCH2CH2S, OCH3), 1.74 (s, 6 H, CH3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  166.54 (CPy, 2), 165.65 (CPy, 6), 158.81 (CPy, 8), 147.42 (CHPy, 10), 135.93 
(CHPy, 4), 135.02 (CHPy, 12), 120.06 (CHPy, 13), 119.89 (CHPy, 11), 118.85 
(CHPy, 5), 117.28 (CHPy, 3), 85.76 (COCH3), 47.26 (CC4), 40.46 (CHH), 38.02 
(SCH2CH2S), 27.29 (CCH3) 
Mass spectrometry  ESI+ (70 eV, MeOH)  
m/z (%):  383.0 (52) [M + Na]+, 361.0 (100) [M]+, 329.0 (37) [M - OMe]+ 
IR   KBr 
ṽ [cm-1]: 3292 (w), 3057 (w), 2970 (m), 2927 (m), 2903 (m), 2861 (w), 1719 (w), 
1574 (s), 1472 (s), 1448 (s), 1428 (s), 1409 (s), 1359 (m), 1293 (w), 1269 
(w), 1165 (w), 114 (m), 1060 (s), 993 (m), 930 (w), 856 (w), 820 (m), 790 
(m), 750 (s), 670 (w), 629 (m), 609 (m), 566 (w) 
Elemental analysis C19H24N2OS2 (360.54 gmol
-1) 
Calculated (%):   C: 63.30, H: 6.71, N: 7.77, S: 17.79 
Found (%):  C: 65.07, H: 6.03, N: 6.78, S: 15.65 
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Synthesis of 2-(6-(prop-2-ynyloxy)-1,4-dithiepan-6-yl)pyridine (L3Ac) 
L3H (0.67 g, 2.96 mmol, 1.0 eq.) and NaH (60 %, 0.12 g, 4.44 mmol, 1.5 eq.) were dissolved in abs. 
THF (30 ml) and stirred under reflux for 30 min. Propargyle bromide (80 % in toluene, 0.12 g, 
2.96 mmol, 1.0 eq.) was added to the formed suspension and the reaction was stirred over night 
at room temperature. Then then reaction was quenched by the addition of brine. The solution 
was extracted with DCM, the combined organic phases were dried over Na2SO4 and the solvent 
was removed under reduced pressure. After column chromatography on silica the product could 
be obtained as yellow solid. 
Yield:   0.63 g (2.37 mmol, 80 %) 
Rf:    0.19 (hexane : ethyl acetate / 5 : 1)  
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.62 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 1 Hz,
 5J(H,H) = 1 Hz, 1 H, CH
Py, 6), 7.74 (ddd, 
3J(H,H) = 9 Hz, 
3J(H,H) = 9 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 4), 7.58 (ddd, 3J(H,H) = 9 Hz, 
3J(H,H) = 3 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 3), 7.25 (ddd, 4J(H,H) = 9 Hz, 
 3J(H,H) = 
3 Hz, 4J(H,H) = 1 Hz, 1 H, CH
Py, 5), 3.91 (d, 4J(H,H) = 3 Hz, 2 H, OCH2), 3.73 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.05 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.06-3.03 (m, 4 
H, SCH2CH2S), 2.41 (t, 3 H, 
4J(H,H) = 3 Hz, 1 H, CCH)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  160.88 (COCH2), 148.61 (C
Py, 2), 137.00 (CHPy, 6), 123.05 (CHPy, 4), 121.49 
(CHPy, 3), 87.72 (CHPy, 5), 80.25 (CCH), 74.15 (CCH), 52.38 (OCH2), 41.38 
(CHH), 38.91 (SCH2CH2S)  
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  266.11 (100) [M + H]+, 210.1 (57) [M - OCH2CCH]
+ 
Elemental analysis C13H15NOS2 (265.39 g/mol) 
Calculated (%):   C: 58.83, H: 5.70, N: 5.28, S: 24.61 
Found (%):  C: 58.36, H: 5.37, N: 4.34, S: 23.95 
 




Synthesis of 1-methyl-2-(6-(prop-2-ynyloxy)-1,4-dithiepan-6-yl)-1H-imidazole (L5Ac) 
L5H (0.68 g, 2.96 mmol, 1.0 eq.) and NaH (60 %, 0.12 g, 4.44 mmol, 1.5 eq.) were dissolved in abs. 
THF (30 ml) and heated under reflux at 60 °C for 30 min. Propargyle bromide (80 % in toluene, 
0.66 g, 2.96 mmol, 1.0 eq.) was added to the formed suspension and the mixture was stirred 
over night at room temperature. Then the reaction was quenched by the addition of brine. The 
solution was extracted with DCM, the combined organic phases were dried over Na2SO4 and the 
solvent was removed under reduced pressure. After column chromatography on silica the 
product could be obtained as yellow solid. 
Yield:   0.52 g (1.92 mmol, 65 %) 
Rf:    0.43 (hexane : ethyl acetate / 1 : 1) 
MP:   112.0 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  6.99 (d, 3J(H,H) = 1 Hz, 1 H, CH
Im, 5), 6.89 (d, 3J(H,H) = 1 Hz, 1 H, CH
Im, 4), 3.92 
(d, 4J(H,H) = 3 Hz, 1 H, OCH2), 3.83 (s, 3 H, NCH3), 3.79 (d, 
2J(H,H) = 15 Hz, 2 H, 
CHH), 3.51 (d, 2J(H,H) = 15 Hz, 2 H, CHH), 3.03-3.01 (m, 4 H, SCH2CH2S), 
2.39 (t, 4J(H,H) = 3 Hz, 1 H, CCH)
 
13C-NMR   (125 MHz, CDCl3) 
δ [ppm]:  145.87 (CIm, 2), 127.13 (1 C, CHIm, 4), 123.89 (CHIm, 5), 84.59 (COCH2), 79.33 
(CCH), 74.34 (CCH) 52.27 (1 C, OCH2), 40.16 (CHH), 38.63 (SCH2CH2S), 
34.45 (NCH3) 
Mass spectrometry  EI+ 
m/z (%):  268 (8) [M]+, 213 (52) [M - OCH2CCH]
+, 113 (100) [C5H10S2]
+ 
IR   KBr 
ṽ [cm-1]: 3188 (m), 2957 (w), 2928 (m), 2855 (m), 2119 (m), 1704 (w), 1612 (w), 
1516 (w), 1479 (m), 1468 (m), 1411 (s), 1372 (m), 1343 (m), 1281 (m), 
1264 (m), 1224 (m), 1196 (w), 1182 (w), 1136 (m), 1122 (m), 1058 (s), 
997 (s), 912 (s), 853 (m), 806 (s), 762 (s), 720 (s), 695 (s), 662 (s), 626 (m), 
580 (m), 486 (w), 446 (w) 
Elemental analysis C12H16N2OS2 (268.40g/mol) 
Calculated (%):   C: 53.70, H: 6.01, N: 10.44, S: 23.89 
Found (%):  C: 55.37, H: 6.34, N: 9.71, S: 22.43 
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Synthesis of 2-(6-(prop-2-yn-1-yloxy)-1,4-dithiepan-6-yl)-6-(2-(pyridin-2-yl)propan-2-yl) 
pyridine (L8Ac) 
L8H (100 mg, 0.29 mmol, 1.0 eq.) and NaH (60 %, 12 mg, 0.32 mmol, 1.1 eq.) were dissolved in 
abs. THF (10 ml) and heated under reflux for 1 h at 60 °C. Propargyle bromide (80 % in toluene, 
47 mg, 0.32 mmol, 1.1 eq.) was added to the formed suspension and the reaction was heated for 
an additional 1 h at 60 °C. The reaction was quenched by the addition of brine. Then the solution 
was extracted with DCM, the combined organic phases were dried over Na2SO4 and the solvent 
was removed under reduced pressure. After column chromatography on silica the product could 
be obtained as brown solid. 
Yield:   102 mg (0.27 mmol, 91 %) 
Rf:    0.45 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.47 (ddd, 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz,
 5J(H,H) = 1 Hz,  1 H, CH
Py, 10), 7.56-7.50 
(m, 2 H, CHPy, 4, 12), 7.22 (dd, 3J(H,H) = 6 Hz,
 4J(H,H) = 1 Hz, 1 H, CH
Py, 3), 7.21 
(ddd, 3J(H,H) = 6 Hz,
 4J(H,H) = 1 Hz,  CH
Py, 5), 7.05-7.00 (dd, 3J(H,H) = 6 Hz,
 
4J(H,H) = 1 Hz, 1 H, CH
Py, 11, 13), 3.74 (d, 2 H, 4J(H,H) = 3 Hz, OCH2), 3.63 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.29 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 2.98-2.85 (m, 
4 H,SCH2CH2S), 2.27 (t, 
4J(H,H) = 3 Hz, 1 H, CCH), 1.75 (s, 6 H, CH3) 
13C-NMR  (75 MHz, CDCl3) 
δ [ppm]:  166.54 (CPy, 2), 165.65 (CPy, 6), 158.81 (CPy, 8), 147.42 (CHPy, 10), 135.93 
(CHPy, 4), 135.02 (CHPy, 12), 120.06 (CHPy, 13), 119.89 (CHPy, 11), 118.85 
(CHPy, 5), 117.28 (CHPy, 3), 85.76 (COCH3), 47.26 (CC4), 40.46 (CHH), 38.02 
(SCH2CH2S), 27.29 (CCH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 423.1 (24) [M + K]+, 407.1 (100) [M + Na]+, 385.0 (49) [M + H]+, 329.0 (35) 
[M - OAc]+, 269.1 (13) [C16H17N2S]
+ 
General Information C21H24N2SO2 (384.56 gmol
-1) 
Calculated (%):   C: 65.59, H: 6.29, N: 7.28, S: 16.68   




Synthesis of N-(tri(pyridin-2-yl)methyl)acetamide (L6Acet) 
The ligand L6Acet was synthesised according to the literature.[339] 
Yield:    71 % (Lit.: 71 %) 
Rf:     0.64 (chloroform: methanol / 9 : 1) 
MP:   145.4 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  9.31 (s, 1 H, NH), 8.53 (d, 3J(H,H) = 6 Hz, 3 H, CH
Py, 3,3’,3’’), 7.62 (dd, 
3J(H,H) = 6 Hz, 
3J(H,H) = 6 Hz, 3 H, CH
Py, 4,4’,4’’), 7.58 (d, 3J(H,H) = 6 Hz, 3 H, CH
Py, 
6,6’,6’’), 7.16 (dd, 3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz, 3 H, CH
Py, 5,5’,5’’), 2.19 (s, 3 H, 
CH3) 
13C-NMR  (75 MHz, CDCl3) 
δ [ppm]:  168.91 (C=O), 160.89 (CPy, 2,2’,2’’), 147.85 (CHPy, 3,3’,3’’), 136.09 (CHPy, 4,4’,4’’), 
124.47 (CHPy, 6,6’,6’’), 122.08 (CHPy, 5,5’,5’’), 70.74 (CNH), 24.18 (CH3) 
Mass spectrometry  EI+ 
m/z (%): 304.1 (3) [M]+, 261.1 (29) [M - C2H3O]
+, 246.0 (37) [M - C2H4NO]
+, 245.0 
(39) [M - C2H5NO]
+, 209.0 (100) [C12H9N3O]
+, 184.0 (42) [C11H10N3]
+ 
IR   KBr 
ṽ [cm-1]: 3277 (s), 3076 (w), 3048 (w), 3007 (w), 2927 (w), 1670 (s), 1588 (m), 
1568 (m), 1498 (s), 1466 (s), 1429 (s), 1369 (m), 1298 (w), 1281 (m), 1199 
(w), 1152 (w), 1121 (w), 1093 (w), 1053 (m), 999 (m), 939 (w), 787 (m), 
768 (m), 749 (s), 695 (w), 662 (m), 621 (m), 586 (m), 558 (m), 534 (w), 
478 (w), 408 (w) 
Elemental analysis C18H16N4O (304.35 gmol
-1) 
Calculated (%):   C: 71.04, H: 5.30, N: 18.41 
Found (%):  C: 70.31, H: 5.26, N: 18.35 
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Synthesis of 6-methoxybenzo[d]thiazol-2-amine (XIII)  
The compound XIII was synthesised according to the literature.[298]  
Yield:   86 % (Lit.: 87 %) 
Rf:    0.30 (hexane : ethyl acetate / 7 : 3) 
MP:   163.2 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.46 (d, 3J(H,H) = 15 Hz, 1 H, CH
4), 7.15 (s, 1 H, CH7), 6.92 (d, 3J(H,H) = 15 Hz, 
1 H, CH5), 5.24 (sb, 2H, NH2) 3.84 (s, 3 H, OCH3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  164.67 (C2), 154.24 (C6), 146.81 (C9), 131.88 (C8), 118.04 (CH4), 112.84 
(CH5), 105.50 (CH7), 55.51 (OCH3) 
Mass spectrometry  EI+ 
m/z (%):  180.1 (88) [M]+, 165.1 (100) [M–NH2]
+, 13.1 (16) [M–N-C-NH2]
+ 
IR   KBr 
ṽ [cm-1]: 3388 (s), 1641 (s), 1545 (s), 1462 (s), 1277 (s), 1205 (s), 1053 (s), 1021 (s), 
806 (s), 3086 (m), 1338 (m), 1134 (m), 846 (m), 709 (m), 615 (m), 446 
(m), 2744 (w), 2062 (w), 1849 (w), 904 (w), 545 (w)  
Elemental analysis C8H8N2OS (180.23 gmol
-1) 
Calculated (%):   C: 53.31, H: 4.47, N: 15.54, S: 17.79 
Found (%):  C: 52.88, H: 4.54, N: 15.47, S: 17.93 
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Synthesis of 2-bromo-6-methoxybenzo[d]thiazole (XIV)  
The compound XIV was synthesised according to the literature.[299] 
Yield:   74 % (Lit.: 79 %) 
Rf:    0.61 (hexane : ethyl acetate / 2 : 1) 
MP:   52 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.85 (d, 3J(H,H) = 9 Hz, 1 H, CH
4), 7.24 (d, 4J(H,H) = 3 Hz, 1 H, CH
7), 7.09 (dd, 
3J(H,H) = 9 Hz, 
4J(H,H) = 3 Hz, 1 H, CH
5), 3.89 (s, 3 H, OCH3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  158.07 (C6), 150.13 (C9), 145.40 (C8), 137.40 (C2), 123.44 (CH 4), 115.76 
(CH 5), 103.92 (CH 7), 55.84 (OCH3) 
Mass spectrometry  EI+ 
m/z (%):  245 (100) [M + H]+, 228 (56) [M - CH3]
+ 
IR   KBr 
ṽ [cm-1]: 3411 (w), 2987 (m), 2975 (m), 1607 (m), 1558 (m), 1493 (s), 1462 (s), 
1437 (s), 1405 (m), 1318 (m), 1275 (s), 1252 (m), 1227 (w), 1210 (s), 1180 
(m), 1152, 1074 (m), 1029 (s), 1012 (s), 886 (w), 843 (m), 807 (s), 223 (w), 
700 (w), 673 (w), 601 (w), 575 (w), 527 (w), 471 (w), 426 (w) 
General information C8H6BrNOS (244.11 gmol
-1) 
Calculated (%):   C: 39.36, H: 2.48, N: 5.74, S: 13.14 




Synthesis of 2-iodo-6-methoxybenzo[d]thiazole (XV) 
To a cooled solution (10 °C) of p-toluene sulfuric acid (6.33 g, 33.3 mmol, 3.0 eq.) and 
6-methoxy-2-benzothiazolamine (2.00 g, 11.1 mmol, 1.0 eq.) in MeCN (45 ml) was slowly added 
a solution of NaNO2 (1.53 g, 22.2 mmol, 2 eq.) and KI (4.61 g, 27.8 mmol, 2.5 eq) in water 
(6.66 ml). During the reaction the temperature has to remain below 20 °C. After stirring an 
additional 3.5 h at this temperature, water (250 ml) was added and the pH value was adjusted to 
9 by addition of a NaHCO3 solution (1 M). Then an aqueous solution of Na2S2O3 (2 M, 24 ml) were 
added to the reaction mixture and the crude product was obtained after extraction with 
chloroform (3 x 70 ml) and removal of the solvent under reduced pressure. Purification was 
done by column chromatography on silica. The product was obtained as brown solid. 
Yield:   1.87 g (6.42 mmol, 58 %) 
Rf:    0.59 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (500 MHz, CDCl3) 
δ [ppm]:  7.92 (d, 3J(H,H) = 15 Hz, 1 H, CH
4), 7.30 (d, 4J(H,H) = 5 Hz, 1 H, CH
7), 7.05 (dd, 
3J(H,H) = 15 Hz, 
4J(H,H) = 5 Hz, 1 H, CH
5), 3.87 (s, 3 H, OCH3)
 
13C-NMR   (125 MHz, CDCl3) 
δ [ppm]:  158.09 (C6), 149.02 (C9), 140.45 (C8), 123.00 (CH4), 115.62 (CH5), 103.09 
(CH7), 101.45 (C2), 55.84 (OCH3) 
Mass spectrometry  EI+ 
m/z (%):  313.9 (16) [M + Na]+, 291.9 (100) [M]+, 165.2 (5) [M - I]+.
 
IR   KBr 
ṽ [cm-1]: 1598 (s), 1477 (s), 1406 (s), 1251 (s), 1223 (s), 952 (s), 812 (s), 1554 (m), 
1319 (m), 1097 (m), 1055 (m), 663 (m), 599 (m), 3109 (w), 2961 (w), 
2827 (w), 1878 (w), 514 (w) 
Elemental analysis C8H6INOS (291.11 gmol
-1) 
Calculated (%):   C: 33.01, H: 2.08, N: 4.81, S: 11.01 
Found (%):  C: 32.25, H: 2.01, N: 4.74, S: 11.03 
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Synthesis of 4-bromo-N-methylaniline (XVI) 
4-bromoaniline (3.02 g, 17.6 mmol, 1.0 eq.) was dissolved in acetonitrile (75 ml) and 
triethylamine (3.4 ml, 24.6 mmol, 1.4 eq.) was added. The solution was stirred for 1 h at room 
temperature before methyl iodide (2.50 g, 17.6 mmol, 1.0 eq.) was added. Then the reaction 
was heated at 60 °C and stirred for 16 h. The solvent was removed under reduced pressure and 
the crude product was purified by column chromatography on silica. The product could be 
obtained as white powder. 
Yield:   1.31 g (7.0 mmol, 40 %) 
Rf:    0.29 (hexane : ethyl acetate / 5 : 1) 
1H-NMR   (200 MHz, CDCl3) 
δ [ppm]:  7.28-7.20 (m, 2 H, CH3,5), 6.51-6.43 (m, 2 H, CH2,6), 3.78 (s, 1 H, NH), 2.81 
(s, 3 H, NCH3) 
Mass spectrometry  EI+ 
m/z (%):  187 (97) [M(81Br)] +, 185 (100) [M(79Br)]+, 105 [M - HBr]+. 
General Information C7H8BrN (186.05 gmol
-1) 
Calculated (%):   C: 45.19, H: 4.33, N: 7.53 
  
 




Synthesis of tert-butyl 4-bromophenylcarbamate (XVII) 
A solution of 4-bromoaniline (2.00 g, 11.6 mmol, 1.0 eq) and di-tert-butyldicarbonate (4.2 g, 
40.4 mmol, 3.5 eq.) in Et3N/CH3OH (10 %, 12 ml) was heated at 50 °C and stirred for 12 h. Then 
the volume was reduced to a small amount and dissolved in ethyl acetate (25 ml). After 
extraction with brine (3 x 15 ml), the organic phase was dried over Na2SO4 and the solvent was 
removed under reduced pressure. Column chromatography on silica provided a white powder.  
Yield:   2.71 g (10.0 mmol, 87 %) 
Rf:    0.30 (hexane : ethyl acetate / 5 : 1) 
MP:   104.1 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.40 (d, 3J(H,H) = 6 Hz, 2 H, CH
3,3’), 7.27 (d, 3J(H,H) = 6 Hz, 2 H, CH
2,2’), 6.52 (s, 
1 H, NH), 1.53 (s, 9 H, C(CH3)3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  152.53 (CO2), 137.49 (C
4), 131.88 (CH2,2’), 120.08 (CH3,3’), 115.44 (C1), 
88.91 (C(CH3)3), 28.33 (C(CH3)3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 270.9 (14) [M]+, 214.9 (48) [M - tBu]+, 170.9 (36) [M - Boc]+, 57.0 (100) 
[tBu]+ 
IR   KBr 
ṽ [cm-1]: 3370 (s), 2984 (s), 2934 (w), 1884 (w), 1696 (s), 1591 (m), 1518 (s), 1449 
(m), 1395 (s), 1366 (s), 1306 (m), 1268 (m), 1238 (m), 1159 (m), 1116 (w), 
1071 (m), 1053 (m), 1024 (m), 1007 (m), 931 (w), 905 (w), 816 (m), 765 
(m), 693 (w), 635 (m), 613 (m), 498 (m), 433 (w) 
General Information C11H14BrNO2 (272.14 gmol
-1) 
Calculated (%):   C: 48.55, H: 5.19, N: 5.15  
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Synthesis of tert-butyl 4-bromophenyl(methyl)carbamate (XVIII) 
A suspension of XVII (2.50 g, 9.2 mmol, 1.0 eq.) (100 ml) and sodium hydride (60%, 0.67 g, 
10.0 mmol, 1.1 eq.) in acetonitrile was stirred for 30 min at 60°C. Afterwards methyl iodide 
(1.42 g. 10.0 mmol, 1.1 eq.) was added and the reaction was stirred at 60°C for 20 h. The solvent 
was removed under reduced pressure and the residue was taken up in chloroform (20 ml) and 
filtered. Then the filtrate was concentrated under reduced pressure. The crude product could be 
obtained as yellow oil, which solidified at 4 °C.  
Yield:   2.11 g (7.4 mmol, 80 %)  
Rf:    0.59 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.19 (d, 3J(H,H) = 9 Hz, 2 H, CH
3,3’), 7.41 (d, 3J(H,H) = 6 Hz, 2 H, CH
2,2’), 3.36 (s, 
3 H, NCH3), 1.51 (s, 9H, C(CH3)3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  154.47 (CO2), 147.80 (C
4), 136.06 (CH3,3’), 134.04 (C1), 124.56 (CH2,2’), 
80.77 (C(CH3)3), 37.09 (NCH3), 28.36 (C(CH3)3) 
Mass spectrometry   ESI+ (70 eV, MeOH) 
m/z (%): 594.9 (20) [2 M + Na]+, 310 (100) [M + Na]+, 253.9 (42) [M - tBu + Na]+, 
230.0 (50) [M - tBu]+ 
IR   KBr 
ṽ [cm-1]: 3333 (w), 2976 (m), 2932 (w), 2834 (w), 1699 (s), 1600 (w), 1514 (s), 
1456 (m), 1441 (m), 1366 (s), 1296 (m), 1247 (s), 1154 (s), 1110 (m), 
1036 (m), 976 (w), 866 (w), 833 (m), 768 (w), 725 (w), 638 (w), 611 (w), 
571 (w), 521 (w), 462 (w) 
General Information C12H16BrNO2 (286.16 gmol
-1) 
Calculated (%):   C: 50.37, H: 5.64, N: 4.89 
  
 




Synthesis of tert-butyl 4-(hydroxy(methoxy)boryl)phenyl(methyl)carbamate (XIX) and tert-
butyl (4-(hydroxy(methoxy)boryl)phenyl)(methyl)carbamate (XX) 
XVIII (2.00 g, 7.0 mmol, 1 eq.) was dissolved in abs. THF (80 ml) and 2.5 M nBuLi (3.08 ml, 
7.7 mmol, 1.1 eq.) was slowly added at -78 °C. The reaction was stirred for 1.5 h at this 
temperature before trimethyl borate (2.39 ml, 21.0 mmol, 1.5 eq.) was added dropwise. After 
stirring at -78 °C for 30 min the reaction was allowed to warm up to room temperature and a 
saturated NH4Cl-solution (80 ml) was added. Stirring for an additional 2 h at room temperature 
completed the reaction. The solution was extracted with DCM (4 x 100 ml), the combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was obtained as a brown solid. The solid was purified by column 
chromatography on silica. First side products were removed by washing with hexane/ethyl 
acetate (2:1) and afterward the products were washed from the silica with methanol.  
Analysis of XIX: 
Yield:   351 mg (1.4 mmol, 20 %) 
Rf:   0.08 (hexane : ethyl acetate / 2 : 1) 
MP:   125.3 °C 
1H-NMR   (200 MHz, CDCl3) 
δ [ppm]:  8.14 (d, 3J(H,H) = 8 Hz, 2 H, CH
3,5), 7.36 (d, 3J(H,H) = 8 Hz, 2 H, CH
2,6), 3.30 (s, 
3 H, NCH3), 1.46 (s, 9 H, C(CH3)3).
 
Mass spectrometry  EI+  
m/z (%): 251 (5) [M]+, 151 (59) [M - boc]+, 57 (100) [C4H9]
+ 
IR KBr 
ṽ [cm-1]: 3359 (s), 3038 (w), 2981 (m), 2936 (w), 2315 (w), 1682 (s), 1604 (m), 
1567 (w), 1512 (w), 1480 (m), 1458 (m), 1429 (m), 1369 (s), 1332 (s), 
1303 (m), 1261 (m), 1164 (m), 1112 (m), 1015 (m), 998 (m), 981 (m), 865 
(m), 840 (s), 774 (s), 723 (m), 662 (m), 648 (s), 631 (m), 600 (w), 571 (w), 
509 (w), 456 (w), 431 (w) 
General Information C12H18BNO4 (251.09 gmol
-1) 
Calculated (%):   C: 57.40, H: 7.23, N: 5.58 
 
Analysis of XX: 
Yield:   4.0 g (14.0 mmol, 47 %) 
Rf:    0.12 (hexane : ethyl acetate / 2 : 1) 
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MP:   107.5 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.98 (s, 1 H, BOH), 7.73 (d, 3J(H,H) = 9 Hz, 2 H, CH
2,2’), 7.21 (d, 3J(H,H) = 9 Hz, 
2 H, CH3,3’), 3.33 (s, 3 H, NCH3), 3.17 (s, 3 H, BOCH3), 1.38 (s, 9 H, C(CH3)3)
 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  153.58 (CO2), 145.02 (C
4), 134.34 (CH3,3’), 123.87 (CH2,2’), 79.57 (C(CH3)3), 
36.78 (NCH3), 27.89 (C(CH3)3) 
Mass spectrometry  ESI+ (70 eV, MeOH)  
m/z (%): 288.1 (100) [M + Na]+, 232.2 (46) [M - OMe]+, 210.1 [M - tBu]+ 
IR KBr 
ṽ [cm-1]: 3318 (s), 2976 (s), 2913 (s), 2870 (s), 2791 (w), 2218 (s), 1665 (s), 1615 
(s), 1565 (m), 1517 (w), 1478 (w), 1414 (m), 1369 (m), 1254 (m), 1198 
(m), 1156 (s), 1109 (m), 1040 (w), 1018 (w), 977 (w), 928 (w), 865 (w), 
940 (w), 770 (w), 723 (m), 652 (w), 573 (w), 535 (m), 505 (w), 465 (w), 
428 (w) 
General Information C12H18BNO4 (251.09 gmol
-1) 
Calculated (%):   C: 57.40, H: 7.23, N: 5.58 
 
 




Synthesis of tert-butyl -4-(6-methoxybenzo[d]thiazol-2-yl)phenyl(methyl)carbamate (XXI) 
Route A 
CuSO4 (0.67 g, 2.67 mmol, 1.3 eq.), tetrakis triphenylposphane palladium (0.12 g, 0.10 mmol, 
0.05 eq.), potassium carbonate (0.57 g, 4.12 mmol, 1.5 eq.) and 1.0 eq. of the halogen XIV or XV 
were suspended in a mixture of DME (5 ml) and water (2 ml). 1.2-1.4 eq. of the mixture of XIX, 
and XX was added to the suspension and the reaction was heated under reflux at 100 °C for 24 h 
to 48 h. The solution was then cooled and ethyl acetate (5 ml) was added. The suspension was 
filtered through a thin layer of celite and the solvent of the filtrate was removed under reduced 
pressure. Column chromatography on silica gave the product as a yellow solid.  
Yield:    0.94 g (2.54 mmol, 95 %) 
Route B  
CuSO4 (0.67 g, 2.67 mmol, 1.3 eq.), tetrakis triphenylposphane palladium (0.12 g, 0.10 mmol, 
0.05 eq.), potassium carbonate (0.57 g, 4.12 mmol, 1.5 eq.) and 1.0 eq. of the halogen XIV or XV 
were suspended in a mixture of DME (5 ml) and water (2 ml). 1.2-1.4 eq. of the mixture of XIX, 
and XX was added to the suspension and under microwave irradiation (250 W) stirred for 0.5 h-
1 h. To the cooled solution ethyl acetate (5 ml) was added and the suspension was filtered 
through a thin layer of celite. The solvent of the filtrate was removed under reduced pressure. 
Column chromatography on silica gave the product as a yellow solid.  
Yield:   0.97 g (2.62 mmol, 98 %) 
Rf:    0.14 (hexane : ethyl acetate / 2 : 1) 
MP:   109.0 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.92 (d, 3J(H,H) = 9 Hz, 1 H, CH
7), 7.91 (d, 4J(H,H) = 6 Hz, 1 H, CH
4), 7.82 (d, 
3J(H,H) = 9 Hz, 2 H, CH
11,11‘), 7.28 (dd, 3J(H,H) = 9 Hz, 
4J(H,H) = 6 Hz, 1 H, CH
5), 
6.65 (d, 3J(H,H) = 9 Hz, 1 H, CH
12,12’), 6.50 (q, 3J(H,H) = 6 Hz, 1 H, CH
12,12’), 3.88 
(s, 3 H, OCH3), 3.28 (d, 3 H,
 3J(H,H) = 6 Hz, NCH3), 1.46 (s, 9 H, C(CH3)3) 
13C-NMR  (75 MHz, CDCl3) 
δ [ppm]:  168.67 (C2), 152.58 (C6), 151.79 (CO2), 147.21 (C
9), 143.09 (C13), 134.23 
(C8), 128.67 (C10), 121.96 (CH11,11’), 120.40 (CH12,12’), 119.73 (CH4), 111.48 
(CH5), 99.51 (CH7), 80.39 (C(CH3)3), 55.08 (OCH3), 29.27 (NCH3), 27.25 
(C(CH3)3) 
Mass spectrometry ESI+ (70 eV, MeOH)  
m/z (%): 763.1 (49) [2M + Na]+, 409.0 (34) [M + K]+, 393.1 (74) [M + Na]+, 371.1 
(100) [M + H]+, 315.0 (66) [M - tBu]+, 271.2 (53) [M - Boc]+ 
IR   KBr 
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ṽ [cm-1]: 3007 (w), 2980 (m), 2939 (w), 2831 (w), 2875 (w), 1709 (s), 1605 (s), 
1566 (m), 1524 (m), 1488 (m), 1463 (s), 1437 (m), 1425 (m), 1397 (w), 
1367 (m), 1347 (m), 1318 (m), 1303 (m), 1283 (m), 1264 (m), 1225 (m), 
1160 (m), 1117 (m), 1105 (m), 1060 (m), 1024 (m), 970 (m), 891 (w), 858 
(m), 845 (m), 827 (s), 766 (m), 686 (w), 670 (m), 624 (w), 592 (m), 561 
(w), 541 (w), 510 (w), 473 (w), 438 (w), 411 (w) 
Elemental analysis C20H22N2O3S (370.14 gmol
-1) 
Calculated (%):   C: 64.84, H: 5.99, N: 7.56, S: 8.66 
Found (%):  C: 64.44, H: 6.06, N: 7.17, S: 8.44 
 




Synthesis of 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol (XXII) 
XXI (0.50 g, 1.35 mmol, 1.0 eq.) and boron tribromide (0.85 g., 3.37 mmol, 2.5 eq.) were 
dissolved in DCM (20 ml) and stirred at room temperature for 16 h. The reaction was quenched 
by addition of diluted HCl (5 %, 2 ml) and a pH value of 7 was adjusted with sodium carbonate. 
Extraction with ethyl acetate (3 x 10 ml), drying of the combined organic layers over Na2SO4 and 
removal of the solvent gave a yellow solid.  
Yield:   0.97 g (3.07 mmol, 91 %)   
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  9.75 (sb, 1 H, COH), 7.75 (d, 3J(H,H) = 9 Hz, 2 H, CH
11,11‘), 7.70 (d, 3J(H,H) = 
9 Hz, 1 H, CH7), 7.30 (d, 4J(H,H) = 6 Hz, 1 H, CH
4), 6.91 (dd, 3J(H,H) = 9 Hz, 
4J(H,H) = 3 Hz, 1 H, CH
5), 6.64 (d, 3J(H,H) = 9 Hz, 2 H, CH
12,12’), 2.75 (s, 3 H, 
NCH3) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  164.47 (C2), 159.79 (C6), 154.87 (CO2), 151.48 (C
9), 147.17 (C13), 134.99 
(C8), 128.14 (C10), 122.23 (CH11,11’), 120.45 (CH12,12’), 115.42 (CH4), 111.61 
(CH5), 106.70 (CH7), 29.49 (NCH3) 
Mass spectrometry ESI+ (70 eV, MeOH)  




ṽ [cm-1]: 1610 (s), 1458 (s), 1240 (s), 1178 (s), 817 (s), 3394 (m), 1540 (m), 
1487 (m), 1340 (m), 1279 (m), 1062 (m), 974 (m), 902 (m), 715 (m), 
582 (m), 505 (m), 2870 (w), 2784 (w), 2662 (w), 538 (w) 
Elemental analysis C14H12N2OS (256.32 gmol
-1) 
Calculated (%):   C: 65.60, H: 4.72, N: 10.93, S: 12.51 
Found (%):  C: 61.35, H: 4.83, N: 10.12, S: 11.78 
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Synthesis of 2-((2-(4-(methylamino)phenyl)benzo[d]thiazol-6-yl)oxy)ethanol (XXIII) 
Potassium hydroxide (33 mg, 0.59 mmol, 1.5 eq.) and XXII (100 mg, 0.39 mmol, 1.0 eq.) were 
dissolved in aqueous ethanol (100 ml) and cooled to 0 °C. A large excess of ethane epoxide was 
added. After 30 min the reaction was allowed to warm to room temperature and stirred for an 
additional 1 h. A pH value of 7 was adjusted with diluted HCl and under reduced pressure the 
solution was reduced to a small amount. DCM was added and the phases were separated. The 
combined organic phases were dried over Na2SO4 and the solvent was removed under reduced 
pressure. The residue was purified by column chromatography on silica. The product was 
obtained as yellow solid. 
Yield:   96 mg (0.32 mmol, 81 %) 
Rf:    0.06 (hexane : ethyl acetate / 2 : 1) 
MP:   148.0 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]: 7.78 (d, 3J(H,H) = 6 Hz, 1 H, CH
4), 7. 76 (d, 3J(H,H) = 9 Hz, 2 H, CH
11,11‘), 7.62 (d, 
3J(H,H) = 6 Hz, 1 H, CH
7), 7.06 (dd, 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz, 1 H, CH
5), 6.64 
(d, 3J(H,H) = 9 Hz, 2 H, CH
12,12’), 4.17 (t, 3J(H,H) = 6 Hz, 2 H, OCH2CH2OH), 3.76 
(t, 3J(H,H) = 6 Hz, 2 H, OCH2CH2OH), 2.75 (s, 3 H, NCH3) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  166.32 (C2), 156.10 (C6), 152.11 (C9), 142.91 (C13), 135.04 (C8), 128.24 
(C10), 122.22 (CH11,11’), 120.25 (CH12,12’), 115.48 (CH4), 111.46 (CH5), 
105.60 (CH7), 70.14 (OCH2CH2OH), 59.55 (OCH2CH2OH), 29.30 (NCH3) 
Mass spectrometry  ESI+ (70 eV, MeOH)  
m/z (%): 623.1 (7) [2M + Na]+, 345.1 (10) [M + K]+, 323.1 (11) [M + Na]+, 301.1 
(100) [M + H]+, 257.0 (8) [C14H13N2OS]
+ 
IR   KBr 
ṽ [cm-1]: 3375 (w), 2938 (w), 2872 (w), 2817 (w), 2361 (w), 2341 (w), 1609 (s), 
1560 (m), 1533 (m), 1509 (w), 1488 (m), 1449 (s), 1414 (w), 1380 (w), 
1336 (m), 1312 (w), 1264 (m), 1225 (m), 1182 (m), 1160 (w), 1126 (w), 
1064 (m), 1006 (w), 971 (w), 935 (m), 887 (w), 827 (s), 702 (w), 629 (w), 
592 (w), 557 (w), 517 (w), 481 (w), 436 (w) 
Elemental analysis C16H16N2O2S (300.38 gmol
-1) 
Calculated (%):   C: 63.98, H: 5.37, N: 9.33, S: 10.67 
Found (%):  C: 61.02, H: 5.54, N: 8.30, S: 10.03 




Synthesis of 2-((2-(4-(methylamino)phenyl)benzo[d]thiazol-6-yl)oxy)ethyl 4-methylbenzene-
sulfonate (XXIV) 
XXIII (50 mg, 0.17, 1.0 eq.) was dissolved in MeCN (80 ml) and treated with NaH (60 %, 4 mg, 
0.20 mmol, 1.2 eq.). The suspension was stirred for 15 min and then 4-toluenesulfonyl chloride 
(38 mg, 0.20 mmol, 1.2 eq.) was added. The mixture was stirred overnight at room temperature. 
Then the reaction was quenched by the addition of brine and the crude product was extracted 
with DCM. The combined organic phases were dried over Na2SO4 and the solvent was removed 
under reduced pressure. The product could be obtained as yellow solid.  
Yield:   77 mg (0.17 mmol, 100 %) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 476.9 (11) [M + Na]+, 455.1 (20) [M + H]+, 301.1 (100) [M - Tos]+, 257.0 
(11) [C14H13N2OS]
+ 
General Information C23H22N2O4S2 (454.56 gmol
-1) 
Calculated (%):   C: 60.77, H: 4.88, N: 6.16, S: 14.11 
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Synthesis of 4-(6-(3-bromopropoxy)benzo[d]thiazol-2-yl)-N-methylaniline (XXV) 
XXII (1.00 g, 0.17 mmol, 1.0 eq.) was dissolved in abs. MeCN (100 ml) and treated with NaH 
(60 %, 4 mg, 0.20 mmol, 1.2 eq.). The suspension was heated under reflux for 30 min at 60 °C. 
Then 1,3-dibromopropane (38 mg, 0.20 mmol, 1.2 eq.) was added and the mixture was stirred 
over night at 60 °C . The reaction was quenched by the addition of brine and the crude product 
was extracted with DCM. The combined organic phases were dried over Na2SO4 and the solvent 
was removed under reduced pressure. The product was purified through column 
chromatography on silica and could be obtained as yellow solid.  
Yield:   0.56 g (3.50 mmol, 88 %) 
Rf:    0.43 (hexane : ethyl acetate / 2 : 1) 
MP:   137.0 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.91-7.87 (m, 3 H, CH4, 11,11’), 7.35 (s, 1 H, CH7) 7.06 (d, 3J(H,H) = 9 Hz, 1 H, 
CH5), 6.67 (d, 3J(H,H) = 9 Hz, 2 H, CH
12,12’), 4.19 (t, 3J(H,H) = 6 Hz, 2 H, OCH2), 
3.66 (t, 3J(H,H) = 6 Hz, 2 H, BrCH2), 2.93 (s, 3 H, NCH3), 2.38 (quint, 
3J(H,H) = 6 Hz, 2 H, CH2CH2CH2) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  165.65 (C2), 155.17 (C6), 150.27 (C13), 148.06 (C9), 134.79 (C8), 127.75 
(CH11,11‘), 121.83 (CH4), 118.98 (C10), 114.33 (CH5), 111.04 (CH12,12‘), 
104.31 (CH7), 65.00 (OCH2), 31.38 (CH2CH2CH2), 29.34 (BrCH2), 28.94 
(NCH3) 
Mass spectrometry  EI+ 
m/z (%): 378 (12) [M + H]+, 296 (7) [M - HBr]+, 270 (10) [M - C2H4Br]
+, 255.0 (100) 
[M - C3H6Br]
+ , 227.0 (10) [C13H11N3S2]
+ 
IR   KBr 
ṽ [cm-1]: 3279 (w), 2925 (w), 2854 (w), 2360 (w), 1609 (s), 1561 (m), 1487 (m), 
1455 (s), 1432 (m), 1416 (m), 1341 (m), 1313 (w), 1281 (m), 1263 (m), 
1209 (m), 1181 (m), 1112 (w), 1063 (m), 1030 (w), 962 (w), 939 (w), 893 
(w), 854 (w), 824 (m), 796 (m), 714 (w), 695 (w), 622 (w), 584 (w), 557 
(w), 507 (w), 482 (w), 433 (w) 
Elemental analysis C17H17BrN2OS (377.30 gmol
-1) 
Calculated (%):   C: 54.12, H: 4.54, N: 7.42, S: 8.50 
Found (%):  C: 60.48, H: 6.01, N: 6.67, S: 8.01 




Synthesis of 4-(6-(but-3-en-1-yloxy)benzo[d]thiazol-2-yl)-N-methylaniline (XXVI) 
L3H (453 g, 2.0 mmol, 1.0 eq.) and NaH (60 %, 80 mg, 2.2 mmol, 1.1 eq.) were dissolved in abs. 
THF (30 ml) and heated under reflux at 60 °C for 30 min. XXV (754 mg, 2.0 mmol, 1.0 eq.) was 
added to the formed suspension and the reaction was stirred for an additional 2 h at 60 °C. The 
reaction was quenched by the addition of brine, extracted with DCM and the combined organic 
phases were dried over Na2SO4. The solvent was removed under reduced pressure and the 
product was purified by column chromatography on silica. The product could be obtained as 
yellow solid. Instead of column chromatography a sauxlette with diethyl ether can also be used 
to extract the product. 
Yield:   553 mg (1.78 mmol, 89 %) 
Rf:    0.29 (hexane : ethyl acetate / 2 : 1) 
MP:   133.7 °C 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.82-7. 78 (m, 3 H, CH4, CH
11,11‘), 7.26 (d, 4J(H,H) = 1 Hz,  1 H, CH
7), 6.98 (dd, 
3J(H,H) = 3 Hz, 
4J(H,H) = 1 Hz, 1 H, CH
5), 6.57 (d, 3J(H,H) = 6 Hz, 2 H, CH
12,12’), 
6.05 (dq, 3J(H,H) = 6 Hz, 
4J(H,H) = 3 Hz, 1 H, CH2=CH), 5.41 (d, 
3J(H,H) = 18 Hz, 
1 H, HCHtrans=CH), 5.24 (d, 
3J(H,H) = 18 Hz, 1 H, HCHcis=CH), 2.38 (d, 
3J(H,H) = 3 Hz, 2 H, CH2O), 2.84 (s, 3 H, NCH3) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  165.43 (C2), 156.21 (C6), 151.33 (C13), 133.14 (CH2=CH), 128.81 (CH
11,11‘), 
122.79 (C9), 117.86 (C10), 115.58 (C8), 115.39 (CH4), 112.07 (CH12,12‘), 
110.86 (CH2=CH), 105.57 (CH
5), 105.32 (CH7), 69.50 (CH2O), 30.36 (NCH3) 
Mass spectrometry  EI+ 
m/z (%): 296 (22) [M]+, 255 (100) [M - vinyl]+, 227 (9) [C13H9NOS]
+ 
IR   KBr 
ṽ [cm-1]: 3287 (w), 3151 (w), 3074 (w), 3038 (w), 2878 (w), 2821 (w), 1608 (s), 
1561 (m), 1487 (s), 1455 (s), 1432 (m), 1417 (m), 1343 (m), 1313 (m), 
1281 (m), 1265 (s), 1211 (m), 1181 (s), 1114 (w), 1061 (m), 1026 (m), 
1005 (w), 965 (w), 927 (w), 894 (w), 859 (w), 826 (m), 795 (m), 766 (w), 
716 (w), 697 (w), 622 (w), 586 (w), 562 (w), 509 (w), 485 (w), 434 (w) 
General Information C18H18N2OS (310.41 gmol
-1) 
Calculated (%):   C: 69.65, H: 5.84, N: 9.02, S: 10.33 
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Synthesis of 4-(6-(3-azidopropoxy)benzo[d]thiazol-2-yl)-N-methylaniline (XXVII) 
Sodium azide (52 mg, 0.80 mmol, 1.5 eq.) and XXV (200 mg, 0.53 mmol, 1.0 eq.) were dissolved 
in DMSO (10 ml) and stirred over night at 120 °C. The solvent was removed under reduced 
pressure and the crude product was suspended in water. The residue was separated by filtration 
and purified by column chromatography.  
Yield:   152 mg (0.45 mmol, 85 %) 
Rf:    0.30 (hexane : ethyl acetate / 2 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.89-7.86 (m, 3 H, CH4, 11,11’), 7.33 (d, 3J(H,H) = 3 Hz, 1 H, CH
7) 7.04 (dd, 
3J(H,H) = 9 Hz, 
4J(H,H) = 3 Hz, 1 H, CH
5), 6.65 (d, 3J(H,H) = 9 Hz, 2 H, CH
12,12’), 
4.12 (t, 3J(H,H) = 6 Hz, 2 H, OCH2), 3.56 (t, 
3J(H,H) = 6 Hz, 2 H, BrCH2), 2.99 (s, 
3 H, NCH3), 2.10 (quint, 
3J(H,H) = 6 Hz, 2 H, CH2CH2CH2) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  165.63 (C2), 155.15 (C6), 150.30 (C13), 148.05 (C9), 134.78 (C8), 127.73 
(CH11,11‘), 121.81 (CH4), 118.99 (C10), 114.28 (CH5), 111.03 (CH12,12‘), 
104.25 (CH7), 64.18 (OCH2), 47.25 (CH2CH2CH2), 29.31 (NCH3), 28.34 
(N3CH2) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 340.1 (100) [M + H]+, 297.1 (86) [M - N3]
+, 257.1 (75) [M - C3H4Br]
+, 255.1 
(8) [M - C3H6Br]
+, 101.0 (42) [C3H7N3O]
+ 
IR   KBr 
ṽ [cm-1]: 3269 (m), 2926 (w), 2877 (w), 2819 (w), 2098 (s), 1608 (s), 1561 (m), 
1536 (w), 1491 (m), 1455 (s), 1416 (w), 1341 (m), 1313 (m), 1283 (m), 
1263 (s), 1223 (s), 1182 (s), 1112 (w), 1064 (m), 1035 (w), 963 (w), 903 
(w), 821 (m), 695 (w), 629 (w), 589 (w), 557 (w), 512 (w), 434 (w) 
Elemental analysis C17H17N5OS (339.41 gmol
-1) 
Calculated (%):   C: 60.16, H: 5.05, N: 20.63, S: 9.45 
Found (%):  C: 61.77, H: 5.27, N: 17.17, S: 10.01 
 
 




Synthesis of 6-bromo-N-ethyl-1,8-naphthalimide (XXVIII) 
XXVIII was synthesised according to the literature.[290] 
Yield:   76 % (Lit.: 78 %)  
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.79 (d, 3J(H,H) = 9 Hz, 1 H, CH
4), 8.59 (d, 3J(H,H) = 9 Hz, 1 H, CH
2), 8.45 (d, 
3J(H,H) = 9 Hz, 1 H, CH
7), 8.07 (d, 3J(H,H) = 9 Hz, 1 H, CH
6), 8.87 (dd, 
3J(H,H) = 9 Hz,
 3J(H,H) = 9 Hz, 1 H, CH
3), 4.26 (q, 3J(H,H) = 9 Hz, 2 H, CH2), 1.36 
(t, 3J(H,H) = 9 Hz, 3 H, CH3) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  163.45 (C=O), 133.23(CH2), 131.98(CH7), 131.17(1 C, C3), 131.09 (CH6), 
130.67 (C5), 130.19 (C1,8), 128.07(C9,10), 35.64 (CH2), 13.30 (CH3) 
Mass spectrometry  EI+  
m/z (%): 304.9 (93) [M(81Br)]+, 302.9 (91) [M(79Br)]+, 276.9 (98) [M(81Br) - C2H4]
+, 
274.9 (100) [M(79Br) - C2H4]
+, 259.9 (22) [M - C2H6N]
+, 232.9 (37) [M- 
C3H6NO]
+ 
General Information C14H10BrNO2 (304.14 gmol
-1) 
Calculated (%):   C: 55.29, H: 3.31, N: 4.61 
   





A solution of XXVIII (152 mg, 0.50 mmol, 1.00 eq.), L5Ac (100 mg, 0.38 mmol, 0.75 eq.), CuSO4 
(63 mg, 0.38 mmol, 0.75 eq.) and sodium ascorbate (0.74 g, 3.75 mmol, 7.50 eq.) were 
suspended in DMSO (30 ml) and stirred under reflux at 110 °C. After 24 h, the reaction was 
allowed to cool to room temperature and a conc. solution of sodium EDTA (50 ml) was added. 
The mixture was stored at 4 °C and the precipitate was separated by filtration. The residue was 
recrystallised from methanol/diethyl ether and further purified by column chromatography on 
silica. The product was obtained as brown solid. 
Yield:   15 mg (0.04 mmol, 8 %) 
Rf:    0.62 (chloroform : methanol / 9 : 1)    
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 1084.7 (8) [2M + Na]+, 569.8 (31) [M + K]+, 553.9 (100) [M + Na]+, 531.9 
(23) [M + H]+, 210.0 (50) [C10H12NS2]
+ 
General Information C27H25N5O3S2 (531.14 gmol
-1) 
Calculated (%):   C: 61.00, H: 4.74, N: 13.17, S: 12.06 
   






A solution of XXVIII (152 mg, 0.50 mmol, 1.00 eq.), L5Ac (128 mg, 0.96 mmol, 0.96 eq.), CuSO4 
(80 mg, 0.96 mmol, 0.96 eq.) and sodium ascorbate (0.95 g, 9.60 mmol, 9.60 eq.) were 
suspended in DMSO (30 ml) and stirred under reflux at 110 °C. After 24 h, the reaction was 
allowed to cool to room temperature and a conc. solution of sodium EDTA (50 ml) was added. 
The mixture was stored at 4 °C and the precipitate was separated by filtration. The residue was 
recrystallised from methanol/diethyl ether and further purified by column chromatography on 
silica. The product was obtained as brown solid. 
Yield:   21 mg (0.04 mmol, 8 %) 
Rf:    0.46 (chloroform : methanol / 2 : 1)   
Mass spectrometry  ESI+ (70 eV, MeOH) 




General Information C26H26N6O3S2 (534.15 gmol
-1) 
Calculated (%):   C: 58.41, H: 4.90, N: 15.72, S: 11.99 
   
 





Sodium L-ascorbate (590 mg, 2.50 mmol, 10 eq.) was added to a solution of copper sulphate 
(42 mg, 0.25 mmol, 1.0 eq.), L3H (67 mg, 0.25 mmol, 1.0 eq.) and XXVII (85 mg, 0.25 mmol, 
1.0 eq.) in DMSO/water (9 : 1, 10 ml). The reaction was stirred for 24 h at room temperature 
before it was quenched by the addition of a conc. solution of EDTA (5 ml). The solution was 
poured into water (100 ml) and cooled to 10 °C. The precipitate was separated by filtration and 
purified by column chromatography on silica.  
Yield:   53 mg (0.09 mmol, 35 %) 
Rf:    0.77 (chloroform : methanol / 9 : 1) 
1H-NMR   (300 MHz, DMSO-d6) 
δ [ppm]:  8.56 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 6), 8.06 (s, 1 H, CHTriazole), 7.75-7.80 (m, 4 H, 
CHPy,3, CHBTA, 11,11‘), 7.64-7.59 (m, 2 H, CHPy,4,  CHBTA, 7), 7.35 (t, 3J(H,H) = 6 Hz, 
1 H CHPy,5), 7.05 (d, 3J(H,H) = 9 Hz, 1 H, CH
BTA, 5), 6.62 (d, 3J(H,H) = 9 Hz, 2 H, 
CHBTA, 12,12’), 6.42 (d, 3J(H,H) = 6 Hz, 1 H, NH), 4.53 (t, 
3J(H,H) = 6 Hz, 2 H, 
OCH2CH2), 4.17 (s, 2 H, OCH2C
Triazole), 4.04 (t, 3J(H,H) = 6 Hz, 2 H, N
TriazoleCH2), 
3.69 (d, 2J(H,H) = 12 Hz, 2 H, CHH), 3.35 (d, 
2J(H,H) = 12 Hz, 2 H, CHH), 2.95 (s, 
4 H, SCH2CH2S), 2.75 (s, 3 H, NCH3), 2.31 (quint, 
3J(H,H) = 6 Hz, 2 H, 
CH2CH2CH2) 
13C-NMR   (75 MHz, DMSO-d6) 
δ [ppm]:  173.87 (CBTA, 2), 160.78 (CHPy, 2), 155.70 (CBTA, 6), 150.35 (CBTA, 13), 148.10 
(CPy, 6), 144.17 (CBTA, 8), 137.09 (CHPy, 4), 135.01 (CTriazole) 131.24 (CHBTA, 11, 
11‘), 123.81 (CBTA, 9), 123.04 (CHPy, 3), 122.23 (CHBTA, 4), 121.71 (CHPy, 5), 
119.50 (CBTA, 10), 115.46 (CHBTA, 5), 111.45 (CHBTA, 12, 12‘), 105.68 (CHBTA, 7), 
101.71 (CHTriazole), 85.21 (OCH2C
Triazole), 65.13 (OCH2CH2), 57.14 
(NTriazoleCH2), 46.48 (CH2CH2CH2), 40.62 (CHH), 40.40 (N
TriazoleCH2), 38.93 
(SCH2CH2S), 29.29 (NCH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 340.1 (100) [M + H]+, 297.1 (86) [M - N3]
+, 257.1 (75) [M - C3H4Br]
+, 255.1 
(8) [M - C3H6Br]
+, 101.0 (42) [C3H7N3O]
+ 
IR   KBr 
ṽ [cm-1]: 3368 (m), 2931 (w), 2873 (w), 1607 (s), 1561 (m), 1532 (w), 1488 (m), 
1454 (s), 1431 (m), 1410 (m), 1387 (w), 1323 (w), 1263 (m), 1219 (m), 
1180 (m), 1156 (w), 1110 (w), 1061 (m), 1046 (s), 1002 (w), 964 (w), 951 
(w), 927 (w), 820 (s), 755 (m), 714 (w), 685 (w), 629 (w), 610 (w), 590 (w), 
549 (w), 514 (w), 437 (w), 405 (w) 
Elemental analysis C30H32N6O2S3 (604.81 gmol
-1) 




Calculated (%):   C: 59.58, H: 5.53, N: 13.90, S: 15.91 
Found (%):  C: 51.96, H: 5.25, N: 11.09, S: 13.34 





Sodium L-ascorbate (566 mg, 2.40 mmol, 10 eq.) was added to a solution of copper sulphate 
(40 mg, 0.24 mmol, 1.0 eq.), L5H (63 mg, 0.24 mmol, 1.0 eq.) and XXVII (81.6 mg, 
0.24 mmol, 1.0 eq.) in DMSO/water (9 : 1, 10 ml). The reaction was stirred for 24 h at room 
temperature before it was quenched by the addition of a conc. EDTA solution (5 ml). The 
Solution was poured into water (100 ml) and cooled to 10 °C. The precipitate was separated by 
filtration and purified by column chromatography on silica.  
Yield:   82 mg (0.13 mmol, 54 %) 
Rf:    0.26 (chloroform : methanol / 1 : 20)   
1H-NMR   (300 MHz, DMSO-d6) 
δ [ppm]:  8.23 (s, 1 H, CHTriazole), 7.92 (d, 3J(H,H) = 9 Hz, 2 H, CH
BTA, 11,11‘), 7.88 (d, 
3J(H,H) = 9 Hz, 1 H, CH
BTA, 5), 7.82 (d, 3J(H,H) = 1 Hz, 1 H, CH
Im, 5), 7.82 (d, 
3J(H,H) = 9 Hz, 1 H, CH
Im, 4), 7.66 (d, 4J(H,H) = 1 Hz, 1 H, CH
BTA, 7), 7.09 (dd, 
3J(H,H) = 9 Hz, 
4J(H,H) = 1 Hz, 1 H, CH
BTA, 5), 6.97 (d, 3J(H,H) = 9 Hz, 2 H, CH
BTA, 
12,12‘), 6. 93 (sb, 3J(H,H) = 6 Hz, 1 H, NH), 4.55 (t, 
3J(H,H) = 6 Hz, 2 H, OCH2CH2), 
4.40 (s, 2 H, OCH2C
Triazole), 3.56 (t, 3J(H,H) = 6 Hz, 2 H, N
TriazoleCH2), 3.99 (s, 
3 H, NImCH3), 3.94 (d, 
2J(H,H) = 18 Hz, 2 H, CHH), 3.60 (d, 
2J(H,H) = 18 Hz, 2 H, 
CHH), 3.02 (s, 4 H, SCH2CH2S), 2.81 (s, 3 H, NCH3), 2.32 (quint, 
3J(H,H) = 6 Hz, 2 H, CH2CH2CH2) 
13C-NMR   (75 MHz, DMSO-d6) 
δ [ppm]:  170.75 (CBTA, 2), 156.10 (CBTA, 6), 146.87 (CIm, 2), 143.85 (CBTA, 13), 142.29 
(CBTA, 8), 134.71 (CTriazole), 128.55 (CHBTA, 11, 11‘), 126.51 (CHIm, 5), 124.68 
(CHTriazole'), 124.52 (C
BTA, 9), 122.06 (CHBTA, 4), 119.50 (CBTA, 10), 118.94 (CHIm, 
4), 116.01 (CHBTA, 5), 114,69 (CHBTA, 12, 12'), 105.68 (CHBTA, 7), 82.97 
(OCH2C
Triazole), 65.20 (OCH2CH2), 58.39 (N
TriazoleCH2), 46.59 (CH2CH2CH2), 




Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  608.1 (100) [M]+, 396.1 (11) [C9H13NS2]
+, 213.1 (60) [M - C9H13NS2]
+ 
IR   KBr 
ṽ [cm-1]: 3416 (m), 2925 (s), 2855 (m), 1068 (s), 1592 (s), 1514 (m), 1484 (m), 
1467 (m), 1416 (m), 1379 (w), 1357 (w), 1315 (w), 1267 (m), 1229 (m), 
1190 (w), 1119 (w), 1057 (m), 1020 (w), 909 (w), 825 (m), 765 (w), 713 
(w), 689 (w), 628 (w), 588 (w), 554 (w), 504 (w), 436 (w) 
Elemental analysis C29H33N7O2S3 (607.81 gmol
-1) 




Calculated (%):   C: 57.31, H: 5.47, N: 16.13, S: 15.83 
Found (%):  C: 53.17, H: 5.50, N: 11.28, S: 13.34 





Sodium L-ascorbate (295 mg, 1.25 mmol, 10 eq.) was added to a solution of copper sulphate 
(21 mg, 0.13 mmol, 1.0 eq.), L8H (48 mg, 0.13 mmol, 1.0 eq.) and XXVII (43 mg, 0.13 mmol, 
1.0 eq.) in DMSO/water (9 : 1, 10 ml) and stirred for 24 h at room temperature. Then the 
reaction was quenched by the addition of a conc. EDTA solution (5 ml). The Solution was poured 
into water (100 ml) and cooled to 10 °C. The precipitate was separated by filtration and purified 
by column chromatography on silica.  
Yield:   15 mg (0.02 mmol, 16 %) 
Rf:    0.76 (chloroform : methanol / 9 : 1) 
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  8.45 (d, 1 H, CHPy, 10), 7.80-7.75 (m, 3 H, CHBTA, 4, 11,11’), 7.65-7.43 (m, 4 H, 
CHPy, 4, 7, 12, CH
Triazole), 7.16 (m, 2 H, CHPy, 3, 5), 7.04-6.94 (m, 3 H, CHBTA, 5,, 
CHPy, 11, 13), 6.56 (d, 3J(H,H) = 6 Hz, 2 H, CH
BTA, 4, 12,12’), 4.51 (t, 3J(H,H) = 9 Hz, 
2 H, OCH2CH2), 4.23 (s, 2 H, OCH2C
Triazole), 3.95 (t, 3J(H,H) = 6 Hz, 2 H, 
NTriazoleCH2), 3.65 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 3.24 (d, 
2J(H,H) = 15 Hz, 2 H, 
CHH), 2.88 (s, 3 H, NCH3), 2.84 (s, 4 H, SCH2CH2S), 2.35 (quint, 
3J(H,H) 
= 6 Hz, 2 H, CH2CH2CH2), 1.74 (s, 6 H, C(CH3)2) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  175.67 (CBTA, 2), 167.03 (CPy, 6), 156.22 (CPy, 8), 155.48 (CPy, 6), 148.36 (CPy, 2), 
146.36 (CHPy, 10), 144.08 (CBTA, 8), 140.98 (CBTA, 13), 137.13 (CHPy, 4), 136.22 
(CHPy, 12), 138.83 (CTriazole), 131.10 (CBTA, 9), 128.78 (CHBTA, 11, 11’), 120.99 
(CHPy, 5), 122.90 (CHBTA, 4), 122.76 (CBTA, 10), 121.67 (CHPy, 11), 120.97 (CHPy, 
13), 118.39 (CHBTA, 5), 115.24 (CHPy, 3), 112.05 (CHBTA, 12, 12’), 105.25 (CHBTA, 
7), 87.27 (OCH2C
Triazole), 68.16 (NTriazoleCH2), 64,69 (OCH2CH2), 58.02 
(NTriazoleCH2), 48.30 (C(CH3)2), 47.00 (C(CH3)2), 41.59 (CHH), 38.97 (NCH3), 
30.35 (SCH2CH2S), 29.91 (CH2CH2CH2), 28.31 (C(CH3)2) 
Mass spectrometry  ESI+ (70 eV, MeOH) 




General Information C38H41N7O2S3 (723.97 gmol
-1) 
Calculated (%):   C: 63.04, H: 5.71, N: 13.54, S: 13.29 














Synthesis of [L1HCu(MeCN)]OTf (1) 
[Cu(MeCN)4]OTf (188 mg, 0.5 mmol, 1.0 eq.) was added to a solution of L
1H (129 mg, 0.5 mmol, 
1.0 eq.) dissolved in abs. MeCN (5 ml). The mixture was stirred over night at room temperature 
and then the complex was precipitated by the addition of diethyl ether (30 ml). The product was 
isolated by filtration and obtained as white solid. 
Yield:   217 mg (0.43 mmol, 85 %)   
1H-NMR   (300 MHz, MeCN-d3) 
δ [ppm]:  8.55 (ddd, 3J(H,H) = 4.8 Hz,
 4J(H,H) = 1.5 Hz, 
5J(H,H) = 0.6 Hz 1 H, CH
Py, 6), 7.88 
(ddd, 3J(H,H) = 7.8 Hz,
 3J(H,H) = 7.8 Hz, 
4J(H,H) = 1.5 Hz, 1 H, CH
Py, 4), 7.70 (ddd, 
3J(H,H) = 7.8 Hz,
 4J(H,H) = 1.5 Hz, 
5J(H,H) = 0.6 Hz, 1 H, CH
Py, 3), 7.37 (ddd, 
3J(H,H) = 7.8 Hz,
 3J(H,H) = 4.8 Hz,
 4J(H,H) = 1.5 Hz, 1 H, CH
Py, 5), 4.61 (sbr, 1 H, 
OH), 3.21 (d, 3J(H,H) = 15.0 Hz, 2 H, CHH), 3.07 (d, 
3J(H,H) = 15.0 Hz, 2 H, 
CHH), 2.43 (q, 3J(H,H) = 6 Hz, 4 H, CH2CH3), 1.98 (s, 3 H, CH3CN), 1.14 (t, 
3J (H,H) = 6 Hz, 6 H, CH2CH3)
 
13C-NMR   (75 MHz, MeCN-d3) 
δ [ppm]:  162.1 (CHPy, 2), 147.7 (CHPy, 6), 137.2 (CHPy, 4), 122.6 (CHPy, 3), 120.8 (CHPy, 5), 
75.9 (COH), 42.2 (CH2), 27.9 (CH2CH3), 13.5 (CH2CH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  639.8 (20) [HL2Cu]
+, 319.9 (100) [M - MeCN]+, 257.9 (11) [HL + H]+ 
General Information C15H22CuF3N2O4S3 (511.08 gmol
-1) 
Calculated (%):   C: 35.25, H: 4.34, N: 5.48, S: 18.82 
11.4 Complex Synthesis 
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Synthesis of [L2HCu(MeCN)]OTf (2) 
[Cu(MeCN)4]OTf (377 mg, 1.0 mmol, 1.0 eq.) was added to a solution of L
2H (271 mg, 1.0 mmol, 
1.0 eq.) dissolved in abs. MeCN (10 ml). The reaction was stirred over night at room temperature 
and then the complex was precipitated by the addition of diethyl ether (30 ml). The product was 
isolated by filtration and obtained as white solid. 
Yield:   416 mg (0.78 mmol, 78 %)   
1H-NMR   (300 MHz, MeCN-d3) 
δ [ppm]:  8.52 (dd, 3J(H,H) = 5.1 Hz, 
4J(H,H) = 2.1 Hz, 1 H, CH
Py, 6), 7.87 (ddd, 
3J(H,H) = 7.8 Hz,
 3J(H,H) = 7.8 Hz, 
4J(H,H) = 2.1 Hz, 1 H, CH
Py, 4), 7.45-7.37 (m, 
2 H, CHPy, 5, CHPy, 3), 3.16 (s, 2 H, CPyCH2), 2.81-2.63 (m, 8 H, CH2, CH2CH3), 
1.99 (s, 3 H, NCCH3), 1.26 (t, 
3J(H,H) = 9.0 Hz, 6 H, CH2CH3) 
13C-NMR   (75 MHz, MeCN-d3) 
δ [ppm]:  159.0 (CHPy, 2), 148.7 (CHPy, 6), 137.7 (CHPy, 4), 126.3 (CHPy, 3), 122.6 (CHPy, 5), 
74.4 (COH), 45.1 (2 C, CH2), 40.8 (C
PyCH2), 27.9 (CH2CH3), 13.4 (CH2CH3)  
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  605.0 (10) [CuL2 + H]
+, 333.9 (100) [M - H]+, 241.0 (32) [L + H]+ 
General Information C16H24CuF3N2O4S3 (525.11 gmol
-1) 
Calculated (%):   C: 36.60, H: 4.61, N: 5.33, S: 18.32 
 




Synthesis of [L3Cu(MeCN)]PF6 (3) 
[Cu(MeCN)4]PF6 (329 mg, 0.89 mmol, 1.0 eq.) was added to a solution of L
3H (200 mg, 0.89 mmol, 
1.0 eq.) dissolved in abs. MeCN (10 ml). The reaction was stirred over night at room temperature 
and afterwards the complex was precipitated by the addition of diethyl ether (30 ml) and 
afterwards crystallised by ether diffusion in into a solution of the crude material in MeCN at 4 °C. 
The product could be obtained as colourless crystals. 
Yield:   324 mg (0.68 mmol, 76 %)    
1H-NMR   (300 MHz, MeCN-d3) 
δ [ppm]:  8.61 (ddd, 3J(H,H) = 5.4 Hz, 
4J(H,H) = 1.8 Hz, 
5J(H,H) = 1.0 Hz, 1 H, CH
Py, 6), 8.03 
(ddd, 3J(H,H) = 8.4 Hz,
 3J(H,H) = 8.4 Hz,
 4J(H,H) = 2.7 Hz, 1 H, CH
Py, 4), 7.96 (ddd, 
3J(H,H) = 8.4 Hz,
 4J(H,H) = 1.2 Hz, 
5J(H,H) = 1.0 Hz 1 H, CH
Py, 3), 7.53 (t, 
3J(H,H) = 8.4 Hz,
 3J(H,H) = 5.4 Hz, 
4J(H,H) = 1.2 Hz, 1 H, CH
Py, 5), 3.29-3.12 (m, 
4 H, CH2, SCH2CH2S) 
13C-NMR   (75 MHz, MeCN-d3) 
δ [ppm]:  162.9 (CHPy, 2), 148.1 (CHPy, 6), 139.6 (CHPy, 4), 123.7 (CHPy, 3), 120.9 (CHPy, 5), 
43.3 (COH), 38.6 (CH2), 37.9 (SCH2CH2S) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 607.9 (14) [HL2Cu]
+, 331.0 (100) [M]+, 290.0 (72) [CuL]+, 228.1 (46) [H2L]
+ 
General Information C12H16CuF6N2OPS2 (476.91 gmol
-1) 
Calculated (%):   C: 30.22, H: 3.38, N: 5.87, S: 13.45 





[Cu(MeCN)4]PF6 (559 mg, 1.5 mmol, 1.0 eq.) was added to a solution of L
4H (428 mg, 1.5 mmol, 
1.0 eq.) dissolved in abs. MeCN (10 ml). The reaction was stirred over night at room temperature 
and afterwards the complex was precipitated by the addition of diethyl ether (20 ml). The 
product was recrystallised from MeCN/Et2O at room temperature. The crude product was 
recrystallised from MeCN/Et2O at room temperature to yield the complex as yellow crystals. 
Yield:   238 mg (0.22 mmol, 44 % with respect to Cu) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 304.0 (7) [CuL]+, 224.1 (25) [L - OH]+, 132.0 (54) [C5H8S2]
+, 104.1 (72) 
[C3H4S2]
+, 62.9 (100) [Cu]+ 
General Information C28H37Cu3F12N5O2P2S4 (1081.90 gmol
-1) 
Calculated (%):   C: 31.01, H: 3.44, N: 6.46, S: 11.83 




Synthesis of [L5HCu(MeCN)]PF6 (5) 
[Cu(MeCN)4]PF6 (186 mg, 0.5 mmol, 1.0 eq.) was added to a solution of L
5H (115 mg, 0.5 mmol, 
1.0 eq.) dissolved in abs. MeCN (10 ml). The reaction was stirred over night at room temperature 
and afterwards the complex was precipitated by the addition of diethyl ether (20 ml). The 
product was crystallised from MeCN/Et2O at room temperature. The complex 5 could be 
obtained as colourless crystals.  
Yield:   156 mg (0.33 mmol, 65 %)   
1H-NMR   (300 MHz, CDCl3) 
δ [ppm]:  7.0 (s, 1 H, CHIm, 5), 6.9 (s, 1 H, CHIm, 4), 4.30 (sbr, 1 H, COH), 3.86 (s, 3H, 
NCH3), 3.39 (d, 
2J(H,H) = 15.0 Hz, 2 H, CHH), 3.24 (d, 
2J(H,H) = 15.0 Hz, 2 H, 
CHH), 3.19 (s, 4 H, SCH2CH2S), 1.99 (s, 3 H, CH3CN) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  148.2 (CHIm, 2) 126.2 (CHIm, 5), 123.5 (CHIm, 4), 76.9 (COH), 43.6 (CH2), 
37.7 (SCH2CH2S), 36.5 (NCH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 522.7 (11) [CuL2]
+, 392.9 (100) [CuL]+, 231.0 (15) [L]+, 213.0 (12) [L - OH]+, 
254.1 (44) [L - OH]+ 
Elemental Analysis C11H17CuF6N3OPS2 (479.91 gmol
-1) 
Calculated (%):   C: 22.53, H: 3.57, N: 8.76, S: 13.36 
Found (%):   C: 28.19, H: 3.87, N: 8.58, S: 13.13 
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Synthesis of [L6HCu(MeCN)]PF6 (6) 
[Cu(MeCN)4]PF6 (186 mg, 0.5 mmol, 1.0 eq.) was added to a solution of L
6H (131 mg, 0.5 mmol, 
1.0 eq.) dissolved in abs. MeCN (10 ml). The reaction was stirred over night at room temperature 
and afterwards the product was crystallised by slow diffusion of diethylether at room 
temperature. The complex 6 could be obtained as colourless crystals.  
Yield:   239 mg (0,47 mmol, 93 %)    
1H-NMR   (300 MHz, DMSO-d6) 
δ [ppm]:  8.78 (d, 3J(H,H) = 6 Hz, 3 H, CH
3,3’,3’’), 8.14 (sbr, 3 H, CH
6,6’,6’’), 8.05 (dd, 
3J(H,H) = 13 Hz,
 3J(H,H) = 12 Hz, 3 H, CH
4,4’,4’’), 7.51 (dd, 3J(H,H) = 8 Hz,
 
3J(H,H) = 12 Hz, 3 H, CH
5,5’,5’’), 4.20 (s, 2 H, CNH2), 2.01 (s, 3 H, CH3CN) 
13C-NMR  (75 MHz, DMSO-d6) 
δ [ppm]:  158.14 (C2,2’,2’’), 149.74 (CH3,3’,3’’), 138.99 (CH4,4’,4’’), 123.43 (CH6,6’,6’’), 
122.92 (CH5,5’,5’’), 118. 03 (CH3CN), 64.32 (CNH2), 1.11 (1 C, CH3CN) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 586.0 (7) [L2Cu - H]
+, 325.0 (100) [M - MeCN]+, 246.1 (75) [L - NH2]
+, 
184.1 (34) [C11H10N3]
+, 80.1 (34) [Pyridine + H]+, 62.9 (69) [Cu]+ 
IR   KBr 
ṽ [cm-1]: 3390 (m), 3321 (w), 3094 (w), 2264 (m), 1591 (s), 1463(s), 1438(s), 1367 
(w), 1312 (m), 1294 (w), 1211 (w), 1164 (m), 1105 (w), 1088 (w), 1064 
(m), 1015 (m), 956 (m), 833 (s), 774 (s), 754 (s), 653 (s), 635 (m), 558 (s), 
511 (m), 483 (m), 447 (w), 419 (m) 
General Information C18H17CuF6N5P (511.87 gmol
-1) 
Calculated (%):   C: 42.24, H: 3.35, N: 13.68 




Synthesis of [L22Cu2Cl2] (7) 
CuCl2 (134 mg, 1.0 mmol, 0.9 eq.) was added to a solution of L
2H (298 mg, 1.1 mmol, 1.0 eq.) 
dissolved in MeOH (40 ml). The suspension was stirred over night at room temperature and then 
the solvent was removed under reduced pressure. The crude product was washed with diethyl 
ether. The complex 7 could be obtained as green solid.  
Yield:   376 mg (0.5 mmol, 91 % with respect to L2H)    
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 605.1 (18) [L2Cu]
+, 334.0 (100) [LCu]+, 192.2 (60) [C11H16NS]
+, 272.2 (44) 
[L + H]+, 254.1 (44) [L - OH]+ 
SQUID  
J12 [cm-1]:  -421 
General Information C26H40Cl2Cu2N2O2S4 (738.87 gmol
-1) 





11.4 Complex Synthesis 
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Synthesis of [L42Cu2(MeCN)2]OTf2 (8) 
[Cu(MeCN)4]OTf (77 mg, 0.2 mmol, 1.0 eq.) was added to a solution of L
4H (50 mg, 0.2 mmol, 
1.0 eq.) dissolved in MeCN (5 ml). The micture was stirred for 1 h under an atmosphere of dry N2 
and was then exposed to air over night. The complex 8 could be crystallised from MeCN/Et2O as 
green crystals. 
Yield:   97 mg (98 μmol, 98 %)    
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 976.3 (23) [L3Cu4 - 3 H]
+, 607.6 (13) [M - 2 MeCN]+, 303.9 (21) [LCu]+, 
264.0 (100) [L + H]+, 224.0 (99) [L - OH]+ 
SQUID  
J12 [cm-1]:  -108  
Elemental analysis C28H34Cu2F6N4O8S6 (988.06 gmol
-1) 
Calculated (%):   C: 34.04, H: 3.47, N: 5.67, S: 19.47 








Synthesis of [L34Cu4]OTf4 (9) 
[Cu(MeCN)4]OTf (377 mg, 1.0 mmol, 1.0 eq.) was added to a solution of L
3H (226 mg, 1.0 mmol, 
1.0 eq.) dissolved in abs. MeCN (5 ml). The mixture was stirred for 1 h under an atmosphere of 
dry N2 and was then exposed to air over night. The complex was precipitated through the 
addition of diethyl ether (10 ml) and crystallised from MeCN/Et2O. The product could be 
obtained as green crystals. 
Yield:    222 mg (0.18 mmol, 72 %)   
Mass spectrometry  ESI+ (70 eV, MeOH) 




J1-4 [cm-1]: -110 
General Information C44H48Cu4F12N4O16S12 (1755.81 gmol
-1) 
Calculated (%):   C: 30.10, H: 2.76, N: 3.19, S: 21.91 
Elemental Analysis M + 2 MeCN 
Calculated (%):   C: 31.37, H: 2.96, N: 4.57, S: 20.94 







11.4 Complex Synthesis 
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Synthesis of [L7HCu]OTf (10) 
[Cu(MeCN)4]OTf (500 mg, 1.32 mmol, 0.6 eq.) was added to a solution of L
7H (500 mg, 
2.07 mmol, 1.0 eq.) dissolved in MeCN (10 ml). The reaction was stirred over night at room 
temperature and the complex precipitated by the addition of DCM (40 ml). The product 10 could 
be obtained as a colourless solid. 
Yield:   438 mg (0.97 mmol, 73 %) 
1H-NMR   (300 MHz, DMSO-d6) 
δ [ppm]:  9.08 (sb, 1 H, CHPy, 6), 8.67 (d, 3J(H,H) = 3 Hz, 1 H, CH
Py, 3), 7.92 (dd, 3J(H,H) = 6 
Hz, 3J(H,H) = 6 Hz, 1 H, CH
Py, 4) 7.50 (m, 1 H, CHPy, 5) 4.42 (sb, 2 H, 
CH2NHCH2), 4.20 (sb, 2 H, CH2NHCH2), 3.60-2.73 (m, 10 H, CH
Cyl, CH2
Cyl) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  303 (82) [M]+, 241 (58) [L + H]+ 
IR   KBr 
ṽ [cm-1]: 3051 (m), 2972 (s), 2931 (s), 2872 (m), 1586 (s), 1553 (s), 1472 (s), 1423 
(s), 1396 (s), 1295 (w), 1174 (s), 1118 (s), 984 (s), 825 (s), 786 (s), 744 (s), 
664 (s) 
Elemental Analysis C12H16CuF3N2O3S3 (453.00 gmol
-1) 
Calculated (%):   C: 31.82, H: 3.56, N: 6.18 
Found (%):   C: 29.59, H: 3.85, N: 6.46 
 




Synthesis of [L7H2Cu]OTf2 (11) 
[Cu(MeCN)4]OTf (250 mg, 0.66 mmol, 0.6 eq.) was added to a solution of L
7H (250 mg, 
1.04 mmol, 1.0 eq.) dissolved in MeCN (10 ml). The reaction was stirred for 1 h under N2- 
atmosphere and then exposed to air over night. The product was crystallised by slow diffusion of 
diethylether into the mixture. The product 11 could be obtained as purple crystals. 
Yield:   447 mg (0.53 mmol, 80%)     
IR   KBr 
ṽ [cm-1]: 3496 (m), 3219 (m), 3179 (m), 2906 (m), 1610 (s), 1573 (w), 1490 (m), 
1438 (m), 1416 (m), 1282 (s), 1251 (s), 1156 (s), 1025 (s), 926 (w), 887 
(w), 825 (s), 769 (s), 639 (s), 623 (s), 573 (m), 516 (m) 
General Information C24H32CuF6N4O5S6 (842.46 gmol
-1) 
Calculated (%):   C: 34.22, H: 3.83, N: 6.65, S: 22.84 
11.4 Complex Synthesis 
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Synthesis of [L8HCu]OTf (12) 
[Cu(MeCN)4]PF6 (93 mg, 0.25 mmol, 1.0 eq.) was added to a solution of L
8H (87 mg, 0.25 mmol, 
1.0 eq.) dissolved in MeCN (3 ml). The reaction was stirred over night at room temperature and 
afterwards the complex was precipitated by the addition of diethyl ether (10 ml). The crude 
product was purified by recrystallisation from MeCN/Et2O at -23 °C. The product 12 could be 
obtained as colourless crystals.  
Yield:   35 mg (57 μmol, 25 %) 
1H-NMR   (500 MHz, MeCN-d3) 
δ [ppm]:  8.63 (dd, 3J(H,H) = 5 Hz, 1 H, CH
Py, 10), 7.83 (dd, 3J(H,H) = 8 Hz,
 3J(H,H) = 8 Hz, 
2 H, CHPy, 4, 12), 7.73 (d, 3J(H,H) = 8 Hz, 2 H, CH
Py, 3, 5), 7.33 (d, 3J(H,H) = 8 Hz, 
1 H, CHPy, 13), 7.31 (dd, 3J(H,H) = 5 Hz, 1 H, CH
Py, 11), 4.63 (sb, 1 H, COH), 
3.31-3.21 (m, 6 H, CHH, SCH2CH2S), 3.11 (d, 
2J(H,H) = 15 Hz, 2 H, CHH), 1.94 
(s, 6 H, C(CH3)2)
 
13C-NMR   (125 MHz, MeCN-d3) 
δ [ppm]:  164.71 (CPy, 2), 163.00 (CPy, 6), 151.50 (CPy, 8), 140.17 (CHPy, 10), 139.63 (CHPy, 
4), 123.74 (CHPy, 12), 123.37 (CHPy, 11), 123.17 (CHPy, 13), 120.82 (CHPy, 5), 
119.85 (CHPy, 3), 46.72 (C(CH3)2), 44.92 (CHH), 38.16 (SCH2CH2S), 28.46 
(C(CH3)2) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  409.0 (100) [M]+, 346.9 (11) [L+ H]+ 
General Information  C18H22CuF6N2OPS2 (555.02 gmol
-1) 
Calculated (%):   C: 38.95, H: 4.00, N: 5.05, S: 11.55 




Synthesis of [L82Zn3(μ-OH)MeOH(MeCN)0.5(H2O)0.5]ClO4  1.5 MeOH (13) 
Zn(ClO4)2  6 H2O (54 mg, 0.14 mmol, 1.0 eq.) in MeOH (1 ml) was added to a solution of L
8H 
(50 mg, 0.14 mmol, 1.0 eq.) in MeOH (3 ml) and stirred over night at room temperature. The 
solvent was removed under reduced pressure and the product was purified by recrystallisation 
from MeCN/MeOH/Et2O. The product 13 could be obtained as colourless crystals.  
Yield:   15 mg (14 μmol, 30 % with respect to zink)   
1H-NMR   (300 MHz, DMSO-d6) 
δ [ppm]:  8.47 (d, 3J(H,H) = 3 Hz, 2 H, CH
Py, 10,10‘), 7.71-7.65 (m, 4 H, CHPy, 4,4‘,5,5‘), 7.41 
(d, 3J(H,H) = 9 Hz, 2 H, CH
Py, 12,12‘), 7.28 (d, 3J(H,H) = 9 Hz , 2 H, CH
Py, 3,3‘), 7.19 
(dd, 3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz, 2 H, CH
Py, 11,11‘), 7.04 (d, 3J(H,H) = 6 Hz, 2 H, 
CHPy, 13,13‘), 5.59 (s, 1 H, OH), 4.11 (q, 3J(H,H) = 6 Hz, 1 H, CH3OH), 3.42 (d, 
2J(H,H) = 12 Hz, 4 H, CHH), 3.18 (d, 
3J(H,H) = 6 Hz, 3 H, CH3OH), 3.04 (d, 
2J(H,H) = 12 Hz, 4 H, CHH), 2.93 (m , 8 H, SCH2CH2S), 2.07 (s, 1 H, CH3CN), 
1.76 (s, 6 H, CH3)  
13C-NMR  (75 MHz, CDCl3) 
δ [ppm]:  166.00 (CPy, 2), 163.02 (CPy, 6), 158.94 (CPy, 8), 148.16 (CHPy, 10), 137.04 
(CHPy, 4), 136.22 (CHPy, 12), 121.14 (CHPy, 13), 121.01 (CHPy, 11), 119.37 
(CHPy, 5), 117.57 (CHPy, 3), 79.87 (COH), 47.76 (CC4), 43.80 (CHH), 38.31 
(SCH2CH2S), 28.13 (CH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  369.0 (22) [L + Na]+, 347.0 (100) [L + H]+, 329.0 (25) [L - OH]+  
General Information C40H54ClN5O8S4Zn3 (1092.47 gmol
-1) 
Calculated (%):   C: 43.97, H: 4.98 N: 6.41, S: 11.74 
11.4 Complex Synthesis 
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Synthesis of [L3MeCu(MeCN)]OTf (14) 
[Cu(MeCN)4]OTf (314 mg, 0.84 mmol, 1.0 eq.) was added to a solution of L
3Me (200 mg, 
0.84 mmol, 1.0 eq.) dissolved in MeCN (10 ml). The reaction was stirred over night at room 
temperature and afterwards the complex was precipitated by the addition of diethyl ether 
(30 ml). The complex was taken up in MeCN and crystallised by slow diffusion of diethylether at 
4 °C. The product 14 could be obtained as colourless crystals.  
Yield:   260 mg (0.52 mmol, 63 %)  
1H-NMR   (500 MHz, acetone-d6) 
δ [ppm]:  8.61 (d, 3J(H,H) = 5 Hz, 1 H, CH
Py, 6), 8.07 (ddd, 3J(H,H) = 8 Hz, 
3J(H,H) = 8 Hz, 
4J(H,H) = 2 Hz, 1 H, CH
Py, 4) 7.81 (d, 3J(H,H) = 8 Hz, 1 H, CH
Py, 3), 7.49 (qd, 
3J(H,H) = 5 Hz, 
4J(H,H) = 2 Hz, 1 H, CH
Py, 5), 3.66 (d, 2J(H,H) = 5 Hz, 2 H, CHH), 
3.52 (d, 2J(H,H) = 5 Hz, 2 H, CHH), 3.42-3.36 (m, 7 H, SCH2CH2S, COCH3) 
13C-NMR   (125 MHz, acetone-d6) 
δ [ppm]:  163.47 (COCH3), 151.43 (C
Py, 2), 139.98 (CHPy, 6), 125.04 (CHPy, 4), 122.94 
(CHPy, 3), 66.07 (CHPy, 5), 52.08 (COCH3), 42.50 (CHH), 40.08 (SCH2CH2S) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 345.0 (21) [M]+, 304.0 (100) [M - MeCN]+, 226.0 (16) [L - H]+, 210.1 (32) 
[L - OMe]+, 62.9 (52) [Cu]+ 
IR   KBr 
ṽ [cm-1]: 1262 (s), 1030 (s), 832 (s), 638 (s), 560 (s), 1595 (m), 1472 (m), 1432 (m), 
1411 (m), 1167 (m), 1147 (m), 1074 (m), 755 (m), 517 (m), 483 (m), 
2985 (w), 2928 (w), 2843 (w), 1371 (w), 1100 (w), 420 (w). 
General Information C14H18CuF3N2O4S3 (495.04 gmol
-1) 
Calculated (%):   C: 33.97, H: 3.66, N: 5.66, S: 19.43 
Elemental Analysis M + MeCN 
Calculated (%):   C: 31.43, H: 4.14, N: 10.12, S: 11.99 
Found (%):   C: 30.11, H: 3.54, N: 10.12, S: 10.61 
 




Synthesis of [L5MeCu(MeCN)]PF6 (15) 
[Cu(MeCN)4]PF6 (377 mg, 1.0 mmol, 1.0 eq.) was added to a solution of L
5Me (244 mg, 1.0 mmol, 
1.0 eq.) dissolved in MeCN (10 ml). The reaction was stirred over night at room temperature and 
afterwards the complex was precipitated by the addition of diethyl ether (30 ml). The complex 
was taken up in MeCN and crystallised through slow ether diffusion 4 °C. The product 15 could 
be obtained as colourless crystals.  
Yield:   373 mg (0.76 mmol, 76 %)   
1H-NMR   (300 MHz, MeCN-d3) 
δ [ppm]:  7.04 (d, 3J(H,H) = 1 Hz, 1 H, CH
Im, 5), 6.91 (d, 3J(H,H) = 1 Hz, 1 H, CH
Im, 4), 3.79 
(s, 3 H, NCH3), 3.50 (d, 
2J(H,H) = 12 Hz, 2 H, CHH), 3.36 (d, 
2J(H,H) = 15 Hz, 
2 H, CHH), 3.19 (s, 3 H, COCH3), 3.12-3.09 (s, 4 H, SCH2CH2S) 
13C-NMR   (75 MHz, CDCl3) 
δ [ppm]:  126.36 (CHIm, 4), 123.76 (CHIm, 5), 50.91 (COCH3), 39.85 (CHH), 37.56 
(SCH2CH2S), 34.43 (1 C, NCH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 550.9 (17) [L2Cu]
+, 306.9 (100) [M - MeCN]+, 245.0 (3) [L + H]+, 213.0 (17) 
[L - OH]+ 
IR   KBr 
ṽ [cm-1]: 3593 (m), 2926 (m), 2855 (w), 2116 (m), 1632 (m), 1539 (w), 1480 (m), 
1411 (m), 1258 (s), 1168 (m), 1070 (m), 1033 (s), 992 (m), 849 (w), 763 
(m), 693 (w), 640 (s), 576 (m), 519 (m) 
Elemental Analysis C12H19CuF6N3OPS2 (493.94 gmol
-1) 
Calculated (%):   C: 29.18, H: 3.88, N: 8.51, S: 12.98 
Found (%):   C: 28.74, H: 3.84, N: 8.99, S: 11.35 
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Synthesis of [L3MeCuMeOH]OTf (16) 
A complex solution of 14 (150 mg, 0.30 mmol, 1.0 eq.) in MeOH (10 ml) was stirred over night at 
room temperature and afterwards the complex was crystallised by slow diffusion of diethylether 
in the complex solution at 4 °C. The product 16 could be obtained as slightly yellow crystals.  
Yield:   136 mg (0.28 mmol, 91 %)  
1H-NMR   (300 MHz, MeOD-d4) 
δ [ppm]:  8.49 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 6), 8.07 (dd, 3J(H,H) = 9 Hz,
 3J(H,H) = 6 Hz, 1 H, 
CHPy, 4), 7.72 (d, 3J(H,H) = 9 Hz, 1 H, CH
Py, 3), 7.44 (dd, 3J(H,H) = 6 Hz,
 3J(H,H) 
= 6 Hz, 1 H, CHPy, 5), 4.09 (q, 3J(H,H) = 3 Hz, 1 H, CH3OH), 3.53 (d,
 3J(H,H) 
= 15 Hz, 2 H, CHH), 3.36 (d, 3J(H,H) = 15 Hz, 2 H, CHH), 3.26-3.16 (m, 10 H, 
CH3, CH3OH, SCH2CH2S) 
13C-NMR   (75 MHz, MeOD-d4) 
δ [ppm]:  160.67 (COCH3), 150.78 (C
Py, 2), 140.08 (CHPy, 6), 125.26 (CHPy, 4), 123.31 
(CHPy, 3), 122.92 (CHPy, 5), 52.40 (COCH3), 44.51 (CHH), 42.52 (SCH2CH2S) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  544.9 (17) [L2Cu]
+, 544.9 (100) [M - MeOH]+, 226.0 (13) [L - CH3]
+ 
Elemental Analysis C13H19CuF3NO5S3 (486.03 gmol
-1) 
Calculated (%):   C: 32.13, H: 3.94, N: 2.88, S: 19.79 
Found (%):   C: 31.88, H: 3.73, N: 2.74, S: 19.57 
 




Synthesis of [L3Me2Zn](OTf)2 (17) 
To a solution of L3Me (100 mg, 0.42 mmol, 1.0 eq.) in MeCN (5 ml) was added ZnOTf2 (150 mg, 
0.42 mmol, 1.0 eq.). The solution was stirred for 16 h at room temperature and the product 17 
precipitated through the addition of diethyl ether (10 ml). 
Yield:   124 mg (0.14 mmol, 71 % with respect to L
3Me)   
1H-NMR   (300 MHz, MeCN-d3) 
δ [ppm]:  8.65 (d, 3J(H,H) = 3 Hz, 2 H, CH
Py, 6,6‘), 7.49 (sbr, 2 H, CH
Py, 3,3‘), 8.18 (dd, 
3J(H,H) = 9 Hz,
 3J(H,H) = 9 Hz, 2 H, CH
Py, 4,4‘) 7.67 (dd, 3J(H,H) = 9 Hz, 
3J(H,H) = 9 Hz, 
2 H, CHPy, 3,3‘), 3.62 (d, 2J(H,H) = 15 Hz, 4 H, CHH), 3.39 (d, 
2J(H,H) = 15 Hz, 4 H, 
CHH), 3.23-3.05 (m, 14 H, SCH2CH2S, COCH3)
 
13C-NMR   (75 MHz, MeCN-d3) 
δ [ppm]:  169.32 (CPy, 2), 146.24 (CHPy, 6), 140.48 (CHPy, 4), 124.72 (CHPy, 3), 122.59 
(CHPy, 5), 84.76 (COCH3), 52.11 (COCH3), 40.04 (CHH), 38.72 (SCH2CH2S) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 453.9 (48) [L + Zn + OTf]+, 321.9 (24) [L + Zn + OH]+, 242.0 (10) [L + H]+, 
210.0 (100) [L - OH]+ 
General Information C24H30F6N2O8S6Zn (846.26 gmol
-1) 
Calculated (%):   C: 34.06, H, 3.57, N: 3.31, S: 22.73 
11.4 Complex Synthesis 
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Synthesis of [L5Me2Zn]( OTf)2 (18) 
ZnOTf2 (149 mg, 0.41 mmol, 1.0 eq.) was added to a solution of L
5Me (100 mg, 0.41 mmol, 1.0 eq.) 
in MeCN (5 ml). The solution was stirred for 16 h at room temperature and the product 18 
precipitated through the addition of diethyl ether (10 ml). 
Yield:   130 mg (0.15 mmol, 75 % with respect to L
5Me)    
1H-NMR   (300 MHz, MeCN-d3) 
δ [ppm]:  7.36 (d, 3J(H,H) = 3 Hz, 2 H, CH
Im, 5,5’), 7.36 (d, 3J(H,H) = 3 Hz, 2 H, CH
Im, 4,4’), 
4.01 (s, 3 H, NCH3), 3.56 (s, 8 H, CH2), 3.25 (s, 6 H, COCH3), 3.10 (s, 8 H, 
SCH2CH2S)
 
13C-NMR   (75 MHz, MeCN-d3) 
δ [ppm]:  142.84 (CIm, 2), 126.06 (CHIm, 4), 118.36 (CHIm, 5), 82.94 (COCH3), 52.01 
(COCH3), 38.05 (CH2), 37.56 (SCH2CH2S), 36.33 (NCH3) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%): 456.8 (34) [L + Zn + OTf]+, 324.9 (30) [L + Zn + OH]+, 245.0 (54) [L + H]+, 
213.1 (100) [L - OH]+ 
General Information C22H32F6N4O8S6Zn (849.97 gmol
-1) 
Calculated (%):   C: 31.00, H: 3.78, N: 6.57, S: 22.57 




Synthesis of [L8MeCu]OTf (19) 
[Cu(MeCN)4]OTf (47 mg, 0.12 mmol, 1.0 eq.) was added to a solution of L
8Me (45 mg, 0.12 mmol, 
1.0 eq.) dissolved in MeCN (5 ml). The reaction was stirred over night at room temperature. The 
complex was precipitated by the addition of diethyl ether (15 ml), taken up in MeCN and 
crystallised through slow ether diffusion 4 °C. The product 19 could be obtained as colourless 
crystals.  
Yield:   56 mg (0.10 mmol, 81 %)  
1H-NMR   (500 MHz, MeCN-d3) 
δ [ppm]:  8.58 (s, 1 H, CHPy, 10), 7.86 (dd, 3J(H,H) = 7 Hz,
 3J(H,H) = 4 Hz, 2 H, CH
Py, 4, 12), 
7.70 (d, 3J(H,H) = 6 Hz, 1 H, CH
Py, 3), 7.54 (d, 3J(H,H) = 4 Hz, 1 H, CH
Py,  5), 7.47 
(d, 3J(H,H) = 7 Hz, 1 H, CH
Py, 13), 7.29 (dd, 3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz, 1 H, CH
Py, 
11), 3.63 (d, 2J(H,H) = 8 Hz, 2 H, CHH), 3.41-3.38 (m, 9 H, CHH, SCH2CH2S, 
COCH3), 1.96 (s, 6 H, C(CH3)2) 
13C-NMR  (125 MHz, MeCN-d3) 
δ [ppm]:  165.49 (CPy, 2), 164.16 (CPy, 6), 151.40 (CPy, 8), 140.03 (CHPy, 10), 139.54 (CHPy, 
4), 123.54 (CHPy, 12), 123.45 (CHPy, 11), 122.94 (CHPy, 13), 121.94 (CHPy, 5), 
120.64 (CHPy, 3), 52.41 (COCH3) 47.77 (C(CH3)2), 42.24 (CHH), 37.77 
(SCH2CH2S), 28.37 (C(CH3)2) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  423.0 (100) [M]+ 
General Information C20H24CuF3N2O4S3 (573.15 gmol
-1) 
Calculated (%):   C: 30.10, H: 2.76, N: 3.19, S: 21.91 
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Synthesis of [L3MeMn(CO)3]OTf (20)  
AgOTf (130 mg, 0.5 mmol, 1.0 eq.) was added to a solution of [Mn(CO)4Br] (138 mg, 0.5 mmol, 
1.0 eq.) in dry acetone (25 ml). The reaction was heated under reflux for 2 h. The precipitating 
AgBr was separated by filtration and L3Me (120 mg, 0.5 mmol, 1.0 eq.) was added to the filtrate. 
The mixture was stirred under reflux at 60 °C for 1.5 h. The solvent was removed under reduced 
pressure and the product was further purified by re-crystallisation from DCM/Et2O at 4 °C. The 
product 20 could be obtained as yellow crystals.  
Yield:   250 mg (47 mmol, 97 %)   
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  296.0 (100) [M - 3 CO]+ 
IR   KBr 
ṽ [cm-1]: 3561 (w), 3441 (w), 3151 (m), 3127 (m), 3090 (w), 2985 (m), 2940 (m), 
2855 (w), 2046 (s), 1980 (s), 1954 (s), 1724 (w), 1622 (w), 1553 (w), 1492 
(m), 1460 (m), 1439 (m), 1426 (m), 1258 (s), 1226 (s), 1157 (s), 1102 (s), 
1580 (w), 1032 (s), 1012 (m), 984 (m), 952 (w), 862 (w), 764 (s), 723 (m), 
700 (w), 674 (m), 640 (s), 573 (w), 545 (m), 517 (s), 495 (w), 474 (m), 440 
(w) 
General Information C15H15F3MnNO7S3 (529.41 gmol
-1) 
Calculated (%):   C: 34.03, H: 2.86, N: 2.65, S: 18.17 
  
 




Synthesis of [L5MeMn(CO)3]OTf (21) 
AgOTf (130 mg, 0.5 mmol, 1.0 eq.) was added to a solution of [Mn(CO)4Br] (138 mg, 0.5 mmol, 
1.0 eq.) in dry acetone (25 ml). The reaction was heated under reflux for 2 h. The precipitating 
AgBr was separated by filtration and L5Me (122 mg, 0.5 mmol, 1.0 eq.) was added to the filtrate. 
The mixture was stirred under reflux at 60 °C for 1.5 h. The solvent was removed under reduced 
pressure and the product was further purified by re-crystallisation from DCM/Et2O at 4 °C. The 
product 21 could be obtained as yellow crystals.  
Yield:   244 mg (0.46 mmol, 92 %)   
1H-NMR   (300 MHz, MeOD-d4) 
δ [ppm]:  7.41 (s, 1 H, CHIm, 4), 7.27 (s, 1 H, CHIm, 5), 3.91 (s, 3 H, COCH3), 3.82 (d, 
J(H,H) = 9 Hz, 2 H, CHH), 3.55 (s, 3 H, NCH3), 3.47 (d, J(H,H) = 9 Hz, 2 H, CHH) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  298.9 (100) [M - 3 CO]+ 
IR   KBr 
ṽ [cm-1]: 3486 (w), 3093 (m), 2909 (w), 2046 (s), 1960 (s), 1940 (s), 1762 (m), 1674 
(w), 1599 (m), 1531 (w), 1465 (m), 1435 (m), 1371 (w), 1283 (s), 1251 (s), 
1225 (s), 1161 (s), 1062 (w), 1031 (s), 998 (w), 969 (w), 931 (w), 899 (w), 
854 (w), 766 (w), 637 (s), 567 (m), 517 (m), 471 (w), 440 (w), 411 (w) 
Elemental analysis C14H16F3MnN2O7S3 (532.41 gmol
-1) 
Calculated (%):   C: 31.58, H: 3.03, N: 5.26, S: 18.07 
Found (%):  C: 31.14, H: 3.05, N: 2.18, S: 17.85 
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Synthesis of [L6HMn(CO)3]OTf (22) 
AgOTf (130 mg, 0.5 mmol, 1.0 eq.) was added to a solution of [Mn(CO)4Br] (138 mg, 0.5 mmol, 
1.0 eq.) in dry acetone (25 ml). The reaction was heated under reflux for 2 h. The precipitating 
AgBr was separated by filtration and L6H (131 mg, 0.5 mmol, 1.0 eq.) was added to the filtrate. 
The mixture was stirred under reflux at 60 °C for 1.5 h. The solvent was removed under reduced 
pressure and the product was further purified by re-crystallisation from DCM/Et2O at 4 °C. The 
product 22 could be obtained as yellow crystals.  
Yield:   259 mg (0.47 mmol, 95 %)     
1H-NMR   (300 MHz, MeOD-d4) 
δ [ppm]:  9.22 (d, 3J(H,H) = 3 Hz, 2 H, CH
Py, 3,3‘), 9.01 (d, 3J(H,H) = 3 Hz, 1 H, CH
Py, 3‘‘), 8.19 
(d, 3J(H,H) = 6 Hz, 2 H, CH
Py, 6,6‘), 8.12 (d, J(H,H) = 6 Hz, 1 H, CH
Py, 6‘‘), 8.98 (dd, 
3J(H,H) = 6 Hz, 
3J(H,H) = 6 Hz, 3 H, CH
Py, 5,5,5‘‘), 7.66 (dd, 3J(H,H) = 3 Hz, 
3J(H,H) = 3 Hz, 1 H, CH
Py, 4‘‘), 9.01 (d, 3J(H,H) = 3 Hz, 1 H, CH
Py, 4,4‘). 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  316.9 (100) [M - 3 CO]+ 
IR   KBr 
ṽ [cm-1]: 3003 (w), 2955 (w), 2923 (w), 2854 (w), 2043 (m), 1967 (m), 1944 (m), 
1586 (w), 1464 (m), 1441 (m), 1417 (m), 1377 (w), 1273 (s), 1253 (s), 
1229 (m), 1179 (m), 1157 (m), 1129 (m), 1078 (m), 1029 (s), 993 (m), 950 
(m), 862 (w), 798 (m), 758 (m), 713 (m), 672 (s), 639 (s), 573 (m), 556 (w), 
518 (s), 487 (m), 469 (w), 405 (w) 
General Information C20H14F3MnN4O6S (550.35 gmol
-1) 
Calculated (%):   C: 43.65, H: 2.56, N: 10.18, S: 5.83 




Synthesis of [L6AcetMn(CO)3]OTf (23) 
AgOTf (130 mg, 0.5 mmol, 1.0 eq.) was added to a solution of [Mn(CO)4Br] (138 mg, 0.5 mmol, 
1.0 eq.) in dry acetone (25 ml). The reaction was heated under reflux for 2 h. The precipitating 
AgBr was separated by filtration and L6Acet (150 mg, 0.5 mmol, 1.0 eq.) was added to the filtrate. 
The mixture was stirred under reflux for 1.5 h at 60 °C. The solvent was removed under reduced 
pressure and the product was further purified by re-crystallisation from DCM/Et2O at 4 °C. The 
product 23 could be obtained as yellow crystals.  
Yield:   148 mg (0.25 mmol, 50 %)   
1H-NMR   (300 MHz, MeOD-d4) 
δ [ppm]:  9.23 (s, 1 H, CHPy), 9.03 (s, 1 H, CHPy), 8.73 (s, 1 H, CHPy), 8.41 (s, 1 H, 
CHPy), 8.15-7.96 (m, 3 H, CHPy), 7.68 (s, 1 H, CHPy), 7.45-7.42 (m, 3 H, 
CHPy), 7.22 (s, 1 H, CHPy), 2.40 (s, 3 H, CH3) 
Mass spectrometry  EI+ (70 eV) 
m/z (%):  358 (86) [M - 3 CO]+, 209 (100) [C13H11N3]
+ 
IR   KBr 
ṽ [cm-1]: 3475 (w), 3092 (m), 2906 (w), 2360 (w), 2045 (s), 1957 (s), 1939 (s), 1761 
(m), 1674 (w), 1597 (m), 1530 (m), 1465 (m), 1435 (m), 1371 (w), 1282 
(s), 1250 (s), 1225 (s), 1161 (s), 1062 (m), 1031 (s), 998 (m), 969 (w), 931 
(w), 901 (w), 855 (w), 766 (m), 677 (w), 637 (s), 567 (m), 517 (m), 471 
(w), 441 (w), 412 (w) 
General Information C22H15F3MnN4O7S (591.38 gmol
-1) 
Calculated (%):   C: 44.68, H: 2.56, N: 9.47, S: 5.42 
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Synthesis of [L3MeCu(CO)]OTf (24) 
CO was bubbled through a solution of 14 (120 mg, 0.35 mmol, 1.0 eq.) in acetone (10 ml) under 
vigorous stirring for 30 min. The product was precipitated by the addition of diethyl ether 
(30 ml). The product 24 could be obtained as white powder after filtration.  
Yield:   72 mg (0.15 mmol, 43 %)    
1H-NMR   (500 MHz, acetone-d6) 
δ [ppm]:  8.73 (d, 3J(H,H) = 4 Hz, 1 H, CH
Py, 6), 8.12 (t, 3J(H,H) = 8 Hz, 1 H, CH
Py, 4), 7.85 
(d, 3J(H,H) = 8 Hz, 1 H, CH
Py, 3), 7.61 (t, 3J(H,H) = 5 Hz, 1 H, CH
Py, 5), 3.53-3.38 
(m, 11 H, CH2, SCH2CH2S, COCH3)
 
13C-NMR   (125 MHz, acetone-d6) 
δ [ppm]:  163.23 (COCH3), 154.16 (C
Py, 2), 150.82 (CHPy, 6), 140.39 (CHPy, 4), 124.98 
(CHPy, 3), 120.30 (CHPy, 5), 52.19 (COCH3), 41.37 (CHH), 38.12 (SCH2CH2S) 
Mass spectrometry  ESI+ (70 eV, MeOH) 
m/z (%):  303.9 (4) [M - CO]+, 264.1 (60) [L + Na]+, 210.0 (100) [L - OH]+ 
IR   KBr 
ṽ [cm-1]: 3480 (m), 2984 (m), 2928 (m), 2841 (m), 2313 (w), 2280 (w), 2255 (w), 
2119 (m), 2020 (w), 1710 (w), 1597 (s), 1571 (m), 1472 (s), 1433 (s), 1414 
(s), 1373 (w), 1287 (s), 1223 (s), 1165 (s), 1101 (s), 1075 (s), 1028 (s), 956 
(m), 955 (m), 929 (w), 900 (w), 854 (m), 800 (m), 784 (s), 757 (m), 714 
(m), 674 (w), 638 (s), 573 (m), 550 (m), 517 (s), 419 (w) 
General Information C13H15CuF3NO5S3 (482.00 gmol
-1) 
Calculated (%):   C: 32.39, H: 3.14, N: 2.91, S: 19.96 




Synthesis of [L5MeCu(CO)]OTf (25) 
[Cu(MeCN)4]OTf (187 mg, 0.5 mmol, 1.0 eq.) was added to a solution of L
5Me (122 mg, 0.5 mmol, 
1.0 eq.) dissolved in acetone (10 ml). CO bubbled was through the reaction solution for 30 min. 
The complex was afterwards precipitated by the addition of diethyl ether (30 ml). The complex 
was taken up in MeCN and crystallised through slow ether diffusion 4 °C. The product could be 
obtained as colourless crystals.  
Yield:   133 mg (0.27 mmol, 55 %)   
1H-NMR   (300 MHz, DMSO-d7) 
δ [ppm]:  7.60 (s, 1 H, CHIm, 4), 7.27 (s, 1 H, CHIm, 5), 4.42 (s, 3 H, COCH3), 3.78-3.44 
(m, 11 H, CH2, NCH3, SCH2CH2S) 
13C-NMR  (75 MHz, DMSO-d7) 
δ [ppm]:  127.34 (CIm, 2), 124.61 (CHIm, 4), 123.64 (CHIm, 5), 80.58 (COCH3), 51.78 
(COCH3), 30.52 (CH2), 37.39 (SCH2CH2S), 35.75 (NCH3) 
IR   KBr 
ṽ [cm-1]: 3495 (w), 3130 (w), 2925 (m), 2853 (w), 2281 (w), 2115 (m), 1632 (m), 
1541 (m), 1481 (m), 1412 (m), 1253 (s), 1162 (s), 1070 (s), 1030 (s), 993 
(m), 853 (w), 761 (m), 727 (w), 693 (w), 640 (s), 575 (m), 518 (m) 
General Information C12H16CuF3N2O5S3 (485.00 gmol
-1) 
Calculated (%):   C: 29.72, H: 3.33, N: 5.78, S: 19.83 
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Synthesis of [L6HCu(CO)]PF6 (26) 
CO was bubbled through a solution of 6 (235mg, 0.35 mmol, 1.0 eq.) in abs. acetone (10 ml) 
under strong stirring for 60 min. The formed precipitate was separated from the solvent and the 
product could be obtained as grey powder.  
Yield:   217 mg (0.44 mmol, 87 %)       
1H-NMR   (500 MHz, DMF-d7) 
δ [ppm]:  9.08 (s, 3 H, CHPy, 3,3’,3’’), 8.46 (s, 3 H, CHPy, 4,4’,4’’), 8.19 (s, 3 H, CHPy, 6,6’,6’’), 
7.64 (dd, 3J(H,H) = 6 Hz,
 3J(H,H) = 6 Hz, 3 H, CH
Py, 5,5’,5’’), 4.25 (s, 2 H, CNH2) 
13C-NMR  (125 MHz, DMF-d7) 
δ [ppm]:  158.34 (CPy, 2,2’,2’’), 151.78 (CHPy, 3,3’,3’’), 140.78 (CHPy, 4,4’,4’’), 124.59 (CHPy, 
6,6’,6’’), 123.64 (CHPy, 5,5’,5’’), 64.92 (CNH2) 
IR   KBr 
ṽ [cm-1]: 3391 (m), 3330 (m), 3127 (w), 3109 (w), 2556 (w), 2102 (s), 2054 (m), 
1996 (w), 1868 (w), 1706 (w), 1595 (s), 1465 (s), 1438 (s), 1318 (w), 1296 
(w), 1216 (w), 1157 (m), 1103 (w), 1090 (m), 1065 (w), 1023 (m), 999 (w), 
959 (s), 899 (w), 870 (s), 843 (s), 766 (s), 755 (s), 652 (s), 558 (s), 
Elemental Analysis C17H14CuF6N4OP (498.83 gmol
-1) 
Calculated (%):   C: 40.93, H: 2.83, N: 11.23  
Found (%):   C: 40.53, H: 2.82, N: 10.98  




11.5 Protocols for Solution Preparation and for the Analytic Experiments 
11.5.1 Stock Solution Preparation 
General Considerations 
Water used for the preparation of stock solutions was either milliQ water or bidestilled water. 
Stock solutions of the peptides, fibrils and ThT were stored in the freezer at 4 °C and CORM stock 
solutions were stored under light exclusion. 
Aβ1-16 Stock Solution 
Stock solutions of the Aβ1-16 peptide (10 mM) were prepared by dissolving Aβ1-16  6 TFA in D2O, 
resulting in a pH ≈ 2. Peptide concentration was dosed by UV/Vis-spectroscopy considering the 
free tyrosine (ε276-ε295 (pH < 9) = 1410 M
-1cm-1).  
Aβ1-40 Stock Solution 
Aβ1-40 stock solution (1 mM) was prepared by dissolving Aβ1-40  X TFA in D2O, resulting in pH ≈ 2. 
Peptide concentration was dosed by UV/Vis-spectroscopy considering the free tyrosine in NaOH 
(0.1 M) (ε293-ε360 (pH > 9) = 2410 M
-1cm-1).  
Fibril Stock Solution of Aβ1-40 
Fibrils (500 μM) were prepared by diluting 200 μl of the Aβ1-40 stock solution (1 mM) in 200 μl 
HEPES buffer (50 mM) and incubation of the resulting solution at 37 °C over 48 h. Fibril formation 
was tested with ThT. 
Myoglobin Stock Solution  
A myoglobin stock solution was prepared by dissolving myoglobin in 0.1 M phosphate buffer 
(7.4). The concentration was determined by UV/Vis dosing at 557 nm in the presence of 
dithionite. Dosing was performed three times at different myoglobin and dithionite 
concentrations. The stock solution was stored under light exclusion at 8 °C. 
Cu2+ and Zn2+Stock Solutions 
Stock solutions of CuSO4 and ZnSO4 were prepared at 10 mM by dissolving the corresponding 
metal salts in D2O. 
Fz Stock Solutions 
The stock solution of Fz (Fz = ferrozine, 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine-4,4’’-disulfonic 
acid) and ThT (Thioflavin T) was prepared at 10 mM in water. 
Stock Solution of Sodium Dithionite 
Stock solutions of sodium dithionite (0.1 M) were freshly prepared directly before use.  
Stock Solutions of the Ligands, the Multifunctional Tools and the CORMs 
The stock solutions of the synthesised compounds were prepared at 10 mM in DMSO or in 
DMSO-d6.  
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Buffer Stock Solutions 
HEPES buffer solutions were prepared by dissolving sodium salt of 2-(4-(2-
hydroxyethyl)piperazin-1-yl)ethanesulfonic acid in water. The pH value was adjusted by adding 
either HCl or NaOH. 
Phosphate buffer solutions were prepared by dissolving appropriate amounts of Na2/K2HPO4 
and Na/KH2PO4 in water. Tuning of the pH value was done by addition of HCl or NaOH. For the 
NMR studies D2O were used instead of water and the pH value was adjusted with DCl and NaOD. 
Tris buffer solutions were prepared by dissolving appropriate amounts of 2-amino-2-
hydroxymethyl-propane-1,3-diol (Tris) in D2O. The pH value was adjusted with DCl and NaOD. 
 
11.5.2 Determination of Stability Constants via UV/Vis 
Stability constants were determined by titration of the chromophoric [Cu(Fz)2]
3- complex 
(Fz = ferrozine, 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine-4,4’’-disulfonic acid). The [Cu(Fz)2]
3- 
complex has a characteristic UV band at 470 nm with an extinction coefficient of 
4320 M-1 cm-1.[145] Upon addition of ligand the UV band decreases, through metal exchange from 
[Cu(Fz)2]
3- to the ligand. Titration conditions for the experiments were 105 μM Fz, 50 μM Cu2+, 
100 μM Na2S2O3 in 0.1 M HEPES buffer (pH 7.4). All stock solution were degassed and saturated 
with argon. A freshly prepared Na2S2O3 solution was used to reduce Cu
2+. Excess of Fz was 
provided to compensates the partially formed [Fe(Fz)3]
4-, visible by the shoulder at 562 nm 
(ε = 2600 M-1 cm-1).[145] The iron trace amounts originate from the used chemicals. For the 
tridentate ligands L3H and L5H 100 μM and for the ligands L6H and L8H 20 μM were added stepwise. 
After each addition of ligand approximately two min were waited before collecting the spectra, 
since this time is required for equilibration and stabilisation of the UV/Vis spectra. At the end of 
the experiment additional Na2S2O3 was added to reduce [CuFz2]
2- formed during the experiment. 
Only a slight increase of the absorbance corresponding to the presence of less than 5 % [CuFz2]
2- 
could be observed. Such a small value is sufficiently weak and can be neglected. Under this 
procedure five up to ten values were recorded and calculations of stability constants were done 
with equation 9, according to the literature (c0 = [Cu
+]initial, c1 = [Fz]initial, c2 = [L
x], aFz = [Fz], 
β2 = 11.6).
[145] The experiment was repeated at least three times to quantify the calculated 
values. 
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11.5.3 Ascorbate Consumption Study 
Ascorbate consumption was followed by UV/Vis spectroscopy at 265 nm (14500 M-1 cm-1) over a 
time period of 5 min in 50 mM phosphate buffer. 100 μM sodium ascorbate, 5 μM Cu2+ and 
7 μM of Ligand and 7 μM of Aβ1-16 were used in the experiments. The order of addition was 
buffer, ascorbate, ligand/Aβ1-16, Cu
2+. The ascorbate stock solutions were freshly prepared and 
no longer used than for 5 h. Each measurement was repeated at least three times to minimise 
errors and quantify the results. 




11.5.4 Cell Viability Assays 
Undifferentiated human neuroblastoma SH-SY5Y cells were grown under standard culture 
conditions in an incubator containing a humidified atmosphere with 5 % CO2 at 37 °C. The 
medium used was DMEM (Dubelcoo’s Modified Eagle’s Medium) supplemented with 15 % foetal 
bovine serum (FBS). For the experiments, SH-SY5Y cells were seeded into 24-well plates at a 
density of 200 000 cells/well. After 24 h incubation, the medium was removed and replaced with 
0.5 ml of DMEM, prior to drug exposure. Cell viability was determined by a mitochondria 
enzyme dependent reaction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) as described elsewhere.[292] Briefly, MTT was added to SH-SY5Y cells after treatment in 
24-well plates at final concentration of 5 mg/ml at 37 °C for 4 h, 24 h after testing the 
compound. Metabolic active cells cleaved the yellow tetrazolium salt MTT to purple formazan 
crystals. The reaction was terminated by removal of the supernatant and addition of 1.5 ml 
DMSO to dissolve the formazan product, following thorough mixing to dissolve the formazan 
product and the absorbance was measured by a multiplate reader at 570 nm. Results were 
expressed as percentage of control. Each assay was performed in triplication of at least three 
wells. The Cell studies as described above were performed by Isabelle Sasaki in the laboratories 
of the Institut de Pharmacologie et de Biologie Structurale (IPBS) in Toulouse, France.  
 
11.5.5 The CO Release Experiment – Myoglobin Assay 
To determine the photo active CO release of the synthesised CORMs a myoglobin assay was 
performed.[329,344,345] Myoglobin (Mb) can be used as CO detector, since CO has a high affinity to 
coordinate at the heme-iron of Mb. Upon coordination and formation of the MbCO complex 
changes the UV/Vis spectra. Mb has a characteristic absorption band at 555 nm (12.9 mM-1 cm-1), 
whereas MbCO has two absorption bands at 540 nm (14.5 mM-1 cm-1) and 577 nm (12.9 mM-1 
cm-1).[350] Thus, by following the absorption at three wavelengths by UV/Vis spectroscopy, the 
amount of released CO can be determined. Correspondingly, the band at 557 nm decreases 
upon formation of MbCO and the bands at 540 nm and 577 nm increase. The samples were 
prepared by transferring the required amount of myoglobin solution in UV/Vis cuvettes. This Mb 
solution was than degassed with argon and a degassed solution of dithionite and phosphate 
buffer were added. The CORM was added and the cuvettes shortly shaken to achieve a 
homogeneously sample. The final concentrations were 10 μM CORM, 10 mM dithionite, 60 μM 
myoglobin and 0.1 M phosphate buffer (pH 7.4). Samples were incubated in the dark between 
1 h and 21 h. Stability in the dark was determined by measuring the UV/Vis spectra of the 
sample every 5 min for 16 h. The samples were irradiated at 365 nm to determine the number of 
released CO molecules. Irradiation times were at the beginning 1 min and after 1 h the 
irradiation time was expanded to 10 min. A spectrum was recorded after each irradiation. The 
measurement was repeated until no further changes could be observed. The number of released 
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Appendix A  
Influence of CO as a Strong Donor  
 
Introduction 
The particular bonding interaction between metal atoms and carbon monoxide (CO) is well 
described by the bonding model according to Dewar-Chatt-Duncanson.[351–353] Metal carbonyls 
can be stabilised by a synergistic donor-acceptor interaction, combining the σ-donor and π-
acceptor character of CO molecules (Figure 57). The 5σ-orbital, which is the highest occupied 
molecule orbital (HOMO) is an anti-bonding orbital predominantly comprises of C 2s, C 2pz and 
O 2pz. Due to the high carbon character coordinates CO end-on via the carbon. Thus, formation 
of a σ-bond with a free, symmetrically equivalent orbital of the metal induces a slight increase of 
the CO bonding order (Figure 58).[354]  
 
Figure 57 Synergistic bonding model of metal carbonyl complexes according to Dewar-Chatt-Duncanson. 
The increased electron density on the metal, due to the σ-bonds, is balanced by π-backbonding 
in the lowest unoccupied molecular orbital (LUMO), the 2π*-orbital, of CO. The magnitude of 
this effect depends on the transition metal, its valency and on co-ligands. If the coordination 
sphere is saturated by strong σ- or π-donors, so that much electron density is pushed to the 
metal, then the π–backbonding becomes favoured. The opposite is present in case of other π-
acceptors as co-ligands. They withdraw electron density from the metal and formation of π-
backbonding to CO is disfavoured. This effect will even increase if the acceptors compete for the 
same d-orbitals, as seen in complexes with CO molecules in trans position.[355] Metal carbonyl 
complexes can be characterised by their specific CO stretching vibrations. The π-backbonding 
increases the electron density in the antibonding orbital of the CO, which therefore weakens the 
bond strength in CO. As a consequence lower wavenumbers (ṽ) for the CO stretching vibration 
can be detected in metal carbonyls.[356] The value is also a sensitive indicator for the electronic 
situation at the metal centre. Thus, performing IR measurements, information about the 
electron density can be obtained. Furthermore, the stretching vibration can be used as an 
indirect measure of the properties of co-ligands in the complex. The tripodal ligands L3Me and 
L5Me, which have shown the best results with respect to Cu+ selectivity, will be used for the 
synthesis of Cu+-containing CO complexes. L6H was also examined in order to study the influence 
of stronger σ-donors.  





Figure 58 Molecular orbital diagram of CO. The 1s-orbitals were omitted since they are not involved in the bonding. 
 
Synthesis and Characterisation of Cu-based CO Complexes 
Precursors for the CO complexes were synthesised by dissolving equimolar amounts of ligand 
(L3Me, L5Me and L6H) and [Cu(MeCN)4]OTf in acetone. The solution was stirred for 30 min and 
afterwards CO gas was bubbled through the reaction solution. After 60 min the gas flow was 
stopped and CO complexes were precipitated by addition of diethyl ether. All three complexes 
could be synthesised in moderate to good yields (43 % - 87 %). The complexes were 
characterised by IR spectroscopy, NMR spectroscopy and also ESI-MS spectrometry. 
Unfortunately, no molecular peak could be observed in the mass spectra, since the CO molecule 
was obviously cleaved in the measurement. Thus, only the CO free [LXCu]+ species were 
recorded. Although no crystal structures could be obtained, formation of [L3MeCu(CO)]OTf (13), 
[L5MeCu(CO)]OTf (14) and [L6HCu(CO)]PF6 (15) could be verified by IR spectroscopy (Figure 59). In 
case of 15 two different binding modes are possible: coordination by all three pyridine groups 
like in 6 or by two pyridine groups and the amine group. Examples for the latter one are given in 
the literature[250] and also by the complexes 22 and 23. The binding mode present in 15 could be 
determined by its 1H-NMR spectrum. The amine shows no significant high field shift and, 
although broadened, only one signal set could be obtained for the three pyridine groups. CO 
stretching vibrations and force constants of the metal carbonyl complexes are summarised in 
Table 28. The force constant k can be calculated by equation 11, with μ as reduced mass, ṽ as CO 
stretching vibration and c as velocity of light.  
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Figure 59 IR absorption spectra for 13 (red, bottom), 14 (blue, middle) and 15 (pink, top) measured in KBr.  
The following order results for the synthesised CO complexes, according to their CO stretch 
frequencies: 13 ≈ 14 > 15 (Table 28). L6H has three pyridine groups which are good σ-donors. 
Upon coordination electron density is pushed to the Cu+ centre and thus available for π-
backbonding to the CO. Thus, in complex 15, the lowest stretching frequencies were found. The 
higher wavenumbers for 13 and 14 are most likely induced by the thioether sidearm. Thioether 
groups are rather weak donors and do not push much electron density on the metal centre. 
Table 28 CO stretching vibrations ṽ co and force constants k of 13, 14 and 15 and literature known complexes 
(tpb = tris(pyrazolyl)borate). 
 ṽCO [cm
-1] k[N m-1] 
13 2118 1813 
14 2114 1806 
15 2102  1786 
free CO[281] 2143 1856 
[tpbH, HCuCO][357]  2080 1748 
[tpbCF3, CF3CuCO][357] 2137 1846 
 
The comparison of 13 and 14 shows, that 13 had slightly higher wavenumber for the CO 
stretching vibration. This difference is induced by the different nitrogen donors in the ligands. 13 
has a pyridine group, whereas 14 has a N-methylimidazole as nitrogen donor. Pyridine is not 
only a good σ-donor but comprises also a π-acceptor character. Therefore, less electron density 
is centred on the metal and is available for the CO back-bond, resulting in a higher stretching 
frequency. Also N-methyimidazole is a π-acceptor, but not as distinct as pyridine. However, the 
difference is with 4 cm-1 only minor. As mentioned in the introduction, the CO stretching 




frequency can indirectly be used to determine the binding properties of the co-ligands. 
Therefore, it can be assumed that both ligands L3Me and L5Me have approximately the same 
binding modes and affinities. L6H instead seems to coordinate stronger to the Cu+. 
The obtained values for the tridentate ligands are rather high in comparison with literature 
known complexes.[358–361] Only a few Cu+ containing complexes are known, which reach similar or 
higher values. One example is the [tpbCF3, CF3CuCO] complex, where electron density is pulled 
away from the metal by the electron withdrawing groups in the ligand.  
 
Conclusion 
Three mononuclear CO complexes were synthesised with L3Me, L5Me and L6H and could be 
characterised by their specific CO vibration modes. By comparison of the CO stretching 
vibrations the properties of the ligands could be evaluated. For L3Me and L5Me only minor 
differences could be observed. L6H with its three pyridine sidearms pushes more electron density 
towards the metal, resulting in a stronger π-backbond from the metal to the CO. Thus, it can be 
assumed that the strong σ-bond character of the pyridine results in stronger copper-ligand bond.  




Attempt to Determine Metal Selectivity  
 
Introduction 
The aim of this study is the synthesis and characterisation of a multifunctional tool, which can be 
used to enlighten the role of Cu+ in AD. Under consideration of inorganic and bioinorganic aspect 
a set of new ligands was synthesised, which should exclusively coordinate Cu+ in aqueous 
solutions. The {NS2} binding mode is a soft donor set, which should not be able to compete with 
the “water pressure” in the M(H2O)X
n+ complexes with exception of Cu+. Cu+ is a special case, 
since water is due to its rather hard character not a good donor for the soft metal ion.[232] 
However, it has to be proven that the theoretical concepts also apply. The ligands were coupled 
via click chemistry to a fluorescence sensor to determine their metal selectivity. As fluorescence 
sensor N-ethyl-1,8-naphtalimide was used, since related systems with the same fluorescent 
subunit are known in the literature (Figure 60).[289,290,362] 
 
Figure 60 Cyclam-based Zn2+ sensor with N-ethyl-1,8-naphtalimide.[290] 
 
Synthesis and Characterisation of Naphthalimide Coupled Ligands 
Starting point for the synthesis of the naphthalimide coupled ligands (NCLs) is the commercially 
available 4-bromophthalic anhydride (Scheme 38). Reaction with ethyl amine in dioxane led to 
the fluorescent active 4-bromo-N-ethyl-1,8-naphtalimide (XXVIII).[290] The following substitution 
of the bromide by an azide and coupling with the alkinated ligands were done in a one pot 
synthesis. XXVIII, ligand, sodium azide, CuSO4  5 H2O and ascorbate were therefore suspended 
in DMSO and heated under reflux for 24 h. The reaction solution was poured into water and the 
crude product precipitated at 4 °C, which was then recrystallised from methanol/diethyl ether. 
The products were further purified by column chromatography on silica. The NCLs were 
characterised by ESI-MS and UV/Vis spectroscopy. 





Scheme 38 Sythesis of naphtalimide coupled ligands NCL3 and NCL5. 
Samples were prepared with 10 μM NCL and 10 μM Mn+ in 0.1 M HEPES buffer (pH 7.4) and 
measured directly after the addition of the metal and after 5 min to determine the metal 
selectivity of the compounds. No changes could be observed in the absorbance or in the 
fluorescence spectra. Thus, the concentration of metal was increased to 50 μM and the 
experiment repeated three times; again no spectral changes could be observed. The ferrozine 
and the NMR experiments presented in chapter 5 proved that the ligands are able to coordinate 
Cu+ even at low concentrations. Thus, dithionite was added to the sample with Cu2+ to reduce it 
in situ. Again, no response could be observed in the spectra. The experiment was also carried 
out in water instead of HEPES to exclude any interaction of the buffer, but without any changes. 
Comparison with the literature known systems show that, in case of the NCLs, the linking unit 
between the chelator and the naphthalimide is expanded by the oxygen and to the next 
coordinating atom the distance is even longer.[290] Thus, it can be assumed that the chain 
between chelator and detector is too long to allow recognition of the metal coordination. 
 





X–ray data for all compounds were collected on a STOE IPDS II diffractometer (graphite 
monochromated Mo–Kα radiation, λ = 0.71073 Å) by use of ω scans at –140 °C. The structures 
were solved by direct methods and refined on F2 using all reflections with SHELX–97.[363] Most 
non-hydrogen atoms were refined anisotropically. Hydrogen atoms were placed in calculated 
positions and assigned to an isotropic displacement parameter of 1.2 / 1.5 Ueq(C) or to an 
isotropic displacement parameter of 0.08 Å2. Atoms of the disordered part were refined 
isotropically. Face-indexed absorption corrections were performed numerically with the 
program X–RED.[364] Details of data collection and important crystal data are summarised in 









Table 29 Crystal data and refinement details of 2, 3 and 4. 
 2 3 4 
empirical formula C16H24CuF3N2O4S3 C28H37Cu2F6N6O2PS4 C34H46Cu3F12N8O2P2S4 
formula weight 525.09 889.93 1207.59 
crystal size [mm³] 0.50 × 0.48 × 0.46 0.14 × 0.10 × 0.07 0.45 × 0.25 × 0.19 
crystal system Monoclinic Monoclinic Triclinic 
space group P21/c P21/n P–1 
a [Å], α [°] 11.8506(5), 90  7.1846(6), 90 12.6311(4), 82.919(3) 
b [Å], β [°]  9.0396(3), 
105.239(3) 
10.8472(6), 93.753(6) 13.5343(5), 69.541(3) 
c [Å], γ[°] 21.0667(8), 90 23.4416(17), 90 16.5686(5), 62.951(2) 
V [Å³] 2177.41(14) 1823.0(2) 2361.35(14) 
Z 4 2 2 
ρ [g/cm³] 1.602 1.621 1.698 
F(000) 1080 908 1222 
µ [mm–1] 1.341 1.507 1.673 
Tmin/ Tmax 0.5005 / 0.6102 0.7603 / 0.8966 0.4899 / 0.7430 
θ range [°] 1.78 - 25.62 1.74 - 26.13 1.31 - 25.63 
hkl range ±14, ±10, –24 - 25 ±8, ±13, ±28 ±15, –15 - 16, ±20 
measured refl. 24864 22493 28687 
unique refl. [Rint] 4082 [0.0497] 22493 [0] 8897 [0.0532] 
observed refl. (I > 2 σ 
(I)) 
3884 17715 7804 
data / restraints / 
param. 
4082 / 0 / 268 22493 / 0 / 229 8897 / 0 / 592 
goodness–of–fit (F²) 1.059 1.087 1.040 
R1, wR2 (I > 2σ(I)) 0.0268, 0.0625 0.0754, 0.2052 0.0447, 0.0991 
R1, wR2 (all data) 0.0288, 0.0635 0.0949, 0.2207 0.0542, 0.1038 
resid. el. dens. [e/Å-³] –0.529 / 0.589 –0.700 / 0.723 –1.872 / 1.112 
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Table 30 Crystal data and refinement details of 5, 6 and 7. 
 5 6 7 
empirical formula C11H17CuF6N3OPS2 C18H17CuF6N5P C26H40Cl2Cu2N2O2S4 
formula weight 479.91 511.88 738.82 
crystal size [mm³] 0.29 × 0.11 × 0.10 0.23 x 0.2 x 0.19 0.50 × 0.32 × 0.06 
crystal system Orthorhombic Triclinic Monoclinic 
space group Pbca P -1 P21/c 
a [Å], α [°] 14.7518(4), 90 8.1427(5), 102.991(5) 10.0478(4), 90 




c [Å], γ[°] 18.8775(8), 90 12.1681(7), 99.336(5) 10.4957(5), 90 
V [Å³] 3527.9(2) 994.43(10) 1612.97(12) 
Z 8 2 2 
ρ [g/cm³] 1.807 1.710 1.521 
F(000) 1936 516 764 
µ [mm–1] 1.631 1.250 1.770 
Tmin/ Tmax 0.4838 / 0.7870 0.8056 / 0.5608 0.5026 / 0.8102 
θ range [°] 2.16 - 26.78 1.80 - 26.74 2.23 - 26.73 
hkl range ±18, –15-16, –22 - 23 ±10, ±13, ±15 ±12, ±21, –10 - 13 
measured refl. 32000 8954 14071 
unique refl. [Rint] 3750 [0.0738] 4203 [0.0453] 3410 [0.0761] 
observed refl. (I > 2 σ 
(I)) 
3120 3672 2949 
data / restraints / 
param. 
3750 / 0 / 232 4203 / 1 / 2871 3410 / 0 / 172 
goodness–of–fit (F²) 1.061 1.064 1.040 
R1, wR2 (I > 2σ(I)) 0.0416, 0.0968 0.0342, 0.0966 0.0357, 0.0945 
R1, wR2 (all data) 0.0554, 0.1028 0.0400, 0.0994 0.0426, 0.0979 
resid. el. dens. [e/Å-³] –0.627 / 0.819 0.563 / -0.417 –0.870 / 0.509 
 
 




Table 31 Crystal data and refinement details of 8, 9 and 11. 
 8 9 11 
empirical formula C28H34Cu2F6N4O8S6 C48H54Cu4F12N6O16S12 C28H38CuF6N6O6S6 
formula weight 988.03 1837.85 924.54 
crystal size [mm³] 0.47 × 0.20 × 0.18 0.29 × 0.28 × 0.17 0.13 x 0.12 x 0.10 
crystal system Triclinic Monoclinic Monoclinic 
space group P–1 C2/c P 21/c 
a [Å], α [°]  7.7088(4), 71.453(4) 20.8538(6), 90 10.2109(9), 90 
b [Å], β [°] 10.9316(5), 88.764(4) 15.6432(4), 99.846(2) 18.3305(10), 91. 
52(7) 
c [Å], γ[°] 11.6881(6), 82.044(4) 20.5563(6), 90 10.2540(8), 90 
V [Å³] 924.54(8) 6607.1(3) 1918.9(2) 
Z 1 4 2 
ρ [g/cm³] 1.775 1.848 1.600 
F(000) 502 3712 950 
µ [mm–1] 1.573 1.752 0.973 
Tmin/ Tmax 0.5695 / 0.7865 0.5420 / 0.7739  
θ range [°] 1.84 - 26.74 1.64 - 26.74 1.99 - 27.05 
hkl range ±9, ±13, ±14 ±26, ±19, ±25 –13 - 12, ±21, –13 - 
12 
measured refl. 12817 29051 17920 
unique refl. [Rint] 3915 [0.0353] 7016 [0.0484] 4176 [0.1070] 
observed refl. (I > 2 σ 
(I)) 
3475 6295 2654 
data / restraints / 
param. 
3915 / 0 / 245 7016 / 0 / 443 4176 / 0 / 246 
goodness–of–fit (F²) 1.037 1.023 1.006 
R1, wR2 (I > 2σ(I)) 0.0235, 0.0582 0.0259, 0.0645 0.0624, 0.0914 
R1, wR2 (all data) 0.0285, 0.0594 0.0303, 0.0663 0.1153, 0.1032 
resid. el. dens. [e/Å-³] –0.274 / 0.419 –0.570 / 0.393 0.510 / -0.686 
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Table 32 Crystal data and refinement details of 12, 13 and 14. 
 12 13 14 
empirical formula C20H27CuF6N2O1.50PS2 C79H109Cl6N9O36S8Zn6 C14H18CuF3N2O4S3 
formula weight 592.07 2622.15 495.02 
crystal size [mm³] 0.39 × 0.35 × 0.07 0.23 x 0.09 x 0.09 0.18 × 0.12 × 0.1 
crystal system Triclinic Triclinic  Triclinic 
space group P–1 P -1 P–1 
a [Å], α [°] 12.5659(6), 
107.283(4) 
11.0317(5), 81.288(4) 7.9460(16), 77.32(3) 
b [Å], β [°] 13.6449(6), 97.414(4) 13.4082(7), 75.873(4) 10.147(2), 75.48(3) 
c [Å], γ[°] 14.7682(6), 96.955(4) 18.6835(9), 73.220(4) 12.670(3), 71.94(3) 
V [Å³] 2363.39(18) 2556.1(2 929.0(3) 
Z 4 1 2 
ρ [g/cm³] 1.664 1.703 1.770 
F(000) 1212 1344 504 
µ [mm–1] 1.235 1.792 1.566 
Tmin/ Tmax 0.4599 / 0.7551 0.8912 / 0.7660 0.5902 / 0.8155 
θ range [°] 1.47 - 26.80 1.59 - 25.63 1.68 - 26.73 
hkl range ±15, –17 - 16, ±18 ±13, ±16, –22 - 19 ±10, ±12, ±15 
measured refl. 21059 19959 8132 
unique refl. [Rint] 9982 [0.0537] 9582 [0.0712] 3914 [0.0387] 
observed refl. (I > 2 σ 
(I)) 
7120 5271 3297 
data / restraints / 
param. 
9982 / 21 / 638 9582 / 19 / 676 3914 / 0 / 245 
goodness–of–fit (F²) 1.004 0.924 1.029 
R1, wR2 (I > 2σ(I)) 0.0402, 0.0797 0.0487, 0.0857 0.0291, 0.0685 
R1, wR2 (all data) 0.0674, 0.0858 0.0953, 0.0933 0.0382, 0.0708 
resid. el. dens. [e/Å-³] –0.594 / 0.449 0.729 / -0.784 –0.478 / 0.418 
 




Table 33 Crystal data and refinement details of 15, 16 and 20. 
 15 16 20 
empirical formula C12H19CuF6N3OPS2 C13H19CuF3NO5S3 C16H17Cl2F3MnNO7S3 
formula weight 493.93 486.01 614.33 
crystal size [mm³] 0.22 × 0.09 × 0.07 0.48 × 0.22 × 0.21 0.41 x 0.18 x 0.06 
crystal system Monoclinic Monoclinic Triclinic 
space group P21/c P21/n P -1 
a [Å], α [°] 13.323(3), 90 10.7299(3), 90 8.8842(7), 100.855(6) 
b [Å], β [°] 20.232(4), 100.90(3) 9.1393(4), 104.082(3) 9.2678(19), 91.343(6) 
c [Å], γ[°] 7.0048(14), 90 19.2963(6), 90 15.3671(13), 
111.388(6)  
V [Å³] 1854.0(6) 1835.40(11) 1151.2(3) 
Z 4 4 2 
ρ [g/cm³] 1.770 1.759 1.772 
F(000) 1000 992 620 
µ [mm–1] 1.554 1.585 1.141 
Tmin/ Tmax 0.7550 / 0.8826 0.4982 / 0.7825 0.9504 / 0.6898 
θ range [°] 1.85 - 26.78 1.99 - 26.71 2.41 - 26.72°. 
hkl range ±16, –24 - 25, ±8 –13 - 12, ±11, ±24 –11 - 9, ±11, ±19 
measured refl. 15565 16389 10327 
unique refl. [Rint] 3881 [0.0767] 3892 [0.0473] 4837 [0.0546] 
observed refl. (I > 2 σ 
(I)) 
2628 3587 3787 
data / restraints / 
param. 
3881 / 134 / 260 3892 / 0 / 239 4837 / 0 / 299 
goodness–of–fit (F²) 0.980 1.042 1.006 
R1, wR2 (I > 2σ(I)) 0.0514, 0.0874 0.0298, 0.0765 0.0388, 0.0843 
R1, wR2 (all data) 0.0912, 0.0969 0.0326, 0.0781 0.0566, 0.0887 
resid. el. dens. [e/Å-³] –0.455 / 0.677 –0.680 / 0.764 0.578 / -0.764 
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Table 34 Crystal data and refinement details of 21, 22 and 23. 
 21 22 23 
empirical formula C14H16F3MnN2O7S3 C43.50H36Cl3F6Mn2N8O1
2.5S2 
C24H21F3MnN4O7.50 
formula weight 532.41 1265.15 629.45 
crystal size [mm³] 0.38 x 0.13 x 0.03 0.37 x 0.17 x 0.07 0.4 x 0.16 x 0.12 
crystal system Monoclinic Triclinic Triclinic 
space group C 2/c P -1 P -1 
a [Å], α [°] 44.3894(17), 90 10.4283(9), 79.649(8) 8.7678(4), 80.831(4) 
b [Å], β [°] 7.9133(2), 123.960(3) 10.4784(11), 
86.381(8) 
11.4794(6), 79.212(4) 
c [Å], γ[°] 28.2058(11), 90 12.7220(13), 
75.236(8) 
13.8531(7), 87.478(4) 
V [Å³] 8217.8(5) 1322.2(2) 1352.01(12) 
Z 16 1 2 
ρ [g/cm³] 1.721 1.589 1.546 
F(000) 4320 640 642 
µ [mm–1] 1.014 0.797 0.639 
Tmin/ Tmax 0.8884 / 0.6061 0.8881 / 0.6751  
θ range [°] 1.45 - 25.65 1.63 - 26.88 1.51 - 26.74 
hkl range ±53, –9 +9, ±34 –12 +13, –13 +12, 
±16 
–9 -11, ±14, –16 - 17 
measured refl. 31697 12696 12039 
unique refl. [Rint] 7749 [0.1004] 5590 [0.0686] 5708 [0.0605] 
observed refl. (I > 2 σ 
(I)) 
5619 3436 4403 
data / restraints / 
param. 
7749 / 0 / 545 5590 / 4 / 365 5708 / 23 / 392 
goodness–of–fit (F²) 1.031 1.001 1.048 
R1, wR2 (I > 2σ(I)) 0.0504, 0.0831 0.0631, 0.1263 0.0509, 0.1296 
R1, wR2 (all data) 0.0835, 0.0910 0.1139, 0.1424 0.0690, 0.1375 
resid. el. dens. [e/Å-³] 0.569 / -0.318 0.782 / -1.012 0.481 / -0.632 
 
 




Table 35 Crystal data and refinement details of L3Me. 
 L3Me 
empirical formula C11H15NOS2 
formula weight 241.36 
crystal size [mm³] 0.31 × 0.20 × 0.17 
crystal system Monoclinic 
space group P21/c 
a [Å], α [°] 8.7459(4), 90 
b [Å], β [°] 7.0971(3), 91.293(3) 
c [Å], γ[°] 18.7746(8), 90 
V [Å³] 1165.05(9) 
Z 4 
ρ [g/cm³] 1.376 
F(000) 512 
µ [mm–1] 0.430 
Tmin/ Tmax 0.7427 / 0.9065 
θ range [°] 2.17 - 26.73 
hkl range ±11, ±8, ±23 
measured refl. 9520 
unique refl. [Rint] 2453 [0.0482] 
observed refl. (I > 2 σ 
(I)) 
2215 
data / restraints / 
param. 
2453 / 0 / 137 
goodness–of–fit (F²) 1.059 
R1, wR2 (I > 2σ(I)) 0.0279, 0.0701 
R1, wR2 (all data) 0.0317, 0.0717 
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List of Abbreviations  
AD Alzheimer's Disease 
APP amyloid precursor protein 
Asp asparagine 
Aβ β-amyloid 
CORM CO releasing molecule 
CPP cell penetrating peptide 
d douplet 
DFT density functional theory 
DMEM  Dubelcoo’s Modified Eagle’s Medium 
EI electron ionisation (MS-technique) 
  ESI electrospray ionisation (MS-technique) 
FBS foetal bovine serum 
Glu glutamine 
His histidine 
IR infrared spectroscopy 
J magnet coupling (SQUID) / NMR coupling constant 
LFSE ligand field stabilising energy 




Met  methionine 
MS mass spectroscopy 
NFT’s neurofibrillary tangles 
NMR nuclear magnetic resonance 
ROS reactive oxygen species 
RT room temperature 
s singlet (NMR) / strong (IR) 









w weak (IR) 
δ NMR shift 
ε extinction coefficient 
μeff effective magnetic moment 
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